warning: Failed to parse `pyproject.toml` during settings discovery:
  TOML parse error at line 105, column 10
      |
  105 | [tool.uv.extra-build-dependencies]
      |          ^^^^^^^^^^^^^^^^^^^^^^^^
  unknown field `extra-build-dependencies`, expected one of `required-version`, `native-tls`, `offline`, `no-cache`, `cache-dir`, `preview`, `python-preference`, `python-downloads`, `concurrent-downloads`, `concurrent-builds`, `concurrent-installs`, `index`, `index-url`, `extra-index-url`, `no-index`, `find-links`, `index-strategy`, `keyring-provider`, `allow-insecure-host`, `resolution`, `prerelease`, `fork-strategy`, `dependency-metadata`, `config-settings`, `no-build-isolation`, `no-build-isolation-package`, `exclude-newer`, `link-mode`, `compile-bytecode`, `no-sources`, `upgrade`, `upgrade-package`, `reinstall`, `reinstall-package`, `no-build`, `no-build-package`, `no-binary`, `no-binary-package`, `python-install-mirror`, `pypy-install-mirror`, `publish-url`, `trusted-publishing`, `check-url`, `pip`, `cache-keys`, `override-dependencies`, `constraint-dependencies`, `build-constraint-dependencies`, `environments`, `required-environments`, `conflicts`, `workspace`, `sources`, `managed`, `package`, `default-groups`, `dev-dependencies`, `build-backend`

2025-10-28 18:37:49 - verifiers.utils.env_utils - INFO - Loading environment: pubmedhard-search
2025-10-28 18:37:49 - verifiers.utils.env_utils - INFO - Using default args: dataset_split='train', max_turns=10, dataset_name='casperhansen/pmc-oa-markdown-qa'
2025-10-28 18:38:35 - verifiers.rubrics.RubricGroup - INFO - Initialized RubricGroup with 2 rubrics
2025-10-28 18:38:35 - verifiers.utils.env_utils - INFO - Successfully loaded environment 'pubmedhard-search'
2025-10-28 18:38:35 - verifiers.utils.eval_utils - INFO - Starting evaluation with model: gpt-5-nano
2025-10-28 18:38:35 - verifiers.utils.eval_utils - INFO - Configuration: num_examples=5, rollouts_per_example=1, max_concurrent=32
2025-10-28 18:38:35 - verifiers.envs.ToolEnv - INFO - eval_dataset is not set, falling back to train dataset
Running 5 rollouts (interleaved):   0%|          | 0/5 [00:00<?, ?it/s]Running 5 rollouts (interleaved):  20%|██        | 1/5 [00:47<03:09, 47.41s/it]Running 5 rollouts (interleaved):  40%|████      | 2/5 [00:50<01:04, 21.62s/it]Running 5 rollouts (interleaved):  60%|██████    | 3/5 [00:52<00:24, 12.46s/it]Running 5 rollouts (interleaved):  80%|████████  | 4/5 [01:03<00:11, 11.98s/it]Running 5 rollouts (interleaved): 100%|██████████| 5/5 [01:20<00:00, 13.55s/it]Running 5 rollouts (interleaved): 100%|██████████| 5/5 [01:20<00:00, 16.02s/it]
2025-10-28 18:39:55 - verifiers.utils.eval_utils - INFO - Evaluation completed in 80.12 seconds
--- Evaluation ---
Environment: pubmedhard-search
Model: gpt-5-nano
Provider: https://api.openai.com/v1/
Examples: 5
Rollouts per example: 1
--- Example ---
╭─────────────────────────────────────────── Step 0 ───────────────────────────────────────────╮
│ ┏━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━┳━━━━━━━━┓ │
│ ┃ Prompt                                 ┃ Completion                             ┃ Reward ┃ │
│ ┡━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━╇━━━━━━━━┩ │
│ │ system: Use search/read tools over     │ assistant:                             │   0.05 │ │
│ │ PubMed OA Markdown to answer           │                                        │        │ │
│ │ concisely.                             │ [tool call]                            │        │ │
│ │                                        │ {                                      │        │ │
│ │ user: How does the interaction between │   "name": "search",                    │        │ │
│ │ mitochondrial uncoupling and BCAA      │   "args": "{\"query\":\"BT2 BCKDK      │        │ │
│ │ catabolic flux in cardiac tissue       │ heart failure cardioprotection         │        │ │
│ │ resolve the paradoxical                │ mitochondrial uncoupling BCAA          │        │ │
│ │ cardioprotective effects of BT2 in     │ catabolism cardiac tissue ablation     │        │ │
│ │ heart failure models, given the        │ systemic BT2 administration            │        │ │
│ │ observed discrepancies between         │ discrepancy PubMed OA\", \"k\": 5}"    │        │ │
│ │ tissue-specific BCKDK ablation and     │ }                                      │        │ │
│ │ systemic BT2 administration?           │                                        │        │ │
│ │                                        │ tool: [{'idx': 0}, {'idx': 990},       │        │ │
│ │                                        │ {'idx': 4762}, {'idx': 1835}, {'idx':  │        │ │
│ │                                        │ 1023}]                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ assistant:                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ [tool call]                            │        │ │
│ │                                        │ {                                      │        │ │
│ │                                        │   "name": "read",                      │        │ │
│ │                                        │   "args": "{\"idx\":0}"                │        │ │
│ │                                        │ }                                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ tool: ---                              │        │ │
│ │                                        │ title: The BCKDK inhibitor BT2 is a    │        │ │
│ │                                        │ chemical uncoupler that lowers         │        │ │
│ │                                        │ mitochondrial ROS                      │        │ │
│ │                                        │   production and de novo lipogenesis   │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Aracely Acevedo                      │        │ │
│ │                                        │ - Anthony E. Jones                     │        │ │
│ │                                        │ - Bezawit T. Danna                     │        │ │
│ │                                        │ - Rory Turner                          │        │ │
│ │                                        │ - Katrina P. Montales                  │        │ │
│ │                                        │ - Cristiane Benincá                    │        │ │
│ │                                        │ - Karen Reue                           │        │ │
│ │                                        │ - Orian S. Shirihai                    │        │ │
│ │                                        │ - Linsey Stiles                        │        │ │
│ │                                        │ - Martina Wallace                      │        │ │
│ │                                        │ - Yibin Wang                           │        │ │
│ │                                        │ - Ambre M. Bertholet                   │        │ │
│ │                                        │ - Ajit S. Divakaruni                   │        │ │
│ │                                        │ journal: bioRxiv                       │        │ │
│ │                                        │ year: 2023                             │        │ │
│ │                                        │ pmcid: PMC10461965                     │        │ │
│ │                                        │ doi: 10.1101/2023.08.15.553413         │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # The BCKDK inhibitor BT2 is a         │        │ │
│ │                                        │ chemical uncoupler that lowers         │        │ │
│ │                                        │ mitochondrial ROS production and de    │        │ │
│ │                                        │ novo lipogenesis                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Elevated levels of branched chain      │        │ │
│ │                                        │ amino acids (BCAAs) and branched-chain │        │ │
│ │                                        │ α-ketoacids (BCKAs) are associated     │        │ │
│ │                                        │ with cardiovascular and metabolic      │        │ │
│ │                                        │ disease, but the molecular mechanisms  │        │ │
│ │                                        │ underlying a putative causal           │        │ │
│ │                                        │ relationship remain unclear. The       │        │ │
│ │                                        │ branched-chain ketoacid dehydrogenase  │        │ │
│ │                                        │ kinase (BCKDK) inhibitor BT2 is often  │        │ │
│ │                                        │ used in preclinical models to increase │        │ │
│ │                                        │ BCAA oxidation and restore             │        │ │
│ │                                        │ steady-state BCAA and BCKA levels. BT2 │        │ │
│ │                                        │ administration is protective in        │        │ │
│ │                                        │ various rodent models of heart failure │        │ │
│ │                                        │ and metabolic disease, but             │        │ │
│ │                                        │ confoundingly, targeted ablation of    │        │ │
│ │                                        │ Bckdk in specific tissues does not     │        │ │
│ │                                        │ reproduce the beneficial effects       │        │ │
│ │                                        │ conferred by pharmacologic inhibition. │        │ │
│ │                                        │ Here we demonstrate that BT2, a        │        │ │
│ │                                        │ lipophilic weak acid, can act as a     │        │ │
│ │                                        │ mitochondrial uncoupler. Measurements  │        │ │
│ │                                        │ of oxygen consumption, mitochondrial   │        │ │
│ │                                        │ membrane potential, and patch-clamp    │        │ │
│ │                                        │ electrophysiology show BT2 increases   │        │ │
│ │                                        │ proton conductance across the          │        │ │
│ │                                        │ mitochondrial inner membrane           │        │ │
│ │                                        │ independently of its inhibitory effect │        │ │
│ │                                        │ on BCKDK. BT2 is roughly five-fold     │        │ │
│ │                                        │ less potent than the prototypical      │        │ │
│ │                                        │ uncoupler 2,4-dinitrophenol (DNP), and │        │ │
│ │                                        │ phenocopies DNP in lowering de novo    │        │ │
│ │                                        │ lipogenesis and mitochondrial          │        │ │
│ │                                        │ superoxide production. The data        │        │ │
│ │                                        │ suggest the therapeutic efficacy of    │        │ │
│ │                                        │ BT2 may be attributable to the         │        │ │
│ │                                        │ well-documented effects of             │        │ │
│ │                                        │ mitochondrial uncoupling in            │        │ │
│ │                                        │ alleviating cardiovascular and         │        │ │
│ │                                        │ metabolic disease.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## INTRODUCTION                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Elevations in circulating levels of    │        │ │
│ │                                        │ the branched-chain amino acids (BCAAs) │        │ │
│ │                                        │ leucine, isoleucine, and valine are a  │        │ │
│ │                                        │ hallmark of metabolic and              │        │ │
│ │                                        │ cardiovascular disease [1–5]. Early    │        │ │
│ │                                        │ studies dating back over fifty years   │        │ │
│ │                                        │ showed elevated blood levels of BCAAs  │        │ │
│ │                                        │ positively correlated with obesity and │        │ │
│ │                                        │ blood insulin levels in patients       │        │ │
│ │                                        │ relative to matched lean individuals   │        │ │
│ │                                        │ [6]. Further studies leveraging        │        │ │
│ │                                        │ unbiased metabolomics have reinforced  │        │ │
│ │                                        │ the links between BCAA accumulation    │        │ │
│ │                                        │ and insulin resistance in both humans  │        │ │
│ │                                        │ and pre-clinical rodent disease models │        │ │
│ │                                        │ [7,8]. In fact, longitudinal studies   │        │ │
│ │                                        │ tracking healthy individuals showed    │        │ │
│ │                                        │ that elevated plasma BCAAs could be    │        │ │
│ │                                        │ predictive of future insulin           │        │ │
│ │                                        │ resistance [8,9].                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As with obesity and insulin            │        │ │
│ │                                        │ resistance, epidemiological studies    │        │ │
│ │                                        │ have also linked elevated circulating  │        │ │
│ │                                        │ levels of both BCAAs and their         │        │ │
│ │                                        │ breakdown products, branched-chain     │        │ │
│ │                                        │ α-ketoacids (BCKAs), with              │        │ │
│ │                                        │ cardiovascular disease. In both humans │        │ │
│ │                                        │ and rodents, several studies point to  │        │ │
│ │                                        │ accumulation of BCAAs and/or BCKAs in  │        │ │
│ │                                        │ heart failure, myocardial infarction   │        │ │
│ │                                        │ (MI) and ischemia, hypertension, and   │        │ │
│ │                                        │ arrhythmia [1,10–14]. Furthermore,     │        │ │
│ │                                        │ elevated plasma BCAAs may be           │        │ │
│ │                                        │ predictive of future obstructive       │        │ │
│ │                                        │ coronary artery disease [15].          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As with other metabolites,             │        │ │
│ │                                        │ steady-state levels of BCAAs are a     │        │ │
│ │                                        │ balance of intake and disposal. BCAAs  │        │ │
│ │                                        │ are essential amino acids for humans   │        │ │
│ │                                        │ and animals, meaning they cannot be    │        │ │
│ │                                        │ synthesized de novo. Dietary intake is │        │ │
│ │                                        │ therefore the predominant source of    │        │ │
│ │                                        │ BCAAs, though a minor proportion may   │        │ │
│ │                                        │ arise from the gut microbiome [4].     │        │ │
│ │                                        │ Along with protein synthesis, BCAA     │        │ │
│ │                                        │ oxidation represents an important sink │        │ │
│ │                                        │ for clearing BCAAs and maintaining     │        │ │
│ │                                        │ homeostatic levels [4,5].              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Oxidation of leucine, isoleucine, and  │        │ │
│ │                                        │ valine is a tightly regulated process. │        │ │
│ │                                        │ Each BCAA is first deaminated by the   │        │ │
│ │                                        │ branched-chain aminotransferase (BCAT) │        │ │
│ │                                        │ to its respective BCKA. These BCKAs    │        │ │
│ │                                        │ then undergo irreversible              │        │ │
│ │                                        │ decarboxylation and esterification to  │        │ │
│ │                                        │ their respective R-CoA molecules by    │        │ │
│ │                                        │ the branched-chain α-ketoacid          │        │ │
│ │                                        │ dehydrogenase (BCKDH). They are        │        │ │
│ │                                        │ eventually incorporated into the TCA   │        │ │
│ │                                        │ cycle as acetyl CoA or succinyl CoA.   │        │ │
│ │                                        │ Much like regulation of the pyruvate   │        │ │
│ │                                        │ dehydrogenase by inhibitory kinases    │        │ │
│ │                                        │ and an activating phosphatase, the     │        │ │
│ │                                        │ BCKDH is inhibited by the BCKDH kinase │        │ │
│ │                                        │ (BCKDK) and activated by the           │        │ │
│ │                                        │ mitochondrial protein phosphatase 2Cm  │        │ │
│ │                                        │ (PP2Cm) [16,17].                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The association between increased BCAA │        │ │
│ │                                        │ and BCKA levels and cardiovascular and │        │ │
│ │                                        │ metabolic disease is well accepted,    │        │ │
│ │                                        │ but it remains unclear whether these   │        │ │
│ │                                        │ elevated levels have a causative role  │        │ │
│ │                                        │ in disease or represent an indirect    │        │ │
│ │                                        │ epiphenomenon. Several                 │        │ │
│ │                                        │ proof-of-concept studies have sought   │        │ │
│ │                                        │ to modify BCAA intake in pre-clinical  │        │ │
│ │                                        │ models to examine how readjusting      │        │ │
│ │                                        │ steady-state levels affects disease    │        │ │
│ │                                        │ pathology. As it relates to insulin    │        │ │
│ │                                        │ resistance, dietary BCAA               │        │ │
│ │                                        │ supplementation has produced mixed     │        │ │
│ │                                        │ results suggesting a complex,          │        │ │
│ │                                        │ contextual effect dependent on the     │        │ │
│ │                                        │ composition of diet and pre-existing   │        │ │
│ │                                        │ health of the animal [4,7]. Dietary    │        │ │
│ │                                        │ restriction of BCAAs, however,         │        │ │
│ │                                        │ reverses insulin resistance in         │        │ │
│ │                                        │ multiple pre-clinical studies [7,18].  │        │ │
│ │                                        │ Although fewer studies are available   │        │ │
│ │                                        │ examining dietary BCAAs on             │        │ │
│ │                                        │ cardiovascular disease, one report     │        │ │
│ │                                        │ noted oral BCAA administration post-MI │        │ │
│ │                                        │ impaired contractility and increased   │        │ │
│ │                                        │ infarct size [19].                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Numerous studies have manipulated      │        │ │
│ │                                        │ metabolic enzymes to alter             │        │ │
│ │                                        │ steady-state BCAA and BCKA levels and  │        │ │
│ │                                        │ examine the disease-modifying impact.  │        │ │
│ │                                        │ Indeed, whole-body deletion or         │        │ │
│ │                                        │ silencing of the PP2Cm increases       │        │ │
│ │                                        │ circulating BCAA levels and promotes   │        │ │
│ │                                        │ heart failure and worsens              │        │ │
│ │                                        │ ischemia/reperfusion (I/R) injury      │        │ │
│ │                                        │ [12,20]. In line with these results,   │        │ │
│ │                                        │ tissue-specific adenoviral             │        │ │
│ │                                        │ overexpression of the phosphatase      │        │ │
│ │                                        │ lowered BCKA and BCAA levels and       │        │ │
│ │                                        │ prevented ischemic injury in the heart │        │ │
│ │                                        │ [21] and reduced hepatic triglyceride  │        │ │
│ │                                        │ accumulation and improved hepatic      │        │ │
│ │                                        │ glucose tolerance [22].                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Some of the strongest evidence for a   │        │ │
│ │                                        │ causative, pathological relationship   │        │ │
│ │                                        │ between dysregulated BCAA metabolism   │        │ │
│ │                                        │ and cardiometabolic disease comes from │        │ │
│ │                                        │ pharmacologic inhibition of the BCKDK  │        │ │
│ │                                        │ with BT2. The small molecule BT2       │        │ │
│ │                                        │ (3,6-dichlorobenzo[b]thiophene-2-carb… │        │ │
│ │                                        │ acid) was designed as a BCKA analog    │        │ │
│ │                                        │ that allosterically binds to the BCKDK │        │ │
│ │                                        │ [23]. Similar to end-product           │        │ │
│ │                                        │ inhibition of the BCKDK by elevated    │        │ │
│ │                                        │ BCKA levels, the compound relieves     │        │ │
│ │                                        │ kinase inhibition on the BCKDH and     │        │ │
│ │                                        │ promotes BCKA oxidation. In            │        │ │
│ │                                        │ preclinical models of heart failure,   │        │ │
│ │                                        │ systemic BT2 administration lowers     │        │ │
│ │                                        │ cardiac BCAAs and BCKAs and provides   │        │ │
│ │                                        │ cardioprotection in response to both   │        │ │
│ │                                        │ transaortic constriction (TAC) as well │        │ │
│ │                                        │ as LAD ligation [12,19–21]. In various │        │ │
│ │                                        │ rodent models of cardiometabolic       │        │ │
│ │                                        │ disease, BT2 lowers circulating BCAA   │        │ │
│ │                                        │ and BCKAs, improves glucose tolerance  │        │ │
│ │                                        │ and insulin sensitivity, and reduces   │        │ │
│ │                                        │ de novo lipogenesis [22,24–26].        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Remarkably, however, the recent        │        │ │
│ │                                        │ development of tissue-specific mouse   │        │ │
│ │                                        │ models has complicated our             │        │ │
│ │                                        │ understanding of how dysregulated BCAA │        │ │
│ │                                        │ metabolism may relate to               │        │ │
│ │                                        │ cardiovascular and metabolic disease.  │        │ │
│ │                                        │ Cardiac-specific loss of BCKDK does    │        │ │
│ │                                        │ not reproduce the protective effects   │        │ │
│ │                                        │ in either hemodynamic or ischemic      │        │ │
│ │                                        │ models of heart failure [27]. It could │        │ │
│ │                                        │ be argued that the proportion of BCAA  │        │ │
│ │                                        │ oxidation in the heart is too low for  │        │ │
│ │                                        │ the cardiac-specific knockout to have  │        │ │
│ │                                        │ an effect on circulating BCAA levels   │        │ │
│ │                                        │ similar to BT2 [28]. However,          │        │ │
│ │                                        │ inducible skeletal muscle-specific     │        │ │
│ │                                        │ Bckdk ablation also failed to elicit   │        │ │
│ │                                        │ cardioprotection despite lowering      │        │ │
│ │                                        │ cardiac BCAAs and plasma BCAAs and     │        │ │
│ │                                        │ BCKAs [27]. Furthermore, tissue        │        │ │
│ │                                        │ specific-loss of BCKDK in skeletal     │        │ │
│ │                                        │ muscle does not reproduce the effects  │        │ │
│ │                                        │ of BT2 in improving insulin            │        │ │
│ │                                        │ sensitivity despite lowering plasma    │        │ │
│ │                                        │ BCAAs and BCKAs [29]. Similar          │        │ │
│ │                                        │ loss-of-function studies show that     │        │ │
│ │                                        │ hepatic BCKDK loss also fails to       │        │ │
│ │                                        │ improve insulin sensitivity [26,29],   │        │ │
│ │                                        │ though the liver has less apparent     │        │ │
│ │                                        │ control over circulating BCAA levels   │        │ │
│ │                                        │ than muscle. While the results could   │        │ │
│ │                                        │ suggest that whole-body BCKDK          │        │ │
│ │                                        │ inhibition cannot be reproduced by     │        │ │
│ │                                        │ Bckdk ablation in individual tissues,  │        │ │
│ │                                        │ they perhaps also suggest an           │        │ │
│ │                                        │ alternative mechanism by which BT2     │        │ │
│ │                                        │ confers protection from heart failure  │        │ │
│ │                                        │ and metabolic disease distinct from    │        │ │
│ │                                        │ BCAA oxidation.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Here we present evidence that BT2 is a │        │ │
│ │                                        │ mitochondrial uncoupler. Measurements  │        │ │
│ │                                        │ of respiration, mitochondrial membrane │        │ │
│ │                                        │ potential, and inner membrane          │        │ │
│ │                                        │ electrophysiology all demonstrate that │        │ │
│ │                                        │ BT2 – a lipophilic weak acid – is      │        │ │
│ │                                        │ itself a chemical uncoupler. BT2 also  │        │ │
│ │                                        │ phenocopies the prototypical uncoupler │        │ │
│ │                                        │ 2,4-dinitrophenol (DNP) in lowering    │        │ │
│ │                                        │ mitochondrial H2O2 efflux and reducing │        │ │
│ │                                        │ de novo lipogenesis. Importantly,      │        │ │
│ │                                        │ chemical uncoupling of mitochondria    │        │ │
│ │                                        │ provides a single, unified mechanism   │        │ │
│ │                                        │ by which BT2 could plausibly confer    │        │ │
│ │                                        │ protection against heart failure       │        │ │
│ │                                        │ (lowering mitochondrial ROS            │        │ │
│ │                                        │ production) and cardiometabolic        │        │ │
│ │                                        │ disease (increasing energy             │        │ │
│ │                                        │ expenditure) independent of effects on │        │ │
│ │                                        │ steady-state BCAA levels.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Animals                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All animal protocols and procedures    │        │ │
│ │                                        │ were approved and performed in         │        │ │
│ │                                        │ accordance with the NIH Guide for the  │        │ │
│ │                                        │ Care and Use of Laboratory Animals and │        │ │
│ │                                        │ the UCLA Animal Research Committee     │        │ │
│ │                                        │ (ARC). C57BL/6J male mice aged 8–12    │        │ │
│ │                                        │ weeks were purchased from The Jackson  │        │ │
│ │                                        │ Laboratory. Male Sprague Dawley rats   │        │ │
│ │                                        │ aged between 7–10 weeks (~200–300 g)   │        │ │
│ │                                        │ were purchased from Envigo.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Reagents                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BT2                                    │        │ │
│ │                                        │ (3,6-dichlorobenzo[b]thiophene-2-carb… │        │ │
│ │                                        │ acid) was purchased from               │        │ │
│ │                                        │ MedChemExpress (#HY114855) and all     │        │ │
│ │                                        │ other uncouplers were purchased from   │        │ │
│ │                                        │ Sigma-Aldrich [FCCP (Carbonyl cyanide  │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine;     │        │ │
│ │                                        │ #C2920), DNP (2,4-dinitrophenol;       │        │ │
│ │                                        │ #42195), Bam15 (#SML-1760)]. Stocks    │        │ │
│ │                                        │ were made and stored at −20°C at the   │        │ │
│ │                                        │ following concentrations: BT2 (40 mM   │        │ │
│ │                                        │ and 400 mM in DMSO); FCCP (10 mM in    │        │ │
│ │                                        │ $95\%$ ethanol); DNP (20 mM in DMSO);  │        │ │
│ │                                        │ Bam15 (40 mM in DMSO).                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Cardiomyocytes                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Neonatal rat ventricular myocytes      │        │ │
│ │                                        │ (NRVMs) were isolated from post-natal  │        │ │
│ │                                        │ P1-P3-day old Sprague Dawley rat pups  │        │ │
│ │                                        │ of mixed sex as previously described   │        │ │
│ │                                        │ [30,31]. Cells were plated onto        │        │ │
│ │                                        │ Agilent Seahorse XF96 cell culture     │        │ │
│ │                                        │ plates or 12-well cell culture dishes  │        │ │
│ │                                        │ coated with $0.1\%$ gelatin (Sigma     │        │ │
│ │                                        │ #G1393) in DMEM/F12 medium (Gibco      │        │ │
│ │                                        │ #11330057) supplemented with $10\%$    │        │ │
│ │                                        │ (v/v) FBS, 100 U/ml penicillin, and    │        │ │
│ │                                        │ 100 μg/mL streptomycin. After 24 hr.,  │        │ │
│ │                                        │ medium was changed to DMEM/F12 lacking │        │ │
│ │                                        │ FBS but with antibiotics as before.    │        │ │
│ │                                        │ Human induced pluripotent stem cell    │        │ │
│ │                                        │ (iPSC) cardiomyocytes (iCell           │        │ │
│ │                                        │ cardiomyocytes; Fujifilm Cellular      │        │ │
│ │                                        │ Dynamics International #01434) were    │        │ │
│ │                                        │ maintained according to manufacturer’s │        │ │
│ │                                        │ guidelines. Cells were grown and       │        │ │
│ │                                        │ maintained in a humidified $5\%$ CO2   │        │ │
│ │                                        │ incubator at 37°C.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mitochondrial membrane potential   │        │ │
│ │                                        │ in cells was measured with TMRE using  │        │ │
│ │                                        │ the Image Xpress Micro Confocal        │        │ │
│ │                                        │ high-content imaging system (Molecular │        │ │
│ │                                        │ Devices). NRVMs and iPSC-derived iCell │        │ │
│ │                                        │ cardiomyocytes were plated onto        │        │ │
│ │                                        │ collagen-coated, black-walled          │        │ │
│ │                                        │ PhenoPlates (Perkin-Elmer) at either   │        │ │
│ │                                        │ 6.0×104 (NRVMs) or 1.5×104 (iCell)     │        │ │
│ │                                        │ cells/well and maintained as described │        │ │
│ │                                        │ earlier in the Materials and Methods.  │        │ │
│ │                                        │ 75 minutes prior to conducting         │        │ │
│ │                                        │ measurements, medium was exchanged for │        │ │
│ │                                        │ DMEM lacking glucose, phenol red, and  │        │ │
│ │                                        │ sodium bicarbonate (Sigma #5030)       │        │ │
│ │                                        │ supplemented with 31.6 mM NaCl, 10 mM  │        │ │
│ │                                        │ glucose, 2 mM glutamine, 2 mM          │        │ │
│ │                                        │ pyruvate, and 5 mM HEPES along with 10 │        │ │
│ │                                        │ nM TMRE (Invitrogen #T669) and 200 nM  │        │ │
│ │                                        │ MitoTracker Green FM (Catalog #        │        │ │
│ │                                        │ M7514). After allowing the dyes to     │        │ │
│ │                                        │ equilibrate for 1 hr., BT2 (80 µM),    │        │ │
│ │                                        │ DNP (10 µM) and FCCP (1 µM) were       │        │ │
│ │                                        │ added, and measurements of the first   │        │ │
│ │                                        │ microplate well began after 15         │        │ │
│ │                                        │ minutes. Circularity is defined with   │        │ │
│ │                                        │ “1” being a perfect circle and “0” a   │        │ │
│ │                                        │ straight line.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## 3T3-L1 adipocytes                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 pre-adipocytes were maintained  │        │ │
│ │                                        │ below $70\%$ confluency in DMEM (Gibco │        │ │
│ │                                        │ #11965) supplemented with $10\%$ (v/v) │        │ │
│ │                                        │ bovine calf serum (ATCC 30-2020),      │        │ │
│ │                                        │ 100U/mL penicillin, 100 μg/mL          │        │ │
│ │                                        │ streptomycin, and 1 mM sodium          │        │ │
│ │                                        │ pyruvate. Cells were plated onto XF96  │        │ │
│ │                                        │ cell culture plates or 12-well tissue  │        │ │
│ │                                        │ culture dishes and allowed to grow for │        │ │
│ │                                        │ 48 hr. ( plating on Day −2). On Day 0, │        │ │
│ │                                        │ differentiation was begun by changing  │        │ │
│ │                                        │ the medium to maintenance medium [DMEM │        │ │
│ │                                        │ supplemented with $10\%$ (v/v) FBS,    │        │ │
│ │                                        │ 100U/mL penicillin, 100 μg/mL          │        │ │
│ │                                        │ streptomycin, 1 mM sodium pyruvate, 10 │        │ │
│ │                                        │ mM HEPES] supplemented with 1 μg/mL    │        │ │
│ │                                        │ insulin (Sigma #I0515), 0.25 μM        │        │ │
│ │                                        │ dexamethasone (Sigma #D4904), 0.5 mM   │        │ │
│ │                                        │ methylisobutylxanthine (IBMX, Sigma    │        │ │
│ │                                        │ I5879), and 100 nM rosiglitazone       │        │ │
│ │                                        │ (Sigma #R2408). On Day 2, medium was   │        │ │
│ │                                        │ changed to maintenance medium          │        │ │
│ │                                        │ supplemented only with 1 μg/mL         │        │ │
│ │                                        │ insulin, and on Days 4 and 6 medium    │        │ │
│ │                                        │ was replaced to maintenance medium     │        │ │
│ │                                        │ with no further additions. Cells were  │        │ │
│ │                                        │ treated with compound on Day 8 as      │        │ │
│ │                                        │ described elsewhere in the Materials   │        │ │
│ │                                        │ and Methods.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## C2C12 myoblasts                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ C2C12 myoblasts were maintained in     │        │ │
│ │                                        │ DMEM (Gibco #11965) supplemented with  │        │ │
│ │                                        │ $10\%$ (v/v) FBS, 100U/mL penicillin,  │        │ │
│ │                                        │ 100 μg/mL streptomycin, and 1 mM       │        │ │
│ │                                        │ sodium pyruvate. Cells with genetic    │        │ │
│ │                                        │ ablation of Slc25a4 and Slc25a5        │        │ │
│ │                                        │ (encoding AAC1 and AAC2) were          │        │ │
│ │                                        │ generated and described previously     │        │ │
│ │                                        │ [32].                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Mitochondrial Isolation             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mitochondrial isolation from rodent    │        │ │
│ │                                        │ heart and liver was conducted          │        │ │
│ │                                        │ according to well established          │        │ │
│ │                                        │ protocols [33] and all steps were      │        │ │
│ │                                        │ conducted on ice or at 4°C.            │        │ │
│ │                                        │ Mitochondrial protein content was      │        │ │
│ │                                        │ measured by the bicinchoninic acid     │        │ │
│ │                                        │ (BCA) assay.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Liver mitochondria                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mouse or rat livers were cleaned,      │        │ │
│ │                                        │ minced, and drained of blood in        │        │ │
│ │                                        │ ice-cold MSHE [210 mannitol, 70 mM     │        │ │
│ │                                        │ sucrose, 5 mM HEPES, 1 mM EGTA, and    │        │ │
│ │                                        │ $0.2\%$ (w/v) fatty acid-free BSA] at  │        │ │
│ │                                        │ pH 7.2 at 4°C. Livers were disrupted   │        │ │
│ │                                        │ with using 2 strokes of a drill-driven │        │ │
│ │                                        │ Teflon-on-glass Dounce homogenizer     │        │ │
│ │                                        │ with roughly 1mL of buffer for every   │        │ │
│ │                                        │ 100 mg of tissue. The homogenate was   │        │ │
│ │                                        │ spun at 12,000g for 10 minutes at 4°C  │        │ │
│ │                                        │ to remove any contaminating fat. The   │        │ │
│ │                                        │ pellet was resuspended and centrifuged │        │ │
│ │                                        │ at 800g for 5 minutes at 4°C to remove │        │ │
│ │                                        │ debris. The supernatant was filtered   │        │ │
│ │                                        │ through two layers of wet cheesecloth  │        │ │
│ │                                        │ and centrifuged at 12,000g for 10      │        │ │
│ │                                        │ minutes at 4°C. The light, ‘fluffy’    │        │ │
│ │                                        │ layer of the pellet was removed, and   │        │ │
│ │                                        │ the mitochondrial pellet was           │        │ │
│ │                                        │ resuspended and centrifuged again at   │        │ │
│ │                                        │ 12,000g at 4°C. For the third and      │        │ │
│ │                                        │ final centrifugation step, the pellet  │        │ │
│ │                                        │ was washed and resuspended in MSHE     │        │ │
│ │                                        │ lacking BSA and centrifuged again at   │        │ │
│ │                                        │ 4°C. The final mitochondrial pellet    │        │ │
│ │                                        │ was resuspended in MSHE lacking BSA    │        │ │
│ │                                        │ and kept at a concentration greater    │        │ │
│ │                                        │ than 100 mg/mL and kept on ice.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Heart mitochondria                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mouse or rat hearts were quickly       │        │ │
│ │                                        │ removed from the euthanized animal     │        │ │
│ │                                        │ while still beating and minced,        │        │ │
│ │                                        │ cleaned of blood, and homogenized      │        │ │
│ │                                        │ using a hand-held tissue disruptor     │        │ │
│ │                                        │ (IKA Ultra-Turrax) in ice-cold MSHE.   │        │ │
│ │                                        │ The homogenate was centrifuged at 900g │        │ │
│ │                                        │ for 10 minutes at 4°C. The supernatant │        │ │
│ │                                        │ was then centrifuged at 9,000g for 10  │        │ │
│ │                                        │ minutes at 4°C, and the remaining      │        │ │
│ │                                        │ pellet was washed and re-centrifuged   │        │ │
│ │                                        │ at 9,000g at 4°C in medium lacking     │        │ │
│ │                                        │ BSA. The final mitochondrial pellet    │        │ │
│ │                                        │ was resuspended in MSHE lacking BSA    │        │ │
│ │                                        │ and kept at a concentration greater    │        │ │
│ │                                        │ than 25 mg/mL and kept on ice.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Respirometry                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All oxygen consumption measurements    │        │ │
│ │                                        │ were conducted using an Agilent        │        │ │
│ │                                        │ Seahorse XF96 or XFe96 Analyzer.       │        │ │
│ │                                        │ Experiments were conducted at 37°C and │        │ │
│ │                                        │ at pH 7.4 (intact cells) or 7.2        │        │ │
│ │                                        │ (isolated mitochondria and             │        │ │
│ │                                        │ permeabilized cells). For experiments  │        │ │
│ │                                        │ with intact or permeabilized cells,    │        │ │
│ │                                        │ only the inner 60 wells were used and  │        │ │
│ │                                        │ the outer rim was filled with 200 μL   │        │ │
│ │                                        │ of PBS throughout the incubation to    │        │ │
│ │                                        │ minimize variance in temperature and   │        │ │
│ │                                        │ evaporative effects across the plate.  │        │ │
│ │                                        │ All respiratory parameters were        │        │ │
│ │                                        │ corrected for non-mitochondrial        │        │ │
│ │                                        │ respiration and background signal from │        │ │
│ │                                        │ the instrument with addition of 200 nM │        │ │
│ │                                        │ rotenone and 1 μM antimycin A and      │        │ │
│ │                                        │ calculated according to well           │        │ │
│ │                                        │ established best practices [34,35].    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Intact cells                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Respiration was measured in NRVMs      │        │ │
│ │                                        │ (4.0×104 cells/well), iPSC             │        │ │
│ │                                        │ cardiomyocytes (1.5×104 cells/well),   │        │ │
│ │                                        │ C2C12 myoblasts (1.5×104 cells/well),  │        │ │
│ │                                        │ and differentiated 3T3-L1 adipocytes   │        │ │
│ │                                        │ (2.5×103 cells/well) in DMEM assay     │        │ │
│ │                                        │ medium composed of DMEM (Sigma #5030)  │        │ │
│ │                                        │ supplemented with 31.6 mM NaCl, 3 mg/L │        │ │
│ │                                        │ phenol red, 5 mM HEPES, 10 mM glucose, │        │ │
│ │                                        │ 2 mM glutamine, and 2 mM pyruvate.     │        │ │
│ │                                        │ Where appropriate, cells were offered  │        │ │
│ │                                        │ oligomycin (2 μM) and maximal          │        │ │
│ │                                        │ respiration was estimated with 750 nM  │        │ │
│ │                                        │ FCCP.                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Permeabilized cells                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Cells were permeabilized with 3 nM     │        │ │
│ │                                        │ recombinant perfringolysin O (PFO) and │        │ │
│ │                                        │ assayed as previously described [36]   │        │ │
│ │                                        │ in MAS buffer [220 mM mannitol, 70 mM  │        │ │
│ │                                        │ sucrose, 10 mM KH2PO4 5 mM MgCl2, 2 mM │        │ │
│ │                                        │ HEPES (pH 7.2 at 37°C), 1 mM EGTA,     │        │ │
│ │                                        │ $0.2\%$ (w/v) BSA]. Where indicated    │        │ │
│ │                                        │ medium was supplemented with 4 mM ADP  │        │ │
│ │                                        │ and either 10 mM pyruvate with 1 mM    │        │ │
│ │                                        │ malate or 10 mM succinate with 2 μM    │        │ │
│ │                                        │ rotenone. Where indicated, oligomycin  │        │ │
│ │                                        │ was used at 2 μM.                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Isolated mitochondria               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Oxygen consumption rates in isolated   │        │ │
│ │                                        │ mitochondria were measured in MAS      │        │ │
│ │                                        │ buffer described previously according  │        │ │
│ │                                        │ to well established protocols [36,37]. │        │ │
│ │                                        │ As indicated in the figure legends,    │        │ │
│ │                                        │ BSA was either omitted from the assay  │        │ │
│ │                                        │ medium or used at $0.001\%$ (w/v) to   │        │ │
│ │                                        │ avoid sequestering lipophilic          │        │ │
│ │                                        │ compounds under investigation. Where   │        │ │
│ │                                        │ indicated, MAS buffer was supplemented │        │ │
│ │                                        │ with 10 mM pyruvate with 1 mM malate   │        │ │
│ │                                        │ (Pyr/Mal), 5 mM glutamate with 5 mM    │        │ │
│ │                                        │ malate (Glu/Mal), or 10 mM succinate   │        │ │
│ │                                        │ with 2 μM rotenone (Succ/Rot).         │        │ │
│ │                                        │ Mitochondria were offered oligomycin   │        │ │
│ │                                        │ at 2 μM and FCCP at 1 μM where         │        │ │
│ │                                        │ indicated.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mitochondrial membrane potential   │        │ │
│ │                                        │ was measured using the quenched        │        │ │
│ │                                        │ fluorescence using a high              │        │ │
│ │                                        │ concentration of tetramethylrhodamine, │        │ │
│ │                                        │ ethyl ester (TMRE) as has been         │        │ │
│ │                                        │ previously described [38]. TMRE        │        │ │
│ │                                        │ fluorescence will self-quench upon     │        │ │
│ │                                        │ accumulation in the mitochondrial      │        │ │
│ │                                        │ matrix at high concentrations. As      │        │ │
│ │                                        │ such, lowering the membrane potential  │        │ │
│ │                                        │ will decrease dye uptake and           │        │ │
│ │                                        │ self-quenching, thereby increasing the │        │ │
│ │                                        │ observed fluorescent signal.           │        │ │
│ │                                        │ Mitochondria isolated from rat liver   │        │ │
│ │                                        │ or rat heart (0.6 mg/mL) were          │        │ │
│ │                                        │ incubated in MAS buffer supplemented   │        │ │
│ │                                        │ with $0.001\%$ BSA, 4 mM ADP, 5 mM     │        │ │
│ │                                        │ succinate, 2 µM rotenone, and 5 µM     │        │ │
│ │                                        │ TMRE at 37°C for 10 minutes in a       │        │ │
│ │                                        │ black-walled 96-well microplate        │        │ │
│ │                                        │ shielded from light. After incubation, │        │ │
│ │                                        │ fluorescence was measured              │        │ │
│ │                                        │ (549ex$\frac{.}{575}$em.) using a      │        │ │
│ │                                        │ Tecan Spark multimode plate reader.    │        │ │
│ │                                        │ Compounds under investigation were     │        │ │
│ │                                        │ added immediately prior to the 10 min. │        │ │
│ │                                        │ incubation period.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Normalization                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All intact and permeabilized cell      │        │ │
│ │                                        │ oxygen consumption rates were          │        │ │
│ │                                        │ normalized to cell number. Cells were  │        │ │
│ │                                        │ immediately fixed after the assay with │        │ │
│ │                                        │ $2\%$ (v/v) paraformaldehyde in PBS    │        │ │
│ │                                        │ and stored at 4°C for up to 14 days.   │        │ │
│ │                                        │ Nuclei were stained with Hoescht       │        │ │
│ │                                        │ (ThermoFisher #33342) overnight at 4°C │        │ │
│ │                                        │ and quantified using the Operetta High │        │ │
│ │                                        │ Content Imaging System (Perkin Elmer). │        │ │
│ │                                        │ All oxygen consumption rates in        │        │ │
│ │                                        │ isolated mitochondria were normalized  │        │ │
│ │                                        │ to microgram of total mitochondrial    │        │ │
│ │                                        │ protein in the microplate well unless  │        │ │
│ │                                        │ otherwise indicated.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Patch-clamp recordings              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Proton conductance across the          │        │ │
│ │                                        │ mitochondrial inner membrane was       │        │ │
│ │                                        │ conducted on mitoplasts derived from   │        │ │
│ │                                        │ mouse heart mitochondria as previously │        │ │
│ │                                        │ described [32,39]. Patch-clamp         │        │ │
│ │                                        │ recording was performed from isolated  │        │ │
│ │                                        │ heart mitoplasts of mice. The          │        │ │
│ │                                        │ mitoplasts used for patch-clamp        │        │ │
│ │                                        │ experiments were 3–5 μm in diameter    │        │ │
│ │                                        │ and typically had membrane             │        │ │
│ │                                        │ capacitances of 0.3–1.2 pF. Both the   │        │ │
│ │                                        │ bath and pipette solutions were        │        │ │
│ │                                        │ formulated to record H+ currents and   │        │ │
│ │                                        │ contained only salts that dissociate   │        │ │
│ │                                        │ into large anions and cations that are │        │ │
│ │                                        │ normally impermeant through ion        │        │ │
│ │                                        │ channels or transporters. A low pH     │        │ │
│ │                                        │ gradient across the IMM was used (pH   │        │ │
│ │                                        │ 7.5 and 7.0 on the matrix and          │        │ │
│ │                                        │ cytosolic sides, respectively).        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Pipettes were filled with 130 mM       │        │ │
│ │                                        │ tetramethylammonium hydroxide (TMA), 1 │        │ │
│ │                                        │ mM EGTA, 2 mM Tris-HCl, and 100 mM     │        │ │
│ │                                        │ HEPES. pH was adjusted to 7.5 with     │        │ │
│ │                                        │ D-gluconic acid, and tonicity was      │        │ │
│ │                                        │ adjusted to ~360 mmol/kg with sucrose. │        │ │
│ │                                        │ Typically, pipettes had resistances of │        │ │
│ │                                        │ 25–35 MΩ, and the access resistance    │        │ │
│ │                                        │ was 40–75 MΩ. Whole-mitoplast IH was   │        │ │
│ │                                        │ recorded in the bath solution          │        │ │
│ │                                        │ containing 100 mM HEPES and 1 mM EGTA  │        │ │
│ │                                        │ (pH adjusted to 7 with Trizma base,    │        │ │
│ │                                        │ and tonicity adjusted to ~300 mmol/kg  │        │ │
│ │                                        │ with sucrose). All experiments were    │        │ │
│ │                                        │ performed under continuous perfusion   │        │ │
│ │                                        │ of the bath solution. All              │        │ │
│ │                                        │ electrophysiological data presented    │        │ │
│ │                                        │ were acquired at 10 kHz and filtered   │        │ │
│ │                                        │ at 1 kHz.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Hydrogen peroxide efflux            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ H2O2 efflux was measured in isolated   │        │ │
│ │                                        │ mitochondria as described previously   │        │ │
│ │                                        │ [40] using a Tecan Spark multimode     │        │ │
│ │                                        │ plate reader and an Amplex Red-based   │        │ │
│ │                                        │ detection system. Mitochondria (2      │        │ │
│ │                                        │ mg/mL) were incubated in SHE buffer    │        │ │
│ │                                        │ (250 mM sucrose, 10 mM HEPES, 1 mM     │        │ │
│ │                                        │ EGTA, pH 7.2 at 37°C) supplemented     │        │ │
│ │                                        │ with 2.5 μM Amplex Red (ThermoFisher   │        │ │
│ │                                        │ #A12222) and 5 U/mL horseradish        │        │ │
│ │                                        │ peroxidase (ThermoFisher #31491). 10   │        │ │
│ │                                        │ mM succinate was added to the          │        │ │
│ │                                        │ incubation, and the rate of H2O2 was   │        │ │
│ │                                        │ measured over 2–3 minutes. The signal  │        │ │
│ │                                        │ was calibrated to known amounts of     │        │ │
│ │                                        │ H2O2 added on top of isolated          │        │ │
│ │                                        │ mitochondria. Compounds under          │        │ │
│ │                                        │ investigation were pre-incubated with  │        │ │
│ │                                        │ mitochondria in SHE buffer for 2–5     │        │ │
│ │                                        │ minutes prior to the addition of       │        │ │
│ │                                        │ succinate.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Cell culture                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 pre-adipocytes were seeded at   │        │ │
│ │                                        │ 2.5×104 cells/well in 12-well dishes   │        │ │
│ │                                        │ and differentiated as described        │        │ │
│ │                                        │ earlier in the Materials and Methods.  │        │ │
│ │                                        │ On Day 8, cells were changed into      │        │ │
│ │                                        │ maintenance medium (made with DMEM     │        │ │
│ │                                        │ A1443001) with the following changes:  │        │ │
│ │                                        │ $2\%$ (v/v) FBS rather than $10\%$ to  │        │ │
│ │                                        │ reduce protein binding of compounds    │        │ │
│ │                                        │ under investigation, and uniformly     │        │ │
│ │                                        │ labeled [13C6]-glucose (Cambridge      │        │ │
│ │                                        │ Isotope Laboratories #CLM-1396) was    │        │ │
│ │                                        │ used instead of 12C unlabeled glucose. │        │ │
│ │                                        │ BT2 (120 µM) and DNP (40 µM) were      │        │ │
│ │                                        │ added during this step and used at     │        │ │
│ │                                        │ higher concentrations than in other    │        │ │
│ │                                        │ experiments to account for binding to  │        │ │
│ │                                        │ albumin in $2\%$ (v/v) FBS. After 72   │        │ │
│ │                                        │ hr. cells were extracted for GC/MS     │        │ │
│ │                                        │ analysis as described below. A matched │        │ │
│ │                                        │ 12-well dish was used for              │        │ │
│ │                                        │ normalization of metabolite levels to  │        │ │
│ │                                        │ cell number. On the day of the         │        │ │
│ │                                        │ extraction, cells were fixed with      │        │ │
│ │                                        │ $2\%$ (v/v) paraformaldehyde in PBS    │        │ │
│ │                                        │ and stored at 4°C for no less than 7   │        │ │
│ │                                        │ days. Nuclei were stained with Hoescht │        │ │
│ │                                        │ (ThermoFisher #33342) overnight at 4°C │        │ │
│ │                                        │ and quantified using the Operetta High │        │ │
│ │                                        │ Content Imaging System (Perkin Elmer). │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Neonatal rat ventricular myocytes were │        │ │
│ │                                        │ seeded at 4.0×105 cells/well in        │        │ │
│ │                                        │ 12-well dishes coated with $0.1\%$     │        │ │
│ │                                        │ (w/v) gelatin in DMEM/F12 medium       │        │ │
│ │                                        │ described earlier. After 24 hr. medium │        │ │
│ │                                        │ was exchanged into custom DMEM         │        │ │
│ │                                        │ formulated without glucose, glutamine, │        │ │
│ │                                        │ or leucine (Sciencell Laboratories)    │        │ │
│ │                                        │ and supplemented with 10 mM glucose, 2 │        │ │
│ │                                        │ mM GlutaMAX, or 0.8 mM leucine, with a │        │ │
│ │                                        │ uniformly labeled [13C6] label on      │        │ │
│ │                                        │ either glucose or leucine (#CLM-2262). │        │ │
│ │                                        │ After 24 hr. cells were extracted for  │        │ │
│ │                                        │ GC/MS analysis as described below.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Derivatization and mass             │        │ │
│ │                                        │ spectrometry                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Cell preparation and stable isotope    │        │ │
│ │                                        │ tracing measuring incorporation of     │        │ │
│ │                                        │ isotopic labels into polar metabolites │        │ │
│ │                                        │ and palmitate was conducted as         │        │ │
│ │                                        │ previously described [41,42].          │        │ │
│ │                                        │ Metabolite extraction was conducted    │        │ │
│ │                                        │ with a Folch-like extraction with a    │        │ │
│ │                                        │ 5:2:5 ratio of                         │        │ │
│ │                                        │ methanol:water:chloroform. 12-well     │        │ │
│ │                                        │ dishes were kept on ice and quickly    │        │ │
│ │                                        │ washed with ice-cold $0.9\%$ (w/v)     │        │ │
│ │                                        │ NaCl. Cells were then scraped in       │        │ │
│ │                                        │ ice-cold methanol and water containing │        │ │
│ │                                        │ 5 µg/mL norvaline (Sigma #N7502), an   │        │ │
│ │                                        │ internal standard. Chloroform          │        │ │
│ │                                        │ containing 20 µM [U-2H31]-palmitate    │        │ │
│ │                                        │ (Cambridge Isotope Laboratories        │        │ │
│ │                                        │ #DLM-215) as an internal standard was  │        │ │
│ │                                        │ then added to the samples. Samples     │        │ │
│ │                                        │ were then vortexed for 1 min and       │        │ │
│ │                                        │ centrifuged at 10,000g for 5 min at    │        │ │
│ │                                        │ 4°C.                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The polar fraction (top layer) was     │        │ │
│ │                                        │ removed and the samples were dried     │        │ │
│ │                                        │ overnight using a refrigerated         │        │ │
│ │                                        │ CentriVap vacuum concentrator          │        │ │
│ │                                        │ (LabConco). Metabolites (50 nmol to 23 │        │ │
│ │                                        │ pmol) were extracted alongside the     │        │ │
│ │                                        │ cell samples to ensure the signal fell │        │ │
│ │                                        │ within the linear detection range of   │        │ │
│ │                                        │ the instrument. The dried polar        │        │ │
│ │                                        │ metabolites were reconstituted in 20   │        │ │
│ │                                        │ µL of $2\%$ (w/v) methoxyamine in      │        │ │
│ │                                        │ pyridine prior to a 45-min incubation  │        │ │
│ │                                        │ at 37°C. Subsequently, 20 µL of        │        │ │
│ │                                        │ MTBSTFA with $1\%$                     │        │ │
│ │                                        │ tert-butyldimethylchlorosilane was     │        │ │
│ │                                        │ added to samples, followed by an       │        │ │
│ │                                        │ additional 45-min incubation at 37°C.  │        │ │
│ │                                        │ Samples were analyzed using Agilent    │        │ │
│ │                                        │ MassHunter software and FluxFix        │        │ │
│ │                                        │ software (http://fluxfix.science) was  │        │ │
│ │                                        │ used to correct for the abundance of   │        │ │
│ │                                        │ natural heavy isotopes against an      │        │ │
│ │                                        │ in-house reference set of unlabeled    │        │ │
│ │                                        │ metabolite standards [43].             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The lower, organic fraction was dried  │        │ │
│ │                                        │ under air and then solubilized in 500  │        │ │
│ │                                        │ µL of acidified methanol [$2\%$ (v/v)  │        │ │
│ │                                        │ H2SO4 in methanol] for 2 hr. at 50°C   │        │ │
│ │                                        │ to generate fatty acid methyl esters   │        │ │
│ │                                        │ (FAMEs). After this incubation, 100 µL │        │ │
│ │                                        │ of saturated NaCl was added, followed  │        │ │
│ │                                        │ by 500 µL of hexane. This mixture was  │        │ │
│ │                                        │ vortexed for 2 min and the upper       │        │ │
│ │                                        │ hexane layer was collected in a new    │        │ │
│ │                                        │ microfuge tube. An additional 500 µL   │        │ │
│ │                                        │ of hexane was added to the original    │        │ │
│ │                                        │ MeOH/NaCl tube and the process         │        │ │
│ │                                        │ repeated to collect any residual FAMEs │        │ │
│ │                                        │ not obtained by the first addition.    │        │ │
│ │                                        │ The pooled hexane extracts were then   │        │ │
│ │                                        │ dried under airflow and resuspended in │        │ │
│ │                                        │ 75 µL of hexane. FAMEs were analyzed   │        │ │
│ │                                        │ by GC-MS analysis. De novo lipid       │        │ │
│ │                                        │ synthesis was estimated by isotopomer  │        │ │
│ │                                        │ spectral analysis (ISA) [42,44] and    │        │ │
│ │                                        │ calculated using MATLAB software.      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Samples were analyzed using a DB-35    │        │ │
│ │                                        │ column (Agilent Technologies).         │        │ │
│ │                                        │ Information regarding additional       │        │ │
│ │                                        │ technical specifications is available  │        │ │
│ │                                        │ elsewhere [41,42].                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## qPCR                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 adipocytes were plated,         │        │ │
│ │                                        │ maintained, and treated with either    │        │ │
│ │                                        │ BT2 or DNP in 12-well dishes           │        │ │
│ │                                        │ identically to those used for GC/MS    │        │ │
│ │                                        │ analysis. Transcript levels were       │        │ │
│ │                                        │ measured using quantitative polymerase │        │ │
│ │                                        │ chain reaction (qPCR). RNA was         │        │ │
│ │                                        │ extracted using the RNeasy Mini Kit    │        │ │
│ │                                        │ (Qiagen, 74106), and cDNA was          │        │ │
│ │                                        │ generated using the High-Capacity cDNA │        │ │
│ │                                        │ Reverse Transcription Kit (Applied     │        │ │
│ │                                        │ Biosystems, 4368814). The PowerUp SYBR │        │ │
│ │                                        │ Green Master Mix kit (Applied          │        │ │
│ │                                        │ Biosystems, A25743) and a QuantStudio  │        │ │
│ │                                        │ 5 (Applied Biosystems) were used for   │        │ │
│ │                                        │ qPCR analysis. *Relative* gene         │        │ │
│ │                                        │ expression was calculated using the    │        │ │
│ │                                        │ ΔΔCt method with 36b4 as a reference   │        │ │
│ │                                        │ gene.                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Statistical analysis                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All statistical parameters, including  │        │ │
│ │                                        │ the number of replicates (n), can be   │        │ │
│ │                                        │ found in the figure legends.           │        │ │
│ │                                        │ Statistical analyses were performed    │        │ │
│ │                                        │ using Graph Pad Prism 5 software. Data │        │ │
│ │                                        │ are presented as the mean ± SEM unless │        │ │
│ │                                        │ otherwise specified. Individual        │        │ │
│ │                                        │ pairwise comparisons were performed    │        │ │
│ │                                        │ using two-tailed Student’s t-test. For │        │ │
│ │                                        │ experiments involving two or more      │        │ │
│ │                                        │ groups, data were analyzed by one-way, │        │ │
│ │                                        │ repeated measures ANOVA followed by    │        │ │
│ │                                        │ Dunnett’s post-hoc multiple            │        │ │
│ │                                        │ comparisons tests against vehicle      │        │ │
│ │                                        │ controls. Data were assumed to follow  │        │ │
│ │                                        │ a normal distribution (no tests were   │        │ │
│ │                                        │ performed). Values denoted as follows  │        │ │
│ │                                        │ were considered significant: *, $p     │        │ │
│ │                                        │ \leq 0.05$; **, $p \leq 0.01$; ***, $p │        │ │
│ │                                        │ \leq 0.001.$                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 uncouples mitochondria in       │        │ │
│ │                                        │ rodent and human cardiomyocytes        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To identify uncharacterized metabolic  │        │ │
│ │                                        │ targets or mechanisms of BT2 action    │        │ │
│ │                                        │ independent of its inhibitory effect   │        │ │
│ │                                        │ on the BCKDK, we measured the effect   │        │ │
│ │                                        │ of BT2 on the oxygen consumption rate  │        │ │
│ │                                        │ in neonatal rat ventricular myocytes   │        │ │
│ │                                        │ (NRVMs). Acute BT2 administration 5    │        │ │
│ │                                        │ minutes prior to initial measurements  │        │ │
│ │                                        │ revealed a consistent increase in the  │        │ │
│ │                                        │ basal respiration rate (Figs. 1A, B).  │        │ │
│ │                                        │ This increase persisted in the         │        │ │
│ │                                        │ presence of the ATP synthase inhibitor │        │ │
│ │                                        │ oligomycin, but no change was observed │        │ │
│ │                                        │ when measuring the maximal respiratory │        │ │
│ │                                        │ capacity with FCCP. The result mimics  │        │ │
│ │                                        │ the hallmark profile of mitochondrial  │        │ │
│ │                                        │ uncoupling [34,45]: BT2 increased      │        │ │
│ │                                        │ mitochondrial oxygen consumption       │        │ │
│ │                                        │ independently of (or ‘uncoupled’ from) │        │ │
│ │                                        │ ATP synthesis. Indeed, the uncoupling  │        │ │
│ │                                        │ response was preserved when            │        │ │
│ │                                        │ cardiomyocytes were stimulated with    │        │ │
│ │                                        │ norepinephrine (Fig. 1B). Moreover,    │        │ │
│ │                                        │ acute BT2 administration also          │        │ │
│ │                                        │ increased respiration associated with  │        │ │
│ │                                        │ proton leak in iCell human             │        │ │
│ │                                        │ iPSC-derived cardiomyocytes both with  │        │ │
│ │                                        │ and without adrenergic activation      │        │ │
│ │                                        │ (Fig. 1C). Given that BT2 acutely      │        │ │
│ │                                        │ increases oligomycin-insensitive       │        │ │
│ │                                        │ respiration in human and rodent        │        │ │
│ │                                        │ cardiomyocytes, we hypothesized that   │        │ │
│ │                                        │ it can act as a chemical uncoupler.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Chemical uncouplers such as FCCP or    │        │ │
│ │                                        │ 2,4-dinitrophenol (DNP) increase the   │        │ │
│ │                                        │ oxygen consumption rate because they   │        │ │
│ │                                        │ stimulate consumption of the           │        │ │
│ │                                        │ mitochondrial membrane potential       │        │ │
│ │                                        │ independently of ATP synthesis,        │        │ │
│ │                                        │ thereby causing increased activity of  │        │ │
│ │                                        │ the respiratory chain [45]. We         │        │ │
│ │                                        │ therefore measured the resting         │        │ │
│ │                                        │ mitochondrial membrane potential in    │        │ │
│ │                                        │ iCell cardiomyocytes and NRVMs in      │        │ │
│ │                                        │ response to acute, 30–45 min.          │        │ │
│ │                                        │ treatment with BT2 (Figs. 1D, E). In   │        │ │
│ │                                        │ both model systems, fluorescence of    │        │ │
│ │                                        │ the lipophilic cation dye TMRE showed  │        │ │
│ │                                        │ a ~$10\%$ decrease in the steady-state │        │ │
│ │                                        │ membrane potential with little change  │        │ │
│ │                                        │ to mitochondrial morphology in         │        │ │
│ │                                        │ response to BT2. This result could be  │        │ │
│ │                                        │ reproduced by the classic uncoupler    │        │ │
│ │                                        │ DNP. Moreover, the changes observed    │        │ │
│ │                                        │ with BT2 and DNP were qualitatively,   │        │ │
│ │                                        │ but not quantitatively, matched by the │        │ │
│ │                                        │ extreme changes in membrane potential  │        │ │
│ │                                        │ observed from the highly potent        │        │ │
│ │                                        │ uncoupler FCCP. The demonstration that │        │ │
│ │                                        │ BT2 slightly lowers the steady-state   │        │ │
│ │                                        │ membrane potential similarly to DNP    │        │ │
│ │                                        │ aligns with the oxygen consumption     │        │ │
│ │                                        │ results and supports the hypothesis    │        │ │
│ │                                        │ that BT2 can act as a chemical         │        │ │
│ │                                        │ uncoupler.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We further sought to determine whether │        │ │
│ │                                        │ our in vitro cardiomyocyte models      │        │ │
│ │                                        │ behaved similarly to recent in vivo    │        │ │
│ │                                        │ human and rodent studies that show or  │        │ │
│ │                                        │ infer little BCAA oxidation in the     │        │ │
│ │                                        │ heart relative to other substrates     │        │ │
│ │                                        │ [27,28]. We offered NRVMs medium with  │        │ │
│ │                                        │ a uniform 13C6 label on either glucose │        │ │
│ │                                        │ or leucine to measure relative         │        │ │
│ │                                        │ incorporation of each substrate into   │        │ │
│ │                                        │ the TCA cycle (Fig. 1F). Incorporation │        │ │
│ │                                        │ of labeled leucine into the TCA cycle  │        │ │
│ │                                        │ intermediates citrate and malate were  │        │ │
│ │                                        │ more than 10-fold lower than           │        │ │
│ │                                        │ incorporation of labeled glucose. The  │        │ │
│ │                                        │ lack of robust rates of BCAA oxidation │        │ │
│ │                                        │ in this system – in addition to the    │        │ │
│ │                                        │ acute time-frame in which BT2          │        │ │
│ │                                        │ increases in proton leak-associated    │        │ │
│ │                                        │ respiration – suggested a mechanism    │        │ │
│ │                                        │ independent of BCKDK inhibition. As    │        │ │
│ │                                        │ such, we sought to confirm this by     │        │ │
│ │                                        │ using reductionist systems where       │        │ │
│ │                                        │ specific metabolic pathways and        │        │ │
│ │                                        │ reactions could be isolated.           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 is a chemical uncoupler         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To formally rule out the involvement   │        │ │
│ │                                        │ of the BCKDK in the uncoupling         │        │ │
│ │                                        │ phenotype observed in rat and human    │        │ │
│ │                                        │ cardiomyocytes, we measured the acute  │        │ │
│ │                                        │ effects of the compound on isolated    │        │ │
│ │                                        │ mitochondria. Isolated mitochondria    │        │ │
│ │                                        │ are a well-defined system that can be  │        │ │
│ │                                        │ used to isolate specific metabolic     │        │ │
│ │                                        │ reactions and pathways [34,46]. We     │        │ │
│ │                                        │ first measured respiration in          │        │ │
│ │                                        │ mitochondria offered specific          │        │ │
│ │                                        │ substrates to isolate the effects of   │        │ │
│ │                                        │ BT2 on targeted metabolic pathways     │        │ │
│ │                                        │ that bypass the BCKDK. In isolated     │        │ │
│ │                                        │ liver mitochondria offered pyruvate    │        │ │
│ │                                        │ and malate, acute BT2 treatment 5      │        │ │
│ │                                        │ minutes prior to measurements elicited │        │ │
│ │                                        │ a similar, specific effect on          │        │ │
│ │                                        │ mitochondrial uncoupling as we had     │        │ │
│ │                                        │ observed in intact cells. BT2 caused a │        │ │
│ │                                        │ concentration-dependent increase in    │        │ │
│ │                                        │ respiration associated with proton     │        │ │
│ │                                        │ leak (‘State 4o’), but no change was   │        │ │
│ │                                        │ observed in ADP-stimulated (‘State 3’) │        │ │
│ │                                        │ or FCCP-stimulated (‘State 3u’)        │        │ │
│ │                                        │ respiration (Figs. 2A, B). In liver    │        │ │
│ │                                        │ mitochondria isolated from both rat    │        │ │
│ │                                        │ and mouse, BT2 showed a similar        │        │ │
│ │                                        │ concentration-dependent increase in    │        │ │
│ │                                        │ State 4o respiration irrespective of   │        │ │
│ │                                        │ whether the mitochondria were provided │        │ │
│ │                                        │ pyruvate, glutamate, or succinate as a │        │ │
│ │                                        │ respiratory substrate (Fig. 2C).       │        │ │
│ │                                        │ Depending on the substrate and         │        │ │
│ │                                        │ species, an increase in proton         │        │ │
│ │                                        │ leak-associated respiration was        │        │ │
│ │                                        │ observed at BT2 concentrations as low  │        │ │
│ │                                        │ as 2.5 μM. In mitochondria isolated    │        │ │
│ │                                        │ from rat and mouse hearts, BT2 also    │        │ │
│ │                                        │ acutely increased State 4o respiration │        │ │
│ │                                        │ independent of substrate provided to   │        │ │
│ │                                        │ the mitochondria (Fig. 2D). In total,  │        │ │
│ │                                        │ respiration with isolated mitochondria │        │ │
│ │                                        │ showed that BT2 can uncouple isolated  │        │ │
│ │                                        │ mitochondria at single-digit           │        │ │
│ │                                        │ micromolar concentrations regardless   │        │ │
│ │                                        │ of the respiratory substrate provided. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As in Figure 1, we sought to           │        │ │
│ │                                        │ corroborate our oxygen consumption     │        │ │
│ │                                        │ results with measurements of the       │        │ │
│ │                                        │ mitochondrial membrane potential. We   │        │ │
│ │                                        │ therefore examined whether acute BT2   │        │ │
│ │                                        │ administration would lower the         │        │ │
│ │                                        │ membrane potential in isolated         │        │ │
│ │                                        │ mitochondria by measuring the loss of  │        │ │
│ │                                        │ quenched TMRE fluorescence [47]. The   │        │ │
│ │                                        │ approach was validated by examining    │        │ │
│ │                                        │ the acute effects of oligomycin and    │        │ │
│ │                                        │ FCCP: ATP synthase inhibition by       │        │ │
│ │                                        │ oligomycin increased the membrane      │        │ │
│ │                                        │ potential and further quenched the     │        │ │
│ │                                        │ TMRE signal, whereas the potent        │        │ │
│ │                                        │ uncoupler FCCP caused a substantial    │        │ │
│ │                                        │ loss of the quenched fluorescence      │        │ │
│ │                                        │ (Fig. 3A). As expected, acute BT2      │        │ │
│ │                                        │ treatment lowered the quenched         │        │ │
│ │                                        │ fluorescence of TMRE in both heart and │        │ │
│ │                                        │ liver mitochondria, indicating a       │        │ │
│ │                                        │ reduced membrane potential and further │        │ │
│ │                                        │ suggesting the compound itself is a    │        │ │
│ │                                        │ chemical uncoupler (Fig. 3B).          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The acute increase in State 4o         │        │ │
│ │                                        │ respiration (Fig. 2) and decrease in   │        │ │
│ │                                        │ membrane potential in isolated         │        │ │
│ │                                        │ mitochondria strongly infer that BT2   │        │ │
│ │                                        │ increases proton conductance across    │        │ │
│ │                                        │ the mitochondrial inner membrane [45]. │        │ │
│ │                                        │ However, a definitive, unassailable    │        │ │
│ │                                        │ measure of mitochondrial uncoupling    │        │ │
│ │                                        │ requires direct measurement of the     │        │ │
│ │                                        │ proton current. We therefore conducted │        │ │
│ │                                        │ patch-clamp electrophysiological       │        │ │
│ │                                        │ measurements of the inner membrane in  │        │ │
│ │                                        │ mitoplasts derived from isolated heart │        │ │
│ │                                        │ mitochondria [48]. Indeed, a           │        │ │
│ │                                        │ measurable increase in proton current  │        │ │
│ │                                        │ could be observed across the inner     │        │ │
│ │                                        │ membrane in response to BT2 (Figs. 3C, │        │ │
│ │                                        │ D). Taken together, results from       │        │ │
│ │                                        │ respirometry, TMRE fluorescence, and   │        │ │
│ │                                        │ membrane electrophysiology all point   │        │ │
│ │                                        │ to a chemical uncoupling property of   │        │ │
│ │                                        │ BT2 independent of its effects on BCAA │        │ │
│ │                                        │ metabolism.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 is ~5-fold less potent than DNP │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ With clear evidence that BT2 can act   │        │ │
│ │                                        │ as a chemical uncoupler, we then       │        │ │
│ │                                        │ sought to gauge its potency in         │        │ │
│ │                                        │ relation to the other well-known       │        │ │
│ │                                        │ uncouplers DNP, FCCP, and Bam15.       │        │ │
│ │                                        │ Similar to these chemical uncouplers,  │        │ │
│ │                                        │ BT2 is lipophilic and contains a       │        │ │
│ │                                        │ functional group that can reversibly   │        │ │
│ │                                        │ dissociate with a proton (Fig. 4A). We │        │ │
│ │                                        │ therefore sought to quantify the       │        │ │
│ │                                        │ potency of BT2 by measuring its        │        │ │
│ │                                        │ concentration-response curve for State │        │ │
│ │                                        │ 4o respiration alongside other         │        │ │
│ │                                        │ chemical uncouplers in isolated liver  │        │ │
│ │                                        │ mitochondria (Figs. 4B, C). Similar to │        │ │
│ │                                        │ DNP, BT2 is a far less potent          │        │ │
│ │                                        │ uncoupler than either FCCP or Bam15,   │        │ │
│ │                                        │ and requires >103-fold more compound   │        │ │
│ │                                        │ to elicit a similar change in proton   │        │ │
│ │                                        │ leak-linked respiration (Fig. 4D).     │        │ │
│ │                                        │ Relative to DNP, roughly 5 times the   │        │ │
│ │                                        │ concentration of BT2 is required to    │        │ │
│ │                                        │ elicit the same change in respiration  │        │ │
│ │                                        │ in mitochondria isolated from both rat │        │ │
│ │                                        │ liver (Fig. 4D) and heart (Fig. 4E).   │        │ │
│ │                                        │ Single-point measurements of quenched  │        │ │
│ │                                        │ TMRE fluorescence also show a similar  │        │ │
│ │                                        │ potency profile for BT2 relative to    │        │ │
│ │                                        │ other uncouplers (Fig. 4F), as more    │        │ │
│ │                                        │ BT2 is required to drop the            │        │ │
│ │                                        │ mitochondrial membrane potential to a  │        │ │
│ │                                        │ similar degree relative to other       │        │ │
│ │                                        │ chemical uncouplers. Encouragingly,    │        │ │
│ │                                        │ quantitative comparison of the proton  │        │ │
│ │                                        │ current amplitude (pA/pF) elicited     │        │ │
│ │                                        │ from 100 µM BT2 in                     │        │ │
│ │                                        │ electrophysiological studies (Fig. 3D) │        │ │
│ │                                        │ is 6-fold lower than that from 100 µM  │        │ │
│ │                                        │ DNP [BT2: 2.52 ± 0.53 (S.E.M.; $$n =   │        │ │
│ │                                        │ 5$$); DNP: 15.82 ± 1.28 (S.E.M.; $$n = │        │ │
│ │                                        │ 9$$) [32]]. Altogether, respiration    │        │ │
│ │                                        │ and membrane potential measurements in │        │ │
│ │                                        │ isolated mitochondria show BT2 is      │        │ │
│ │                                        │ three orders of magnitude less potent  │        │ │
│ │                                        │ than Bam15 and FCCP, and broadly       │        │ │
│ │                                        │ 5-fold milder than the well-studied    │        │ │
│ │                                        │ and prototypical uncoupler DNP.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 uncouples via both              │        │ │
│ │                                        │ AAC-dependent and AAC-independent      │        │ │
│ │                                        │ mechanisms                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Chemical uncouplers have at least two  │        │ │
│ │                                        │ distinct mechanisms: (i) a             │        │ │
│ │                                        │ conventional model whereby weak        │        │ │
│ │                                        │ acid/anion cycling across the          │        │ │
│ │                                        │ mitochondrial inner membrane           │        │ │
│ │                                        │ dissipates the proton gradient across  │        │ │
│ │                                        │ the inner membrane [49], and (ii)      │        │ │
│ │                                        │ stimulating proton conductance through │        │ │
│ │                                        │ the ADP/ATP carrier (AAC) by binding   │        │ │
│ │                                        │ to the nucleotide translocation site   │        │ │
│ │                                        │ [32,50,51]. As such, we sought to      │        │ │
│ │                                        │ determine whether BT2 also uncoupled   │        │ │
│ │                                        │ via both AAC-dependent and             │        │ │
│ │                                        │ AAC-independent mechanisms to provide  │        │ │
│ │                                        │ further evidence that it is a          │        │ │
│ │                                        │ conventional chemical uncoupler. We    │        │ │
│ │                                        │ employed both pharmacologic and        │        │ │
│ │                                        │ genetic strategies to inhibit AAC      │        │ │
│ │                                        │ activity and measured BT2-stimulated   │        │ │
│ │                                        │ increases in State 4o respiration. In  │        │ │
│ │                                        │ isolated rat liver mitochondria,       │        │ │
│ │                                        │ inhibition of adenine nucleotide       │        │ │
│ │                                        │ translocation with                     │        │ │
│ │                                        │ carboxyatractyloside (CATR) had a      │        │ │
│ │                                        │ predictable effect of inhibiting       │        │ │
│ │                                        │ ADP-stimulated respiration similarly   │        │ │
│ │                                        │ to oligomycin (Fig. 5A). Quantifying   │        │ │
│ │                                        │ the increase in State 4o respiration   │        │ │
│ │                                        │ from BT2 in the presence and absence   │        │ │
│ │                                        │ of CATR showed that AAC inhibition     │        │ │
│ │                                        │ limited the chemical uncoupling        │        │ │
│ │                                        │ independently of the substrate         │        │ │
│ │                                        │ provided (Figs. 5B, C). To verify if   │        │ │
│ │                                        │ the results could extend to intact     │        │ │
│ │                                        │ cells, we quantified the effect of BT2 │        │ │
│ │                                        │ on respiration in C2C12 myoblasts with │        │ │
│ │                                        │ both Slc25a4 (encoding AAC1) and       │        │ │
│ │                                        │ Slc25a5 (encoding AAC2) genetically    │        │ │
│ │                                        │ ablated (‘double-knockout’ DKO) [32].  │        │ │
│ │                                        │ In both intact (Fig. 5D–F) and         │        │ │
│ │                                        │ permeabilized cells (Fig. 5F), loss of │        │ │
│ │                                        │ Aac1 and Aac2 again resulted in the    │        │ │
│ │                                        │ partial loss of BT2-stimulated         │        │ │
│ │                                        │ uncoupling. In sum, results from both  │        │ │
│ │                                        │ pharmacologic and genetic loss of AAC  │        │ │
│ │                                        │ function point to BT2 having           │        │ │
│ │                                        │ AAC-dependent and AAC-independent      │        │ │
│ │                                        │ mechanisms of mitochondrial uncoupling │        │ │
│ │                                        │ similar to other well-characterized    │        │ │
│ │                                        │ chemical uncouplers.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 phenocopies DNP and lowers      │        │ │
│ │                                        │ mitochondrial H2O2 efflux              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Having demonstrated that BT2 can act   │        │ │
│ │                                        │ as a chemical uncoupler distinct from  │        │ │
│ │                                        │ its inhibition of the BCKDK, we next   │        │ │
│ │                                        │ examined whether BT2 can reproduce     │        │ │
│ │                                        │ hallmark biochemical and physiological │        │ │
│ │                                        │ responses resulting from chemical      │        │ │
│ │                                        │ uncoupling. For example, it is well    │        │ │
│ │                                        │ known that some forms of mitochondrial │        │ │
│ │                                        │ superoxide production are steeply      │        │ │
│ │                                        │ dependent on the mitochondrial         │        │ │
│ │                                        │ membrane potential [40,52]. As such,   │        │ │
│ │                                        │ even mild chemical uncoupling that     │        │ │
│ │                                        │ fractionally lowers the membrane       │        │ │
│ │                                        │ potential can have a profound effect   │        │ │
│ │                                        │ in lowering mitochondrial reactive     │        │ │
│ │                                        │ oxygen species (ROS) production.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Previous work has shown that BT2       │        │ │
│ │                                        │ treatment reduces ROS production in    │        │ │
│ │                                        │ cells ([21]). In in vivo pre-clinical  │        │ │
│ │                                        │ heart failure models, BT2              │        │ │
│ │                                        │ administration preserves cardiac       │        │ │
│ │                                        │ functions known to be sensitive to     │        │ │
│ │                                        │ oxidative stress and protects from     │        │ │
│ │                                        │ ROS-associated I/R and MI injury. ([   │        │ │
│ │                                        │ 12,20,21]). However, in these systems  │        │ │
│ │                                        │ it is difficult to discriminate        │        │ │
│ │                                        │ whether the beneficial effects of BT2  │        │ │
│ │                                        │ result from BCKDK inhibition or other  │        │ │
│ │                                        │ uncharacterized mechanisms. We         │        │ │
│ │                                        │ therefore tested whether BT2 could     │        │ │
│ │                                        │ directly lower mitochondrial           │        │ │
│ │                                        │ superoxide production derived from the │        │ │
│ │                                        │ respiratory chain.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Isolated rat heart mitochondria were   │        │ │
│ │                                        │ offered succinate to generate          │        │ │
│ │                                        │ superoxide resulting from a high       │        │ │
│ │                                        │ proton motive force and reduced CoQ    │        │ │
│ │                                        │ pool (i.e., “reverse electron          │        │ │
│ │                                        │ transport”). Rates of superoxide       │        │ │
│ │                                        │ production (measured as H2O2 efflux)   │        │ │
│ │                                        │ were quantitatively comparable to      │        │ │
│ │                                        │ previous reports [40], and the signal  │        │ │
│ │                                        │ responds appropriately by reporting    │        │ │
│ │                                        │ high rates of superoxide production in │        │ │
│ │                                        │ the presence of antimycin (Fig. 6A, B) │        │ │
│ │                                        │ [53]. As expected, BT2 significantly   │        │ │
│ │                                        │ reduced mitochondrial H2O2 efflux.     │        │ │
│ │                                        │ Importantly, the result could be       │        │ │
│ │                                        │ phenocopied with the chemical          │        │ │
│ │                                        │ uncouplers DNP and FCCP, each of which │        │ │
│ │                                        │ are structurally dissimilar and have   │        │ │
│ │                                        │ no reported effects on the BCKDK. As   │        │ │
│ │                                        │ such, the data indicate that           │        │ │
│ │                                        │ mitochondrial uncoupling could be a    │        │ │
│ │                                        │ mechanism by which BT2 can reduce      │        │ │
│ │                                        │ mitochondrial ROS production           │        │ │
│ │                                        │ independently of BCAA and BCKA         │        │ │
│ │                                        │ metabolism.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 phenocopies DNP and reduces de  │        │ │
│ │                                        │ novo lipogenesis                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Although attenuation of mitochondrial  │        │ │
│ │                                        │ ROS production by chemical uncoupling  │        │ │
│ │                                        │ is a plausible mechanism for the       │        │ │
│ │                                        │ cardioprotection afforded by BT2, it   │        │ │
│ │                                        │ almost certainly cannot explain why    │        │ │
│ │                                        │ BT2 protects from insulin resistance   │        │ │
│ │                                        │ and hepatic steatosis. However,        │        │ │
│ │                                        │ another hallmark response to chemical  │        │ │
│ │                                        │ uncouplers is increased energy         │        │ │
│ │                                        │ expenditure. Uncouplers create a       │        │ │
│ │                                        │ ‘futile cycle’ where dissipation of    │        │ │
│ │                                        │ the mitochondrial membrane potential   │        │ │
│ │                                        │ stimulates respiratory chain activity  │        │ │
│ │                                        │ [45,48]. This shifts the energy        │        │ │
│ │                                        │ balance towards nutrient oxidation and │        │ │
│ │                                        │ away from lipid storage and            │        │ │
│ │                                        │ accumulation. Decades of experimental  │        │ │
│ │                                        │ evidence in rodents and humans support │        │ │
│ │                                        │ this mechanism [54–57], and chemical   │        │ │
│ │                                        │ uncoupling is consistent with the      │        │ │
│ │                                        │ myriad and sometimes rapid effects of  │        │ │
│ │                                        │ BT2 in various metabolic disease       │        │ │
│ │                                        │ models [26,58].                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We examined whether BT2 could          │        │ │
│ │                                        │ phenocopy DNP in increasing energy     │        │ │
│ │                                        │ expenditure and reducing de novo       │        │ │
│ │                                        │ lipogenesis in differentiated 3T3-L1   │        │ │
│ │                                        │ adipocytes. Indeed, acute treatment    │        │ │
│ │                                        │ with either BT2 or DNP increased the   │        │ │
│ │                                        │ basal oxygen consumption rate due to   │        │ │
│ │                                        │ increased proton leak-linked           │        │ │
│ │                                        │ respiration (Fig. 7A, B). We then      │        │ │
│ │                                        │ conducted stable isotope tracing with  │        │ │
│ │                                        │ uniformly labeled 13C6-glucose to      │        │ │
│ │                                        │ further characterize any shared        │        │ │
│ │                                        │ effects of BT2 and DNP. Both compounds │        │ │
│ │                                        │ also increased relative incorporation  │        │ │
│ │                                        │ of glucose into the TCA cycle          │        │ │
│ │                                        │ metabolites citrate and malate (Fig.   │        │ │
│ │                                        │ 7C) and decreased the steady-state     │        │ │
│ │                                        │ abundance of these and other TCA cycle │        │ │
│ │                                        │ intermediates (Fig. 7D), a profile     │        │ │
│ │                                        │ consistent with an increased metabolic │        │ │
│ │                                        │ rate. Taken together, the respirometry │        │ │
│ │                                        │ and GC/MS data demonstrate that BT2    │        │ │
│ │                                        │ can increase energy expenditure via    │        │ │
│ │                                        │ mitochondrial uncoupling.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Lastly, we examined the effect of BT2  │        │ │
│ │                                        │ and DNP on de novo lipogenesis (DNL),  │        │ │
│ │                                        │ reasoning that increased uncoupling    │        │ │
│ │                                        │ would decrease lipid accumulation.     │        │ │
│ │                                        │ Treatment of differentiated 3T3-L1     │        │ │
│ │                                        │ adipocytes for 72 hr. with either BT2  │        │ │
│ │                                        │ or DNP significantly reduced mRNA      │        │ │
│ │                                        │ levels of both a master                │        │ │
│ │                                        │ transcriptional regulator of lipid     │        │ │
│ │                                        │ synthesis (Srebpf1) as well as         │        │ │
│ │                                        │ individual enzymes involved in DNL     │        │ │
│ │                                        │ (Acly, Acaca, Fasn) (Fig. 7E).         │        │ │
│ │                                        │ Importantly, levels of Cpt1a – the     │        │ │
│ │                                        │ gene encoding carnitine                │        │ │
│ │                                        │ palmitoyltransferase-1a, which is      │        │ │
│ │                                        │ rate-controlling for long chain fatty  │        │ │
│ │                                        │ acid oxidation – were unchanged with   │        │ │
│ │                                        │ DNP and increased with BT2. This       │        │ │
│ │                                        │ result demonstrates that the reduction │        │ │
│ │                                        │ in DNL genes is not due to toxicity or │        │ │
│ │                                        │ other experimental artifacts, but      │        │ │
│ │                                        │ rather due to a specific shift away    │        │ │
│ │                                        │ from lipid synthesis.                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ *Beyond* gene expression, we validated │        │ │
│ │                                        │ that BT2 reduced DNL by GC/MS analysis │        │ │
│ │                                        │ of fatty acids. BT2 or DNP treatment   │        │ │
│ │                                        │ for 72 hr. reduced steady state levels │        │ │
│ │                                        │ of myristate (14:0), palmitate (16:0), │        │ │
│ │                                        │ and stearate (18:0) (Fig. 7F).         │        │ │
│ │                                        │ Furthermore, in contrast to increased  │        │ │
│ │                                        │ labeling of TCA cycle intermediates    │        │ │
│ │                                        │ (Fig. 7C), incorporation of            │        │ │
│ │                                        │ 13C6-glucose into palmitate was        │        │ │
│ │                                        │ decreased in response to administering │        │ │
│ │                                        │ either compound (Fig. 7G). To estimate │        │ │
│ │                                        │ the rate of palmitate synthesis, we    │        │ │
│ │                                        │ applied isotopomer spectral analysis   │        │ │
│ │                                        │ (ISA) to model the rate of de novo     │        │ │
│ │                                        │ palmitate synthesis [g(t) parameter]   │        │ │
│ │                                        │ and contribution of glucose-derived    │        │ │
│ │                                        │ carbon to the lipogenic acetyl CoA     │        │ │
│ │                                        │ pool (‘D’ parameter) [44]. As in other │        │ │
│ │                                        │ assays, BT2 and DNP showed qualitative │        │ │
│ │                                        │ similarities as both decreased the     │        │ │
│ │                                        │ estimated rate of DNL but did not      │        │ │
│ │                                        │ appreciably change the ‘D’ parameter   │        │ │
│ │                                        │ (Fig. 7H, I, Supplemental Table 1).    │        │ │
│ │                                        │ Overall, the gene expression,          │        │ │
│ │                                        │ respiration, and mass spectrometry     │        │ │
│ │                                        │ data show that BT2 phenocopies DNP in  │        │ │
│ │                                        │ increasing energy expenditure and      │        │ │
│ │                                        │ lowering de novo lipogenesis. Thus,    │        │ │
│ │                                        │ the results establish chemical         │        │ │
│ │                                        │ uncoupling as a putative mechanism to  │        │ │
│ │                                        │ explain the therapeutic effects of BT2 │        │ │
│ │                                        │ on cardiometabolic disease (Fig. 8).   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## DISCUSSION                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Here we provide evidence that the      │        │ │
│ │                                        │ BCKDK inhibitor BT2 is also a chemical │        │ │
│ │                                        │ uncoupler. Measurements of oxygen      │        │ │
│ │                                        │ consumption, mitochondrial membrane    │        │ │
│ │                                        │ potential, and H+ conductance all show │        │ │
│ │                                        │ BT2 consumes the membrane potential    │        │ │
│ │                                        │ independently of ATP synthesis and     │        │ │
│ │                                        │ uncouples mitochondria. BT2 stimulates │        │ │
│ │                                        │ proton conductance acutely (<5         │        │ │
│ │                                        │ minutes) and in reductionist systems   │        │ │
│ │                                        │ bypassing BCKDK activity (i.e.,        │        │ │
│ │                                        │ isolated mitochondria offered various  │        │ │
│ │                                        │ substrates as well as patch clamp      │        │ │
│ │                                        │ electrophysiology of the mitochondrial │        │ │
│ │                                        │ inner membrane), demonstrating it is a │        │ │
│ │                                        │ bona fide chemical uncoupler           │        │ │
│ │                                        │ independent of BCAA metabolism.        │        │ │
│ │                                        │ Chemical uncoupling is a plausible,    │        │ │
│ │                                        │ unifying mechanism for how BT2 can be  │        │ │
│ │                                        │ therapeutic in various models of       │        │ │
│ │                                        │ cardiovascular and metabolic disease   │        │ │
│ │                                        │ independent of its effects on BCAA     │        │ │
│ │                                        │ metabolism.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ With respect to heart failure, it is   │        │ │
│ │                                        │ generally accepted that excessive      │        │ │
│ │                                        │ mitochondrial ROS production is an     │        │ │
│ │                                        │ important pathological driver of       │        │ │
│ │                                        │ cardiovascular disease [59–62]. A      │        │ │
│ │                                        │ well-known property of uncouplers is   │        │ │
│ │                                        │ limiting mitochondrial superoxide      │        │ │
│ │                                        │ production by lowering the             │        │ │
│ │                                        │ mitochondrial protonmotive force,      │        │ │
│ │                                        │ thereby oxidizing the NADH/NAD+ and    │        │ │
│ │                                        │ QH2/Q pools and lowering the           │        │ │
│ │                                        │ probability of superoxide formation    │        │ │
│ │                                        │ [52,63]. In addition to a direct       │        │ │
│ │                                        │ effect on reducing mitochondrial ROS   │        │ │
│ │                                        │ production from the respiratory chain, │        │ │
│ │                                        │ mitochondrial uncoupling is also       │        │ │
│ │                                        │ likely to have an indirect effect in   │        │ │
│ │                                        │ lowering ROS production by blocking    │        │ │
│ │                                        │ induction of the permeability          │        │ │
│ │                                        │ transition pore (PTP) [64–66]. The     │        │ │
│ │                                        │ mitochondrial membrane potential       │        │ │
│ │                                        │ provides the driving force for calcium │        │ │
│ │                                        │ uptake, and uncoupling mitigates the   │        │ │
│ │                                        │ pathological matrix Ca2+ overload that │        │ │
│ │                                        │ triggers mitochondrial swelling and    │        │ │
│ │                                        │ pathological opening of the PTP        │        │ │
│ │                                        │ [66,67]. Importantly, both FCCP and    │        │ │
│ │                                        │ DNP confer cardioprotection in ex vivo │        │ │
│ │                                        │ models of I/R injury using the         │        │ │
│ │                                        │ Langendorff-perfused rat heart model   │        │ │
│ │                                        │ [68,69], and heterologous expression   │        │ │
│ │                                        │ of UCP1 in the mouse heart protects    │        │ │
│ │                                        │ from ischemic damage and lowers        │        │ │
│ │                                        │ markers of oxidative stress [70].      │        │ │
│ │                                        │ These proof-of-concept studies         │        │ │
│ │                                        │ reinforce the notion that attenuation  │        │ │
│ │                                        │ of ROS production via chemical         │        │ │
│ │                                        │ uncoupling may explain why BT2 could   │        │ │
│ │                                        │ be cardioprotective independent of its │        │ │
│ │                                        │ function as a BCKDK inhibitor.         │        │ │
│ │                                        │ Moreover, it should be reinforced that │        │ │
│ │                                        │ given the steep dependence of ROS      │        │ │
│ │                                        │ production and calcium uptake on the   │        │ │
│ │                                        │ protonmotive force, even mild chemical │        │ │
│ │                                        │ uncoupling that fractionally lowers    │        │ │
│ │                                        │ the membrane potential can have a      │        │ │
│ │                                        │ substantive effect in lowering         │        │ │
│ │                                        │ mitochondrial reactive oxygen species  │        │ │
│ │                                        │ (ROS) production [40,52].              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Regarding metabolic disease, it is     │        │ │
│ │                                        │ well known that administration of      │        │ │
│ │                                        │ chemical uncouplers and the resultant  │        │ │
│ │                                        │ increase in energy expenditure can     │        │ │
│ │                                        │ reduce insulin resistance, obesity,    │        │ │
│ │                                        │ and hepatic steatosis in preclinical   │        │ │
│ │                                        │ rodent models [54,71]. In fact, DNP    │        │ │
│ │                                        │ was an effective anti-obesity          │        │ │
│ │                                        │ treatment in the 1930s, but a poor     │        │ │
│ │                                        │ safety profile and narrow therapeutic  │        │ │
│ │                                        │ window – rather than a lack of         │        │ │
│ │                                        │ efficacy – discontinued its clinical   │        │ │
│ │                                        │ use [72,73]. Indeed, in vivo           │        │ │
│ │                                        │ administration of BT2 in rodents       │        │ │
│ │                                        │ qualitatively mimics the effect of     │        │ │
│ │                                        │ other chemical uncouplers. In various  │        │ │
│ │                                        │ preclinical models, BT2 is protective  │        │ │
│ │                                        │ from glucose intolerance, insulin      │        │ │
│ │                                        │ insensitivity, triglyceride            │        │ │
│ │                                        │ accumulation, and hepatic inflammation │        │ │
│ │                                        │ similarly to DNP derivatives or Bam15  │        │ │
│ │                                        │ [22,24,26,29,58,74,75]. Several        │        │ │
│ │                                        │ reports demonstrate BT2 administration │        │ │
│ │                                        │ does not change body weight            │        │ │
│ │                                        │ [22,24,29]. However, this may be may   │        │ │
│ │                                        │ be consistent with a mild uncoupler    │        │ │
│ │                                        │ roughly five-fold less potent than     │        │ │
│ │                                        │ DNP, and BT2 promotes a slight         │        │ │
│ │                                        │ reduction in the respiratory exchange  │        │ │
│ │                                        │ ratio in Zucker fatty rats [22].       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The identification of a chemical       │        │ │
│ │                                        │ uncoupling function for BT2 can        │        │ │
│ │                                        │ readily explain some phenomena that    │        │ │
│ │                                        │ are difficult to reconcile with a      │        │ │
│ │                                        │ primary effect on BCAA metabolism. For │        │ │
│ │                                        │ example, previous reports show BT2     │        │ │
│ │                                        │ elicits a rapid euglycemic effect in   │        │ │
│ │                                        │ glucose clamp studies less than an     │        │ │
│ │                                        │ hour after administration [26].        │        │ │
│ │                                        │ Although this time frame is likely     │        │ │
│ │                                        │ inconsistent with remodeling of BCAA   │        │ │
│ │                                        │ metabolism, it is consistent with      │        │ │
│ │                                        │ prior work showing acute effects on    │        │ │
│ │                                        │ energy expenditure by DNP [58].        │        │ │
│ │                                        │ Moreover, our demonstration that DNP   │        │ │
│ │                                        │ phenocopies BT2 in altering gene       │        │ │
│ │                                        │ expression related to lipid metabolism │        │ │
│ │                                        │ suggests that chemical uncoupling      │        │ │
│ │                                        │ could also explain why BT2 treatment   │        │ │
│ │                                        │ blocks phosphorylation of acetyl CoA   │        │ │
│ │                                        │ carboxylase at multiple sites in a     │        │ │
│ │                                        │ manner not consistent with PP2Cm       │        │ │
│ │                                        │ overexpression [22].                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A critical aspect of our finding that  │        │ │
│ │                                        │ BT2 is a chemical uncoupler is         │        │ │
│ │                                        │ determining whether the in vitro       │        │ │
│ │                                        │ concentrations required to stimulate   │        │ │
│ │                                        │ uncoupling are relevant for in vivo    │        │ │
│ │                                        │ studies. Our observation that BT2      │        │ │
│ │                                        │ concentrations as low as 2.5μM         │        │ │
│ │                                        │ increase State 4o respiration raise    │        │ │
│ │                                        │ the possibility that BT2 could elicit  │        │ │
│ │                                        │ a mild uncoupling effect given that    │        │ │
│ │                                        │ the concentrations achieved in vivo    │        │ │
│ │                                        │ likely approach, if not surpass, the   │        │ │
│ │                                        │ half-maximal inhibitory concentration  │        │ │
│ │                                        │ for BCKDK inhibition (IC50 = 3–4μM)    │        │ │
│ │                                        │ [23]. Peak circulating plasma          │        │ │
│ │                                        │ concentrations of BT2 (~1.0 mM for 40  │        │ │
│ │                                        │ mg/kg; ~1.8 mM for 120 mg/kg) [76] and │        │ │
│ │                                        │ plasma protein binding measurements    │        │ │
│ │                                        │ ($99.3\%$ protein bound) [23] suggest  │        │ │
│ │                                        │ maximal, free BT2 concentrations reach │        │ │
│ │                                        │ single-digit micromolar concentrations │        │ │
│ │                                        │ and above. Moreover, pharmacokinetic   │        │ │
│ │                                        │ (PK) data indicate a longer half-life  │        │ │
│ │                                        │ in plasma relative to DNP and a        │        │ │
│ │                                        │ clearance profile in plasma more       │        │ │
│ │                                        │ similar to a controlled-release DNP    │        │ │
│ │                                        │ analog [58,76]. Although tissue        │        │ │
│ │                                        │ concentrations are a far more          │        │ │
│ │                                        │ informative parameter, it is likely    │        │ │
│ │                                        │ that BT2 would behave similarly to DNP │        │ │
│ │                                        │ as a lipophilic, membrane-targeting    │        │ │
│ │                                        │ drug that can accumulate in tissues at │        │ │
│ │                                        │ concentrations at the same order of    │        │ │
│ │                                        │ magnitude as circulating plasma levels │        │ │
│ │                                        │ [58,77]. Our demonstration that BT2 is │        │ │
│ │                                        │ roughly a five-fold weaker uncoupler   │        │ │
│ │                                        │ than DNP may help explain why the drug │        │ │
│ │                                        │ is tolerable at doses that would be    │        │ │
│ │                                        │ egregiously toxic for DNP. In total,   │        │ │
│ │                                        │ available PK data support that         │        │ │
│ │                                        │ chemical uncoupling should be a        │        │ │
│ │                                        │ relevant, in vivo mechanism for BT2.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In addition to chemical uncoupling, it │        │ │
│ │                                        │ may be that other off-target effects   │        │ │
│ │                                        │ of BT2 contribute to observed in vitro │        │ │
│ │                                        │ and in vivo phenotypes. For example,   │        │ │
│ │                                        │ recent reports highlight shared        │        │ │
│ │                                        │ pharmacology between angiotensin II    │        │ │
│ │                                        │ type 1 receptor blockers (ARBs) and    │        │ │
│ │                                        │ BT2 [78]. Encouragingly, regulation of │        │ │
│ │                                        │ the renin-angiotensin system may       │        │ │
│ │                                        │ mechanistically explain the effect of  │        │ │
│ │                                        │ BT2 on blood pressure despite Bckdk    │        │ │
│ │                                        │ ablation [27]. Additional work         │        │ │
│ │                                        │ suggests that BCKAs can inhibit the    │        │ │
│ │                                        │ mitochondrial pyruvate carrier [79].   │        │ │
│ │                                        │ As BT2 acts as a branched-chain        │        │ │
│ │                                        │ 2-oxoacid analog, it may also inhibit  │        │ │
│ │                                        │ the MPC or other mitochondrial         │        │ │
│ │                                        │ transporters or dehydrogenases. In     │        │ │
│ │                                        │ fact, an inhibitory effect on pyruvate │        │ │
│ │                                        │ metabolism could explain our           │        │ │
│ │                                        │ observation that BT2 stimulates Cpt1a  │        │ │
│ │                                        │ expression in differentiated 3T3-L1    │        │ │
│ │                                        │ adipocytes while DNP does not [80].    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In summary, our data suggest that      │        │ │
│ │                                        │ chemical uncoupling by BT2 can explain │        │ │
│ │                                        │ many of the observed therapeutic       │        │ │
│ │                                        │ benefits attributed to enhanced BCKDH  │        │ │
│ │                                        │ activity, and encourage exploration of │        │ │
│ │                                        │ alternative hypotheses for existing    │        │ │
│ │                                        │ data. For example, overexpression of   │        │ │
│ │                                        │ the PP2Cm can reproduce some of the    │        │ │
│ │                                        │ beneficial effects of BT2, but it is   │        │ │
│ │                                        │ unclear to what extent this is due to  │        │ │
│ │                                        │ BCKDH activity or other targets due to │        │ │
│ │                                        │ enzyme promiscuity [22,81]. It may     │        │ │
│ │                                        │ also be that the insulin-sensitizing   │        │ │
│ │                                        │ effects of sodium phenylbutyrate [25]  │        │ │
│ │                                        │ – a lipophilic weak acid – are         │        │ │
│ │                                        │ somewhat attributable to chemical      │        │ │
│ │                                        │ uncoupling. Perhaps the strongest      │        │ │
│ │                                        │ evidence against an alternative role   │        │ │
│ │                                        │ for BT2 is the demonstration that the  │        │ │
│ │                                        │ drug does not provide cardioprotection │        │ │
│ │                                        │ in whole-body Bckdk−/− mice [27].      │        │ │
│ │                                        │ However, these animals are             │        │ │
│ │                                        │ characterized by developmental         │        │ │
│ │                                        │ impairments, neurological defects, and │        │ │
│ │                                        │ growth abnormalities that may warrant  │        │ │
│ │                                        │ cautious interpretation of results     │        │ │
│ │                                        │ [27,82]. Nonetheless, the data         │        │ │
│ │                                        │ demonstrating that BT2 is a chemical   │        │ │
│ │                                        │ uncoupler (i) reinforces the           │        │ │
│ │                                        │ therapeutic promise of chemical        │        │ │
│ │                                        │ uncoupling for a myriad of             │        │ │
│ │                                        │ cardiovascular and metabolic diseases, │        │ │
│ │                                        │ and (ii) further highlights the        │        │ │
│ │                                        │ importance of understanding to what    │        │ │
│ │                                        │ extent BCAA accumulation is causative  │        │ │
│ │                                        │ or associative in cardiovascular and   │        │ │
│ │                                        │ metabolic disease pathogenesis.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. McGarrah R.W., White P.J..          │        │ │
│ │                                        │ **Branched-chain amino acids in        │        │ │
│ │                                        │ cardiovascular disease.**. *Nature     │        │ │
│ │                                        │ Reviews. Cardiology* (2023.0) **20**   │        │ │
│ │                                        │ 77-89. DOI: 10.1038/S41569-022-00760-3 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. White P.J., Newgard C.B..           │        │ │
│ │                                        │ **Branched-chain amino acids in        │        │ │
│ │                                        │ disease.**. *Science (New York, N.Y.)* │        │ │
│ │                                        │ (2019.0) **363** 582-3. DOI:           │        │ │
│ │                                        │ 10.1126/SCIENCE.AAV0558                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Sun H., Wang Y.. **Branched chain   │        │ │
│ │                                        │ amino acid metabolic reprogramming in  │        │ │
│ │                                        │ heart failure.**. *Biochimica et       │        │ │
│ │                                        │ Biophysica Acta (BBA) - Molecular      │        │ │
│ │                                        │ Basis of Disease* (2016.0) **1862**    │        │ │
│ │                                        │ 2270-5. DOI:                           │        │ │
│ │                                        │ 10.1016/J.BBADIS.2016.09.009           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Neinast M., Murashige D., Arany Z.. │        │ │
│ │                                        │ *Branched Chain Amino Acids.* (2019.0) │        │ │
│ │                                        │ **81** 139-64. DOI:                    │        │ │
│ │                                        │ 10.1146/Annurev-Physiol-020518-114455  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Vanweert F., Schrauwen P., Phielix  │        │ │
│ │                                        │ E.. **Role of branched-chain amino     │        │ │
│ │                                        │ acid metabolism in the pathogenesis of │        │ │
│ │                                        │ obesity and type 2 diabetes-related    │        │ │
│ │                                        │ metabolic disturbances BCAA metabolism │        │ │
│ │                                        │ in type 2 diabetes.**. *Nutrition &    │        │ │
│ │                                        │ Diabetes* (2022.0) **12** 1-13. DOI:   │        │ │
│ │                                        │ 10.1038/s41387-022-00213-3             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Felig P., Marliss E., Cahill G.F..  │        │ │
│ │                                        │ **Plasma amino acid levels and insulin │        │ │
│ │                                        │ secretion in obesity.**. *The New      │        │ │
│ │                                        │ England Journal of Medicine* (1969.0)  │        │ │
│ │                                        │ **281** 811-6. DOI:                    │        │ │
│ │                                        │ 10.1056/NEJM196910092811503            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. White P.J., McGarrah R.W., Herman   │        │ │
│ │                                        │ M.A., Bain J.R., Shah S.H., Newgard    │        │ │
│ │                                        │ C.B.. **Insulin action, type 2         │        │ │
│ │                                        │ diabetes, and branched-chain amino     │        │ │
│ │                                        │ acids: A two-way street.**. *Molecular │        │ │
│ │                                        │ Metabolism* (2021.0) **52**. DOI:      │        │ │
│ │                                        │ 10.1016/J.MOLMET.2021.101261           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Newgard C.B., An J., Bain J.R.,     │        │ │
│ │                                        │ Muehlbauer M.J., Stevens R.D., Lien    │        │ │
│ │                                        │ L.F.. **A branched-chain amino         │        │ │
│ │                                        │ acid-related metabolic signature that  │        │ │
│ │                                        │ differentiates obese and lean humans   │        │ │
│ │                                        │ and contributes to insulin             │        │ │
│ │                                        │ resistance.**. *Cell Metabolism*       │        │ │
│ │                                        │ (2009.0) **9** 311-26. DOI:            │        │ │
│ │                                        │ 10.1016/J.CMET.2009.02.002             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Wang T.J., Larson M.G., Vasan R.S., │        │ │
│ │                                        │ Cheng S., Rhee E.P., McCabe E..        │        │ │
│ │                                        │ **Metabolite profiles and the risk of  │        │ │
│ │                                        │ developing diabetes.**. *Nature        │        │ │
│ │                                        │ Medicine* (2011.0) **17** 448-53. DOI: │        │ │
│ │                                        │ 10.1038/nm.2307                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Flores-Guerrero J.L., Groothof D., │        │ │
│ │                                        │ Connelly M.A., Otvos J.D., Bakker      │        │ │
│ │                                        │ S.J.L., Dullaart R.P.F..               │        │ │
│ │                                        │ **Concentration of branched-chain      │        │ │
│ │                                        │ amino acids is a strong risk marker    │        │ │
│ │                                        │ for incident hypertension.**.          │        │ │
│ │                                        │ *Hypertension* (2019.0) **74**         │        │ │
│ │                                        │ 1428-35. DOI:                          │        │ │
│ │                                        │ 10.1161/HYPERTENSIONAHA.119.13735      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Tobias D.K., Lawler P.R., Harada   │        │ │
│ │                                        │ P.H., Demler O. V., Ridker P.M.,       │        │ │
│ │                                        │ Manson J.A.E.. **Circulating           │        │ │
│ │                                        │ Branched-Chain Amino Acids and         │        │ │
│ │                                        │ Incident Cardiovascular Disease in a   │        │ │
│ │                                        │ Prospective Cohort of US Women.        │        │ │
│ │                                        │ Circulation.**. *Genomic and Precision │        │ │
│ │                                        │ Medicine* (2018.0) **11** e002157.     │        │ │
│ │                                        │ DOI: 10.1161/CIRCGEN.118.002157/-/DC1  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Sun H., Olson K.C., Gao C.,        │        │ │
│ │                                        │ Prosdocimo D.A., Zhou M., Wang Z..     │        │ │
│ │                                        │ **Catabolic defect of branched-chain   │        │ │
│ │                                        │ amino acids promotes heart failure.**. │        │ │
│ │                                        │ *Circulation* (2016.0) **133**         │        │ │
│ │                                        │ 2038-49. DOI:                          │        │ │
│ │                                        │ 10.1161/CIRCULATIONAHA.115.020226/-/D… │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Bhattacharya S., Granger C.B.,     │        │ │
│ │                                        │ Craig D., Haynes C., Bain J., Stevens  │        │ │
│ │                                        │ R.D.. **Validation of the association  │        │ │
│ │                                        │ between a branched chain amino acid    │        │ │
│ │                                        │ metabolite profile and extremes of     │        │ │
│ │                                        │ coronary artery disease in patients    │        │ │
│ │                                        │ referred for cardiac                   │        │ │
│ │                                        │ catheterization.**. *Atherosclerosis*  │        │ │
│ │                                        │ (2014.0) **232** 191-6. DOI:           │        │ │
│ │                                        │ 10.1016/j.atherosclerosis.2013.10.036  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Portero V., Nicol T., Podliesna    │        │ │
│ │                                        │ S., Marchal G.A., Baartscheer A.,      │        │ │
│ │                                        │ Casini S.. **Chronically elevated      │        │ │
│ │                                        │ branched chain amino acid levels are   │        │ │
│ │                                        │ pro-arrhythmic.**. *Cardiovascular     │        │ │
│ │                                        │ Research* (2022.0) **118** 1742. DOI:  │        │ │
│ │                                        │ 10.1093/CVR/CVAB207                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Shah S.H., Sun J.L., Stevens R.D., │        │ │
│ │                                        │ Bain J.R., Muehlbauer M.J., Pieper     │        │ │
│ │                                        │ K.S.. **Baseline metabolomic profiles  │        │ │
│ │                                        │ predict cardiovascular events in       │        │ │
│ │                                        │ patients at risk for coronary artery   │        │ │
│ │                                        │ disease.**. *American Heart Journal*   │        │ │
│ │                                        │ (2012.0) **163** 844-850. DOI:         │        │ │
│ │                                        │ 10.1016/J.AHJ.2012.02.005              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Lu G., Sun H., She P., Youn J.Y.,  │        │ │
│ │                                        │ Warburton S., Ping P.. **Protein       │        │ │
│ │                                        │ phosphatase 2Cm is a critical          │        │ │
│ │                                        │ regulator of branched-chain amino acid │        │ │
│ │                                        │ catabolism in mice and cultured        │        │ │
│ │                                        │ cells.**. *The Journal of Clinical     │        │ │
│ │                                        │ Investigation* (2009.0) **119**        │        │ │
│ │                                        │ 1678-87. DOI: 10.1172/JCI38151         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. Harris R.A., Joshi M., Jeoung      │        │ │
│ │                                        │ N.H., Obayashi M.. **Overview of the   │        │ │
│ │                                        │ molecular and biochemical basis of     │        │ │
│ │                                        │ branched-chain amino acid              │        │ │
│ │                                        │ catabolism.**. *The Journal of         │        │ │
│ │                                        │ Nutrition* (2005.0) **135**. DOI:      │        │ │
│ │                                        │ 10.1093/JN/135.6.1527S                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Cummings N.E., Williams E.M.,      │        │ │
│ │                                        │ Kasza I., Konon E.N., Schaid M.D.,     │        │ │
│ │                                        │ Schmidt B.A.. **Restoration of         │        │ │
│ │                                        │ metabolic health by decreased          │        │ │
│ │                                        │ consumption of branched-chain amino    │        │ │
│ │                                        │ acids.**. *The Journal of Physiology*  │        │ │
│ │                                        │ (2018.0) **596** 623-45. DOI:          │        │ │
│ │                                        │ 10.1113/JP275075                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Wang W., Zhang F., Xia Y., Zhao    │        │ │
│ │                                        │ S., Yan W., Wang H.. **Defective       │        │ │
│ │                                        │ branched chain amino acid catabolism   │        │ │
│ │                                        │ contributes to cardiac dysfunction and │        │ │
│ │                                        │ remodeling following myocardial        │        │ │
│ │                                        │ infarction.**. *American Journal of    │        │ │
│ │                                        │ Physiology. Heart and Circulatory      │        │ │
│ │                                        │ Physiology* (2016.0) **311** H1160-9.  │        │ │
│ │                                        │ DOI: 10.1152/AJPHEART.00114.2016       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. Li T., Zhang Z., Kolwicz S.C.,     │        │ │
│ │                                        │ Raftery D., Sun H., Correspondence     │        │ │
│ │                                        │ R.T.. **Defective Branched-Chain Amino │        │ │
│ │                                        │ Acid Catabolism Disrupts Glucose       │        │ │
│ │                                        │ Metabolism and Sensitizes the Heart to │        │ │
│ │                                        │ Ischemia-Reperfusion Injury.**. *Cell  │        │ │
│ │                                        │ Metabolism* (2017.0) **25** 374-85.    │        │ │
│ │                                        │ DOI: 10.1016/j.cmet.2016.11.005        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Lian K., Guo X., Wang Q., Liu Y.,  │        │ │
│ │                                        │ Wang R.T., Gao C.. **PP2Cm             │        │ │
│ │                                        │ overexpression alleviates MI/R injury  │        │ │
│ │                                        │ mediated by a BCAA catabolism defect   │        │ │
│ │                                        │ and oxidative stress in diabetic       │        │ │
│ │                                        │ mice.**. *European Journal of          │        │ │
│ │                                        │ Pharmacology* (2020.0) **866**. DOI:   │        │ │
│ │                                        │ 10.1016/J.EJPHAR.2019.172796           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. White P.J., McGarrah R.W.,         │        │ │
│ │                                        │ Grimsrud P.A., Tso S.C., Yang W.H.,    │        │ │
│ │                                        │ Haldeman J.M.. **The BCKDH Kinase and  │        │ │
│ │                                        │ Phosphatase Integrate BCAA and Lipid   │        │ │
│ │                                        │ Metabolism via Regulation of           │        │ │
│ │                                        │ ATP-Citrate Lyase.**. *Cell            │        │ │
│ │                                        │ Metabolism* (2018.0) **27** 1281-1293. │        │ │
│ │                                        │ DOI: 10.1016/J.CMET.2018.04.015        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Tso S.C., Gui W.J., Wu C.Y.,       │        │ │
│ │                                        │ Chuang J.L., Qi X., Skvorak K.J..      │        │ │
│ │                                        │ **Benzothiophene Carboxylate           │        │ │
│ │                                        │ Derivatives as Novel Allosteric        │        │ │
│ │                                        │ Inhibitors of Branched-chain           │        │ │
│ │                                        │ α-Ketoacid Dehydrogenase Kinase.**.    │        │ │
│ │                                        │ *The Journal of Biological Chemistry*  │        │ │
│ │                                        │ (2014.0) **289** 20583. DOI:           │        │ │
│ │                                        │ 10.1074/JBC.M114.569251                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Zhou M., Shao J., Wu C.Y., Shu L., │        │ │
│ │                                        │ Dong W., Liu Y.. **Targeting BCAA      │        │ │
│ │                                        │ catabolism to treat obesity-associated │        │ │
│ │                                        │ insulin resistance.**. *Diabetes*      │        │ │
│ │                                        │ (2019.0) **68** 1730-46. DOI:          │        │ │
│ │                                        │ 10.2337/DB18-0927/-/DC1                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Vanweert F., Neinast M., Tapia     │        │ │
│ │                                        │ E.E., van de Weijer T., Hoeks J.,      │        │ │
│ │                                        │ Schrauwen-Hinderling V.B.. **A         │        │ │
│ │                                        │ randomized placebo-controlled clinical │        │ │
│ │                                        │ trial for pharmacological activation   │        │ │
│ │                                        │ of BCAA catabolism in patients with    │        │ │
│ │                                        │ type 2 diabetes.**. *Nature            │        │ │
│ │                                        │ Communications* (2022.0) **13**. DOI:  │        │ │
│ │                                        │ 10.1038/S41467-022-31249-9             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Bollinger E., Peloquin M., Libera  │        │ │
│ │                                        │ J., Albuquerque B., Pashos E.,         │        │ │
│ │                                        │ Shipstone A.. **BDK inhibition acts as │        │ │
│ │                                        │ a catabolic switch to mimic fasting    │        │ │
│ │                                        │ and improve metabolism in mice.**.     │        │ │
│ │                                        │ *Molecular Metabolism* (2022.0)        │        │ │
│ │                                        │ **66**. DOI:                           │        │ │
│ │                                        │ 10.1016/J.MOLMET.2022.101611           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. Murashige D., Jung J.W., Neinast   │        │ │
│ │                                        │ M.D., Levin M.G., Chu Q., Lambert      │        │ │
│ │                                        │ J.P.. **Extra-cardiac BCAA catabolism  │        │ │
│ │                                        │ lowers blood pressure and protects     │        │ │
│ │                                        │ from heart failure.**. *Cell           │        │ │
│ │                                        │ Metabolism* (2022.0) **34** 1749-1764. │        │ │
│ │                                        │ DOI: 10.1016/J.CMET.2022.09.008        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Murashige D., Jang C., Neinast M., │        │ │
│ │                                        │ Edwards J.J., Cowan A., Hyman M.C..    │        │ │
│ │                                        │ **Comprehensive quantification of fuel │        │ │
│ │                                        │ use by the failing and nonfailing      │        │ │
│ │                                        │ human heart.**. *Science (New York,    │        │ │
│ │                                        │ N.Y.)* (2020.0) **370** 364-8. DOI:    │        │ │
│ │                                        │ 10.1126/SCIENCE.ABC8861                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Blair M.C., Neinast M.D., Jang C., │        │ │
│ │                                        │ Chu Q., Jung J.W., Axsom J..           │        │ │
│ │                                        │ **Branched-chain amino acid catabolism │        │ │
│ │                                        │ in muscle affects systemic BCAA levels │        │ │
│ │                                        │ but not insulin resistance.**. *Nature │        │ │
│ │                                        │ Metabolism* (2023.0) **5** 589-606.    │        │ │
│ │                                        │ DOI: 10.1038/S42255-023-00794-Y        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Rubio M., Avitabile D., Fischer    │        │ │
│ │                                        │ K., Emmanuel G., Gude N., Miyamoto S.. │        │ │
│ │                                        │ **Cardioprotective stimuli mediate     │        │ │
│ │                                        │ phosphoinositide 3-kinase and          │        │ │
│ │                                        │ phosphoinositide dependent kinase 1    │        │ │
│ │                                        │ nuclear accumulation in                │        │ │
│ │                                        │ cardiomyocytes.**. *Journal of         │        │ │
│ │                                        │ Molecular and Cellular Cardiology*     │        │ │
│ │                                        │ (2009.0) **47** 96-103. DOI:           │        │ │
│ │                                        │ 10.1016/J.YJMCC.2009.02.022            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Li S., Yokota T., Wang P., ten     │        │ │
│ │                                        │ Hoeve J., Ma F., Le T.M..              │        │ │
│ │                                        │ **Cardiomyocytes disrupt pyrimidine    │        │ │
│ │                                        │ biosynthesis in nonmyocytes to         │        │ │
│ │                                        │ regulate heart repair.**. *The Journal │        │ │
│ │                                        │ of Clinical Investigation* (2022.0)    │        │ │
│ │                                        │ **132**. DOI: 10.1172/JCI149711        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Bertholet A.M., Natale A.M.,       │        │ │
│ │                                        │ Bisignano P., Suzuki J., Fedorenko A., │        │ │
│ │                                        │ Hamilton J.. **Mitochondrial           │        │ │
│ │                                        │ uncouplers induce proton leak by       │        │ │
│ │                                        │ activating AAC and UCP1.**. *Nature*   │        │ │
│ │                                        │ (2022.0) **606** 180-7. DOI:           │        │ │
│ │                                        │ 10.1038/S41586-022-04747-5             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Acín-Pérez R., Montales K.P.,      │        │ │
│ │                                        │ Nguyen K.B., Brownstein A.J., Stiles   │        │ │
│ │                                        │ L., Divakaruni A.S.. **Isolation of    │        │ │
│ │                                        │ Mitochondria from Mouse Tissues for    │        │ │
│ │                                        │ Functional Analysis.**. *Methods in    │        │ │
│ │                                        │ Molecular Biology (Clifton, N.J.)*     │        │ │
│ │                                        │ (2023.0) **2675** 77-96. DOI:          │        │ │
│ │                                        │ 10.1007/978-1-0716-3247-5              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 34. Divakaruni A.S., Jastroch M.. **A  │        │ │
│ │                                        │ practical guide for the analysis,      │        │ │
│ │                                        │ standardization and interpretation of  │        │ │
│ │                                        │ oxygen consumption measurements.**.    │        │ │
│ │                                        │ *Nature Metabolism* (2022.0) **4**     │        │ │
│ │                                        │ 978-94. DOI:                           │        │ │
│ │                                        │ 10.1038/S42255-022-00619-4             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 35. Divakaruni A.S., Paradyse A.,      │        │ │
│ │                                        │ Ferrick D.A., Murphy A.N., Jastroch    │        │ │
│ │                                        │ M.. **Analysis and interpretation of   │        │ │
│ │                                        │ microplate-based oxygen consumption    │        │ │
│ │                                        │ and pH data.**. *Methods in            │        │ │
│ │                                        │ Enzymology,.* (2014.0)                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 36. Yang K., Doan M.T., Stiles L.,     │        │ │
│ │                                        │ Divakaruni A.S.. **Measuring           │        │ │
│ │                                        │ CPT-1-mediated respiration in          │        │ │
│ │                                        │ permeabilized cells and isolated       │        │ │
│ │                                        │ mitochondria.**. *STAR Protocols*      │        │ │
│ │                                        │ (2021.0) **2**. DOI:                   │        │ │
│ │                                        │ 10.1016/J.XPRO.2021.100687             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 37. Rogers G.W., Brand M.D., Petrosyan │        │ │
│ │                                        │ S., Ashok D., Elorza A.A., Ferrick     │        │ │
│ │                                        │ D.A.. **High throughput microplate     │        │ │
│ │                                        │ respiratory measurements using minimal │        │ │
│ │                                        │ quantities of isolated                 │        │ │
│ │                                        │ mitochondria.**. *PLoS ONE* (2011.0).  │        │ │
│ │                                        │ DOI: 10.1371/journal.pone.0021746      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 38. Orr A.L., Ashok D., Sarantos M.R., │        │ │
│ │                                        │ Ng R., Shi T., Gerencser A.A.. **Novel │        │ │
│ │                                        │ Inhibitors of Mitochondrial            │        │ │
│ │                                        │ sn-Glycerol 3-phosphate                │        │ │
│ │                                        │ Dehydrogenase.**. *PLOS ONE* (2014.0)  │        │ │
│ │                                        │ **9** e89938. DOI:                     │        │ │
│ │                                        │ 10.1371/JOURNAL.PONE.0089938           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 39. Bertholet A.M.. **The Use of the   │        │ │
│ │                                        │ Patch-Clamp Technique to Study the     │        │ │
│ │                                        │ Thermogenic Capacity of                │        │ │
│ │                                        │ Mitochondria.**. *Journal of           │        │ │
│ │                                        │ Visualized Experiments : JoVE*         │        │ │
│ │                                        │ (2021.0) **2021**. DOI: 10.3791/62618  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 40. Robb E.L., Hall A.R., Prime T.A.,  │        │ │
│ │                                        │ Eaton S., Szibor M., Viscomi C..       │        │ │
│ │                                        │ **Control of mitochondrial superoxide  │        │ │
│ │                                        │ production by reverse electron         │        │ │
│ │                                        │ transport at complex I.**. *Journal of │        │ │
│ │                                        │ Biological Chemistry* (2018.0). DOI:   │        │ │
│ │                                        │ 10.1074/jbc.RA118.003647               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 41. Vacanti N.M., Divakaruni A.S.,     │        │ │
│ │                                        │ Green C.R., Parker S.J., Henry R.R.,   │        │ │
│ │                                        │ Ciaraldi T.P.. **Regulation of         │        │ │
│ │                                        │ substrate utilization by the           │        │ │
│ │                                        │ mitochondrial pyruvate carrier.**.     │        │ │
│ │                                        │ *Molecular Cell* (2014.0). DOI:        │        │ │
│ │                                        │ 10.1016/j.molcel.2014.09.024           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 42. Cordes T., Metallo C.M..           │        │ │
│ │                                        │ **Quantifying intermediary metabolism  │        │ │
│ │                                        │ and lipogenesis in cultured mammalian  │        │ │
│ │                                        │ cells using stable isotope tracing and │        │ │
│ │                                        │ mass spectrometry.**. *Methods in      │        │ │
│ │                                        │ Molecular Biology,.* (2019.0)          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 43. Trefely S., Ashwell P., Snyder     │        │ │
│ │                                        │ N.W.. **FluxFix: Automatic             │        │ │
│ │                                        │ isotopologue normalization for         │        │ │
│ │                                        │ metabolic tracer analysis.**. *BMC     │        │ │
│ │                                        │ Bioinformatics* (2016.0). DOI:         │        │ │
│ │                                        │ 10.1186/s12859-016-1360-7              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 44. Kharroubi A.T., Masterson T.M.,    │        │ │
│ │                                        │ Aldaghlas T.A., Kennedy K.A., Kelleher │        │ │
│ │                                        │ J.K.. *n.d. Isotopomer spectral        │        │ │
│ │                                        │ analysis of triglyceride fatty acid    │        │ │
│ │                                        │ synthesis in 3T3-Ll cells.*            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 45. Divakaruni A.S., Brand M.D.. **The │        │ │
│ │                                        │ regulation and physiology of           │        │ │
│ │                                        │ mitochondrial proton leak.**.          │        │ │
│ │                                        │ *Physiology (Bethesda, Md.)* (2011.0). │        │ │
│ │                                        │ DOI: 10.1152/physiol.00046.2010        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 46. Brand M.D., Nicholls D.G..         │        │ │
│ │                                        │ **Assessing mitochondrial dysfunction  │        │ │
│ │                                        │ in cells.**. *Biochemical Journal*     │        │ │
│ │                                        │ (2011.0). DOI: 10.1042/BJ20110162      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 47. Orr A.L., Quinlan C.L.,            │        │ │
│ │                                        │ Perevoshchikova I. V., Brand M.D.. **A │        │ │
│ │                                        │ refined analysis of superoxide         │        │ │
│ │                                        │ production by mitochondrial            │        │ │
│ │                                        │ sn-glycerol 3-phosphate                │        │ │
│ │                                        │ dehydrogenase.**. *The Journal of      │        │ │
│ │                                        │ Biological Chemistry* (2012.0) **287** │        │ │
│ │                                        │ 42921-35. DOI: 10.1074/JBC.M112.397828 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 48. Bertholet A.M., Kirichok Y..       │        │ │
│ │                                        │ **Mitochondrial H + Leak and           │        │ │
│ │                                        │ Thermogenesis.**. *Annual Review of    │        │ │
│ │                                        │ Physiology* (2022.0) **84** 381-407.   │        │ │
│ │                                        │ DOI:                                   │        │ │
│ │                                        │ 10.1146/ANNUREV-PHYSIOL-021119-034405  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 49. Nicholls D.G., Ferguson S.J..      │        │ │
│ │                                        │ *Bioenergetics 4.* (2013.0)            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 50. Andreyev A.Y., Bondareva T.O.,     │        │ │
│ │                                        │ Dedukhova V.I., Mokhova E.N.,          │        │ │
│ │                                        │ Skulachev V.P., Volkov N.I..           │        │ │
│ │                                        │ **Carboxyatractylate inhibits the      │        │ │
│ │                                        │ uncoupling effect of free fatty        │        │ │
│ │                                        │ acids.**. *FEBS Letters* (1988.0)      │        │ │
│ │                                        │ **226** 265-9. DOI:                    │        │ │
│ │                                        │ 10.1016/0014-5793(88)81436-4           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 51. Lou P.H., Hansen B.S., Olsen P.H., │        │ │
│ │                                        │ Tullin S., Murphy M.P., Brand M.D..    │        │ │
│ │                                        │ **Mitochondrial uncouplers with an     │        │ │
│ │                                        │ extraordinary dynamic range.**.        │        │ │
│ │                                        │ *Biochemical Journal* (2007.0) **407** │        │ │
│ │                                        │ 129-40. DOI: 10.1042/BJ20070606        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 52. Korshunov S.S., Skulachev V.P.,    │        │ │
│ │                                        │ Starkov A.A.. **High protonic          │        │ │
│ │                                        │ potential actuates a mechanism of      │        │ │
│ │                                        │ production of reactive oxygen species  │        │ │
│ │                                        │ in mitochondria.**. *FEBS Letters*     │        │ │
│ │                                        │ (1997.0) **416** 15-8. DOI:            │        │ │
│ │                                        │ 10.1016/S0014-5793(97)01159-9          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 53. Affourtit C., Quinlan C.L., Brand  │        │ │
│ │                                        │ M.D.. **Measurement of proton leak and │        │ │
│ │                                        │ electron leak in isolated              │        │ │
│ │                                        │ mitochondria.**. *Methods in Molecular │        │ │
│ │                                        │ Biology* (2012.0). DOI:                │        │ │
│ │                                        │ 10.1007/978-1-61779-382-0_11           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 54. Goedeke L., Perry R.J., Shulman    │        │ │
│ │                                        │ G.I.. **Emerging Pharmacological       │        │ │
│ │                                        │ Targets for the Treatment of           │        │ │
│ │                                        │ Nonalcoholic Fatty Liver Disease,      │        │ │
│ │                                        │ Insulin Resistance, and Type 2         │        │ │
│ │                                        │ Diabetes.**. *Annual Review of         │        │ │
│ │                                        │ Pharmacology and Toxicology* (2019.0)  │        │ │
│ │                                        │ **59** 65-87. DOI:                     │        │ │
│ │                                        │ 10.1146/ANNUREV-PHARMTOX-010716-104727 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 55. Childress E.S., Alexopoulos S.J.,  │        │ │
│ │                                        │ Hoehn K.L., Santos W.L.. **Small       │        │ │
│ │                                        │ Molecule Mitochondrial Uncouplers and  │        │ │
│ │                                        │ Their Therapeutic Potential.**.        │        │ │
│ │                                        │ *Journal of Medicinal Chemistry*       │        │ │
│ │                                        │ (2018.0) **61** 4641-55. DOI:          │        │ │
│ │                                        │ 10.1021/ACS.JMEDCHEM.7B01182           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 56. Kajimura S., Saito M.. *A New Era  │        │ │
│ │                                        │ in Brown Adipose Tissue Biology:       │        │ │
│ │                                        │ Molecular Control of Brown Fat         │        │ │
│ │                                        │ Development and Energy Homeostasis.*   │        │ │
│ │                                        │ (2014.0) **76** 225-49. DOI:           │        │ │
│ │                                        │ 10.1146/Annurev-Physiol-021113-170252  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 57. Cannon B., Nedergaard J.. **Brown  │        │ │
│ │                                        │ Adipose Tissue: Function and           │        │ │
│ │                                        │ Physiological Significance.**.         │        │ │
│ │                                        │ *Physiological Reviews* (2004.0). DOI: │        │ │
│ │                                        │ 10.1152/physrev.00015.2003             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 58. Perry R.J., Zhang D., Zhang X.M.,  │        │ │
│ │                                        │ Boyer J.L., Shulman G.I..              │        │ │
│ │                                        │ **Controlled-release mitochondrial     │        │ │
│ │                                        │ protonophore reverses diabetes and     │        │ │
│ │                                        │ protonophore reverses diabetes and     │        │ │
│ │                                        │ steatohepatitis in rats.**. *Science*  │        │ │
│ │                                        │ (2015.0) **347** 1253-6. DOI:          │        │ │
│ │                                        │ 10.1126/science.aaa0672                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 59. Cadenas S.. **ROS and redox        │        │ │
│ │                                        │ signaling in myocardial                │        │ │
│ │                                        │ ischemia-reperfusion injury and        │        │ │
│ │                                        │ cardioprotection.**. *Free Radical     │        │ │
│ │                                        │ Biology and Medicine* (2018.0) **117** │        │ │
│ │                                        │ 76-89. DOI:                            │        │ │
│ │                                        │ 10.1016/J.FREERADBIOMED.2018.01.024    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 60. Peoples J.N., Saraf A., Ghazal N., │        │ │
│ │                                        │ Pham T.T., Kwong J.Q.. **Mitochondrial │        │ │
│ │                                        │ dysfunction and oxidative stress in    │        │ │
│ │                                        │ heart disease.**. *Experimental &      │        │ │
│ │                                        │ Molecular Medicine* (2019.0) **51**    │        │ │
│ │                                        │ 1-13. DOI: 10.1038/s12276-019-0355-7   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 61. Weissman D., Maack C.. **Redox     │        │ │
│ │                                        │ signaling in heart failure and         │        │ │
│ │                                        │ therapeutic implications.**. *Free     │        │ │
│ │                                        │ Radical Biology and Medicine* (2021.0) │        │ │
│ │                                        │ **171** 345-64. DOI:                   │        │ │
│ │                                        │ 10.1016/J.FREERADBIOMED.2021.05.013    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 62. Chouchani E.T., Pell V.R., James   │        │ │
│ │                                        │ A.M., Work L.M., Saeb-Parsy K., Frezza │        │ │
│ │                                        │ C.. **A Unifying Mechanism for         │        │ │
│ │                                        │ Mitochondrial Superoxide Production    │        │ │
│ │                                        │ during Ischemia-Reperfusion Injury.**. │        │ │
│ │                                        │ *Cell Metabolism* (2016.0) **23**      │        │ │
│ │                                        │ 254-63. DOI:                           │        │ │
│ │                                        │ 10.1016/J.CMET.2015.12.009             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 63. Murphy M.P.. **How mitochondria    │        │ │
│ │                                        │ produce reactive oxygen species.**.    │        │ │
│ │                                        │ *The Biochemical Journal* (2009.0)     │        │ │
│ │                                        │ **417** 1-13. DOI: 10.1042/BJ20081386  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 64. Murphy E., Steenbergen C..         │        │ │
│ │                                        │ **Regulation of Mitochondrial Ca2+     │        │ │
│ │                                        │ Uptake.**. *Annual Review of           │        │ │
│ │                                        │ Physiology* (2021.0) **83** 107-26.    │        │ │
│ │                                        │ DOI:                                   │        │ │
│ │                                        │ 10.1146/ANNUREV-PHYSIOL-031920-092419  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 65. Finkel T., Menazza S., Holmström   │        │ │
│ │                                        │ K.M., Parks R.J., Liu J., Sun J..      │        │ │
│ │                                        │ **The ins and outs of mitochondrial    │        │ │
│ │                                        │ calcium.**. *Circulation Research*     │        │ │
│ │                                        │ (2015.0) 1810-9. DOI:                  │        │ │
│ │                                        │ 10.1161/CIRCRESAHA.116.305484          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 66. Bernardi P.. **The mitochondrial   │        │ │
│ │                                        │ permeability transition pore: A        │        │ │
│ │                                        │ mystery solved?**. *Frontiers in       │        │ │
│ │                                        │ Physiology* (2013.0). DOI:             │        │ │
│ │                                        │ 10.3389/fphys.2013.00095               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 67. Reynolds I.J., Hastings T.G..      │        │ │
│ │                                        │ **Glutamate induces the production of  │        │ │
│ │                                        │ reactive oxygen species in cultured    │        │ │
│ │                                        │ forebrain neurons following NMDA       │        │ │
│ │                                        │ receptor activation.**. *Journal of    │        │ │
│ │                                        │ Neuroscience* (1995.0) **15** 3318-27. │        │ │
│ │                                        │ DOI:                                   │        │ │
│ │                                        │ 10.1523/JNEUROSCI.15-05-03318.1995     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 68. Brennan J.P., Southworth R.,       │        │ │
│ │                                        │ Medina R.A., Davidson S.M., Duchen     │        │ │
│ │                                        │ M.R., Shattock M.J.. **Mitochondrial   │        │ │
│ │                                        │ uncoupling, with low concentration     │        │ │
│ │                                        │ FCCP, induces ROS-dependent            │        │ │
│ │                                        │ cardioprotection independent of KATP   │        │ │
│ │                                        │ channel activation.**. *Cardiovascular │        │ │
│ │                                        │ Research* (2006.0) **72** 313-21. DOI: │        │ │
│ │                                        │ 10.1016/J.CARDIORES.2006.07.019        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 69. Minners J., Van Den Bos E.J.,      │        │ │
│ │                                        │ Yellon D.M., Schwalb H., Opie L.H.,    │        │ │
│ │                                        │ Sack M.N.. **Dinitrophenol,            │        │ │
│ │                                        │ cyclosporin A, and trimetazidine       │        │ │
│ │                                        │ modulate preconditioning in the        │        │ │
│ │                                        │ isolated rat heart: Support for a      │        │ │
│ │                                        │ mitochondrial role in                  │        │ │
│ │                                        │ cardioprotection.**. *Cardiovascular   │        │ │
│ │                                        │ Research* (2000.0) **47** 68-73. DOI:  │        │ │
│ │                                        │ 10.1016/S0008-6363(00)00069-9/2/47-1-… │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 70. Hoerter J., Gonzalez-Barroso       │        │ │
│ │                                        │ M.D.M., Couplan E., Mateo P., Gelly    │        │ │
│ │                                        │ C., Cassard-Doulcier A.M..             │        │ │
│ │                                        │ **Mitochondrial Uncoupling Protein 1   │        │ │
│ │                                        │ Expressed in the Heart of Transgenic   │        │ │
│ │                                        │ Mice Protects Against                  │        │ │
│ │                                        │ Ischemic-Reperfusion Damage.**.        │        │ │
│ │                                        │ *Circulation* (2004.0) **110** 528-33. │        │ │
│ │                                        │ DOI:                                   │        │ │
│ │                                        │ 10.1161/01.CIR.0000137824.30476.0E     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 71. Leak M.H.+., Ambre T., Bertholet   │        │ │
│ │                                        │ M., Kirichok Y.. *Annual Review of     │        │ │
│ │                                        │ Physiology* (2021.0). DOI:             │        │ │
│ │                                        │ 10.1146/annurev-physiol-021119         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 72. Harper J.A., Dickinson K., Brand   │        │ │
│ │                                        │ M.D.. **Mitochondrial uncoupling as a  │        │ │
│ │                                        │ target for drug development for the    │        │ │
│ │                                        │ treatment of obesity.**. *Obesity      │        │ │
│ │                                        │ Reviews* (2001.0) **2** 255-65. DOI:   │        │ │
│ │                                        │ 10.1046/J.1467-789X.2001.00043.X       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 73. Grundlingh J., Dargan P.I.,        │        │ │
│ │                                        │ El-Zanfaly M., Wood D.M..              │        │ │
│ │                                        │ **2,4-Dinitrophenol (DNP): A Weight    │        │ │
│ │                                        │ Loss Agent with Significant Acute      │        │ │
│ │                                        │ Toxicity and Risk of Death.**.         │        │ │
│ │                                        │ *Journal of Medical Toxicology*        │        │ │
│ │                                        │ (2011.0) **7** 205. DOI:               │        │ │
│ │                                        │ 10.1007/S13181-011-0162-6              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 74. Abulizi A., Perry R.J., Camporez   │        │ │
│ │                                        │ J.P.G., Jurczak M.J., Petersen K.F.,   │        │ │
│ │                                        │ Aspichueta P.. **A controlled-release  │        │ │
│ │                                        │ mitochondrial protonophore reverses    │        │ │
│ │                                        │ hypertriglyceridemia, nonalcoholic     │        │ │
│ │                                        │ steatohepatitis, and diabetes in       │        │ │
│ │                                        │ lipodystrophic mice.**. *FASEB         │        │ │
│ │                                        │ Journal* (2017.0) **31** 2916-24. DOI: │        │ │
│ │                                        │ 10.1096/fj.201700001R                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 75. Alexopoulos S.J., Chen S.Y.,       │        │ │
│ │                                        │ Brandon A.E., Salamoun J.M., Byrne     │        │ │
│ │                                        │ F.L., Garcia C.J.. **Mitochondrial     │        │ │
│ │                                        │ uncoupler BAM15 reverses diet-induced  │        │ │
│ │                                        │ obesity and insulin resistance in      │        │ │
│ │                                        │ mice.**. *Nature Communications*       │        │ │
│ │                                        │ (2020.0) **11**. DOI:                  │        │ │
│ │                                        │ 10.1038/S41467-020-16298-2             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 76. Voronova V., Sokolov V., Morias    │        │ │
│ │                                        │ Y., Boezelman M.J., Wågberg M.,        │        │ │
│ │                                        │ Henricsson M.. **Evaluation of         │        │ │
│ │                                        │ therapeutic strategies targeting BCAA  │        │ │
│ │                                        │ catabolism using a systems             │        │ │
│ │                                        │ pharmacology model.**. *Frontiers in   │        │ │
│ │                                        │ Pharmacology* (2022.0) **13** 993422.  │        │ │
│ │                                        │ DOI: 10.3389/FPHAR.2022.993422/BIBTEX  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 77. Meyer L.F., Rajadhyaksha P.M.,     │        │ │
│ │                                        │ Shah D.K.. **Physiologically-based     │        │ │
│ │                                        │ pharmacokinetic model for              │        │ │
│ │                                        │ 2,4-dinitrophenol.**. *Journal of      │        │ │
│ │                                        │ Pharmacokinetics and Pharmacodynamics* │        │ │
│ │                                        │ (2022.0) **49** 325-36. DOI:           │        │ │
│ │                                        │ 10.1007/S10928-022-09806-Y             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 78. Liu S., Kormos B.L., Knafels J.D., │        │ │
│ │                                        │ Sahasrabudhe P. V., Rosado A., Sommese │        │ │
│ │                                        │ R.F.. **Structural studies identify    │        │ │
│ │                                        │ angiotensin II receptor blocker-like   │        │ │
│ │                                        │ compounds as branched-chain ketoacid   │        │ │
│ │                                        │ dehydrogenase kinase inhibitors.**.    │        │ │
│ │                                        │ *Journal of Biological Chemistry*      │        │ │
│ │                                        │ (2023.0) **299** 102959. DOI:          │        │ │
│ │                                        │ 10.1016/j.jbc.2023.102959              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 79. Nishi K., Yoshii A., Abell L.,     │        │ │
│ │                                        │ Zhou B., Frausto R., Ritterhoff J..    │        │ │
│ │                                        │ **Branched-chain keto acids inhibit    │        │ │
│ │                                        │ mitochondrial pyruvate carrier and     │        │ │
│ │                                        │ suppress gluconeogenesis in            │        │ │
│ │                                        │ hepatocytes.**. *Cell Reports*         │        │ │
│ │                                        │ (2023.0) **42**. DOI:                  │        │ │
│ │                                        │ 10.1016/J.CELREP.2023.112641           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 80. Hue L., Taegtmeyer H.. **The       │        │ │
│ │                                        │ Randle cycle revisited: A new head for │        │ │
│ │                                        │ an old hat.**. *American Journal of    │        │ │
│ │                                        │ Physiology - Endocrinology and         │        │ │
│ │                                        │ Metabolism* (2009.0). DOI:             │        │ │
│ │                                        │ 10.1152/ajpendo.00093.2009             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 81. Chen M.J., Dixon J.E., Manning G.. │        │ │
│ │                                        │ **Genomics and evolution of protein    │        │ │
│ │                                        │ phosphatases.**. *Science Signaling*   │        │ │
│ │                                        │ (2017.0) **10**. DOI:                  │        │ │
│ │                                        │ 10.1126/SCISIGNAL.AAG1796/SUPPL_FILE/… │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 82. Joshi M.A., Jeoung N.H., Obayashi  │        │ │
│ │                                        │ M., Hattab E.M., Brocken E.G., Liechty │        │ │
│ │                                        │ E.A.. **Impaired growth and            │        │ │
│ │                                        │ neurological abnormalities in          │        │ │
│ │                                        │ branched-chain alpha-keto acid         │        │ │
│ │                                        │ dehydrogenase kinase-deficient         │        │ │
│ │                                        │ mice.**. *The Biochemical Journal*     │        │ │
│ │                                        │ (2006.0) **400** 153-62. DOI:          │        │ │
│ │                                        │ 10.1042/BJ20060869                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 83. Chen M., Gao C., Yu J., Ren S.,    │        │ │
│ │                                        │ Wang M., Wynn R.M.. **Therapeutic      │        │ │
│ │                                        │ Effect of Targeting Branched-Chain     │        │ │
│ │                                        │ Amino Acid Catabolic Flux in           │        │ │
│ │                                        │ Pressure-Overload Induced Heart        │        │ │
│ │                                        │ Failure.**. *Journal of the American   │        │ │
│ │                                        │ Heart Association* (2019.0) **8**.     │        │ │
│ │                                        │ DOI: 10.1161/JAHA.118.011625           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │ title: The BCKDK inhibitor BT2 is a    │        │ │
│ │                                        │ chemical uncoupler that lowers         │        │ │
│ │                                        │ mitochondrial ROS                      │        │ │
│ │                                        │   production and de novo lipogenesis   │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Aracely Acevedo                      │        │ │
│ │                                        │ - Anthony E. Jones                     │        │ │
│ │                                        │ - Bezawit T. Danna                     │        │ │
│ │                                        │ - Rory Turner                          │        │ │
│ │                                        │ - Katrina P. Montales                  │        │ │
│ │                                        │ - Cristiane Benincá                    │        │ │
│ │                                        │ - Karen Reue                           │        │ │
│ │                                        │ - Orian S. Shirihai                    │        │ │
│ │                                        │ - Linsey Stiles                        │        │ │
│ │                                        │ - Martina Wallace                      │        │ │
│ │                                        │ - Yibin Wang                           │        │ │
│ │                                        │ - Ambre M. Bertholet                   │        │ │
│ │                                        │ - Ajit S. Divakaruni                   │        │ │
│ │                                        │ journal: The Journal of Biological     │        │ │
│ │                                        │ Chemistry                              │        │ │
│ │                                        │ year: 2024                             │        │ │
│ │                                        │ pmcid: PMC10910128                     │        │ │
│ │                                        │ doi: 10.1016/j.jbc.2024.105702         │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # The BCKDK inhibitor BT2 is a         │        │ │
│ │                                        │ chemical uncoupler that lowers         │        │ │
│ │                                        │ mitochondrial ROS production and de    │        │ │
│ │                                        │ novo lipogenesis                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Body                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Elevations in circulating levels of    │        │ │
│ │                                        │ the branched-chain amino acids         │        │ │
│ │                                        │ (BCAAs), leucine, isoleucine, and      │        │ │
│ │                                        │ valine, are a hallmark of metabolic    │        │ │
│ │                                        │ and cardiovascular disease [1, 2, 3,   │        │ │
│ │                                        │ 4, 5]. Early studies dating back over  │        │ │
│ │                                        │ 50 years showed that elevated blood    │        │ │
│ │                                        │ levels of BCAAs positively correlated  │        │ │
│ │                                        │ with obesity and blood insulin levels  │        │ │
│ │                                        │ in patients relative to matched lean   │        │ │
│ │                                        │ individuals [6]. Further studies       │        │ │
│ │                                        │ leveraging unbiased metabolomics have  │        │ │
│ │                                        │ reinforced the links between BCAA      │        │ │
│ │                                        │ accumulation and insulin resistance in │        │ │
│ │                                        │ both humans and preclinical rodent     │        │ │
│ │                                        │ disease models [7, 8]. In fact,        │        │ │
│ │                                        │ longitudinal studies tracking healthy  │        │ │
│ │                                        │ individuals showed that elevated       │        │ │
│ │                                        │ plasma BCAAs could be predictive of    │        │ │
│ │                                        │ future insulin resistance [8, 9].      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As with obesity and insulin            │        │ │
│ │                                        │ resistance, epidemiological studies    │        │ │
│ │                                        │ have also linked elevated circulating  │        │ │
│ │                                        │ levels of both BCAAs and their         │        │ │
│ │                                        │ breakdown products, branched-chain     │        │ │
│ │                                        │ α-ketoacids (BCKAs), with              │        │ │
│ │                                        │ cardiovascular disease. In both humans │        │ │
│ │                                        │ and rodents, several studies point to  │        │ │
│ │                                        │ accumulation of BCAAs and/or BCKAs in  │        │ │
│ │                                        │ heart failure, myocardial infarction   │        │ │
│ │                                        │ (MI) and ischemia, hypertension, and   │        │ │
│ │                                        │ arrhythmia [1, 10, 11, 12, 13, 14].    │        │ │
│ │                                        │ Furthermore, elevated plasma BCAAs may │        │ │
│ │                                        │ be predictive of future obstructive    │        │ │
│ │                                        │ coronary artery disease [15].          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Steady-state levels of BCAAs are a     │        │ │
│ │                                        │ balance of intake and disposal. BCAAs  │        │ │
│ │                                        │ are essential amino acids for humans   │        │ │
│ │                                        │ and animals, meaning they cannot be    │        │ │
│ │                                        │ synthesized de novo. Dietary intake is │        │ │
│ │                                        │ therefore the predominant source of    │        │ │
│ │                                        │ BCAAs, though a minor proportion may   │        │ │
│ │                                        │ arise from the gut microbiome [4].     │        │ │
│ │                                        │ Along with protein synthesis, BCAA     │        │ │
│ │                                        │ oxidation represents an important sink │        │ │
│ │                                        │ for clearing BCAAs and maintaining     │        │ │
│ │                                        │ homeostatic levels [4, 5].             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Oxidation of leucine, isoleucine, and  │        │ │
│ │                                        │ valine is a tightly regulated process. │        │ │
│ │                                        │ Each BCAA is first deaminated by the   │        │ │
│ │                                        │ branched-chain aminotransferase to its │        │ │
│ │                                        │ respective BCKA. These BCKAs then      │        │ │
│ │                                        │ undergo irreversible decarboxylation   │        │ │
│ │                                        │ and esterification to their respective │        │ │
│ │                                        │ R-CoA molecules by the branched-chain  │        │ │
│ │                                        │ α-ketoacid dehydrogenase (BCKDH). They │        │ │
│ │                                        │ are eventually incorporated into the   │        │ │
│ │                                        │ tricarboxylic acid (TCA) cycle as      │        │ │
│ │                                        │ acetyl CoA or succinyl CoA. Much like  │        │ │
│ │                                        │ regulation of the pyruvate             │        │ │
│ │                                        │ dehydrogenase by inhibitory kinases    │        │ │
│ │                                        │ and an activating phosphatase, the     │        │ │
│ │                                        │ BCKDH is inhibited by the BCKDH kinase │        │ │
│ │                                        │ (BCKDK) and activated by the           │        │ │
│ │                                        │ mitochondrial protein phosphatase 2Cm  │        │ │
│ │                                        │ (PP2Cm) [16, 17].                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The association between increased BCAA │        │ │
│ │                                        │ and BCKA levels and cardiovascular and │        │ │
│ │                                        │ metabolic disease is well accepted,    │        │ │
│ │                                        │ but it remains unclear whether these   │        │ │
│ │                                        │ elevated levels have a causative role  │        │ │
│ │                                        │ in disease or represent an indirect    │        │ │
│ │                                        │ epiphenomenon. Several                 │        │ │
│ │                                        │ proof-of-concept studies have sought   │        │ │
│ │                                        │ to modify BCAA intake in preclinical   │        │ │
│ │                                        │ models to examine how readjusting      │        │ │
│ │                                        │ steady-state levels affects disease    │        │ │
│ │                                        │ pathology. As it relates to insulin    │        │ │
│ │                                        │ resistance, dietary BCAA               │        │ │
│ │                                        │ supplementation has produced mixed     │        │ │
│ │                                        │ results suggesting a complex and       │        │ │
│ │                                        │ contextual effect dependent on the     │        │ │
│ │                                        │ composition of diet and pre-existing   │        │ │
│ │                                        │ health of the animal [4, 7]. Dietary   │        │ │
│ │                                        │ restriction of BCAAs, however,         │        │ │
│ │                                        │ reverses insulin resistance in         │        │ │
│ │                                        │ multiple preclinical studies [7, 18].  │        │ │
│ │                                        │ Although fewer studies are available   │        │ │
│ │                                        │ examining dietary BCAAs on             │        │ │
│ │                                        │ cardiovascular disease, one report     │        │ │
│ │                                        │ noted that oral BCAA administration    │        │ │
│ │                                        │ post-MI impaired contractility and     │        │ │
│ │                                        │ increased infarct size [19].           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Numerous studies have manipulated      │        │ │
│ │                                        │ metabolic enzymes to alter             │        │ │
│ │                                        │ steady-state BCAA and BCKA levels and  │        │ │
│ │                                        │ examined the disease-modifying impact. │        │ │
│ │                                        │ Indeed, whole-body deletion or         │        │ │
│ │                                        │ silencing of the PP2Cm increases       │        │ │
│ │                                        │ circulating BCAA levels and promotes   │        │ │
│ │                                        │ heart failure and worsens              │        │ │
│ │                                        │ ischemia/reperfusion (I/R) injury [12, │        │ │
│ │                                        │ 20]. In line with these results,       │        │ │
│ │                                        │ tissue-specific adenoviral             │        │ │
│ │                                        │ overexpression of this phosphatase     │        │ │
│ │                                        │ lowered BCKA and BCAA levels and       │        │ │
│ │                                        │ prevented ischemic injury in the heart │        │ │
│ │                                        │ [21] and reduced hepatic triglyceride  │        │ │
│ │                                        │ accumulation and improved hepatic      │        │ │
│ │                                        │ glucose tolerance [22].                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Some of the strongest evidence for a   │        │ │
│ │                                        │ causative and pathological             │        │ │
│ │                                        │ relationship between dysregulated BCAA │        │ │
│ │                                        │ metabolism and cardiometabolic disease │        │ │
│ │                                        │ comes from pharmacologic inhibition of │        │ │
│ │                                        │ the BCKDK with BT2                     │        │ │
│ │                                        │ (3,6-dichlorobenzo[b]thiophene-2-carb… │        │ │
│ │                                        │ acid). The small molecule BT2 was      │        │ │
│ │                                        │ designed as a BCKA analog that         │        │ │
│ │                                        │ allosterically binds to the BCKDK      │        │ │
│ │                                        │ [23]. Similar to end-product           │        │ │
│ │                                        │ inhibition of BCKDK by elevated BCKA   │        │ │
│ │                                        │ levels, the compound relieves kinase   │        │ │
│ │                                        │ inhibition on the BCKDH and promotes   │        │ │
│ │                                        │ BCKA oxidation. In preclinical models  │        │ │
│ │                                        │ of heart failure, systemic BT2         │        │ │
│ │                                        │ administration lowers cardiac BCAAs    │        │ │
│ │                                        │ and BCKAs and provides                 │        │ │
│ │                                        │ cardioprotection in response to both   │        │ │
│ │                                        │ transaortic constriction as well as    │        │ │
│ │                                        │ left anterior descending artery        │        │ │
│ │                                        │ ligation [12, 19, 20, 21]. In various  │        │ │
│ │                                        │ rodent models of cardiometabolic       │        │ │
│ │                                        │ disease, BT2 lowers circulating BCAA   │        │ │
│ │                                        │ and BCKAs, improves glucose tolerance  │        │ │
│ │                                        │ and insulin sensitivity, and reduces   │        │ │
│ │                                        │ de novo lipogenesis (DNL) [22, 24, 25, │        │ │
│ │                                        │ 26].                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Remarkably, however, the recent        │        │ │
│ │                                        │ development of tissue-specific mouse   │        │ │
│ │                                        │ models has complicated our             │        │ │
│ │                                        │ understanding of how dysregulated BCAA │        │ │
│ │                                        │ metabolism may relate to               │        │ │
│ │                                        │ cardiovascular and metabolic disease.  │        │ │
│ │                                        │ Cardiac-specific loss of BCKDK does    │        │ │
│ │                                        │ not reproduce the protective effects   │        │ │
│ │                                        │ in either hemodynamic models or        │        │ │
│ │                                        │ ischemic models of heart failure [27]. │        │ │
│ │                                        │ It could be argued that the proportion │        │ │
│ │                                        │ of BCAA oxidation in the heart is too  │        │ │
│ │                                        │ low for the cardiac-specific knockout  │        │ │
│ │                                        │ to have an effect on circulating BCAA  │        │ │
│ │                                        │ levels similar to BT2 [28]. However,   │        │ │
│ │                                        │ inducible skeletal muscle–specific     │        │ │
│ │                                        │ Bckdk ablation also failed to elicit   │        │ │
│ │                                        │ cardioprotection despite lowering      │        │ │
│ │                                        │ cardiac BCAAs and plasma BCAAs and     │        │ │
│ │                                        │ BCKAs [27]. Furthermore,               │        │ │
│ │                                        │ tissue-specific loss of BCKDK in       │        │ │
│ │                                        │ skeletal muscle does not reproduce the │        │ │
│ │                                        │ effects of BT2 in improving insulin    │        │ │
│ │                                        │ sensitivity despite lowering plasma    │        │ │
│ │                                        │ BCAAs and BCKAs [29]. Similar          │        │ │
│ │                                        │ loss-of-function studies show that     │        │ │
│ │                                        │ hepatic BCKDK loss also fails to       │        │ │
│ │                                        │ improve insulin sensitivity [26, 29],  │        │ │
│ │                                        │ though the liver has less apparent     │        │ │
│ │                                        │ control over circulating BCAA levels   │        │ │
│ │                                        │ than muscle. While the results could   │        │ │
│ │                                        │ suggest that whole-body BCKDK          │        │ │
│ │                                        │ inhibition cannot be reproduced by     │        │ │
│ │                                        │ Bckdk ablation in individual tissues,  │        │ │
│ │                                        │ they perhaps also suggest an           │        │ │
│ │                                        │ alternative mechanism by which BT2     │        │ │
│ │                                        │ confers protection from heart failure  │        │ │
│ │                                        │ and metabolic disease distinct from    │        │ │
│ │                                        │ BCAA oxidation.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Here, we present evidence that BT2 is  │        │ │
│ │                                        │ a mitochondrial uncoupler.             │        │ │
│ │                                        │ Measurements of respiration,           │        │ │
│ │                                        │ mitochondrial membrane potential, and  │        │ │
│ │                                        │ inner membrane electrophysiology all   │        │ │
│ │                                        │ demonstrate that BT2—a lipophilic weak │        │ │
│ │                                        │ acid—is itself a chemical uncoupler.   │        │ │
│ │                                        │ BT2 also phenocopies the prototypical  │        │ │
│ │                                        │ uncoupler 2,4-dinitrophenol (DNP) in   │        │ │
│ │                                        │ lowering mitochondrial hydrogen        │        │ │
│ │                                        │ peroxide (H2O2) efflux and reducing    │        │ │
│ │                                        │ DNL. Chemical uncoupling of            │        │ │
│ │                                        │ mitochondria provides a single and     │        │ │
│ │                                        │ parsimonious mechanism by which BT2    │        │ │
│ │                                        │ could plausibly confer protection      │        │ │
│ │                                        │ against heart failure (lowering        │        │ │
│ │                                        │ mitochondrial reactive oxygen species  │        │ │
│ │                                        │ [ROS] production) and cardiometabolic  │        │ │
│ │                                        │ disease (increasing energy             │        │ │
│ │                                        │ expenditure) independent of effects on │        │ │
│ │                                        │ steady-state BCAA levels.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Elevated levels of branched chain      │        │ │
│ │                                        │ amino acids (BCAAs) and branched-chain │        │ │
│ │                                        │ α-ketoacids are associated with        │        │ │
│ │                                        │ cardiovascular and metabolic disease,  │        │ │
│ │                                        │ but the molecular mechanisms           │        │ │
│ │                                        │ underlying a putative causal           │        │ │
│ │                                        │ relationship remain unclear. The       │        │ │
│ │                                        │ branched-chain ketoacid dehydrogenase  │        │ │
│ │                                        │ kinase (BCKDK) inhibitor BT2           │        │ │
│ │                                        │ (3,6-dichlorobenzo[b]thiophene-2-carb… │        │ │
│ │                                        │ acid) is often used in preclinical     │        │ │
│ │                                        │ models to increase BCAA oxidation and  │        │ │
│ │                                        │ restore steady-state BCAA and          │        │ │
│ │                                        │ branched-chain α-ketoacid levels. BT2  │        │ │
│ │                                        │ administration is protective in        │        │ │
│ │                                        │ various rodent models of heart failure │        │ │
│ │                                        │ and metabolic disease, but             │        │ │
│ │                                        │ confoundingly, targeted ablation of    │        │ │
│ │                                        │ Bckdk in specific tissues does not     │        │ │
│ │                                        │ reproduce the beneficial effects       │        │ │
│ │                                        │ conferred by pharmacologic inhibition. │        │ │
│ │                                        │ Here, we demonstrate that BT2, a       │        │ │
│ │                                        │ lipophilic weak acid, can act as a     │        │ │
│ │                                        │ mitochondrial uncoupler. Measurements  │        │ │
│ │                                        │ of oxygen consumption, mitochondrial   │        │ │
│ │                                        │ membrane potential, and patch-clamp    │        │ │
│ │                                        │ electrophysiology show that BT2        │        │ │
│ │                                        │ increases proton conductance across    │        │ │
│ │                                        │ the mitochondrial inner membrane       │        │ │
│ │                                        │ independently of its inhibitory effect │        │ │
│ │                                        │ on BCKDK. BT2 is roughly sixfold less  │        │ │
│ │                                        │ potent than the prototypical uncoupler │        │ │
│ │                                        │ 2,4-dinitrophenol and phenocopies      │        │ │
│ │                                        │ 2,4-dinitrophenol in lowering de novo  │        │ │
│ │                                        │ lipogenesis and mitochondrial          │        │ │
│ │                                        │ superoxide production. The data        │        │ │
│ │                                        │ suggest that the therapeutic efficacy  │        │ │
│ │                                        │ of BT2 may be attributable to the      │        │ │
│ │                                        │ well-documented effects of             │        │ │
│ │                                        │ mitochondrial uncoupling in            │        │ │
│ │                                        │ alleviating cardiovascular and         │        │ │
│ │                                        │ metabolic disease.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 uncouples mitochondria in       │        │ │
│ │                                        │ rodent and human cardiomyocytes        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To identify uncharacterized metabolic  │        │ │
│ │                                        │ targets or mechanisms of BT2 action    │        │ │
│ │                                        │ independent of its inhibitory effect   │        │ │
│ │                                        │ on the BCKDK, we measured the effect   │        │ │
│ │                                        │ of BT2 on the oxygen consumption rate  │        │ │
│ │                                        │ in neonatal rat ventricular myocytes   │        │ │
│ │                                        │ (NRVMs). Acute BT2 administration 5    │        │ │
│ │                                        │ min prior to initial measurements      │        │ │
│ │                                        │ revealed a consistent increase in the  │        │ │
│ │                                        │ basal respiration rate (Fig. 1, A and  │        │ │
│ │                                        │ B). This increase persisted in the     │        │ │
│ │                                        │ presence of the ATP synthase inhibitor │        │ │
│ │                                        │ oligomycin, but no change was observed │        │ │
│ │                                        │ when measuring the maximal respiratory │        │ │
│ │                                        │ capacity with FCCP (carbonyl cyanide   │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine).    │        │ │
│ │                                        │ The result mimics the hallmark profile │        │ │
│ │                                        │ of mitochondrial uncoupling [30, 31]:  │        │ │
│ │                                        │ BT2 increased mitochondrial oxygen     │        │ │
│ │                                        │ consumption independently of (or       │        │ │
│ │                                        │ “uncoupled” from) ATP synthesis.       │        │ │
│ │                                        │ Indeed, the uncoupling response was    │        │ │
│ │                                        │ preserved when cardiomyocytes were     │        │ │
│ │                                        │ stimulated with norepinephrine (Fig.   │        │ │
│ │                                        │ 1B) and was observed at concentrations │        │ │
│ │                                        │ as low as 5 μM (Fig. 1C). Moreover,    │        │ │
│ │                                        │ acute BT2 administration also          │        │ │
│ │                                        │ increased respiration associated with  │        │ │
│ │                                        │ proton leak in iCell human-induced     │        │ │
│ │                                        │ pluripotent stem cell (iPSC)–derived   │        │ │
│ │                                        │ cardiomyocytes, with and without       │        │ │
│ │                                        │ adrenergic activation (Fig. 1D). Given │        │ │
│ │                                        │ that BT2 acutely increases             │        │ │
│ │                                        │ oligomycin-insensitive respiration in  │        │ │
│ │                                        │ human and rodent cardiomyocytes, we    │        │ │
│ │                                        │ hypothesized that it can act as a      │        │ │
│ │                                        │ chemical uncoupler. Figure 1BT2        │        │ │
│ │                                        │ acutely uncouples mitochondria in rat  │        │ │
│ │                                        │ and human cardiomyocytes. A,           │        │ │
│ │                                        │ representative oxygen consumption      │        │ │
│ │                                        │ trace of neonatal rat ventricular      │        │ │
│ │                                        │ myocytes (NRVMs) offered 40 μM BT2, 80 │        │ │
│ │                                        │ μM BT2, or vehicle control (DMSO) 5    │        │ │
│ │                                        │ min prior to conducting measurements.  │        │ │
│ │                                        │ Forty micro molars and eighty micro    │        │ │
│ │                                        │ molars BT2 were chosen as              │        │ │
│ │                                        │ concentrations because they are        │        │ │
│ │                                        │ 10-fold above the EC50 (40 μM) or      │        │ │
│ │                                        │ previously used in the literature (80  │        │ │
│ │                                        │ μM) [84]. ( $$n = 10$$ technical       │        │ │
│ │                                        │ replicates from a single experiment).  │        │ │
│ │                                        │ B, collated oxygen consumption rate    │        │ │
│ │                                        │ parameters for NRVMs offered 40 μM BT2 │        │ │
│ │                                        │ in the presence or the absence of 1 μM │        │ │
│ │                                        │ norepinephrine. ( $$n = 4$$ biological │        │ │
│ │                                        │ replicates). C, proton leak–linked     │        │ │
│ │                                        │ respiration in NRVMs. Experiments      │        │ │
│ │                                        │ conducted as in (A and B). [ BT2] = 5, │        │ │
│ │                                        │ 10, 20, 40, and 80 μM. ($$n = 4$$      │        │ │
│ │                                        │ biological replicates). D, collated    │        │ │
│ │                                        │ oxygen consumption rate parameters for │        │ │
│ │                                        │ human iPSC-derived iCell               │        │ │
│ │                                        │ cardiomyocytes offered 40 μM BT2 in    │        │ │
│ │                                        │ the presence or the absence of 1 μM    │        │ │
│ │                                        │ norepinephrine as in (B). ( $$n = 4$$  │        │ │
│ │                                        │ biological replicates). E,             │        │ │
│ │                                        │ representative images for iCell        │        │ │
│ │                                        │ cardiomyocytes treated for 20 to 40    │        │ │
│ │                                        │ min with 80 μM BT2, 10 μM DNP, 1 μM    │        │ │
│ │                                        │ FCCP, or vehicle control. Ten nano     │        │ │
│ │                                        │ molars TMRE and two hundred nano       │        │ │
│ │                                        │ molars MitoTracker Green FM were given │        │ │
│ │                                        │ 1 h to equilibrate prior to compound   │        │ │
│ │                                        │ addition (further details available in │        │ │
│ │                                        │ the Experimental procedures section).  │        │ │
│ │                                        │ F, left, average TMRE intensity        │        │ │
│ │                                        │ relative to vehicle control for        │        │ │
│ │                                        │ treatments as in (D) with iCell        │        │ │
│ │                                        │ cardiomyocytes (top) and NRVMs         │        │ │
│ │                                        │ (bottom). Right, circularity as a      │        │ │
│ │                                        │ measure of mitochondrial morphology    │        │ │
│ │                                        │ for treatments as in (D) with iCell    │        │ │
│ │                                        │ cardiomyocytes (top) and NRVMs         │        │ │
│ │                                        │ (bottom). ( $$n = 7$$–15 technical     │        │ │
│ │                                        │ replicates collated from $$n = 3$$     │        │ │
│ │                                        │ biological replicates for each cell    │        │ │
│ │                                        │ type). G, left, simplified schematic   │        │ │
│ │                                        │ of uniformly labeled 13C6-glucose or   │        │ │
│ │                                        │ 13C6-leucine enriching TCA cycle       │        │ │
│ │                                        │ intermediates. Right, mole percent     │        │ │
│ │                                        │ enrichment (M.P.E.) of TCA cycle       │        │ │
│ │                                        │ intermediates citrate and malate in    │        │ │
│ │                                        │ NRVMs with the 13C label provided on   │        │ │
│ │                                        │ either glucose or leucine. ( $$n = 3$$ │        │ │
│ │                                        │ biological replicates). Panels (B–D,   │        │ │
│ │                                        │ and G) show data as mean ± SD of       │        │ │
│ │                                        │ individual biological replicates.      │        │ │
│ │                                        │ Panels (A and F) show data as mean ±   │        │ │
│ │                                        │ SD from technical replicates.          │        │ │
│ │                                        │ Statistical analysis was conducted     │        │ │
│ │                                        │ with a pairwise Student’s t test {[(B  │        │ │
│ │                                        │ and C), each BT2 concentration against │        │ │
│ │                                        │ vehicle control], and (D)} or ANOVA    │        │ │
│ │                                        │ followed by Dunnett’s posthoc multiple │        │ │
│ │                                        │ comparison tests (E) as appropriate.   │        │ │
│ │                                        │ ∗$p \leq 0.05$; ∗∗$p \leq 0.01$; and   │        │ │
│ │                                        │ ∗∗∗$p \leq 0.001.$ BT2,                │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DMSO, dimethyl sulfoxide; DNP,   │        │ │
│ │                                        │ 2,4-dinitrophenol; FCCP, carbonyl      │        │ │
│ │                                        │ cyanide                                │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine;     │        │ │
│ │                                        │ iPSC, induced pluripotent stem cell;   │        │ │
│ │                                        │ TCA, tricarboxylic acid; TMRE,         │        │ │
│ │                                        │ tetramethylrhodamine, ethyl ester.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Chemical uncouplers such as FCCP or    │        │ │
│ │                                        │ DNP increase the oxygen consumption    │        │ │
│ │                                        │ rate because they stimulate            │        │ │
│ │                                        │ consumption of the mitochondrial       │        │ │
│ │                                        │ membrane potential independently of    │        │ │
│ │                                        │ ATP synthesis, thereby causing         │        │ │
│ │                                        │ increased activity of the respiratory  │        │ │
│ │                                        │ chain [31]. We therefore measured the  │        │ │
│ │                                        │ resting mitochondrial membrane         │        │ │
│ │                                        │ potential in iCell cardiomyocytes and  │        │ │
│ │                                        │ NRVMs in response to acute treatment   │        │ │
│ │                                        │ with BT2 (Fig. 1, E and F). In both    │        │ │
│ │                                        │ model systems, fluorescence of the     │        │ │
│ │                                        │ lipophilic cation dye TMRE             │        │ │
│ │                                        │ (tetramethylrhodamine, ethyl ester)    │        │ │
│ │                                        │ showed a ∼$10\%$ decrease in the       │        │ │
│ │                                        │ steady-state membrane potential with   │        │ │
│ │                                        │ little change to mitochondrial         │        │ │
│ │                                        │ morphology in response to BT2. This    │        │ │
│ │                                        │ result could be reproduced by the      │        │ │
│ │                                        │ classic uncoupler DNP. Moreover, the   │        │ │
│ │                                        │ changes observed with BT2 and DNP were │        │ │
│ │                                        │ qualitatively, but not quantitatively, │        │ │
│ │                                        │ matched by the extreme changes in      │        │ │
│ │                                        │ membrane potential observed from the   │        │ │
│ │                                        │ highly potent uncoupler FCCP. The      │        │ │
│ │                                        │ demonstration that BT2 slightly lowers │        │ │
│ │                                        │ the steady-state membrane potential    │        │ │
│ │                                        │ similarly to DNP aligns with the       │        │ │
│ │                                        │ oxygen consumption results and         │        │ │
│ │                                        │ supports the hypothesis that BT2 can   │        │ │
│ │                                        │ act as a chemical uncoupler.           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We further sought to determine whether │        │ │
│ │                                        │ our in vitro cardiomyocyte models      │        │ │
│ │                                        │ behaved similarly to recent in vivo    │        │ │
│ │                                        │ human and rodent studies that show or  │        │ │
│ │                                        │ infer little BCAA oxidation in the     │        │ │
│ │                                        │ heart relative to other substrates     │        │ │
│ │                                        │ [27, 28]. We offered NRVMs medium with │        │ │
│ │                                        │ a uniform 13C6 label on either glucose │        │ │
│ │                                        │ or leucine to measure relative         │        │ │
│ │                                        │ incorporation of each substrate into   │        │ │
│ │                                        │ the TCA cycle (Fig. 1G). Incorporation │        │ │
│ │                                        │ of labeled leucine into the TCA cycle  │        │ │
│ │                                        │ intermediates citrate and malate was   │        │ │
│ │                                        │ more than 10-fold lower than           │        │ │
│ │                                        │ incorporation of labeled glucose.      │        │ │
│ │                                        │ Furthermore, BT2 stimulated uncoupled  │        │ │
│ │                                        │ respiration in a range of cultured     │        │ │
│ │                                        │ cell lines, including those that       │        │ │
│ │                                        │ lacked measurable incorporation of     │        │ │
│ │                                        │ labeled leucine into TCA cycle         │        │ │
│ │                                        │ intermediates (Fig. S1). Altogether,   │        │ │
│ │                                        │ the demonstration that BT2 could       │        │ │
│ │                                        │ uncouple respiration in cells with     │        │ │
│ │                                        │ marginal rates of BCAA oxidation—in    │        │ │
│ │                                        │ addition to the acute time frame in    │        │ │
│ │                                        │ which BT2 increases in proton          │        │ │
│ │                                        │ leak–associated respiration—suggested  │        │ │
│ │                                        │ a mechanism independent of BCKDK       │        │ │
│ │                                        │ inhibition. As such, we sought to      │        │ │
│ │                                        │ confirm this by using reductionist     │        │ │
│ │                                        │ systems where specific metabolic       │        │ │
│ │                                        │ pathways and reactions could be        │        │ │
│ │                                        │ isolated.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 is a chemical uncoupler         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To formally rule out the involvement   │        │ │
│ │                                        │ of BCKDK activity in the uncoupling    │        │ │
│ │                                        │ phenotype observed in rat and human    │        │ │
│ │                                        │ cardiomyocytes, we measured the acute  │        │ │
│ │                                        │ effects of the compound on isolated    │        │ │
│ │                                        │ mitochondria. Isolated mitochondria    │        │ │
│ │                                        │ are a well-defined system that can be  │        │ │
│ │                                        │ used to isolate specific metabolic     │        │ │
│ │                                        │ reactions and pathways [30, 32]. We    │        │ │
│ │                                        │ first measured respiration in          │        │ │
│ │                                        │ mitochondria offered specific          │        │ │
│ │                                        │ substrates to isolate the effects of   │        │ │
│ │                                        │ BT2 on targeted metabolic pathways     │        │ │
│ │                                        │ that bypass the BCKDK. In isolated     │        │ │
│ │                                        │ liver mitochondria offered pyruvate    │        │ │
│ │                                        │ and malate, acute BT2 treatment 5 min  │        │ │
│ │                                        │ prior to measurements elicited a       │        │ │
│ │                                        │ similar and specific effect on         │        │ │
│ │                                        │ mitochondrial uncoupling as we had     │        │ │
│ │                                        │ observed in intact cells. BT2 caused a │        │ │
│ │                                        │ concentration-dependent increase in    │        │ │
│ │                                        │ respiration associated with proton     │        │ │
│ │                                        │ leak (“state 4o”), but no change was   │        │ │
│ │                                        │ observed in ADP-stimulated (“state 3”) │        │ │
│ │                                        │ or FCCP-stimulated (“state 3u”)        │        │ │
│ │                                        │ respiration (Fig. 2, A and B). In      │        │ │
│ │                                        │ liver mitochondria isolated from both  │        │ │
│ │                                        │ rat and mouse, BT2 showed a similar    │        │ │
│ │                                        │ concentration-dependent increase in    │        │ │
│ │                                        │ state 4o respiration irrespective of   │        │ │
│ │                                        │ whether the mitochondria were provided │        │ │
│ │                                        │ pyruvate, glutamate, or succinate as a │        │ │
│ │                                        │ respiratory substrate (Fig. 2C).       │        │ │
│ │                                        │ Depending on the substrate and         │        │ │
│ │                                        │ species, an increase in proton         │        │ │
│ │                                        │ leak–associated respiration was        │        │ │
│ │                                        │ observed at BT2 concentrations as low  │        │ │
│ │                                        │ as 2.5 μM. In mitochondria isolated    │        │ │
│ │                                        │ from rat and mouse hearts, BT2 also    │        │ │
│ │                                        │ acutely increased state 4o respiration │        │ │
│ │                                        │ independent of the substrate provided  │        │ │
│ │                                        │ to the mitochondria (Fig. 2D). In      │        │ │
│ │                                        │ total, respiration with isolated       │        │ │
│ │                                        │ mitochondria showed that BT2 can       │        │ │
│ │                                        │ uncouple isolated mitochondria at      │        │ │
│ │                                        │ single-digit micromolar concentrations │        │ │
│ │                                        │ regardless of the respiratory          │        │ │
│ │                                        │ substrate provided. Figure 2BT2        │        │ │
│ │                                        │ increases state 4orespiration in       │        │ │
│ │                                        │ isolated mitochondria. A,              │        │ │
│ │                                        │ representative oxygen consumption      │        │ │
│ │                                        │ trace of isolated liver mitochondria   │        │ │
│ │                                        │ acutely treated with vehicle control,  │        │ │
│ │                                        │ 20 μM BT2, or 40 μM BT2 5 min prior to │        │ │
│ │                                        │ initial measurements. Mitochondria     │        │ │
│ │                                        │ were offered pyruvate, malate, and ADP │        │ │
│ │                                        │ in the experimental medium, and        │        │ │
│ │                                        │ respiration was measured in response   │        │ │
│ │                                        │ to sequential injections of            │        │ │
│ │                                        │ oligomycin, FCCP, and rotenone with    │        │ │
│ │                                        │ antimycin A. ($$n = 5$$ technical      │        │ │
│ │                                        │ replicates from a single experiment).  │        │ │
│ │                                        │ B, collated oxygen consumption rate    │        │ │
│ │                                        │ parameters for isolated liver          │        │ │
│ │                                        │ mitochondria as in (A). ( $$n = 4$$    │        │ │
│ │                                        │ biological replicates). C, state 4o    │        │ │
│ │                                        │ respiration in isolated mitochondria   │        │ │
│ │                                        │ from rat liver (top) or mouse liver    │        │ │
│ │                                        │ (bottom). Experiments conducted as in  │        │ │
│ │                                        │ (A) with pyruvate/malate (left),       │        │ │
│ │                                        │ glutamate/malate (middle), or          │        │ │
│ │                                        │ succinate/rotenone (right) offered as  │        │ │
│ │                                        │ respiratory substrates. [ BT2] = 2.5,  │        │ │
│ │                                        │ 5, 10, 20, 40, and 80 μM. ($$n = 4$$   │        │ │
│ │                                        │ biological replicates). D, state 4o    │        │ │
│ │                                        │ respiration in isolated mitochondria   │        │ │
│ │                                        │ from rat heart (top) or mouse heart    │        │ │
│ │                                        │ (bottom) acutely offered either        │        │ │
│ │                                        │ vehicle control (DMSO) or 40 μM BT2 5  │        │ │
│ │                                        │ min prior to initial measurements.     │        │ │
│ │                                        │ Experiments conducted as in (A) with   │        │ │
│ │                                        │ either pyruvate/malate (left) or       │        │ │
│ │                                        │ succinate/rotenone (right) offered as  │        │ │
│ │                                        │ respiratory substrates. Panels (B–D)   │        │ │
│ │                                        │ show data as mean ± SD of individual   │        │ │
│ │                                        │ biological replicates. A, shows data   │        │ │
│ │                                        │ as mean ± SD from technical            │        │ │
│ │                                        │ replicates. Statistical analysis was   │        │ │
│ │                                        │ conducted with a pairwise Student’s t  │        │ │
│ │                                        │ test {[(C), each BT2 concentration     │        │ │
│ │                                        │ against vehicle control] or (D)} or    │        │ │
│ │                                        │ ANOVA followed by Dunnett’s posthoc    │        │ │
│ │                                        │ multiple comparison tests (B) as       │        │ │
│ │                                        │ appropriate. ∗$p \leq 0.05$; ∗∗$p \leq │        │ │
│ │                                        │ 0.01.$ BT2,                            │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DMSO, dimethyl sulfoxide; FCCP,  │        │ │
│ │                                        │ carbonyl cyanide                       │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As in Figure 1, we sought to           │        │ │
│ │                                        │ corroborate our oxygen consumption     │        │ │
│ │                                        │ results with measurements of the       │        │ │
│ │                                        │ mitochondrial membrane potential. We   │        │ │
│ │                                        │ therefore examined whether acute BT2   │        │ │
│ │                                        │ administration would lower the         │        │ │
│ │                                        │ membrane potential in isolated         │        │ │
│ │                                        │ mitochondria by measuring the loss of  │        │ │
│ │                                        │ quenched TMRE fluorescence [33]. The   │        │ │
│ │                                        │ approach was validated by examining    │        │ │
│ │                                        │ the acute effects of oligomycin and    │        │ │
│ │                                        │ FCCP: ATP synthase inhibition by       │        │ │
│ │                                        │ oligomycin increased the membrane      │        │ │
│ │                                        │ potential and further quenched the     │        │ │
│ │                                        │ TMRE signal, whereas the potent        │        │ │
│ │                                        │ uncoupler FCCP caused a substantial    │        │ │
│ │                                        │ loss of the quenched fluorescence      │        │ │
│ │                                        │ (Fig. 3A). As expected, acute BT2      │        │ │
│ │                                        │ treatment lowered the quenched         │        │ │
│ │                                        │ fluorescence of TMRE in both heart and │        │ │
│ │                                        │ liver mitochondria, indicating a       │        │ │
│ │                                        │ reduced membrane potential and further │        │ │
│ │                                        │ suggesting that the compound itself is │        │ │
│ │                                        │ a chemical uncoupler (Fig. 3B).Figure  │        │ │
│ │                                        │ 3BT2 lowers membrane potential in      │        │ │
│ │                                        │ isolated mitochondria and increases    │        │ │
│ │                                        │ proton conductance across              │        │ │
│ │                                        │ themitochondrialinnermembrane. A,      │        │ │
│ │                                        │ quenched TMRE fluorescence in isolated │        │ │
│ │                                        │ rat liver mitochondria offered         │        │ │
│ │                                        │ succinate, rotenone, and ADP as        │        │ │
│ │                                        │ described in the Experimental          │        │ │
│ │                                        │ procedures section. Mitochondria were  │        │ │
│ │                                        │ offered oligomycin (1 μg/mg            │        │ │
│ │                                        │ mitochondrial protein) or FCCP (1 μM)  │        │ │
│ │                                        │ 5 min prior to measurements as         │        │ │
│ │                                        │ controls to demonstrate the signal     │        │ │
│ │                                        │ responds appropriately to known        │        │ │
│ │                                        │ effector compounds. ( $$n = 3$$        │        │ │
│ │                                        │ biological replicates). B, quenched    │        │ │
│ │                                        │ TMRE fluorescence as in (A) in         │        │ │
│ │                                        │ response to 40 μM BT2, 80 μM BT2, or   │        │ │
│ │                                        │ vehicle controls in isolated rat heart │        │ │
│ │                                        │ (left) or rat liver (right)            │        │ │
│ │                                        │ mitochondria. ( $$n = 4$$ biological   │        │ │
│ │                                        │ replicates). C, representative current │        │ │
│ │                                        │ induced by 100 μM BT2 recorded from    │        │ │
│ │                                        │ heart mitoplasts. Traces are shown     │        │ │
│ │                                        │ before (control, black) and after      │        │ │
│ │                                        │ (red) the addition of BT2 to the bath  │        │ │
│ │                                        │ solution. The voltage protocol is      │        │ │
│ │                                        │ indicated above the trace. Bath        │        │ │
│ │                                        │ (cytosolic side of the inner           │        │ │
│ │                                        │ mitochondrial membrane) and pipette    │        │ │
│ │                                        │ (matrix side) pH are indicated in the  │        │ │
│ │                                        │ pipette–mitoplast diagram. D,          │        │ │
│ │                                        │ aggregate current densities at −160 mV │        │ │
│ │                                        │ from the protocol described in (C).    │        │ │
│ │                                        │ BT2-dependent currents correspond to   │        │ │
│ │                                        │ the difference between the control     │        │ │
│ │                                        │ current and that in the presence of    │        │ │
│ │                                        │ BT2. Currents were normalized per      │        │ │
│ │                                        │ membrane capacitance to obtain current │        │ │
│ │                                        │ densities (pA/pF). ( $$n = 5$$         │        │ │
│ │                                        │ biological replicates). All data are   │        │ │
│ │                                        │ shown as mean ± SD of individual       │        │ │
│ │                                        │ biological replicates. Statistical     │        │ │
│ │                                        │ analysis was conducted with ANOVA      │        │ │
│ │                                        │ followed by Dunnett’s posthoc multiple │        │ │
│ │                                        │ comparisons tests. ∗$p \leq 0.05.$     │        │ │
│ │                                        │ BT2,                                   │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; FCCP, carbonyl cyanide           │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine;     │        │ │
│ │                                        │ TMRE, tetramethylrhodamine, ethyl      │        │ │
│ │                                        │ ester.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The acute increase in state 4o         │        │ │
│ │                                        │ respiration (Fig. 2) and decrease in   │        │ │
│ │                                        │ membrane potential in isolated         │        │ │
│ │                                        │ mitochondria strongly infer that BT2   │        │ │
│ │                                        │ increases proton conductance across    │        │ │
│ │                                        │ the inner mitochondrial membrane (IMM) │        │ │
│ │                                        │ [31]. However, a definitive and        │        │ │
│ │                                        │ unassailable measure of mitochondrial  │        │ │
│ │                                        │ uncoupling requires direct measurement │        │ │
│ │                                        │ of the proton current. We therefore    │        │ │
│ │                                        │ conducted patch-clamp                  │        │ │
│ │                                        │ electrophysiological measurements of   │        │ │
│ │                                        │ the inner membrane in mitoplasts       │        │ │
│ │                                        │ derived from isolated heart            │        │ │
│ │                                        │ mitochondria [34]. Indeed, a           │        │ │
│ │                                        │ measurable increase in proton current  │        │ │
│ │                                        │ could be observed across the inner     │        │ │
│ │                                        │ membrane in response to BT2 (Fig. 3, C │        │ │
│ │                                        │ and D). Taken together, results from   │        │ │
│ │                                        │ respirometry, TMRE fluorescence, and   │        │ │
│ │                                        │ membrane electrophysiology all point   │        │ │
│ │                                        │ to a chemical uncoupling property of   │        │ │
│ │                                        │ BT2 independent of its effects on BCAA │        │ │
│ │                                        │ metabolism.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 is approximately sixfold less   │        │ │
│ │                                        │ potent than DNP                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ With clear evidence that BT2 can act   │        │ │
│ │                                        │ as a chemical uncoupler, we then       │        │ │
│ │                                        │ sought to gauge its potency in         │        │ │
│ │                                        │ relation to the other well-known       │        │ │
│ │                                        │ uncouplers DNP, FCCP, and Bam15.       │        │ │
│ │                                        │ Similar to these chemical uncouplers,  │        │ │
│ │                                        │ BT2 is lipophilic and contains a       │        │ │
│ │                                        │ functional group that can reversibly   │        │ │
│ │                                        │ dissociate with a proton (Fig. 4A). We │        │ │
│ │                                        │ therefore sought to quantify the       │        │ │
│ │                                        │ potency of BT2 by measuring its        │        │ │
│ │                                        │ concentration-response curve for state │        │ │
│ │                                        │ 4o respiration alongside other         │        │ │
│ │                                        │ chemical uncouplers in isolated liver  │        │ │
│ │                                        │ mitochondria (Fig. 4, B and C).        │        │ │
│ │                                        │ Similar to DNP, BT2 is a far less      │        │ │
│ │                                        │ potent uncoupler than either FCCP or   │        │ │
│ │                                        │ Bam15 and requires >103-fold more      │        │ │
│ │                                        │ compound to elicit a similar change in │        │ │
│ │                                        │ proton leak–linked respiration (Fig.   │        │ │
│ │                                        │ 4D). Relative to DNP, roughly six      │        │ │
│ │                                        │ times the concentration of BT2 is      │        │ │
│ │                                        │ required to elicit the same change in  │        │ │
│ │                                        │ respiration in mitochondria isolated   │        │ │
│ │                                        │ from both rat liver (Fig. 4D) and      │        │ │
│ │                                        │ heart (Fig. 4E). Single-point          │        │ │
│ │                                        │ measurements of quenched TMRE          │        │ │
│ │                                        │ fluorescence also show a similar       │        │ │
│ │                                        │ potency profile for BT2 relative to    │        │ │
│ │                                        │ other uncouplers (Fig. 4F), as more    │        │ │
│ │                                        │ BT2 is required to drop the            │        │ │
│ │                                        │ mitochondrial membrane potential to a  │        │ │
│ │                                        │ similar degree relative to other       │        │ │
│ │                                        │ chemical uncouplers. Encouragingly,    │        │ │
│ │                                        │ quantitative comparison of the proton  │        │ │
│ │                                        │ current amplitude (pA/pF) elicited     │        │ │
│ │                                        │ from 100 μM BT2 in                     │        │ │
│ │                                        │ electrophysiological studies (Fig. 3D) │        │ │
│ │                                        │ is broadly sixfold lower than that     │        │ │
│ │                                        │ from previous measurements of 100 μM   │        │ │
│ │                                        │ DNP (BT2: 2.52 ± 0.53 [SEM; $$n =      │        │ │
│ │                                        │ 5$$]; DNP: 15.82 ± 1.28 [SEM; $$n =    │        │ │
│ │                                        │ 9$$] [35]). Higher concentrations of   │        │ │
│ │                                        │ BT2 disrupted the integrity of the     │        │ │
│ │                                        │ inner membrane such that proton        │        │ │
│ │                                        │ currents could not be reliably         │        │ │
│ │                                        │ quantified, precluding multipoint      │        │ │
│ │                                        │ comparisons between BT2 and DNP (Fig.  │        │ │
│ │                                        │ S2). Altogether, respiration and       │        │ │
│ │                                        │ membrane potential measurements in     │        │ │
│ │                                        │ isolated mitochondria show BT2 is      │        │ │
│ │                                        │ three orders of magnitude less potent  │        │ │
│ │                                        │ than Bam15 and FCCP and about sixfold  │        │ │
│ │                                        │ milder than the well-studied and       │        │ │
│ │                                        │ prototypical uncoupler DNP.Figure 4BT2 │        │ │
│ │                                        │ is a less potent chemical uncoupler    │        │ │
│ │                                        │ than FCCP, Bam15, and DNP.A, chemical  │        │ │
│ │                                        │ structures of BT2, DNP, Bam15, and     │        │ │
│ │                                        │ FCCP with the functional group for     │        │ │
│ │                                        │ weak acid/anion cycling highlighted in │        │ │
│ │                                        │ blue. B, representative trace of       │        │ │
│ │                                        │ isolated liver mitochondria acutely    │        │ │
│ │                                        │ offered 40 μM BT2, 10 μM DNP, or 50 nM │        │ │
│ │                                        │ Bam15. Assay medium is supplemented    │        │ │
│ │                                        │ with pyruvate, malate, and ADP as      │        │ │
│ │                                        │ before. ( $$n = 4$$ technical          │        │ │
│ │                                        │ replicates from a single experiment).  │        │ │
│ │                                        │ C, aggregate fold change in state 4o   │        │ │
│ │                                        │ respiration relative to vehicle        │        │ │
│ │                                        │ controls from experiments conducted as │        │ │
│ │                                        │ in (B). [ FCCP] and [Bam15] = 400,     │        │ │
│ │                                        │ 200, 100, 50, 25 nM; [DNP] = 16, 8, 4, │        │ │
│ │                                        │ 2, 1, 500 nM; [BT2] = 2.5, 5, 10, 20,  │        │ │
│ │                                        │ 40, and 80 μM. ($$n = 4$$ biological   │        │ │
│ │                                        │ replicates). D, data extrapolated from │        │ │
│ │                                        │ experiments conducted in (A and B)     │        │ │
│ │                                        │ measuring difference in concentration  │        │ │
│ │                                        │ required to elicit a twofold and       │        │ │
│ │                                        │ threefold change in the state 4o rate  │        │ │
│ │                                        │ relative to vehicle controls. ( $$n =  │        │ │
│ │                                        │ 4$$ biological replicates). E, values  │        │ │
│ │                                        │ calculated as in (A)–(C) except with   │        │ │
│ │                                        │ isolated rat heart mitochondria. ( $$n │        │ │
│ │                                        │ = 4$$ biological replicates). F,       │        │ │
│ │                                        │ mitochondrial membrane potential       │        │ │
│ │                                        │ measurements using quenched TMRE       │        │ │
│ │                                        │ fluorescence with isolated liver       │        │ │
│ │                                        │ mitochondria as in Figure 2, A–C. ($$n │        │ │
│ │                                        │ = 4$$ biological replicates). Panels   │        │ │
│ │                                        │ (C–F) show data as mean ± SD of        │        │ │
│ │                                        │ individual biological replicates. The  │        │ │
│ │                                        │ means are presented for panel (C)      │        │ │
│ │                                        │ rather than individual data points for │        │ │
│ │                                        │ clarity. Panel (B) shows data as mean  │        │ │
│ │                                        │ ± SD from technical replicates.        │        │ │
│ │                                        │ Statistical analysis was conducted     │        │ │
│ │                                        │ with ANOVA followed by Dunnett’s       │        │ │
│ │                                        │ posthoc multiple comparisons tests     │        │ │
│ │                                        │ (F). ∗$p \leq 0.05.$ BT2,              │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DNP, 2,4-dinitrophenol; FCCP,    │        │ │
│ │                                        │ carbonyl cyanide                       │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine;     │        │ │
│ │                                        │ TMRE, tetramethylrhodamine, ethyl      │        │ │
│ │                                        │ ester.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 uncouples via both ADP/ATP      │        │ │
│ │                                        │ carrier–dependent and ADP/ATP          │        │ │
│ │                                        │ carrier–independent mechanisms         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Chemical uncouplers have at least two  │        │ │
│ │                                        │ distinct mechanisms: (i) a             │        │ │
│ │                                        │ conventional model whereby weak        │        │ │
│ │                                        │ acid/anion cycling across the IMM      │        │ │
│ │                                        │ dissipates the proton gradient across  │        │ │
│ │                                        │ the inner membrane [36] and (ii)       │        │ │
│ │                                        │ stimulating proton conductance through │        │ │
│ │                                        │ the ADP/ATP carrier (AAC) by binding   │        │ │
│ │                                        │ to the nucleotide translocation site   │        │ │
│ │                                        │ [35, 37, 38]. As such, we sought to    │        │ │
│ │                                        │ determine whether BT2 also uncoupled   │        │ │
│ │                                        │ via both AAC-dependent and             │        │ │
│ │                                        │ AAC-independent mechanisms to provide  │        │ │
│ │                                        │ further evidence that it is a          │        │ │
│ │                                        │ conventional chemical uncoupler. We    │        │ │
│ │                                        │ employed both pharmacologic and        │        │ │
│ │                                        │ genetic strategies to inhibit AAC      │        │ │
│ │                                        │ activity and measure BT2-stimulated    │        │ │
│ │                                        │ increases in state 4o respiration. In  │        │ │
│ │                                        │ isolated rat liver mitochondria,       │        │ │
│ │                                        │ inhibition of adenine nucleotide       │        │ │
│ │                                        │ translocation with                     │        │ │
│ │                                        │ carboxyatractyloside had a predictable │        │ │
│ │                                        │ effect of inhibiting ADP-stimulated    │        │ │
│ │                                        │ respiration similarly to oligomycin    │        │ │
│ │                                        │ (Fig. 5A). Quantifying the increase in │        │ │
│ │                                        │ state 4o respiration from BT2 in the   │        │ │
│ │                                        │ presence and the absence of            │        │ │
│ │                                        │ carboxyatractyloside showed that AAC   │        │ │
│ │                                        │ inhibition limited the chemical        │        │ │
│ │                                        │ uncoupling independently of the        │        │ │
│ │                                        │ substrate provided (Fig. 5, B and C).  │        │ │
│ │                                        │ To verify if the results could extend  │        │ │
│ │                                        │ to intact cells, we quantified the     │        │ │
│ │                                        │ effect of BT2 on respiration in C2C12  │        │ │
│ │                                        │ myoblasts with both Slc25a4 (encoding  │        │ │
│ │                                        │ AAC1) and Slc25a5 (encoding AAC2)      │        │ │
│ │                                        │ genetically ablated                    │        │ │
│ │                                        │ (“double-knockout”) [35]. In both      │        │ │
│ │                                        │ intact (Fig. 5, D–F) and permeabilized │        │ │
│ │                                        │ cells (Fig. 5F), loss of Aac1 and Aac2 │        │ │
│ │                                        │ again resulted in the partial loss of  │        │ │
│ │                                        │ BT2-stimulated uncoupling. In sum,     │        │ │
│ │                                        │ results from both pharmacologic and    │        │ │
│ │                                        │ genetic loss of AAC function point to  │        │ │
│ │                                        │ BT2 having AAC-dependent and           │        │ │
│ │                                        │ AAC-independent mechanisms of          │        │ │
│ │                                        │ mitochondrial uncoupling similar to    │        │ │
│ │                                        │ other well-characterized chemical      │        │ │
│ │                                        │ uncouplers. Figure 5BT2 uncouples via  │        │ │
│ │                                        │ both AAC-dependent and AAC-independent │        │ │
│ │                                        │ mechanisms. A, isolated rat liver      │        │ │
│ │                                        │ mitochondria acutely offered 80 μM     │        │ │
│ │                                        │ BT2, 5 μM carboxyatractyloside (CATR), │        │ │
│ │                                        │ both 80 μM BT2 and 5 μM CATR, or       │        │ │
│ │                                        │ vehicle control 5 min prior to         │        │ │
│ │                                        │ conducting measurements. Mitochondria  │        │ │
│ │                                        │ were offered pyruvate, malate, and ADP │        │ │
│ │                                        │ as before. ( $$n = 10$$ technical      │        │ │
│ │                                        │ replicates from a single experiment).  │        │ │
│ │                                        │ B, collated state 4o respiration from  │        │ │
│ │                                        │ experiments as in (A) from rat liver   │        │ │
│ │                                        │ mitochondria offered either            │        │ │
│ │                                        │ pyruvate/malate (left) or              │        │ │
│ │                                        │ succinate/rotenone (right). ( $$n =    │        │ │
│ │                                        │ 4$$ biological replicates). C,         │        │ │
│ │                                        │ collated state 4o respiration from     │        │ │
│ │                                        │ experiments as in (A and B) plotted as │        │ │
│ │                                        │ a stacked bar chart to gauge the       │        │ │
│ │                                        │ proportion of CATR-sensitive (white)   │        │ │
│ │                                        │ and CATR-insensitive (gray)            │        │ │
│ │                                        │ uncoupling. ( $$n = 4$$ biological     │        │ │
│ │                                        │ replicates). D, intact C2C12 myoblasts │        │ │
│ │                                        │ with or without genetic ablation of    │        │ │
│ │                                        │ AAC1 and AAC2 (DKO) assayed in DMEM    │        │ │
│ │                                        │ supplemented with glucose, pyruvate,   │        │ │
│ │                                        │ and glutamine as described in the      │        │ │
│ │                                        │ Experimental procedures section. 80 μM │        │ │
│ │                                        │ BT2 was offered acutely 5 min prior to │        │ │
│ │                                        │ conducting measurements. ( $$n = 10$$  │        │ │
│ │                                        │ technical replicates from a single     │        │ │
│ │                                        │ experiment). E, collated proton        │        │ │
│ │                                        │ leak–linked respiration from           │        │ │
│ │                                        │ experiments using intact C2C12         │        │ │
│ │                                        │ myoblasts as in (D). ( $$n = 5$$       │        │ │
│ │                                        │ biological replicates). F, collated    │        │ │
│ │                                        │ proton leak–linked respiration from    │        │ │
│ │                                        │ experiments as in (D and E) plotted as │        │ │
│ │                                        │ a stacked bar chart to gauge the       │        │ │
│ │                                        │ proportion of AAC-dependent (white)    │        │ │
│ │                                        │ and AAC-independent (gray) uncoupling. │        │ │
│ │                                        │ Conditions are intact cells offered    │        │ │
│ │                                        │ DMEM supplemented as in (D) (left) and │        │ │
│ │                                        │ permeabilized myoblasts offered either │        │ │
│ │                                        │ pyruvate/malate (middle) or            │        │ │
│ │                                        │ succinate/rotenone (right). ( $$n =    │        │ │
│ │                                        │ 5$$ biological replicates). Panels (B, │        │ │
│ │                                        │ C, E, and F) show data as mean ± SD of │        │ │
│ │                                        │ individual biological replicates. The  │        │ │
│ │                                        │ means are presented for panels (C and  │        │ │
│ │                                        │ F) rather than individual data points  │        │ │
│ │                                        │ for clarity. Panels (A and D) show     │        │ │
│ │                                        │ data as mean ± SD from technical       │        │ │
│ │                                        │ replicates. Statistical analysis was   │        │ │
│ │                                        │ conducted with ANOVA followed by       │        │ │
│ │                                        │ Dunnett’s posthoc multiple comparison  │        │ │
│ │                                        │ tests. ∗$p \leq 0.05$; ∗∗$p \leq       │        │ │
│ │                                        │ 0.01$; ∗∗∗$p \leq 0.001.$ AAC, ADP/ATP │        │ │
│ │                                        │ carrier; BT2,                          │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DMEM, Dulbecco's modified        │        │ │
│ │                                        │ Eagle's medium.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 phenocopies DNP and lowers      │        │ │
│ │                                        │ mitochondrial H2O2 efflux              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Having demonstrated that BT2 can act   │        │ │
│ │                                        │ as a chemical uncoupler distinct from  │        │ │
│ │                                        │ its inhibition of the BCKDK, we next   │        │ │
│ │                                        │ examined whether BT2 can reproduce     │        │ │
│ │                                        │ hallmark biochemical and physiological │        │ │
│ │                                        │ responses resulting from chemical      │        │ │
│ │                                        │ uncoupling. For example, it is well    │        │ │
│ │                                        │ known that some forms of mitochondrial │        │ │
│ │                                        │ superoxide production are steeply      │        │ │
│ │                                        │ dependent on the mitochondrial         │        │ │
│ │                                        │ membrane potential [39, 40]. As such,  │        │ │
│ │                                        │ even mild chemical uncoupling that     │        │ │
│ │                                        │ fractionally lowers the membrane       │        │ │
│ │                                        │ potential can have a profound effect   │        │ │
│ │                                        │ in lowering mitochondrial ROS          │        │ │
│ │                                        │ production.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Previous work has shown that BT2       │        │ │
│ │                                        │ treatment reduces ROS production in    │        │ │
│ │                                        │ cells [21]. In in vivo preclinical     │        │ │
│ │                                        │ heart failure models, BT2              │        │ │
│ │                                        │ administration preserves cardiac       │        │ │
│ │                                        │ functions known to be sensitive to     │        │ │
│ │                                        │ oxidative stress and protects from     │        │ │
│ │                                        │ ROS-associated I/R and MI injury [12,  │        │ │
│ │                                        │ 20, 21]. However, in these systems, it │        │ │
│ │                                        │ is difficult to discriminate whether   │        │ │
│ │                                        │ the beneficial effects of BT2 result   │        │ │
│ │                                        │ from BCKDK inhibition or other         │        │ │
│ │                                        │ uncharacterized mechanisms. We         │        │ │
│ │                                        │ therefore tested whether BT2 could     │        │ │
│ │                                        │ directly lower mitochondrial           │        │ │
│ │                                        │ superoxide production derived from the │        │ │
│ │                                        │ respiratory chain.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Isolated rat heart mitochondria were   │        │ │
│ │                                        │ offered succinate to generate          │        │ │
│ │                                        │ superoxide resulting from a high       │        │ │
│ │                                        │ proton motive force and reduced CoQ    │        │ │
│ │                                        │ pool (i.e., “reverse electron          │        │ │
│ │                                        │ transport”). Rates of superoxide       │        │ │
│ │                                        │ production (measured as H2O2 efflux)   │        │ │
│ │                                        │ were quantitatively comparable to      │        │ │
│ │                                        │ previous reports [40], and the signal  │        │ │
│ │                                        │ responded appropriately by reporting   │        │ │
│ │                                        │ high rates of superoxide production in │        │ │
│ │                                        │ the presence of antimycin A (Fig. 6, A │        │ │
│ │                                        │ and B) [41]. As expected, BT2          │        │ │
│ │                                        │ significantly reduced mitochondrial    │        │ │
│ │                                        │ H2O2 efflux. Importantly, the result   │        │ │
│ │                                        │ could be phenocopied with the chemical │        │ │
│ │                                        │ uncouplers DNP and FCCP, each of which │        │ │
│ │                                        │ are structurally dissimilar and have   │        │ │
│ │                                        │ no reported effects on BCKDK. As such, │        │ │
│ │                                        │ the data indicate that mitochondrial   │        │ │
│ │                                        │ uncoupling could be a mechanism by     │        │ │
│ │                                        │ which BT2 can reduce mitochondrial ROS │        │ │
│ │                                        │ production independently of BCAA and   │        │ │
│ │                                        │ BCKA metabolism. Figure 6BT2 lowers    │        │ │
│ │                                        │ mitochondrial H2O2efflux. A,           │        │ │
│ │                                        │ representative standard curve of       │        │ │
│ │                                        │ exogenous H2O2 added on top of         │        │ │
│ │                                        │ isolated mitochondria. ( $$n = 3$$     │        │ │
│ │                                        │ technical replicates from a single     │        │ │
│ │                                        │ experiment). B, H2O2 efflux in         │        │ │
│ │                                        │ isolated mitochondria offered          │        │ │
│ │                                        │ succinate in response to addition of   │        │ │
│ │                                        │ 80 μM BT2, 20 μM DNP, 100 nM FCCP, 1   │        │ │
│ │                                        │ μM antimycin A, or vehicle control. (  │        │ │
│ │                                        │ $$n = 3$$–4 biological replicates).    │        │ │
│ │                                        │ Panel (A) shows data as mean ± SD of   │        │ │
│ │                                        │ individual technical replicates. Panel │        │ │
│ │                                        │ (B) shows data as mean ± SD of         │        │ │
│ │                                        │ biological replicates. Statistical     │        │ │
│ │                                        │ analysis was conducted with ANOVA      │        │ │
│ │                                        │ followed by Dunnett’s posthoc multiple │        │ │
│ │                                        │ comparisons tests for the chemical     │        │ │
│ │                                        │ uncouplers. A pairwise Student’s t     │        │ │
│ │                                        │ test was conducted between vehicle     │        │ │
│ │                                        │ controls and antimycin A. ∗∗$p \leq    │        │ │
│ │                                        │ 0.01$; ∗∗∗$p \leq 0.001.$ BT2,         │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DNP, 2,4-dinitrophenol; FCCP,    │        │ │
│ │                                        │ carbonyl cyanide                       │        │ │
│ │                                        │ 4-trifluoromethoxyphenylhydrazine;     │        │ │
│ │                                        │ H2O2, hydrogen peroxide.               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 phenocopies DNP and reduces DNL │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Although attenuation of mitochondrial  │        │ │
│ │                                        │ ROS production by chemical uncoupling  │        │ │
│ │                                        │ is a plausible mechanism for the       │        │ │
│ │                                        │ cardioprotection afforded by BT2, it   │        │ │
│ │                                        │ almost certainly cannot explain why    │        │ │
│ │                                        │ BT2 protects from insulin resistance   │        │ │
│ │                                        │ and hepatic steatosis. However,        │        │ │
│ │                                        │ another hallmark response to chemical  │        │ │
│ │                                        │ uncouplers is increased energy         │        │ │
│ │                                        │ expenditure. Uncouplers create a       │        │ │
│ │                                        │ “futile cycle” where dissipation of    │        │ │
│ │                                        │ the mitochondrial membrane potential   │        │ │
│ │                                        │ stimulates respiratory chain activity  │        │ │
│ │                                        │ [31, 34]. This shifts the energy       │        │ │
│ │                                        │ balance toward nutrient oxidation and  │        │ │
│ │                                        │ away from lipid storage and            │        │ │
│ │                                        │ accumulation. Decades of experimental  │        │ │
│ │                                        │ evidence in rodents and humans support │        │ │
│ │                                        │ this mechanism [42, 43, 44, 45], and   │        │ │
│ │                                        │ chemical uncoupling is consistent with │        │ │
│ │                                        │ the myriad and sometimes rapid effects │        │ │
│ │                                        │ of BT2 in various metabolic disease    │        │ │
│ │                                        │ models [26, 46].                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We examined whether BT2 could          │        │ │
│ │                                        │ phenocopy DNP in increasing cellular   │        │ │
│ │                                        │ energy expenditure and reducing DNL in │        │ │
│ │                                        │ differentiated 3T3-L1 adipocytes.      │        │ │
│ │                                        │ Indeed, acute treatment with either    │        │ │
│ │                                        │ BT2 or DNP increased the basal oxygen  │        │ │
│ │                                        │ consumption rate because of increased  │        │ │
│ │                                        │ proton leak–linked respiration (Fig.   │        │ │
│ │                                        │ 7, A and B). We then conducted stable  │        │ │
│ │                                        │ isotope tracing with uniformly labeled │        │ │
│ │                                        │ 13C6-glucose to further characterize   │        │ │
│ │                                        │ any shared effects of BT2 and DNP.     │        │ │
│ │                                        │ Both compounds increased relative      │        │ │
│ │                                        │ incorporation of glucose into the TCA  │        │ │
│ │                                        │ cycle metabolites citrate and malate   │        │ │
│ │                                        │ (Fig. 7C) and decreased the            │        │ │
│ │                                        │ steady-state abundance of these and    │        │ │
│ │                                        │ other TCA cycle intermediates (Fig.    │        │ │
│ │                                        │ 7D), a profile consistent with an      │        │ │
│ │                                        │ increased metabolic rate. Taken        │        │ │
│ │                                        │ together, the respirometry and GC–MS   │        │ │
│ │                                        │ data demonstrate that BT2 can increase │        │ │
│ │                                        │ cellular energy expenditure via        │        │ │
│ │                                        │ mitochondrial uncoupling. Figure 7BT2  │        │ │
│ │                                        │ increases cellular energy expenditure  │        │ │
│ │                                        │ and decreases de novo lipogenesis. A,  │        │ │
│ │                                        │ representative oxygen consumption      │        │ │
│ │                                        │ trace of differentiated 3T3-L1         │        │ │
│ │                                        │ adipocytes acutely offered 40 μM BT2   │        │ │
│ │                                        │ or 10 μM DNP 10 min prior to initial   │        │ │
│ │                                        │ measurements in DMEM supplemented with │        │ │
│ │                                        │ glucose, pyruvate, and glutamine as    │        │ │
│ │                                        │ described in the Experimental          │        │ │
│ │                                        │ procedures section. ( $$n = 5$$        │        │ │
│ │                                        │ technical replicates from a single     │        │ │
│ │                                        │ experiment). B, collated oxygen        │        │ │
│ │                                        │ consumption rate parameters for 3T3-L1 │        │ │
│ │                                        │ cells as in (A). ( $$n = 5$$           │        │ │
│ │                                        │ biological replicates). C, left,       │        │ │
│ │                                        │ simplified schematic of uniformly      │        │ │
│ │                                        │ labeled 13C6-glucose enriching TCA     │        │ │
│ │                                        │ cycle intermediates and palmitate.     │        │ │
│ │                                        │ Right, mole percent enrichment         │        │ │
│ │                                        │ (M.P.E.) from 13C6-glucose of TCA      │        │ │
│ │                                        │ cycle intermediates citrate and malate │        │ │
│ │                                        │ in differentiated 3T3-L1 adipocytes    │        │ │
│ │                                        │ treated for 72 h with 120 μM BT2 or 40 │        │ │
│ │                                        │ μM DNP in medium containing $2\%$      │        │ │
│ │                                        │ serum. High concentrations of drug     │        │ │
│ │                                        │ were used to account for drug binding  │        │ │
│ │                                        │ to serum albumin. ( $$n = 3$$          │        │ │
│ │                                        │ biological replicates). D, relative    │        │ │
│ │                                        │ metabolite abundances of TCA cycle     │        │ │
│ │                                        │ intermediates, adjusted for cell       │        │ │
│ │                                        │ number, for experiments conducted as   │        │ │
│ │                                        │ in (C). ( $$n = 3$$ biological         │        │ │
│ │                                        │ replicates). E, quantitative PCR       │        │ │
│ │                                        │ analysis for genes associated with de  │        │ │
│ │                                        │ novo lipogenesis as well as Cpt1a for  │        │ │
│ │                                        │ cells treated as in (C). ( $$n = 5$$–8 │        │ │
│ │                                        │ biological replicates). F, abundances  │        │ │
│ │                                        │ of fatty acids for experiments         │        │ │
│ │                                        │ conducted as in (C). ( $$n = 3$$–4     │        │ │
│ │                                        │ biological replicates). G, M.P.E. from │        │ │
│ │                                        │ 13C6-glucose into palmitate for        │        │ │
│ │                                        │ experiments conducted as in (C). ( $$n │        │ │
│ │                                        │ = 5$$ biological replicates). H, rate  │        │ │
│ │                                        │ of de novo lipogenesis [g(t)           │        │ │
│ │                                        │ parameter] calculated by isotopomer    │        │ │
│ │                                        │ spectral analysis (ISA) for            │        │ │
│ │                                        │ experiments conducted as in (C).       │        │ │
│ │                                        │ Averages provided by the model for     │        │ │
│ │                                        │ each biological replicate are          │        │ │
│ │                                        │ presented. Predicted g(t) values and   │        │ │
│ │                                        │ $95\%$ confidence intervals for each   │        │ │
│ │                                        │ technical replicate are provided in    │        │ │
│ │                                        │ Table S1. ( $$n = 4$$ biological       │        │ │
│ │                                        │ replicates). I, fractional             │        │ │
│ │                                        │ contribution of glucose to the         │        │ │
│ │                                        │ lipogenic acetyl CoA pool (“D”         │        │ │
│ │                                        │ parameter) calculated by ISA. Averages │        │ │
│ │                                        │ provided by the model for each         │        │ │
│ │                                        │ biological replicate are presented.    │        │ │
│ │                                        │ Predicted “D” values and $95\%$        │        │ │
│ │                                        │ confidence intervals for each          │        │ │
│ │                                        │ technical replicate are provided in    │        │ │
│ │                                        │ Table S1. ( $$n = 4$$ biological       │        │ │
│ │                                        │ replicates). Panels (B–I) show data as │        │ │
│ │                                        │ mean ± SD of individual biological     │        │ │
│ │                                        │ replicates. Panel (A) shows data as    │        │ │
│ │                                        │ mean ± SD from technical replicates.   │        │ │
│ │                                        │ Statistical analysis was conducted     │        │ │
│ │                                        │ with ANOVA followed by Dunnett’s       │        │ │
│ │                                        │ posthoc multiple comparison tests. ∗$p │        │ │
│ │                                        │ \leq 0.05$; ∗∗$p \leq 0.01$; and ∗∗∗$p │        │ │
│ │                                        │ \leq 0.001.$ BT2,                      │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; DMEM, Dulbecco's modified        │        │ │
│ │                                        │ Eagle's medium; DNP,                   │        │ │
│ │                                        │ 2,4-dinitrophenol; TCA, tricarboxylic  │        │ │
│ │                                        │ acid.                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Finally, we examined the effect of BT2 │        │ │
│ │                                        │ and DNP on DNL, reasoning that         │        │ │
│ │                                        │ increased uncoupling would decrease    │        │ │
│ │                                        │ lipid accumulation. Treatment of       │        │ │
│ │                                        │ differentiated 3T3-L1 adipocytes for   │        │ │
│ │                                        │ 72 h with either BT2 or DNP            │        │ │
│ │                                        │ significantly reduced mRNA levels of   │        │ │
│ │                                        │ both a master transcriptional          │        │ │
│ │                                        │ regulator of lipid synthesis (Srebpf1) │        │ │
│ │                                        │ as well as individual enzymes involved │        │ │
│ │                                        │ in DNL (Acly, Acaca, and Fasn) (Fig.   │        │ │
│ │                                        │ 7E). Importantly, levels of Cpt1a—the  │        │ │
│ │                                        │ gene encoding carnitine                │        │ │
│ │                                        │ palmitoyltransferase-1a, which is rate │        │ │
│ │                                        │ controlling for long-chain fatty acid  │        │ │
│ │                                        │ oxidation—were unchanged with DNP and  │        │ │
│ │                                        │ increased with BT2. This result        │        │ │
│ │                                        │ demonstrates that the reduction in DNL │        │ │
│ │                                        │ genes is not because of toxicity or    │        │ │
│ │                                        │ other experimental artifacts but       │        │ │
│ │                                        │ rather because of a specific shift     │        │ │
│ │                                        │ away from lipid synthesis.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ *Beyond* gene expression, we validated │        │ │
│ │                                        │ that BT2 reduced DNL by GC–MS analysis │        │ │
│ │                                        │ of fatty acids. BT2 treatment or DNP   │        │ │
│ │                                        │ treatment for 72 h reduced             │        │ │
│ │                                        │ steady-state levels of myristate       │        │ │
│ │                                        │ (14:0), palmitate (16:0), and stearate │        │ │
│ │                                        │ (18:0) (Fig. 7F). Furthermore, in      │        │ │
│ │                                        │ contrast to increased labeling of TCA  │        │ │
│ │                                        │ cycle intermediates (Fig. 7C),         │        │ │
│ │                                        │ incorporation of 13C6-glucose into     │        │ │
│ │                                        │ palmitate was decreased in response to │        │ │
│ │                                        │ administering either compound (Fig.    │        │ │
│ │                                        │ 7G). To estimate the rate of palmitate │        │ │
│ │                                        │ synthesis, we applied isotopomer       │        │ │
│ │                                        │ spectral analysis to model the rate of │        │ │
│ │                                        │ de novo palmitate synthesis [g(t)      │        │ │
│ │                                        │ parameter] and contribution of         │        │ │
│ │                                        │ glucose-derived carbon to the          │        │ │
│ │                                        │ lipogenic acetyl CoA pool (“D”         │        │ │
│ │                                        │ parameter) [47]. As in other assays,   │        │ │
│ │                                        │ BT2 and DNP showed qualitative         │        │ │
│ │                                        │ similarities as both decreased the     │        │ │
│ │                                        │ estimated rate of DNL but did not      │        │ │
│ │                                        │ appreciably change the “D” parameter   │        │ │
│ │                                        │ (Fig. 7, H and I and Table S1).        │        │ │
│ │                                        │ Overall, the gene expression,          │        │ │
│ │                                        │ respiration, and mass spectrometry     │        │ │
│ │                                        │ data show that BT2 phenocopies DNP in  │        │ │
│ │                                        │ increasing energy expenditure and      │        │ │
│ │                                        │ lowering DNL. Thus, the results        │        │ │
│ │                                        │ establish chemical uncoupling as a     │        │ │
│ │                                        │ putative mechanism to explain the      │        │ │
│ │                                        │ therapeutic effects of BT2 on          │        │ │
│ │                                        │ cardiometabolic disease (Fig.          │        │ │
│ │                                        │ 8).Figure 8BT2 uncouples mitochondria  │        │ │
│ │                                        │ to increase energy expenditure, lower  │        │ │
│ │                                        │ superoxide production, and reduce de   │        │ │
│ │                                        │ novo lipogenesis. AAC, ATP/ADP         │        │ │
│ │                                        │ carrier; ATP, ATP Synthase; BT2,       │        │ │
│ │                                        │ 3,6-dichlorobenzo[b]thiophene-2-carbo… │        │ │
│ │                                        │ acid; ETC, electron transport chain;   │        │ │
│ │                                        │ IMS, intermembrane space.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Discussion                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Here, we provide evidence that the     │        │ │
│ │                                        │ BCKDK inhibitor BT2 is also a chemical │        │ │
│ │                                        │ uncoupler. Measurements of oxygen      │        │ │
│ │                                        │ consumption, mitochondrial membrane    │        │ │
│ │                                        │ potential, and H+ conductance all show │        │ │
│ │                                        │ that BT2 consumes the membrane         │        │ │
│ │                                        │ potential independently of ATP         │        │ │
│ │                                        │ synthesis and uncouples mitochondria.  │        │ │
│ │                                        │ BT2 stimulates proton conductance      │        │ │
│ │                                        │ acutely (<5 min) in reductionist       │        │ │
│ │                                        │ systems bypassing BCKDK activity       │        │ │
│ │                                        │ (i.e., isolated mitochondria offered   │        │ │
│ │                                        │ various substrates as well as          │        │ │
│ │                                        │ patch-clamp electrophysiology of the   │        │ │
│ │                                        │ IMM), demonstrating that it is a bona  │        │ │
│ │                                        │ fide chemical uncoupler independent of │        │ │
│ │                                        │ BCAA metabolism. Chemical uncoupling   │        │ │
│ │                                        │ is a plausible and unifying mechanism  │        │ │
│ │                                        │ for how BT2 can be therapeutic in      │        │ │
│ │                                        │ various models of cardiovascular and   │        │ │
│ │                                        │ metabolic disease independent of its   │        │ │
│ │                                        │ effects on BCAA metabolism.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ With respect to heart failure, it is   │        │ │
│ │                                        │ generally accepted that excessive      │        │ │
│ │                                        │ mitochondrial ROS production is an     │        │ │
│ │                                        │ important pathological driver of       │        │ │
│ │                                        │ cardiovascular disease [48, 49, 50,    │        │ │
│ │                                        │ 51]. A well-known property of          │        │ │
│ │                                        │ uncouplers is limiting mitochondrial   │        │ │
│ │                                        │ superoxide production by lowering the  │        │ │
│ │                                        │ mitochondrial proton motive force,     │        │ │
│ │                                        │ thereby oxidizing the NADH/NAD+ and    │        │ │
│ │                                        │ QH2/Q pools and lowering the           │        │ │
│ │                                        │ probability of superoxide formation    │        │ │
│ │                                        │ [39, 52]. In addition to a direct      │        │ │
│ │                                        │ effect on reducing mitochondrial ROS   │        │ │
│ │                                        │ production from the respiratory chain, │        │ │
│ │                                        │ mitochondrial uncoupling is also       │        │ │
│ │                                        │ likely to have an indirect effect in   │        │ │
│ │                                        │ lowering ROS production by blocking    │        │ │
│ │                                        │ induction of the permeability          │        │ │
│ │                                        │ transition pore [53, 54, 55]. The      │        │ │
│ │                                        │ mitochondrial membrane potential       │        │ │
│ │                                        │ provides the driving force for calcium │        │ │
│ │                                        │ uptake, and uncoupling mitigates the   │        │ │
│ │                                        │ pathological matrix Ca2+ overload that │        │ │
│ │                                        │ triggers mitochondrial swelling and    │        │ │
│ │                                        │ opening of the permeability transition │        │ │
│ │                                        │ pore [55, 56]. Importantly, both FCCP  │        │ │
│ │                                        │ and DNP confer cardioprotection in ex  │        │ │
│ │                                        │ vivo models of I/R injury using the    │        │ │
│ │                                        │ Langendorff-perfused rat heart model   │        │ │
│ │                                        │ [57, 58], and heterologous expression  │        │ │
│ │                                        │ of UCP1 in the mouse heart protects    │        │ │
│ │                                        │ from ischemic damage and lowers        │        │ │
│ │                                        │ markers of oxidative stress [59].      │        │ │
│ │                                        │ These proof-of-concept studies         │        │ │
│ │                                        │ reinforce the notion that attenuation  │        │ │
│ │                                        │ of ROS production via chemical         │        │ │
│ │                                        │ uncoupling may explain why BT2 could   │        │ │
│ │                                        │ be cardioprotective independent of its │        │ │
│ │                                        │ function as a BCKDK inhibitor.         │        │ │
│ │                                        │ Moreover, it should be reinforced that │        │ │
│ │                                        │ given the steep dependence of ROS      │        │ │
│ │                                        │ production and calcium uptake on the   │        │ │
│ │                                        │ proton motive force, even mild         │        │ │
│ │                                        │ chemical uncoupling that fractionally  │        │ │
│ │                                        │ lowers the membrane potential can have │        │ │
│ │                                        │ a substantive effect in lowering       │        │ │
│ │                                        │ mitochondrial ROS production [39, 40]. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Regarding metabolic disease, it is     │        │ │
│ │                                        │ well known that administration of      │        │ │
│ │                                        │ chemical uncouplers and the resultant  │        │ │
│ │                                        │ increase in energy expenditure can     │        │ │
│ │                                        │ reduce insulin resistance, obesity,    │        │ │
│ │                                        │ and hepatic steatosis in preclinical   │        │ │
│ │                                        │ rodent models [42, 60]. In fact, DNP   │        │ │
│ │                                        │ was an effective antiobesity treatment │        │ │
│ │                                        │ in the 1930s, but a poor safety        │        │ │
│ │                                        │ profile and narrow therapeutic         │        │ │
│ │                                        │ window—rather than a lack of           │        │ │
│ │                                        │ efficacy—discontinued its clinical use │        │ │
│ │                                        │ [61, 62]. Indeed, in vivo              │        │ │
│ │                                        │ administration of BT2 in rodents       │        │ │
│ │                                        │ qualitatively mimics the effect of     │        │ │
│ │                                        │ other chemical uncouplers. In various  │        │ │
│ │                                        │ preclinical models, BT2 is protective  │        │ │
│ │                                        │ from glucose intolerance, insulin      │        │ │
│ │                                        │ insensitivity, triglyceride            │        │ │
│ │                                        │ accumulation, and hepatic inflammation │        │ │
│ │                                        │ similarly to DNP derivatives or Bam15  │        │ │
│ │                                        │ [22, 24, 26, 29, 46, 63, 64]. Several  │        │ │
│ │                                        │ reports demonstrate that BT2           │        │ │
│ │                                        │ administration does not change body    │        │ │
│ │                                        │ weight [22, 24, 29]. However, this may │        │ │
│ │                                        │ be consistent with a mild uncoupler    │        │ │
│ │                                        │ roughly sixfold less potent than DNP,  │        │ │
│ │                                        │ and BT2 slightly reduces in the        │        │ │
│ │                                        │ respiratory exchange ratio in Zucker   │        │ │
│ │                                        │ fatty rats [22].                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The identification of a chemical       │        │ │
│ │                                        │ uncoupling function for BT2 can        │        │ │
│ │                                        │ readily explain some phenomena that    │        │ │
│ │                                        │ are difficult to reconcile with a      │        │ │
│ │                                        │ primary effect on BCAA metabolism. For │        │ │
│ │                                        │ example, previous reports show that    │        │ │
│ │                                        │ BT2 elicits a rapid euglycemic effect  │        │ │
│ │                                        │ in glucose clamp studies less than an  │        │ │
│ │                                        │ hour after administration [26].        │        │ │
│ │                                        │ Although this time frame is likely     │        │ │
│ │                                        │ inconsistent with remodeling of BCAA   │        │ │
│ │                                        │ metabolism, it is consistent with      │        │ │
│ │                                        │ prior work showing acute effects on    │        │ │
│ │                                        │ energy expenditure by DNP [46].        │        │ │
│ │                                        │ Moreover, our demonstration that DNP   │        │ │
│ │                                        │ phenocopies BT2 in altering gene       │        │ │
│ │                                        │ expression related to lipid metabolism │        │ │
│ │                                        │ suggests that chemical uncoupling      │        │ │
│ │                                        │ could also explain why BT2 treatment   │        │ │
│ │                                        │ blocks phosphorylation of acetyl CoA   │        │ │
│ │                                        │ carboxylase at multiple sites in a     │        │ │
│ │                                        │ manner not consistent with PP2Cm       │        │ │
│ │                                        │ overexpression [22].                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A critical aspect of our finding that  │        │ │
│ │                                        │ BT2 is a chemical uncoupler is         │        │ │
│ │                                        │ determining whether the in vitro       │        │ │
│ │                                        │ concentrations required to stimulate   │        │ │
│ │                                        │ uncoupling are relevant for in vivo    │        │ │
│ │                                        │ studies. Our observation that BT2      │        │ │
│ │                                        │ concentrations as low as 2.5 μM        │        │ │
│ │                                        │ increase state 4o respiration raise    │        │ │
│ │                                        │ the possibility that BT2 could elicit  │        │ │
│ │                                        │ a mild uncoupling effect given that    │        │ │
│ │                                        │ the concentrations achieved in vivo    │        │ │
│ │                                        │ likely approach, if not surpass, the   │        │ │
│ │                                        │ half-maximal inhibitory concentration  │        │ │
│ │                                        │ for BCKDK inhibition (IC50 = 3–4 μM)   │        │ │
│ │                                        │ [23]. Peak circulating plasma          │        │ │
│ │                                        │ concentrations of BT2 (∼1.0 mM for 40  │        │ │
│ │                                        │ mg/kg; ∼1.8 mM for 120 mg/kg) [65] and │        │ │
│ │                                        │ plasma protein binding measurements    │        │ │
│ │                                        │ ($99.3\%$ protein bound) [23] suggest  │        │ │
│ │                                        │ that maximal and free BT2              │        │ │
│ │                                        │ concentrations reach single-digit      │        │ │
│ │                                        │ micromolar concentrations and above.   │        │ │
│ │                                        │ Moreover, pharmacokinetic data         │        │ │
│ │                                        │ indicate a longer half-life in plasma  │        │ │
│ │                                        │ relative to DNP and a clearance        │        │ │
│ │                                        │ profile in plasma more similar to a    │        │ │
│ │                                        │ controlled-release DNP analog [46,     │        │ │
│ │                                        │ 65]. Although tissue concentrations    │        │ │
│ │                                        │ are a far more informative parameter,  │        │ │
│ │                                        │ it is likely that BT2 would behave     │        │ │
│ │                                        │ similarly to DNP as a lipophilic       │        │ │
│ │                                        │ membrane-targeting drug that can       │        │ │
│ │                                        │ accumulate in tissues at               │        │ │
│ │                                        │ concentrations at the same order of    │        │ │
│ │                                        │ magnitude as circulating plasma levels │        │ │
│ │                                        │ [46, 66]. Our demonstration that BT2   │        │ │
│ │                                        │ is roughly a sixfold weaker uncoupler  │        │ │
│ │                                        │ than DNP may help explain why the drug │        │ │
│ │                                        │ is tolerable at doses that would be    │        │ │
│ │                                        │ egregiously toxic for DNP. In total,   │        │ │
│ │                                        │ available pharmacokinetic data support │        │ │
│ │                                        │ that chemical uncoupling should be a   │        │ │
│ │                                        │ relevant in vivo mechanism for BT2.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BCKDK inhibitors with greater potency  │        │ │
│ │                                        │ than BT2 have been recently developed  │        │ │
│ │                                        │ and evaluated in preclinical models of │        │ │
│ │                                        │ heart failure and diet-induced obesity │        │ │
│ │                                        │ [67]. For example, the thiophene       │        │ │
│ │                                        │ PF-07208254 has an IC50 10-fold lower  │        │ │
│ │                                        │ than BT2 and protects from transaortic │        │ │
│ │                                        │ constriction–induced cardiac           │        │ │
│ │                                        │ impairment and high-fat diet–induced   │        │ │
│ │                                        │ metabolic dysfunction. However,        │        │ │
│ │                                        │ despite improved potency, data suggest │        │ │
│ │                                        │ that PF-07208254 has to be             │        │ │
│ │                                        │ administered at a similar dose to BT2  │        │ │
│ │                                        │ to elicit comparable in vivo results.  │        │ │
│ │                                        │ Indeed, PF-07208254 is also a          │        │ │
│ │                                        │ lipophilic weak acid and comparably    │        │ │
│ │                                        │ sized relative to BT2. Moreover, a     │        │ │
│ │                                        │ series of bulkier thiazole compounds   │        │ │
│ │                                        │ were identified that exhibit           │        │ │
│ │                                        │ extraordinary potency against the      │        │ │
│ │                                        │ BCKDK (∼103-fold more potent than BT2) │        │ │
│ │                                        │ but do not improve metabolic end       │        │ │
│ │                                        │ points [67]. These data are consistent │        │ │
│ │                                        │ with BT2 possessing a mechanism of     │        │ │
│ │                                        │ action discrete from BCKDK activity,   │        │ │
│ │                                        │ and studies examining whether          │        │ │
│ │                                        │ PF-07208254 can act as a chemical      │        │ │
│ │                                        │ uncoupler would be clarifying.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Of course, it may be that other        │        │ │
│ │                                        │ off-target effects of BT2 in addition  │        │ │
│ │                                        │ to chemical uncoupling contribute to   │        │ │
│ │                                        │ observed in vitro and in vivo          │        │ │
│ │                                        │ phenotypes. For example, recent        │        │ │
│ │                                        │ reports highlight shared pharmacology  │        │ │
│ │                                        │ between angiotensin II type 1 receptor │        │ │
│ │                                        │ blockers and BT2 [68]. Encouragingly,  │        │ │
│ │                                        │ regulation of the renin–angiotensin    │        │ │
│ │                                        │ system may mechanistically explain the │        │ │
│ │                                        │ effect of BT2 on blood pressure        │        │ │
│ │                                        │ despite Bckdk ablation [27], a result  │        │ │
│ │                                        │ unlikely to be directly caused by      │        │ │
│ │                                        │ mitochondrial uncoupling. Additional   │        │ │
│ │                                        │ work suggests that BCKAs can inhibit   │        │ │
│ │                                        │ the mitochondrial pyruvate carrier     │        │ │
│ │                                        │ [69]. As BT2 acts as a branched-chain  │        │ │
│ │                                        │ 2-oxoacid analog, it may also inhibit  │        │ │
│ │                                        │ the mitochondrial pyruvate carrier and │        │ │
│ │                                        │ other mitochondrial transporters or    │        │ │
│ │                                        │ dehydrogenases. In fact, an inhibitory │        │ │
│ │                                        │ effect on pyruvate metabolism could    │        │ │
│ │                                        │ explain our observation that BT2       │        │ │
│ │                                        │ stimulates Cpt1a expression in         │        │ │
│ │                                        │ differentiated 3T3-L1 adipocytes,      │        │ │
│ │                                        │ whereas DNP does not [70].             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In summary, our data suggest that      │        │ │
│ │                                        │ chemical uncoupling by BT2 can explain │        │ │
│ │                                        │ many of the observed therapeutic       │        │ │
│ │                                        │ benefits attributed to enhanced BCKDH  │        │ │
│ │                                        │ activity and encourage exploration of  │        │ │
│ │                                        │ alternative hypotheses for existing    │        │ │
│ │                                        │ data. For example, overexpression of   │        │ │
│ │                                        │ the PP2Cm can reproduce some of the    │        │ │
│ │                                        │ beneficial effects of BT2, but it is   │        │ │
│ │                                        │ unclear to what extent this is due to  │        │ │
│ │                                        │ BCKDH activity or other targets        │        │ │
│ │                                        │ because of enzyme promiscuity [22,     │        │ │
│ │                                        │ 71]. It may also be that the           │        │ │
│ │                                        │ insulin-sensitizing effects of sodium  │        │ │
│ │                                        │ phenylbutyrate [25]—a lipophilic weak  │        │ │
│ │                                        │ acid—are somewhat attributable to      │        │ │
│ │                                        │ chemical uncoupling. Perhaps the       │        │ │
│ │                                        │ strongest evidence against an          │        │ │
│ │                                        │ alternative role for BT2 is the        │        │ │
│ │                                        │ demonstration that the drug does not   │        │ │
│ │                                        │ provide cardioprotection in whole-body │        │ │
│ │                                        │ Bckdk−/− mice [27]. However, these     │        │ │
│ │                                        │ animals are characterized by           │        │ │
│ │                                        │ developmental impairments,             │        │ │
│ │                                        │ neurological defects, and growth       │        │ │
│ │                                        │ abnormalities that may warrant         │        │ │
│ │                                        │ cautious interpretation of results     │        │ │
│ │                                        │ [27, 72]. Nonetheless, the data        │        │ │
│ │                                        │ demonstrating that BT2 is a chemical   │        │ │
│ │                                        │ uncoupler (i) reinforces the           │        │ │
│ │                                        │ therapeutic promise of chemical        │        │ │
│ │                                        │ uncoupling for a myriad of             │        │ │
│ │                                        │ cardiovascular and metabolic diseases  │        │ │
│ │                                        │ and (ii) further highlights the        │        │ │
│ │                                        │ importance of understanding to what    │        │ │
│ │                                        │ extent BCAA accumulation is causative  │        │ │
│ │                                        │ or associative in cardiovascular and   │        │ │
│ │                                        │ metabolic disease pathogenesis.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Animals                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All animal protocols and procedures    │        │ │
│ │                                        │ were approved and performed in         │        │ │
│ │                                        │ accordance with the National           │        │ │
│ │                                        │ Institutes of Health Guide for the     │        │ │
│ │                                        │ Care and Use of Laboratory Animals and │        │ │
│ │                                        │ the UCLA Animal Research Committee.    │        │ │
│ │                                        │ C57BL/6J male mice aged 8 to 12 weeks  │        │ │
│ │                                        │ were purchased from The Jackson        │        │ │
│ │                                        │ Laboratory. Male Sprague–Dawley rats   │        │ │
│ │                                        │ aged between 7 and 10 weeks (∼200–300  │        │ │
│ │                                        │ g) were purchased from Envigo.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Reagents                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BT2 was purchased from MedChemExpress  │        │ │
│ │                                        │ (catalog no.: HY114855), and all other │        │ │
│ │                                        │ uncouplers were purchased from         │        │ │
│ │                                        │ Sigma–Aldrich (FCCP [catalog no.:      │        │ │
│ │                                        │ C2920], DNP [catalog no.: 42195], and  │        │ │
│ │                                        │ Bam15 [catalog no.: SML-1760]). Stocks │        │ │
│ │                                        │ were made and stored at −20 °C at the  │        │ │
│ │                                        │ following concentrations: BT2 (40 mM   │        │ │
│ │                                        │ and 400 mM in dimethyl sulfoxide       │        │ │
│ │                                        │ [DMSO]), FCCP (10 mM in $95\%$         │        │ │
│ │                                        │ ethanol), DNP (20 mM in DMSO), and     │        │ │
│ │                                        │ Bam15 (40 mM in DMSO).                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Cardiomyocytes                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ NRVMs were isolated from postnatal     │        │ │
│ │                                        │ P1–P3-day-old Sprague–Dawley rat pups  │        │ │
│ │                                        │ of mixed sex as previously described   │        │ │
│ │                                        │ [73, 74]. Cells were plated onto       │        │ │
│ │                                        │ Agilent Seahorse XF96 cell culture     │        │ │
│ │                                        │ plates or 12-well cell culture dishes  │        │ │
│ │                                        │ coated with $0.1\%$ gelatin (Sigma;    │        │ │
│ │                                        │ catalog no.: G1393) in Dulbecco's      │        │ │
│ │                                        │ modified Eagle's medium (DMEM)/F12     │        │ │
│ │                                        │ medium (Gibco; catalog no.: 11330057)  │        │ │
│ │                                        │ supplemented with $10\%$ (v/v) fetal   │        │ │
│ │                                        │ bovine serum (FBS), 100 U/ml           │        │ │
│ │                                        │ penicillin, and 100 μg/ml              │        │ │
│ │                                        │ streptomycin. After 24 h, medium was   │        │ │
│ │                                        │ changed to DMEM/F12 lacking FBS but    │        │ │
│ │                                        │ with antibiotics as before. Human iPSC │        │ │
│ │                                        │ cardiomyocytes (iCell cardiomyocytes;  │        │ │
│ │                                        │ Fujifilm Cellular Dynamics             │        │ │
│ │                                        │ International; catalog no.: 01434)     │        │ │
│ │                                        │ were maintained according to the       │        │ │
│ │                                        │ manufacturer’s guidelines. Cells were  │        │ │
│ │                                        │ grown and maintained in a humidified   │        │ │
│ │                                        │ $5\%$ CO2 incubator at 37 °C.          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mitochondrial membrane potential   │        │ │
│ │                                        │ in cells was measured with TMRE using  │        │ │
│ │                                        │ the Image Xpress Micro Confocal        │        │ │
│ │                                        │ High-Content Imaging System (Molecular │        │ │
│ │                                        │ Devices). NRVMs and iPSC-derived iCell │        │ │
│ │                                        │ cardiomyocytes were plated onto        │        │ │
│ │                                        │ collagen-coated and black-walled       │        │ │
│ │                                        │ PhenoPlates (PerkinElmer) at either    │        │ │
│ │                                        │ 6.0 × 104 (NRVMs) or 1.5 × 104 (iCell) │        │ │
│ │                                        │ cells/well and maintained as described │        │ │
│ │                                        │ earlier in the Experimental procedures │        │ │
│ │                                        │ section. About 75 min prior to         │        │ │
│ │                                        │ conducting measurements, medium was    │        │ │
│ │                                        │ exchanged for DMEM lacking glucose,    │        │ │
│ │                                        │ phenol red, and sodium bicarbonate     │        │ │
│ │                                        │ (Sigma; catalog no.: 5030)             │        │ │
│ │                                        │ supplemented with 31.6 mM NaCl, 10 mM  │        │ │
│ │                                        │ glucose, 2 mM glutamine, 2 mM          │        │ │
│ │                                        │ pyruvate, and 5 mM Hepes along with 10 │        │ │
│ │                                        │ nM TMRE (Invitrogen; catalog no.:      │        │ │
│ │                                        │ T669) and 200 nM MitoTracker Green FM  │        │ │
│ │                                        │ (MTG; catalog no.: M7514). After       │        │ │
│ │                                        │ allowing the dyes to equilibrate for 1 │        │ │
│ │                                        │ h, BT2 (80 μM), DNP (10 μM), and FCCP  │        │ │
│ │                                        │ (1 μM) were added. Plates were treated │        │ │
│ │                                        │ with compounds of interest and         │        │ │
│ │                                        │ immediately transported to the core    │        │ │
│ │                                        │ facility where the plate was put into  │        │ │
│ │                                        │ the instrument. Measurements are       │        │ │
│ │                                        │ listed 20 to 40 min after treatment to │        │ │
│ │                                        │ reflect the time from which the cells  │        │ │
│ │                                        │ were treated with drug until the       │        │ │
│ │                                        │ measurements were taken in the last    │        │ │
│ │                                        │ microplate wells. The plating schemes  │        │ │
│ │                                        │ for each of the biological replicates  │        │ │
│ │                                        │ were altered (i.e., at times the       │        │ │
│ │                                        │ control group was in the left corner   │        │ │
│ │                                        │ of the plate that was initially read   │        │ │
│ │                                        │ by the instrument; during other        │        │ │
│ │                                        │ experiments, the drug treatments were  │        │ │
│ │                                        │ in this position) so that temporal     │        │ │
│ │                                        │ differences in how the plate was read  │        │ │
│ │                                        │ could not skew any results.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Images were acquired with the 50 μm    │        │ │
│ │                                        │ slit confocal mode and a 40× (1.2      │        │ │
│ │                                        │ numerical aperture) water lens in      │        │ │
│ │                                        │ Z-stack mode of 1 μm slices with a     │        │ │
│ │                                        │ total of six slices. Analysis was      │        │ │
│ │                                        │ performed in the MetaXpress (Molecular │        │ │
│ │                                        │ Devices) software clamping the         │        │ │
│ │                                        │ analysis parameters for all acquired   │        │ │
│ │                                        │ images. Maximum Z-projections of MTG   │        │ │
│ │                                        │ were used for morphologic analysis,    │        │ │
│ │                                        │ and the sum of Z-projections of TMRE   │        │ │
│ │                                        │ was used for quantification of         │        │ │
│ │                                        │ intensity. A TopHat filter was applied │        │ │
│ │                                        │ on the MTG images for better           │        │ │
│ │                                        │ definition of structures and           │        │ │
│ │                                        │ equalization of fluorescence. The      │        │ │
│ │                                        │ images were thresholded and            │        │ │
│ │                                        │ transformed into a binary              │        │ │
│ │                                        │ segmentation. This segmented area was  │        │ │
│ │                                        │ used to measure the average intensity  │        │ │
│ │                                        │ of TMRE and the circularity of         │        │ │
│ │                                        │ mitochondria. Circularity is defined   │        │ │
│ │                                        │ with “1” being a perfect circle and    │        │ │
│ │                                        │ “0” a straight line.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## 3T3-L1 adipocytes                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 preadipocytes were purchased    │        │ │
│ │                                        │ directly from the American Type        │        │ │
│ │                                        │ Culture Collection (ATCC) explicitly   │        │ │
│ │                                        │ for use in this study and maintained   │        │ │
│ │                                        │ below $70\%$ confluency in DMEM        │        │ │
│ │                                        │ (Gibco; catalog no.: 11965)            │        │ │
│ │                                        │ supplemented with $10\%$ (v/v) bovine  │        │ │
│ │                                        │ calf serum (ATCC; catalog no.:         │        │ │
│ │                                        │ 30-2020), 100 U/ml penicillin, 100     │        │ │
│ │                                        │ μg/ml streptomycin, and 1 mM sodium    │        │ │
│ │                                        │ pyruvate. Cells were plated onto XF96  │        │ │
│ │                                        │ cell culture plates or 12-well tissue  │        │ │
│ │                                        │ culture dishes and allowed to grow for │        │ │
│ │                                        │ 48 h (plating on day −2). On day 0,    │        │ │
│ │                                        │ differentiation was begun by changing  │        │ │
│ │                                        │ the medium to maintenance medium (DMEM │        │ │
│ │                                        │ supplemented with $10\%$ [v/v] FBS,    │        │ │
│ │                                        │ 100 U/ml penicillin, 100 μg/ml         │        │ │
│ │                                        │ streptomycin, 1 mM sodium pyruvate, 10 │        │ │
│ │                                        │ mM Hepes) further supplemented with 1  │        │ │
│ │                                        │ μg/ml insulin (Sigma; catalog no.:     │        │ │
│ │                                        │ I0515), 0.25 μM dexamethasone (Sigma;  │        │ │
│ │                                        │ catalog no.: D4904), 0.5 mM            │        │ │
│ │                                        │ methylisobutylxanthine (Sigma; catalog │        │ │
│ │                                        │ no.: I5879), and 100 nM rosiglitazone  │        │ │
│ │                                        │ (Sigma; catalog no.: R2408). On day 2, │        │ │
│ │                                        │ medium was changed to maintenance      │        │ │
│ │                                        │ medium supplemented only with 1 μg/ml  │        │ │
│ │                                        │ insulin, and on days 4 and 6, medium   │        │ │
│ │                                        │ was replaced to maintenance medium     │        │ │
│ │                                        │ with no further additions. Cells were  │        │ │
│ │                                        │ treated with compound on day 8 as      │        │ │
│ │                                        │ described elsewhere in the             │        │ │
│ │                                        │ Experimental procedures section. Cell  │        │ │
│ │                                        │ lines were free from mycoplasma        │        │ │
│ │                                        │ contamination for all experiments.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 preadipocytes were seeded at    │        │ │
│ │                                        │ 2.5 × 104 cells/well in 12-well dishes │        │ │
│ │                                        │ and differentiated as described        │        │ │
│ │                                        │ earlier in the Experimental procedures │        │ │
│ │                                        │ section. On day 8, cells were changed  │        │ │
│ │                                        │ into maintenance medium (made with     │        │ │
│ │                                        │ DMEM; catalog no.: A1443001) with the  │        │ │
│ │                                        │ following changes: $2\%$ (v/v) FBS     │        │ │
│ │                                        │ rather than $10\%$ to reduce protein   │        │ │
│ │                                        │ binding of compounds under             │        │ │
│ │                                        │ investigation, and uniformly labeled   │        │ │
│ │                                        │ [13C6]-glucose (Cambridge Isotope      │        │ │
│ │                                        │ Laboratories; catalog no.: CLM-1396)   │        │ │
│ │                                        │ was used instead of 12C-unlabeled      │        │ │
│ │                                        │ glucose. BT2 (120 μM) and DNP (40 μM)  │        │ │
│ │                                        │ were added during this step and used   │        │ │
│ │                                        │ at higher concentrations than in other │        │ │
│ │                                        │ experiments to account for binding to  │        │ │
│ │                                        │ albumin in $2\%$ (v/v) FBS. After 72   │        │ │
│ │                                        │ h, cells were extracted for GC–MS      │        │ │
│ │                                        │ analysis as described later. A matched │        │ │
│ │                                        │ 12-well dish was used for              │        │ │
│ │                                        │ normalization of metabolite levels to  │        │ │
│ │                                        │ cell number. On the day of the         │        │ │
│ │                                        │ extraction, cells were fixed with      │        │ │
│ │                                        │ $2\%$ (v/v) paraformaldehyde in PBS    │        │ │
│ │                                        │ and stored at 4 oC for no less than 7  │        │ │
│ │                                        │ days. Nuclei were stained with Hoescht │        │ │
│ │                                        │ (ThermoFisher; catalog no.: 33342)     │        │ │
│ │                                        │ overnight at 4 oC and quantified using │        │ │
│ │                                        │ the Operetta High Content Imaging      │        │ │
│ │                                        │ System (PerkinElmer).                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## C2C12 myoblasts                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ C2C12 myoblasts were purchased         │        │ │
│ │                                        │ directly from ATCC explicitly for use  │        │ │
│ │                                        │ in this study and maintained in DMEM   │        │ │
│ │                                        │ (Gibco; catalog no.: 11965)            │        │ │
│ │                                        │ supplemented with $10\%$ (v/v) FBS,    │        │ │
│ │                                        │ 100 U/ml penicillin, 100 μg/ml         │        │ │
│ │                                        │ streptomycin, and 1 mM sodium          │        │ │
│ │                                        │ pyruvate. Cells with genetic ablation  │        │ │
│ │                                        │ of Slc25a4 and Slc25a5 (encoding AAC1  │        │ │
│ │                                        │ and AAC2) were generated and described │        │ │
│ │                                        │ previously [35]. Cell lines were free  │        │ │
│ │                                        │ from mycoplasma contamination for all  │        │ │
│ │                                        │ experiments.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## HepG2 hepatocytes                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ HepG2 hepatocytes purchased directly   │        │ │
│ │                                        │ from ATCC explicitly for use in this   │        │ │
│ │                                        │ study and were maintained in MEM       │        │ │
│ │                                        │ (Gibco; catalog no.: 11095)            │        │ │
│ │                                        │ supplemented with $10\%$ (v/v) FBS,    │        │ │
│ │                                        │ 100 U/ml penicillin, 100 μg/ml         │        │ │
│ │                                        │ streptomycin, and 2 mM GlutaMAX. Cell  │        │ │
│ │                                        │ lines were free from mycoplasma        │        │ │
│ │                                        │ contamination for all experiments.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Mitochondrial isolation             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mitochondrial isolation from rodent    │        │ │
│ │                                        │ heart and liver was conducted          │        │ │
│ │                                        │ according to well-established          │        │ │
│ │                                        │ protocols [75] and all steps were      │        │ │
│ │                                        │ conducted on ice or at 4 °C.           │        │ │
│ │                                        │ Mitochondrial protein content was      │        │ │
│ │                                        │ measured by the bicinchoninic acid     │        │ │
│ │                                        │ assay.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Liver mitochondria                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mouse livers or rat livers were        │        │ │
│ │                                        │ cleaned, minced, and drained of blood  │        │ │
│ │                                        │ in ice-cold MSHE (210 mannitol, 70 mM  │        │ │
│ │                                        │ sucrose, 5 mM Hepes, 1 mM EGTA, and    │        │ │
│ │                                        │ $0.2\%$ [w/v] fatty acid–free serum    │        │ │
│ │                                        │ albumin [BSA]) at pH 7.2 at 4 °C.      │        │ │
│ │                                        │ Livers were disrupted using two        │        │ │
│ │                                        │ strokes of a drill-driven              │        │ │
│ │                                        │ Teflon-on-glass Dounce homogenizer     │        │ │
│ │                                        │ with roughly 1 ml of buffer for every  │        │ │
│ │                                        │ 100 mg of tissue. The homogenate was   │        │ │
│ │                                        │ spun at 12,000g for 10 min at 4 °C to  │        │ │
│ │                                        │ remove any contaminating fat. The      │        │ │
│ │                                        │ pellet was resuspended and centrifuged │        │ │
│ │                                        │ at 800g for 5 min at 4 °C to remove    │        │ │
│ │                                        │ debris. The supernatant was filtered   │        │ │
│ │                                        │ through two layers of wet cheesecloth  │        │ │
│ │                                        │ and centrifuged at 12,000g for 10 min  │        │ │
│ │                                        │ at 4 °C. The light, “fluffy” layer of  │        │ │
│ │                                        │ the pellet was removed, and the        │        │ │
│ │                                        │ mitochondrial pellet was resuspended   │        │ │
│ │                                        │ and centrifuged again at 12,000g at 4  │        │ │
│ │                                        │ °C. For the third and final            │        │ │
│ │                                        │ centrifugation step, the pellet was    │        │ │
│ │                                        │ washed and resuspended in MSHE lacking │        │ │
│ │                                        │ BSA and centrifuged again at 4 °C. The │        │ │
│ │                                        │ final mitochondrial pellet was         │        │ │
│ │                                        │ resuspended in MSHE lacking BSA and    │        │ │
│ │                                        │ kept at a concentration greater than   │        │ │
│ │                                        │ 100 mg/ml and kept on ice.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Heart mitochondria                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mouse hearts or rat hearts were        │        │ │
│ │                                        │ quickly removed from the euthanized    │        │ │
│ │                                        │ animal while still beating and minced, │        │ │
│ │                                        │ cleaned off blood, and homogenized     │        │ │
│ │                                        │ using a hand-held tissue disruptor     │        │ │
│ │                                        │ (IKA Ultra-Turrax) in ice-cold MSHE.   │        │ │
│ │                                        │ The homogenate was centrifuged at 900g │        │ │
│ │                                        │ for 10 min at 4 °C. The supernatant    │        │ │
│ │                                        │ was then centrifuged at 9000g for 10   │        │ │
│ │                                        │ min at 4 °C, and the remaining pellet  │        │ │
│ │                                        │ was washed and recentrifuged at 9000g  │        │ │
│ │                                        │ at 4 °C in medium lacking BSA. The     │        │ │
│ │                                        │ final mitochondrial pellet was         │        │ │
│ │                                        │ resuspended in MSHE lacking BSA and    │        │ │
│ │                                        │ kept at a concentration greater than   │        │ │
│ │                                        │ 25 mg/ml and kept on ice.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Respirometry                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All oxygen consumption measurements    │        │ │
│ │                                        │ were conducted using an Agilent        │        │ │
│ │                                        │ Seahorse XF96 or XFe96 Analyzer.       │        │ │
│ │                                        │ Experiments were conducted at 37 °C    │        │ │
│ │                                        │ and at pH 7.4 (intact cells) or 7.2    │        │ │
│ │                                        │ (isolated mitochondria and             │        │ │
│ │                                        │ permeabilized cells). For experiments  │        │ │
│ │                                        │ with intact cells or permeabilized     │        │ │
│ │                                        │ cells, only the inner 60 wells were    │        │ │
│ │                                        │ used and the outer rim was filled with │        │ │
│ │                                        │ 200 μl of PBS throughout the           │        │ │
│ │                                        │ incubation to minimize variance in     │        │ │
│ │                                        │ temperature and evaporative effects    │        │ │
│ │                                        │ across the plate. All respiratory      │        │ │
│ │                                        │ parameters were corrected for          │        │ │
│ │                                        │ nonmitochondrial respiration and       │        │ │
│ │                                        │ background signal from the instrument  │        │ │
│ │                                        │ with addition of 200 nM rotenone and 1 │        │ │
│ │                                        │ μM antimycin A and calculated          │        │ │
│ │                                        │ according to well-established best     │        │ │
│ │                                        │ practices [30, 76].                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Intact cells                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Respiration was measured in NRVMs (4.0 │        │ │
│ │                                        │ × 104 cells/well), iPSC cardiomyocytes │        │ │
│ │                                        │ (1.5 × 104 cells/well), C2C12          │        │ │
│ │                                        │ myoblasts (1.5 × 104 cells/well), and  │        │ │
│ │                                        │ differentiated 3T3-L1 adipocytes (2.5  │        │ │
│ │                                        │ × 103 cells/well) in DMEM assay medium │        │ │
│ │                                        │ composed of DMEM (Sigma; catalog no.:  │        │ │
│ │                                        │ 5030) supplemented with 31.6 mM NaCl,  │        │ │
│ │                                        │ 3 mg/l phenol red, 5 mM Hepes, 10 mM   │        │ │
│ │                                        │ glucose, 2 mM glutamine, and 2 mM      │        │ │
│ │                                        │ pyruvate. Where appropriate, cells     │        │ │
│ │                                        │ were offered oligomycin (2 μM), and    │        │ │
│ │                                        │ maximal respiration was estimated with │        │ │
│ │                                        │ 750 nM FCCP.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Permeabilized cells                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Cells were permeabilized with 3 nM     │        │ │
│ │                                        │ recombinant perfringolysin O and       │        │ │
│ │                                        │ assayed as previously described [77]   │        │ │
│ │                                        │ in MAS buffer (220 mM mannitol, 70 mM  │        │ │
│ │                                        │ sucrose, 10 mM KH2PO4, 5 mM MgCl2, 2   │        │ │
│ │                                        │ mM Hepes [pH 7.2 at 37 °C], 1 mM EGTA, │        │ │
│ │                                        │ $0.2\%$ [w/v] BSA). Where indicated    │        │ │
│ │                                        │ medium was supplemented with 4 mM ADP  │        │ │
│ │                                        │ and 10 mM pyruvate with 1 mM malate, 5 │        │ │
│ │                                        │ mM glutamate with 5 mM malate, or 10   │        │ │
│ │                                        │ mM succinate with 2 μM rotenone.       │        │ │
│ │                                        │ Oligomycin (2 μM) and rotenone (200    │        │ │
│ │                                        │ nM) with antimycin A (1 μM) were       │        │ │
│ │                                        │ offered during the course of the assay │        │ │
│ │                                        │ to calculate respiratory parameters    │        │ │
│ │                                        │ according to standard practice.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Isolated mitochondria               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Oxygen consumption rates in isolated   │        │ │
│ │                                        │ mitochondria were measured in MAS      │        │ │
│ │                                        │ buffer described previously according  │        │ │
│ │                                        │ to well-established protocols [77,     │        │ │
│ │                                        │ 78]. As indicated in the figure        │        │ │
│ │                                        │ legends, BSA was either omitted from   │        │ │
│ │                                        │ the assay medium or used at $0.001\%$  │        │ │
│ │                                        │ (w/v) to avoid sequestering lipophilic │        │ │
│ │                                        │ compounds under investigation. Where   │        │ │
│ │                                        │ indicated, MAS buffer was supplemented │        │ │
│ │                                        │ with 10 mM pyruvate with 1 mM malate   │        │ │
│ │                                        │ (Pyr/Mal), 5 mM glutamate with 5 mM    │        │ │
│ │                                        │ malate (Glu/Mal), or 10 mM succinate   │        │ │
│ │                                        │ with 2 μM rotenone (Succ/Rot).         │        │ │
│ │                                        │ Mitochondria were offered oligomycin   │        │ │
│ │                                        │ at 2 μM and FCCP at 1 μM where         │        │ │
│ │                                        │ indicated.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mitochondrial membrane potential   │        │ │
│ │                                        │ was measured using the quenched        │        │ │
│ │                                        │ fluorescence using a high              │        │ │
│ │                                        │ concentration of TMRE as has been      │        │ │
│ │                                        │ previously described [79]. TMRE        │        │ │
│ │                                        │ fluorescence will self-quench upon     │        │ │
│ │                                        │ accumulation in the mitochondrial      │        │ │
│ │                                        │ matrix at high concentrations. As      │        │ │
│ │                                        │ such, lowering the membrane potential  │        │ │
│ │                                        │ will decrease dye uptake and           │        │ │
│ │                                        │ self-quenching, thereby increasing the │        │ │
│ │                                        │ observed fluorescent signal.           │        │ │
│ │                                        │ Mitochondria isolated from rat liver   │        │ │
│ │                                        │ or rat heart (0.6 mg/ml) were          │        │ │
│ │                                        │ incubated in MAS buffer supplemented   │        │ │
│ │                                        │ with $0.001\%$ BSA, 4 mM ADP, 5 mM     │        │ │
│ │                                        │ succinate, 2 μM rotenone, and 5 μM     │        │ │
│ │                                        │ TMRE at 37 °C for 10 min in a          │        │ │
│ │                                        │ black-walled 96-well microplate        │        │ │
│ │                                        │ shielded from light. After incubation, │        │ │
│ │                                        │ fluorescence was measured (549         │        │ │
│ │                                        │ excitation/575 emission) using a Tecan │        │ │
│ │                                        │ Spark multimode plate reader.          │        │ │
│ │                                        │ Compounds under investigation were     │        │ │
│ │                                        │ immediately added prior to the 10 min  │        │ │
│ │                                        │ incubation period.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Normalization                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All intact and permeabilized cell      │        │ │
│ │                                        │ oxygen consumption rates were          │        │ │
│ │                                        │ normalized to cell number. Cells were  │        │ │
│ │                                        │ immediately fixed after the assay with │        │ │
│ │                                        │ $2\%$ (v/v) paraformaldehyde in PBS    │        │ │
│ │                                        │ and stored at 4 oC for up to 14 days.  │        │ │
│ │                                        │ Nuclei were stained with Hoechst       │        │ │
│ │                                        │ (ThermoFisher; catalog no.: 33342)     │        │ │
│ │                                        │ overnight at 4 oC and quantified using │        │ │
│ │                                        │ the Operetta High Content Imaging      │        │ │
│ │                                        │ System (PerkinElmer). All oxygen       │        │ │
│ │                                        │ consumption rates in isolated          │        │ │
│ │                                        │ mitochondria were normalized to        │        │ │
│ │                                        │ microgram of total mitochondrial       │        │ │
│ │                                        │ protein in the microplate well unless  │        │ │
│ │                                        │ otherwise indicated.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Patch-clamp recordings              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Proton conductance across the IMM was  │        │ │
│ │                                        │ conducted on mitoplasts derived from   │        │ │
│ │                                        │ mouse heart mitochondria as previously │        │ │
│ │                                        │ described [35, 80]. Mitoplasts         │        │ │
│ │                                        │ isolated from heart mitochondria have  │        │ │
│ │                                        │ been used previously to characterize   │        │ │
│ │                                        │ other H+ currents induced by compounds │        │ │
│ │                                        │ such as free fatty acids and chemical  │        │ │
│ │                                        │ uncouplers including DNP and FCCP.     │        │ │
│ │                                        │ Cardiac mitoplasts are well accepted   │        │ │
│ │                                        │ as representative of the nonadipose    │        │ │
│ │                                        │ tissue H+ current and exhibit similar  │        │ │
│ │                                        │ biophysical characteristics with       │        │ │
│ │                                        │ skeletal muscle and liver. Patch-clamp │        │ │
│ │                                        │ recording was performed from isolated  │        │ │
│ │                                        │ heart mitoplasts of mice. The          │        │ │
│ │                                        │ mitoplasts used for patch-clamp        │        │ │
│ │                                        │ experiments were 3 to 5 μm in diameter │        │ │
│ │                                        │ and typically had membrane             │        │ │
│ │                                        │ capacitances of 0.3 to 1.2 pF. Both    │        │ │
│ │                                        │ the bath and pipette solutions were    │        │ │
│ │                                        │ formulated to record H+ currents and   │        │ │
│ │                                        │ contained only salts that dissociate   │        │ │
│ │                                        │ into large anions and cations that are │        │ │
│ │                                        │ normally impermeant through ion        │        │ │
│ │                                        │ channels or transporters. A low pH     │        │ │
│ │                                        │ gradient across the IMM was used (pH   │        │ │
│ │                                        │ 7.5 and 7.0 on the matrix and          │        │ │
│ │                                        │ cytosolic sides, respectively).        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Pipettes were filled with 130 mM       │        │ │
│ │                                        │ tetramethylammonium hydroxide, 1 mM    │        │ │
│ │                                        │ EGTA, 2 mM Tris–HCl, and 100 mM Hepes. │        │ │
│ │                                        │ pH was adjusted to 7.5 with d-gluconic │        │ │
│ │                                        │ acid, and tonicity was adjusted to     │        │ │
│ │                                        │ ∼360 mmol/kg with sucrose. Typically,  │        │ │
│ │                                        │ pipettes had resistances of 25 to 35   │        │ │
│ │                                        │ MΩ, and the access resistance was 40   │        │ │
│ │                                        │ to 75 MΩ. Whole-mitoplast IH was       │        │ │
│ │                                        │ recorded in the bath solution          │        │ │
│ │                                        │ containing 100 mM Hepes and 1 mM EGTA  │        │ │
│ │                                        │ (pH adjusted to 7 with Trizma base,    │        │ │
│ │                                        │ and tonicity adjusted to ∼300 mmol/kg  │        │ │
│ │                                        │ with sucrose). All experiments were    │        │ │
│ │                                        │ performed under continuous perfusion   │        │ │
│ │                                        │ of the bath solution. All              │        │ │
│ │                                        │ electrophysiological data presented    │        │ │
│ │                                        │ were acquired at 10 kHz and filtered   │        │ │
│ │                                        │ at 1 kHz.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## H2O2 efflux                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ H2O2 efflux was measured in isolated   │        │ │
│ │                                        │ mitochondria as described previously   │        │ │
│ │                                        │ [40] using a Tecan Spark multimode     │        │ │
│ │                                        │ plate reader and an Amplex Red–based   │        │ │
│ │                                        │ detection system. Mitochondria (2      │        │ │
│ │                                        │ mg/ml) were incubated in SHE buffer    │        │ │
│ │                                        │ (250 mM sucrose, 10 mM Hepes, 1 mM     │        │ │
│ │                                        │ EGTA, pH 7.2 at 37 °C) supplemented    │        │ │
│ │                                        │ with 2.5 μM Amplex Red (ThermoFisher;  │        │ │
│ │                                        │ catalog no.: A12222) and 5 U/ml        │        │ │
│ │                                        │ horseradish peroxidase (ThermoFisher;  │        │ │
│ │                                        │ catalog no.: 31491). About 10 mM       │        │ │
│ │                                        │ succinate was added to the incubation, │        │ │
│ │                                        │ and the rate of H2O2 was measured over │        │ │
│ │                                        │ 2 to 3 min. The signal was calibrated  │        │ │
│ │                                        │ to known amounts of H2O2 added on top  │        │ │
│ │                                        │ of isolated mitochondria. Compounds    │        │ │
│ │                                        │ under investigation were preincubated  │        │ │
│ │                                        │ with mitochondria in SHE buffer for 2  │        │ │
│ │                                        │ to 5 min prior to the addition of      │        │ │
│ │                                        │ succinate.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## NRVMs                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ NRVMs were seeded at 4.0 × 105         │        │ │
│ │                                        │ cells/well in 12-well dishes coated    │        │ │
│ │                                        │ with $0.1\%$ (w/v) gelatin in DMEM/F12 │        │ │
│ │                                        │ medium described earlier. After 24 h,  │        │ │
│ │                                        │ medium was exchanged into custom DMEM  │        │ │
│ │                                        │ formulated without glucose, glutamine, │        │ │
│ │                                        │ or leucine (Sciencell Laboratories)    │        │ │
│ │                                        │ and supplemented with 10 mM glucose, 2 │        │ │
│ │                                        │ mM GlutaMAX, or 0.8 mM leucine, with a │        │ │
│ │                                        │ uniformly labeled [13C6] label on      │        │ │
│ │                                        │ either glucose or leucine (catalog     │        │ │
│ │                                        │ no.: CLM-2262). After 24 h, cells were │        │ │
│ │                                        │ extracted for GC–MS analysis as        │        │ │
│ │                                        │ described later.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Immortalized cell lines             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ C2C12 myoblasts (2.0 × 105 cells/well) │        │ │
│ │                                        │ or HepG2 hepatocytes (4.0 × 105        │        │ │
│ │                                        │ cells/well) were seeded into 6-well    │        │ │
│ │                                        │ dishes. After 24 h, medium was         │        │ │
│ │                                        │ exchanged into custom DMEM formulated  │        │ │
│ │                                        │ without glucose, glutamine, or leucine │        │ │
│ │                                        │ (Sciencell Laboratories) and           │        │ │
│ │                                        │ supplemented with 10 mM glucose, 2 mM  │        │ │
│ │                                        │ glutamine, or 0.8 mM leucine, with a   │        │ │
│ │                                        │ uniform 13C label on either glucose,   │        │ │
│ │                                        │ leucine, or glutamine (catalog no.:    │        │ │
│ │                                        │ CLM-1822). After 24 h, cells were      │        │ │
│ │                                        │ extracted for GC–MS analysis as        │        │ │
│ │                                        │ described later.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Derivatization and mass             │        │ │
│ │                                        │ spectrometry                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Cell preparation and stable isotope    │        │ │
│ │                                        │ tracing measuring incorporation of     │        │ │
│ │                                        │ isotopic labels into polar metabolites │        │ │
│ │                                        │ and palmitate was conducted as         │        │ │
│ │                                        │ previously described [81, 82].         │        │ │
│ │                                        │ Metabolite extraction was conducted    │        │ │
│ │                                        │ with a Folch-like method using a 5:2:5 │        │ │
│ │                                        │ ratio of methanol:water:chloroform.    │        │ │
│ │                                        │ About 12-well dishes were kept on ice  │        │ │
│ │                                        │ and quickly washed with ice-cold       │        │ │
│ │                                        │ $0.9\%$ (w/v) NaCl. Cells were then    │        │ │
│ │                                        │ scraped in ice-cold methanol and water │        │ │
│ │                                        │ containing 5 μg/ml norvaline (Sigma;   │        │ │
│ │                                        │ catalog no.: N7502), an internal       │        │ │
│ │                                        │ standard. Chloroform containing 20 μM  │        │ │
│ │                                        │ [U-2H31]-palmitate (Cambridge Isotope  │        │ │
│ │                                        │ Laboratories; catalog no.: DLM-215) as │        │ │
│ │                                        │ an internal standard was then added to │        │ │
│ │                                        │ the samples. Samples were then         │        │ │
│ │                                        │ vortexed for 1 min and centrifuged at  │        │ │
│ │                                        │ 10,000g for 5 min at 4 °C.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The polar fraction (top layer) was     │        │ │
│ │                                        │ removed, and the samples were dried    │        │ │
│ │                                        │ overnight using a refrigerated         │        │ │
│ │                                        │ CentriVap vacuum concentrator          │        │ │
│ │                                        │ (LabConco). Metabolites (50 nmol to 23 │        │ │
│ │                                        │ pmol) were extracted alongside the     │        │ │
│ │                                        │ cell samples to ensure the signal fell │        │ │
│ │                                        │ within the linear detection range of   │        │ │
│ │                                        │ the instrument. The dried polar        │        │ │
│ │                                        │ metabolites were reconstituted in 20   │        │ │
│ │                                        │ μl of $2\%$ (w/v) methoxyamine in      │        │ │
│ │                                        │ pyridine prior to a 45 min incubation  │        │ │
│ │                                        │ at 37 °C. Subsequently, 20 μl of       │        │ │
│ │                                        │ MTBSTFA with $1\%$                     │        │ │
│ │                                        │ tert-butyldimethylchlorosilane was     │        │ │
│ │                                        │ added to samples, followed by an       │        │ │
│ │                                        │ additional 45 min incubation at 37 °C. │        │ │
│ │                                        │ Samples were analyzed using Agilent    │        │ │
│ │                                        │ MassHunter software, and FluxFix       │        │ │
│ │                                        │ software (http://fluxfix.science) was  │        │ │
│ │                                        │ used to correct for the abundance of   │        │ │
│ │                                        │ natural heavy isotopes against an      │        │ │
│ │                                        │ in-house reference set of unlabeled    │        │ │
│ │                                        │ metabolite standards [83].             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The lower organic fraction was dried   │        │ │
│ │                                        │ under air and then solubilized in 500  │        │ │
│ │                                        │ μl of acidified methanol ($2\%$ [v/v]  │        │ │
│ │                                        │ H2SO4 in methanol) for 2 h at 50 °C to │        │ │
│ │                                        │ generate fatty acid methyl esters      │        │ │
│ │                                        │ (FAMEs). After this incubation, 100 μl │        │ │
│ │                                        │ of saturated NaCl was added, followed  │        │ │
│ │                                        │ by 500 μl of hexane. This mixture was  │        │ │
│ │                                        │ vortexed for 2 min, and the upper      │        │ │
│ │                                        │ hexane layer was collected in a new    │        │ │
│ │                                        │ microfuge tube. An additional 500 μl   │        │ │
│ │                                        │ of hexane was added to the original    │        │ │
│ │                                        │ MeOH–NaCl tube, and the process was    │        │ │
│ │                                        │ repeated to collect any residual FAMEs │        │ │
│ │                                        │ not obtained by the first addition.    │        │ │
│ │                                        │ The pooled hexane extracts were then   │        │ │
│ │                                        │ dried under airflow and resuspended in │        │ │
│ │                                        │ 75 μl of hexane. FAMEs were analyzed   │        │ │
│ │                                        │ by GC–MS analysis. De novo lipid       │        │ │
│ │                                        │ synthesis was estimated by isotopomer  │        │ │
│ │                                        │ spectral analysis [47, 82] and         │        │ │
│ │                                        │ calculated using MATLAB (MathWorks)    │        │ │
│ │                                        │ software.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Samples were analyzed using a DB-35    │        │ │
│ │                                        │ column (Agilent Technologies).         │        │ │
│ │                                        │ Information regarding additional       │        │ │
│ │                                        │ technical specifications is available  │        │ │
│ │                                        │ elsewhere [81, 82].                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Quantitative PCR                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3T3-L1 adipocytes were plated,         │        │ │
│ │                                        │ maintained, and treated with either    │        │ │
│ │                                        │ BT2 or DNP in 12-well dishes           │        │ │
│ │                                        │ identically to those used for GC–MS    │        │ │
│ │                                        │ analysis. Transcript levels were       │        │ │
│ │                                        │ measured using quantitative PCR. RNA   │        │ │
│ │                                        │ was extracted using the RNeasy Mini    │        │ │
│ │                                        │ Kit (Qiagen; catalog no.: 74106), and  │        │ │
│ │                                        │ complementary DNA was generated using  │        │ │
│ │                                        │ the High-Capacity cDNA Reverse         │        │ │
│ │                                        │ Transcription Kit (Applied Biosystems; │        │ │
│ │                                        │ catalog no.: 4368814). The PowerUp     │        │ │
│ │                                        │ SYBR Green Master Mix kit (Applied     │        │ │
│ │                                        │ Biosystems; catalog no.: A25743) and a │        │ │
│ │                                        │ QuantStudio 5 (Applied Biosystems)     │        │ │
│ │                                        │ were used for quantitative PCR         │        │ │
│ │                                        │ analysis. *Relative* gene expression   │        │ │
│ │                                        │ was calculated using the ΔΔCt method   │        │ │
│ │                                        │ with 36b4 as a reference gene.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Statistical analysis                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All statistical parameters, including  │        │ │
│ │                                        │ the number of biological replicates    │        │ │
│ │                                        │ (n), can be found in the figure        │        │ │
│ │                                        │ legends. Statistical analyses were     │        │ │
│ │                                        │ performed using GraphPad Prism 5       │        │ │
│ │                                        │ software (GraphPad Software, Inc).     │        │ │
│ │                                        │ Data are presented as the mean ±       │        │ │
│ │                                        │ standard deviation unless otherwise    │        │ │
│ │                                        │ specified. Where appropriate,          │        │ │
│ │                                        │ individual data points representing    │        │ │
│ │                                        │ values from each independent           │        │ │
│ │                                        │ biological replicate are presented, in │        │ │
│ │                                        │ accordance with the American Society   │        │ │
│ │                                        │ for Biochemistry and Molecular Biology │        │ │
│ │                                        │ best practices. Individual pairwise    │        │ │
│ │                                        │ comparisons were performed using       │        │ │
│ │                                        │ two-tailed Student’s t test. For       │        │ │
│ │                                        │ analysis involving more than two       │        │ │
│ │                                        │ groups, data were analyzed by          │        │ │
│ │                                        │ repeated-measures ANOVA followed by    │        │ │
│ │                                        │ Dunnett’s post hoc multiple comparison │        │ │
│ │                                        │ tests (compared against vehicle        │        │ │
│ │                                        │ controls unless otherwise specified).  │        │ │
│ │                                        │ Data were assumed to follow a normal   │        │ │
│ │                                        │ distribution (no tests were            │        │ │
│ │                                        │ performed). Values denoted as follows  │        │ │
│ │                                        │ were considered statistically          │        │ │
│ │                                        │ significant: ∗$p \leq 0.05$; ∗∗$p \leq │        │ │
│ │                                        │ 0.01$; and ∗∗∗$p \leq 0.001.$          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Data availability                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All data supporting the findings in    │        │ │
│ │                                        │ this study are available from the      │        │ │
│ │                                        │ corresponding author upon request.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Supporting information              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ This article contains supporting       │        │ │
│ │                                        │ information.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Supporting information                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Conflict of interest                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Y. W. is a scientific founder and paid │        │ │
│ │                                        │ consultant for Ramino Therapeutics. A. │        │ │
│ │                                        │ S. D. has previously served as a paid  │        │ │
│ │                                        │ consultant for Agilent Technologies.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Author contributions                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A. A., A. S. D., and Y. W.             │        │ │
│ │                                        │ conceptualization; A. A., A. E. J., B. │        │ │
│ │                                        │ D., C. B., L. S., M. W., A. M. B., and │        │ │
│ │                                        │ A. S. D. methodology; A. A., A. E. J., │        │ │
│ │                                        │ B. D., R. T., C. B., M. W., A. M. B.,  │        │ │
│ │                                        │ and A. S. D. formal analysis; A. A.,   │        │ │
│ │                                        │ A. E. J., B. D., K. P. M., C. B., L.   │        │ │
│ │                                        │ S., A. M. B., and A. S. D.             │        │ │
│ │                                        │ investigation; O. S. S., M. W., Y. W., │        │ │
│ │                                        │ A. M. B., and A. S. D. resources; A.   │        │ │
│ │                                        │ A., A. E. J., R. T., C. B., M. W., A.  │        │ │
│ │                                        │ M. B., and A. S. D. data curation; A.  │        │ │
│ │                                        │ A. and A. S. D. writing–original       │        │ │
│ │                                        │ draft; A. A., A. E. J., B. D., R. T.,  │        │ │
│ │                                        │ K. P. M., C. B., K. R., O. S. S., L.   │        │ │
│ │                                        │ S., M. W., Y. W., A. M. B., and A. S.  │        │ │
│ │                                        │ D. writing–review & editing; A. A., K. │        │ │
│ │                                        │ R., O. S. S., Y. W., A. M. B., and A.  │        │ │
│ │                                        │ S. D. supervision; K. R., O. S. S., Y. │        │ │
│ │                                        │ W., and A. S. D. project               │        │ │
│ │                                        │ administration; M. W., Y. W., A. M.    │        │ │
│ │                                        │ B., and A. S. D. funding acquisition.  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Funding and additional information  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A. S. D. is supported by the           │        │ │
│ │                                        │ $\frac{10.13039}{100000002}$National   │        │ │
│ │                                        │ Institutes of Health grants            │        │ │
│ │                                        │ R35GM138003 and P30DK063491 as well as │        │ │
│ │                                        │ the W. M.                              │        │ │
│ │                                        │ $\frac{10.13039}{100000888}$Keck       │        │ │
│ │                                        │ Foundation (grant no.: 995337) and the │        │ │
│ │                                        │ $\frac{10.13039}{100004322}$Agilent    │        │ │
│ │                                        │ Early Career Professor Award. A. M. B. │        │ │
│ │                                        │ is supported by the                    │        │ │
│ │                                        │ $\frac{10.13039}{100000002}$National   │        │ │
│ │                                        │ Institutes of Health grant R35GM143097 │        │ │
│ │                                        │ and the Pew Scholars in Biomedical     │        │ │
│ │                                        │ Sciences. Y. W. is supported by the    │        │ │
│ │                                        │ $\frac{10.13039}{100000005}$Department │        │ │
│ │                                        │ of Defense CDMRP (grant no.:           │        │ │
│ │                                        │ PR191670). R. T. and M. W. are         │        │ │
│ │                                        │ supported by an Ad Astra Fellowship.   │        │ │
│ │                                        │ A. E. J. was supported by the          │        │ │
│ │                                        │ $\frac{10.13039}{100007185}$UCLA Tumor │        │ │
│ │                                        │ Cell Biology Training Program (grant   │        │ │
│ │                                        │ no.: T32 CA009056). The content is     │        │ │
│ │                                        │ solely the responsibility of the       │        │ │
│ │                                        │ authors and does not necessarily       │        │ │
│ │                                        │ represent the official views of the    │        │ │
│ │                                        │ National Institutes of Health.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. McGarrah R.W., White P.J..          │        │ │
│ │                                        │ **Branched-chain amino acids in        │        │ │
│ │                                        │ cardiovascular disease**. *Nat. Rev.   │        │ │
│ │                                        │ Cardiol.* (2023) **20** 77-89. PMID:   │        │ │
│ │                                        │ 36064969                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. White P.J., Newgard C.B..           │        │ │
│ │                                        │ **Branched-chain amino acids in        │        │ │
│ │                                        │ disease**. *Science (New York, N.Y.)*  │        │ │
│ │                                        │ (2019) **363** 582-583. PMID: 30733403 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Sun H., Wang Y.. **Branched chain   │        │ │
│ │                                        │ amino acid metabolic reprogramming in  │        │ │
│ │                                        │ heart failure**. *Biochim. Biophys.    │        │ │
│ │                                        │ Acta Mol. Basis Dis.* (2016) **1862**  │        │ │
│ │                                        │ 2270-2275                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Neinast M., Murashige D., Arany Z.. │        │ │
│ │                                        │ **Branched chain amino acids**. *Annu. │        │ │
│ │                                        │ Rev. Physiol.* (2019) **81** 139-164.  │        │ │
│ │                                        │ PMID: 30485760                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Vanweert F., Schrauwen P., Phielix  │        │ │
│ │                                        │ E.. **Role of branched-chain amino     │        │ │
│ │                                        │ acid metabolism in the pathogenesis of │        │ │
│ │                                        │ obesity and type 2 diabetes-related    │        │ │
│ │                                        │ metabolic disturbances BCAA metabolism │        │ │
│ │                                        │ in type 2 diabetes**. *Nutr. Diabetes* │        │ │
│ │                                        │ (2022) **12** 35. PMID: 35931683       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Felig P., Marliss E., Cahill G.F..  │        │ │
│ │                                        │ **Plasma amino acid levels and insulin │        │ │
│ │                                        │ secretion in obesity**. *New Engl. J.  │        │ │
│ │                                        │ Med.* (1969) **281** 811-816. PMID:    │        │ │
│ │                                        │ 5809519                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. White P.J., McGarrah R.W., Herman   │        │ │
│ │                                        │ M.A., Bain J.R., Shah S.H., Newgard    │        │ │
│ │                                        │ C.B.. **Insulin action, type 2         │        │ │
│ │                                        │ diabetes, and branched-chain amino     │        │ │
│ │                                        │ acids: a two-way street**. *Mol.       │        │ │
│ │                                        │ Metab.* (2021) **52**. DOI:            │        │ │
│ │                                        │ 10.1016/J.MOLMET.2021.101261           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Newgard C.B., An J., Bain J.R.,     │        │ │
│ │                                        │ Muehlbauer M.J., Stevens R.D., Lien    │        │ │
│ │                                        │ L.F.. **A branched-chain amino         │        │ │
│ │                                        │ acid-related metabolic signature that  │        │ │
│ │                                        │ differentiates obese and lean humans   │        │ │
│ │                                        │ and contributes to insulin             │        │ │
│ │                                        │ resistance**. *Cell Metab.* (2009)     │        │ │
│ │                                        │ **9** 311-326. PMID: 19356713          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Wang T.J., Larson M.G., Vasan R.S., │        │ │
│ │                                        │ Cheng S., Rhee E.P., McCabe E..        │        │ │
│ │                                        │ **Metabolite profiles and the risk of  │        │ │
│ │                                        │ developing diabetes**. *Nat. Med.*     │        │ │
│ │                                        │ (2011) **17** 448-453. PMID: 21423183  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Flores-Guerrero J.L., Groothof D., │        │ │
│ │                                        │ Connelly M.A., Otvos J.D., Bakker      │        │ │
│ │                                        │ S.J.L., Dullaart R.P.F..               │        │ │
│ │                                        │ **Concentration of branched-chain      │        │ │
│ │                                        │ amino acids is a strong risk marker    │        │ │
│ │                                        │ for incident hypertension**.           │        │ │
│ │                                        │ *Hypertension* (2019) **74**           │        │ │
│ │                                        │ 1428-1435. PMID: 31587574              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Tobias D.K., Lawler P.R., Harada   │        │ │
│ │                                        │ P.H., Demler O.V., Ridker P.M., Manson │        │ │
│ │                                        │ J.A.E.. **Circulating branched-chain   │        │ │
│ │                                        │ amino acids and incident               │        │ │
│ │                                        │ cardiovascular disease in a            │        │ │
│ │                                        │ prospective cohort of US women**.      │        │ │
│ │                                        │ *Circ. Genomic Precision Med.* (2018)  │        │ │
│ │                                        │ **11**                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Sun H., Olson K.C., Gao C.,        │        │ │
│ │                                        │ Prosdocimo D.A., Zhou M., Wang Z..     │        │ │
│ │                                        │ **Catabolic defect of branched-chain   │        │ │
│ │                                        │ amino acids promotes heart failure**.  │        │ │
│ │                                        │ *Circulation* (2016) **133**           │        │ │
│ │                                        │ 2038-2049. PMID: 27059949              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Bhattacharya S., Granger C.B.,     │        │ │
│ │                                        │ Craig D., Haynes C., Bain J., Stevens  │        │ │
│ │                                        │ R.D.. **Validation of the association  │        │ │
│ │                                        │ between a branched chain amino acid    │        │ │
│ │                                        │ metabolite profile and extremes of     │        │ │
│ │                                        │ coronary artery disease in patients    │        │ │
│ │                                        │ referred for cardiac                   │        │ │
│ │                                        │ catheterization**. *Atherosclerosis*   │        │ │
│ │                                        │ (2014) **232** 191-196. PMID: 24401236 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Portero V., Nicol T., Podliesna    │        │ │
│ │                                        │ S., Marchal G.A., Baartscheer A.,      │        │ │
│ │                                        │ Casini S.. **Chronically elevated      │        │ │
│ │                                        │ branched chain amino acid levels are   │        │ │
│ │                                        │ pro-arrhythmic**. *Cardiovasc. Res.*   │        │ │
│ │                                        │ (2022) **118** 1742. PMID: 34142125    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Shah S.H., Sun J.L., Stevens R.D., │        │ │
│ │                                        │ Bain J.R., Muehlbauer M.J., Pieper     │        │ │
│ │                                        │ K.S.. **Baseline metabolomic profiles  │        │ │
│ │                                        │ predict cardiovascular events in       │        │ │
│ │                                        │ patients at risk for coronary artery   │        │ │
│ │                                        │ disease**. *Am. Heart J.* (2012)       │        │ │
│ │                                        │ **163** 844-850.e1. PMID: 22607863     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Lu G., Sun H., She P., Youn J.Y.,  │        │ │
│ │                                        │ Warburton S., Ping P.. **Protein       │        │ │
│ │                                        │ phosphatase 2Cm is a critical          │        │ │
│ │                                        │ regulator of branched-chain amino acid │        │ │
│ │                                        │ catabolism in mice and cultured        │        │ │
│ │                                        │ cells**. *J. Clin. Invest.* (2009)     │        │ │
│ │                                        │ **119** 1678-1687. PMID: 19411760      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. Harris R.A., Joshi M., Jeoung      │        │ │
│ │                                        │ N.H., Obayashi M.. **Overview of the   │        │ │
│ │                                        │ molecular and biochemical basis of     │        │ │
│ │                                        │ branched-chain amino acid              │        │ │
│ │                                        │ catabolism**. *J. Nutr.* (2005)        │        │ │
│ │                                        │ **135**. DOI: 10.1093/JN/135.6.1527S   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Cummings N.E., Williams E.M.,      │        │ │
│ │                                        │ Kasza I., Konon E.N., Schaid M.D.,     │        │ │
│ │                                        │ Schmidt B.A.. **Restoration of         │        │ │
│ │                                        │ metabolic health by decreased          │        │ │
│ │                                        │ consumption of branched-chain amino    │        │ │
│ │                                        │ acids**. *J. Physiol.* (2018) **596**  │        │ │
│ │                                        │ 623-645. PMID: 29266268                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Wang W., Zhang F., Xia Y., Zhao    │        │ │
│ │                                        │ S., Yan W., Wang H.. **Defective       │        │ │
│ │                                        │ branched chain amino acid catabolism   │        │ │
│ │                                        │ contributes to cardiac dysfunction and │        │ │
│ │                                        │ remodeling following myocardial        │        │ │
│ │                                        │ infarction**. *Am. J. Physiol. Heart   │        │ │
│ │                                        │ Circ. Physiol.* (2016) **311**         │        │ │
│ │                                        │ H1160-H1169. PMID: 27542406            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. Li T., Zhang Z., Kolwicz S.C.,     │        │ │
│ │                                        │ Raftery D., Sun H., Correspondence     │        │ │
│ │                                        │ R.T.. **Defective branched-chain amino │        │ │
│ │                                        │ acid catabolism disrupts glucose       │        │ │
│ │                                        │ metabolism and sensitizes the heart to │        │ │
│ │                                        │ ischemia-reperfusion injury**. *Cell   │        │ │
│ │                                        │ Metab.* (2017) **25** 374-385. PMID:   │        │ │
│ │                                        │ 28178567                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Lian K., Guo X., Wang Q., Liu Y.,  │        │ │
│ │                                        │ Wang R.T., Gao C.. **PP2Cm             │        │ │
│ │                                        │ overexpression alleviates MI/R injury  │        │ │
│ │                                        │ mediated by a BCAA catabolism defect   │        │ │
│ │                                        │ and oxidative stress in diabetic       │        │ │
│ │                                        │ mice**. *Eur. J. Pharmacol.* (2020)    │        │ │
│ │                                        │ **866**. DOI:                          │        │ │
│ │                                        │ 10.1016/J.EJPHAR.2019.172796           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. White P.J., McGarrah R.W.,         │        │ │
│ │                                        │ Grimsrud P.A., Tso S.C., Yang W.H.,    │        │ │
│ │                                        │ Haldeman J.M.. **The BCKDH kinase and  │        │ │
│ │                                        │ phosphatase integrate BCAA and lipid   │        │ │
│ │                                        │ metabolism via regulation of           │        │ │
│ │                                        │ ATP-citrate lyase**. *Cell Metab.*     │        │ │
│ │                                        │ (2018) **27** 1281-1293.e7. PMID:      │        │ │
│ │                                        │ 29779826                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Tso S.C., Gui W.J., Wu C.Y.,       │        │ │
│ │                                        │ Chuang J.L., Qi X., Skvorak K.J..      │        │ │
│ │                                        │ **Benzothiophene carboxylate           │        │ │
│ │                                        │ derivatives as novel allosteric        │        │ │
│ │                                        │ inhibitors of branched-chain           │        │ │
│ │                                        │ α-ketoacid dehydrogenase kinase**. *J. │        │ │
│ │                                        │ Biol. Chem.* (2014) **289**            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Zhou M., Shao J., Wu C.Y., Shu L., │        │ │
│ │                                        │ Dong W., Liu Y.. **Targeting BCAA      │        │ │
│ │                                        │ catabolism to treat obesity-associated │        │ │
│ │                                        │ insulin resistance**. *Diabetes*       │        │ │
│ │                                        │ (2019) **68** 1730-1746. PMID:         │        │ │
│ │                                        │ 31167878                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Vanweert F., Neinast M., Tapia     │        │ │
│ │                                        │ E.E., van de Weijer T., Hoeks J.,      │        │ │
│ │                                        │ Schrauwen-Hinderling V.B.. **A         │        │ │
│ │                                        │ randomized placebo-controlled clinical │        │ │
│ │                                        │ trial for pharmacological activation   │        │ │
│ │                                        │ of BCAA catabolism in patients with    │        │ │
│ │                                        │ type 2 diabetes**. *Nat. Commun.*      │        │ │
│ │                                        │ (2022) **13**. DOI:                    │        │ │
│ │                                        │ 10.1038/S41467-022-31249-9             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Bollinger E., Peloquin M., Libera  │        │ │
│ │                                        │ J., Albuquerque B., Pashos E.,         │        │ │
│ │                                        │ Shipstone A.. **BDK inhibition acts as │        │ │
│ │                                        │ a catabolic switch to mimic fasting    │        │ │
│ │                                        │ and improve metabolism in mice**.      │        │ │
│ │                                        │ *Mol. Metab.* (2022) **66**. DOI:      │        │ │
│ │                                        │ 10.1016/J.MOLMET.2022.101611           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. Murashige D., Jung J.W., Neinast   │        │ │
│ │                                        │ M.D., Levin M.G., Chu Q., Lambert      │        │ │
│ │                                        │ J.P.. **Extra-cardiac BCAA catabolism  │        │ │
│ │                                        │ lowers blood pressure and protects     │        │ │
│ │                                        │ from heart failure**. *Cell Metab.*    │        │ │
│ │                                        │ (2022) **34** 1749-1764.e7. PMID:      │        │ │
│ │                                        │ 36223763                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Murashige D., Jang C., Neinast M., │        │ │
│ │                                        │ Edwards J.J., Cowan A., Hyman M.C..    │        │ │
│ │                                        │ **Comprehensive quantification of fuel │        │ │
│ │                                        │ use by the failing and nonfailing      │        │ │
│ │                                        │ human heart**. *Science (New York,     │        │ │
│ │                                        │ N.Y.)* (2020) **370** 364-368. PMID:   │        │ │
│ │                                        │ 33060364                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Blair M.C., Neinast M.D., Jang C., │        │ │
│ │                                        │ Chu Q., Jung J.W., Axsom J..           │        │ │
│ │                                        │ **Branched-chain amino acid catabolism │        │ │
│ │                                        │ in muscle affects systemic BCAA levels │        │ │
│ │                                        │ but not insulin resistance**. *Nat.    │        │ │
│ │                                        │ Metab.* (2023) **5** 589-606. PMID:    │        │ │
│ │                                        │ 37100997                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Divakaruni A.S., Jastroch M.. **A  │        │ │
│ │                                        │ practical guide for the analysis,      │        │ │
│ │                                        │ standardization and interpretation of  │        │ │
│ │                                        │ oxygen consumption measurements**.     │        │ │
│ │                                        │ *Nat. Metab.* (2022) **4** 978-994.    │        │ │
│ │                                        │ PMID: 35971004                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Divakaruni A.S., Brand M.D.. **The │        │ │
│ │                                        │ regulation and physiology of           │        │ │
│ │                                        │ mitochondrial proton leak**.           │        │ │
│ │                                        │ *Physiology (Bethesda, Md.)* (2011).   │        │ │
│ │                                        │ DOI: 10.1152/physiol.00046.2010        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Brand M.D., Nicholls D.G..         │        │ │
│ │                                        │ **Assessing mitochondrial dysfunction  │        │ │
│ │                                        │ in cells**. *Biochem. J.* (2011). DOI: │        │ │
│ │                                        │ 10.1042/BJ20110162                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Orr A.L., Quinlan C.L.,            │        │ │
│ │                                        │ Perevoshchikova I.V., Brand M.D.. **A  │        │ │
│ │                                        │ refined analysis of superoxide         │        │ │
│ │                                        │ production by mitochondrial            │        │ │
│ │                                        │ sn-glycerol 3-phosphate                │        │ │
│ │                                        │ dehydrogenase**. *J. Biol. Chem.*      │        │ │
│ │                                        │ (2012) **287** 42921-42935. PMID:      │        │ │
│ │                                        │ 23124204                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 34. Bertholet A.M., Kirichok Y..       │        │ │
│ │                                        │ **Mitochondrial H + leak and           │        │ │
│ │                                        │ thermogenesis**. *Annu. Rev. Physiol.* │        │ │
│ │                                        │ (2022) **84** 381-407. PMID: 34758268  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 35. Bertholet A.M., Natale A.M.,       │        │ │
│ │                                        │ Bisignano P., Suzuki J., Fedorenko A., │        │ │
│ │                                        │ Hamilton J.. **Mitochondrial           │        │ │
│ │                                        │ uncouplers induce proton leak by       │        │ │
│ │                                        │ activating AAC and UCP1**. *Nature*    │        │ │
│ │                                        │ (2022) **606** 180-187. PMID: 35614225 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 36. Nicholls D.G., Ferguson S.J..      │        │ │
│ │                                        │ (2013)                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 37. Andreyev A.Y., Bondareva T.O.,     │        │ │
│ │                                        │ Dedukhova V.I., Mokhova E.N.,          │        │ │
│ │                                        │ Skulachev V.P., Volkov N.I..           │        │ │
│ │                                        │ **Carboxyatractylate inhibits the      │        │ │
│ │                                        │ uncoupling effect of free fatty        │        │ │
│ │                                        │ acids**. *FEBS Lett.* (1988) **226**   │        │ │
│ │                                        │ 265-269. PMID: 3338558                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 38. Lou P.H., Hansen B.S., Olsen P.H., │        │ │
│ │                                        │ Tullin S., Murphy M.P., Brand M.D..    │        │ │
│ │                                        │ **Mitochondrial uncouplers with an     │        │ │
│ │                                        │ extraordinary dynamic range**.         │        │ │
│ │                                        │ *Biochem. J.* (2007) **407** 129-140.  │        │ │
│ │                                        │ PMID: 17608618                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 39. Korshunov S.S., Skulachev V.P.,    │        │ │
│ │                                        │ Starkov A.A.. **High protonic          │        │ │
│ │                                        │ potential actuates a mechanism of      │        │ │
│ │                                        │ production of reactive oxygen species  │        │ │
│ │                                        │ in mitochondria**. *FEBS Lett.* (1997) │        │ │
│ │                                        │ **416** 15-18. PMID: 9369223           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 40. Robb E.L., Hall A.R., Prime T.A.,  │        │ │
│ │                                        │ Eaton S., Szibor M., Viscomi C..       │        │ │
│ │                                        │ **Control of mitochondrial superoxide  │        │ │
│ │                                        │ production by reverse electron         │        │ │
│ │                                        │ transport at complex I**. *J. Biol.    │        │ │
│ │                                        │ Chem.* (2018). DOI:                    │        │ │
│ │                                        │ 10.1074/jbc.RA118.003647               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 41. Affourtit C., Quinlan C.L., Brand  │        │ │
│ │                                        │ M.D.. **Measurement of proton leak and │        │ │
│ │                                        │ electron leak in isolated              │        │ │
│ │                                        │ mitochondria**. *Methods Mol. Biol.*   │        │ │
│ │                                        │ (2012). DOI:                           │        │ │
│ │                                        │ 10.1007/978-1-61779-382-0_11           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 42. Goedeke L., Perry R.J., Shulman    │        │ │
│ │                                        │ G.I.. **Emerging pharmacological       │        │ │
│ │                                        │ targets for the treatment of           │        │ │
│ │                                        │ nonalcoholic fatty liver disease,      │        │ │
│ │                                        │ insulin resistance, and type 2         │        │ │
│ │                                        │ diabetes**. *Annu. Rev. Pharmacol.     │        │ │
│ │                                        │ Toxicol.* (2019) **59** 65-87. PMID:   │        │ │
│ │                                        │ 30625285                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 43. Childress E.S., Alexopoulos S.J.,  │        │ │
│ │                                        │ Hoehn K.L., Santos W.L.. **Small       │        │ │
│ │                                        │ molecule mitochondrial uncouplers and  │        │ │
│ │                                        │ their therapeutic potential**. *J.     │        │ │
│ │                                        │ Med. Chem.* (2018) **61** 4641-4655.   │        │ │
│ │                                        │ PMID: 29156129                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 44. Kajimura S., Saito M.. **A new era │        │ │
│ │                                        │ in Brown adipose tissue Biology:       │        │ │
│ │                                        │ molecular control of Brown fat         │        │ │
│ │                                        │ development and energy homeostasis**.  │        │ │
│ │                                        │ *Annu. Rev. Physiol.* (2014) **76**    │        │ │
│ │                                        │ 225-249. PMID: 24188710                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 45. Cannon B., Nedergaard J.. **Brown  │        │ │
│ │                                        │ adipose tissue: function and           │        │ │
│ │                                        │ physiological significance**.          │        │ │
│ │                                        │ *Physiol. Rev.* (2004). DOI:           │        │ │
│ │                                        │ 10.1152/physrev.00015.2003             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 46. Perry R.J., Zhang D., Zhang X.M.,  │        │ │
│ │                                        │ Boyer J.L., Shulman G.I..              │        │ │
│ │                                        │ **Controlled-release mitochondrial     │        │ │
│ │                                        │ protonophore reverses diabetes and     │        │ │
│ │                                        │ protonophore reverses diabetes and     │        │ │
│ │                                        │ steatohepatitis in rats**. *Science*   │        │ │
│ │                                        │ (2015) **347** 1253-1256. PMID:        │        │ │
│ │                                        │ 25721504                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 47. Kharroubi A.T., Masterson T.M.,    │        │ │
│ │                                        │ Aldaghlas T.A., Kennedy K.A., Kelleher │        │ │
│ │                                        │ J.K.. **Isotopomer spectral analysis   │        │ │
│ │                                        │ of triglyceride fatty acid synthesis   │        │ │
│ │                                        │ in 3T3-L1 cells**. *Am J Physiol       │        │ │
│ │                                        │ Endocrinol Metab* (1992) **263**       │        │ │
│ │                                        │ E667-E675                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 48. Cadenas S.. **ROS and redox        │        │ │
│ │                                        │ signaling in myocardial                │        │ │
│ │                                        │ ischemia-reperfusion injury and        │        │ │
│ │                                        │ cardioprotection**. *Free Radic. Biol. │        │ │
│ │                                        │ Med.* (2018) **117** 76-89. PMID:      │        │ │
│ │                                        │ 29373843                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 49. Peoples J.N., Saraf A., Ghazal N., │        │ │
│ │                                        │ Pham T.T., Kwong J.Q.. **Mitochondrial │        │ │
│ │                                        │ dysfunction and oxidative stress in    │        │ │
│ │                                        │ heart disease**. *Exp. Mol. Med.*      │        │ │
│ │                                        │ (2019) **51** 1-13                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 50. Weissman D., Maack C.. **Redox     │        │ │
│ │                                        │ signaling in heart failure and         │        │ │
│ │                                        │ therapeutic implications**. *Free      │        │ │
│ │                                        │ Radic. Biol. Med.* (2021) **171**      │        │ │
│ │                                        │ 345-364. PMID: 34019933                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 51. Chouchani E.T., Pell V.R., James   │        │ │
│ │                                        │ A.M., Work L.M., Saeb-Parsy K., Frezza │        │ │
│ │                                        │ C.. **A unifying mechanism for         │        │ │
│ │                                        │ mitochondrial superoxide production    │        │ │
│ │                                        │ during ischemia-reperfusion injury**.  │        │ │
│ │                                        │ *Cell Metab.* (2016) **23** 254-263.   │        │ │
│ │                                        │ PMID: 26777689                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 52. Murphy M.P.. **How mitochondria    │        │ │
│ │                                        │ produce reactive oxygen species**.     │        │ │
│ │                                        │ *Biochem. J.* (2009) **417** 1-13.     │        │ │
│ │                                        │ PMID: 19061483                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 53. Murphy E., Steenbergen C..         │        │ │
│ │                                        │ **Regulation of mitochondrial Ca2+     │        │ │
│ │                                        │ uptake**. *Annu. Rev. Physiol.* (2021) │        │ │
│ │                                        │ **83** 107-126. PMID: 33141632         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 54. Finkel T., Menazza S., Holmström   │        │ │
│ │                                        │ K.M., Parks R.J., Liu J., Sun J..      │        │ │
│ │                                        │ **The ins and outs of mitochondrial    │        │ │
│ │                                        │ calcium**. *Circ. Res.* (2015). DOI:   │        │ │
│ │                                        │ 10.1161/CIRCRESAHA.116.305484          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 55. Bernardi P.. **The mitochondrial   │        │ │
│ │                                        │ permeability transition pore: a        │        │ │
│ │                                        │ mystery solved?**. *Front. Physiol.*   │        │ │
│ │                                        │ (2013). DOI: 10.3389/fphys.2013.00095  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 56. Reynolds I.J., Hastings T.G..      │        │ │
│ │                                        │ **Glutamate induces the production of  │        │ │
│ │                                        │ reactive oxygen species in cultured    │        │ │
│ │                                        │ forebrain neurons following NMDA       │        │ │
│ │                                        │ receptor activation**. *J. Neurosci.*  │        │ │
│ │                                        │ (1995) **15** 3318-3327. PMID: 7751912 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 57. Brennan J.P., Southworth R.,       │        │ │
│ │                                        │ Medina R.A., Davidson S.M., Duchen     │        │ │
│ │                                        │ M.R., Shattock M.J.. **Mitochondrial   │        │ │
│ │                                        │ uncoupling, with low concentration     │        │ │
│ │                                        │ FCCP, induces ROS-dependent            │        │ │
│ │                                        │ cardioprotection independent of KATP   │        │ │
│ │                                        │ channel activation**. *Cardiovasc.     │        │ │
│ │                                        │ Res.* (2006) **72** 313-321. PMID:     │        │ │
│ │                                        │ 16950237                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 58. Minners J., Van Den Bos E.J.,      │        │ │
│ │                                        │ Yellon D.M., Schwalb H., Opie L.H.,    │        │ │
│ │                                        │ Sack M.N.. **Dinitrophenol,            │        │ │
│ │                                        │ cyclosporin A, and trimetazidine       │        │ │
│ │                                        │ modulate preconditioning in the        │        │ │
│ │                                        │ isolated rat heart: support for a      │        │ │
│ │                                        │ mitochondrial role in                  │        │ │
│ │                                        │ cardioprotection**. *Cardiovasc. Res.* │        │ │
│ │                                        │ (2000) **47** 68-73. PMID: 10869531    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 59. Hoerter J., Gonzalez-Barroso       │        │ │
│ │                                        │ M.D.M., Couplan E., Mateo P., Gelly    │        │ │
│ │                                        │ C., Cassard-Doulcier A.M..             │        │ │
│ │                                        │ **Mitochondrial uncoupling protein 1   │        │ │
│ │                                        │ expressed in the heart of transgenic   │        │ │
│ │                                        │ mice protects against                  │        │ │
│ │                                        │ ischemic-reperfusion damage**.         │        │ │
│ │                                        │ *Circulation* (2004) **110** 528-533.  │        │ │
│ │                                        │ PMID: 15262832                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 60. Leak M.H.+., Ambre T., Bertholet   │        │ │
│ │                                        │ M., Kirichok Y.. *Annu. Rev. Physiol.* │        │ │
│ │                                        │ (2021). DOI:                           │        │ │
│ │                                        │ 10.1146/annurev-physiol-021119         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 61. Harper J.A., Dickinson K., Brand   │        │ │
│ │                                        │ M.D.. **Mitochondrial uncoupling as a  │        │ │
│ │                                        │ target for drug development for the    │        │ │
│ │                                        │ treatment of obesity**. *Obes. Rev.*   │        │ │
│ │                                        │ (2001) **2** 255-265. PMID: 12119996   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 62. Grundlingh J., Dargan P.I.,        │        │ │
│ │                                        │ El-Zanfaly M., Wood D.M..              │        │ │
│ │                                        │ **2,4-Dinitrophenol (DNP): a weight    │        │ │
│ │                                        │ loss agent with significant acute      │        │ │
│ │                                        │ toxicity and risk of death**. *J. Med. │        │ │
│ │                                        │ Toxicol.* (2011) **7** 205. PMID:      │        │ │
│ │                                        │ 21739343                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 63. Abulizi A., Perry R.J., Camporez   │        │ │
│ │                                        │ J.P.G., Jurczak M.J., Petersen K.F.,   │        │ │
│ │                                        │ Aspichueta P.. **A controlled-release  │        │ │
│ │                                        │ mitochondrial protonophore reverses    │        │ │
│ │                                        │ hypertriglyceridemia, nonalcoholic     │        │ │
│ │                                        │ steatohepatitis, and diabetes in       │        │ │
│ │                                        │ lipodystrophic mice**. *FASEB J.*      │        │ │
│ │                                        │ (2017) **31** 2916-2924. PMID:         │        │ │
│ │                                        │ 28330852                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 64. Alexopoulos S.J., Chen S.Y.,       │        │ │
│ │                                        │ Brandon A.E., Salamoun J.M., Byrne     │        │ │
│ │                                        │ F.L., Garcia C.J.. **Mitochondrial     │        │ │
│ │                                        │ uncoupler BAM15 reverses diet-induced  │        │ │
│ │                                        │ obesity and insulin resistance in      │        │ │
│ │                                        │ mice**. *Nat. Commun.* (2020) **11**.  │        │ │
│ │                                        │ DOI: 10.1038/S41467-020-16298-2        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 65. Voronova V., Sokolov V., Morias    │        │ │
│ │                                        │ Y., Boezelman M.J., Wågberg M.,        │        │ │
│ │                                        │ Henricsson M.. **Evaluation of         │        │ │
│ │                                        │ therapeutic strategies targeting BCAA  │        │ │
│ │                                        │ catabolism using a systems             │        │ │
│ │                                        │ pharmacology model**. *Front.          │        │ │
│ │                                        │ Pharmacol.* (2022) **13**              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 66. Meyer L.F., Rajadhyaksha P.M.,     │        │ │
│ │                                        │ Shah D.K.. **Physiologically-based     │        │ │
│ │                                        │ pharmacokinetic model for              │        │ │
│ │                                        │ 2,4-dinitrophenol**. *J.               │        │ │
│ │                                        │ Pharmacokinet. Pharmacodynamics*       │        │ │
│ │                                        │ (2022) **49** 325-336                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 67. Roth Flach R.J., Bollinger E.,     │        │ │
│ │                                        │ Reyes A.R., Laforest B., Kormos B.L.,  │        │ │
│ │                                        │ Liu S.. **Small molecule               │        │ │
│ │                                        │ branched-chain ketoacid dehydrogenase  │        │ │
│ │                                        │ kinase (BDK) inhibitors with opposing  │        │ │
│ │                                        │ effects on BDK protein levels**. *Nat. │        │ │
│ │                                        │ Commun.* (2023) **14** 1-14. PMID:     │        │ │
│ │                                        │ 36596776                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 68. Liu S., Kormos B.L., Knafels J.D., │        │ │
│ │                                        │ Sahasrabudhe P.V., Rosado A., Sommese  │        │ │
│ │                                        │ R.F.. **Structural studies identify    │        │ │
│ │                                        │ angiotensin II receptor blocker-like   │        │ │
│ │                                        │ compounds as branched-chain ketoacid   │        │ │
│ │                                        │ dehydrogenase kinase inhibitors**. *J. │        │ │
│ │                                        │ Biol. Chem.* (2023) **299**            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 69. Nishi K., Yoshii A., Abell L.,     │        │ │
│ │                                        │ Zhou B., Frausto R., Ritterhoff J..    │        │ │
│ │                                        │ **Branched-chain keto acids inhibit    │        │ │
│ │                                        │ mitochondrial pyruvate carrier and     │        │ │
│ │                                        │ suppress gluconeogenesis in            │        │ │
│ │                                        │ hepatocytes**. *Cell Rep.* (2023)      │        │ │
│ │                                        │ **42**. DOI:                           │        │ │
│ │                                        │ 10.1016/J.CELREP.2023.112641           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 70. Hue L., Taegtmeyer H.. **The       │        │ │
│ │                                        │ Randle cycle revisited: a new head for │        │ │
│ │                                        │ an old hat**. *Am. J. Physiol.         │        │ │
│ │                                        │ Endocrinol. Metab.* (2009). DOI:       │        │ │
│ │                                        │ 10.1152/ajpendo.00093.2009             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 71. Chen M.J., Dixon J.E., Manning G.. │        │ │
│ │                                        │ **Genomics and evolution of protein    │        │ │
│ │                                        │ phosphatases**. *Sci. Signal.* (2017)  │        │ │
│ │                                        │ **10** eaag1796. PMID: 28400531        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 72. Joshi M.A., Jeoung N.H., Obayashi  │        │ │
│ │                                        │ M., Hattab E.M., Brocken E.G., Liechty │        │ │
│ │                                        │ E.A.. **Impaired growth and            │        │ │
│ │                                        │ neurological abnormalities in          │        │ │
│ │                                        │ branched-chain alpha-keto acid         │        │ │
│ │                                        │ dehydrogenase kinase-deficient mice**. │        │ │
│ │                                        │ *Biochem. J.* (2006) **400** 153-162.  │        │ │
│ │                                        │ PMID: 16875466                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 73. Rubio M., Avitabile D., Fischer    │        │ │
│ │                                        │ K., Emmanuel G., Gude N., Miyamoto S.. │        │ │
│ │                                        │ **Cardioprotective stimuli mediate     │        │ │
│ │                                        │ phosphoinositide 3-kinase and          │        │ │
│ │                                        │ phosphoinositide dependent kinase 1    │        │ │
│ │                                        │ nuclear accumulation in                │        │ │
│ │                                        │ cardiomyocytes**. *J. Mol. Cell        │        │ │
│ │                                        │ Cardiol.* (2009) **47** 96-103. PMID:  │        │ │
│ │                                        │ 19269295                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 74. Li S., Yokota T., Wang P., ten     │        │ │
│ │                                        │ Hoeve J., Ma F., Le T.M..              │        │ │
│ │                                        │ **Cardiomyocytes disrupt pyrimidine    │        │ │
│ │                                        │ biosynthesis in nonmyocytes to         │        │ │
│ │                                        │ regulate heart repair**. *J. Clin.     │        │ │
│ │                                        │ Invest.* (2022) **132**. DOI:          │        │ │
│ │                                        │ 10.1172/JCI149711                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 75. Acín-Pérez R., Montales K.P.,      │        │ │
│ │                                        │ Nguyen K.B., Brownstein A.J., Stiles   │        │ │
│ │                                        │ L., Divakaruni A.S.. **Isolation of    │        │ │
│ │                                        │ mitochondria from mouse tissues for    │        │ │
│ │                                        │ functional analysis**. *Methods Mol.   │        │ │
│ │                                        │ Biol. (Clifton, N.J.)* (2023) **2675** │        │ │
│ │                                        │ 77-96                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 76. Divakaruni A.S., Paradyse A.,      │        │ │
│ │                                        │ Ferrick D.A., Murphy A.N., Jastroch    │        │ │
│ │                                        │ M.. **Analysis and interpretation of   │        │ │
│ │                                        │ microplate-based oxygen consumption    │        │ │
│ │                                        │ and pH data**. *Methods Enzymol.*      │        │ │
│ │                                        │ (2014) **547** 309-354. PMID: 25416364 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 77. Yang K., Doan M.T., Stiles L.,     │        │ │
│ │                                        │ Divakaruni A.S.. **Measuring           │        │ │
│ │                                        │ CPT-1-mediated respiration in          │        │ │
│ │                                        │ permeabilized cells and isolated       │        │ │
│ │                                        │ mitochondria**. *STAR Protoc.* (2021)  │        │ │
│ │                                        │ **2**. DOI: 10.1016/J.XPRO.2021.100687 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 78. Rogers G.W., Brand M.D., Petrosyan │        │ │
│ │                                        │ S., Ashok D., Elorza A.A., Ferrick     │        │ │
│ │                                        │ D.A.. **High throughput microplate     │        │ │
│ │                                        │ respiratory measurements using minimal │        │ │
│ │                                        │ quantities of isolated mitochondria**. │        │ │
│ │                                        │ *PLoS One* (2011). DOI:                │        │ │
│ │                                        │ 10.1371/journal.pone.0021746           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 79. Orr A.L., Ashok D., Sarantos M.R., │        │ │
│ │                                        │ Ng R., Shi T., Gerencser A.A.. **Novel │        │ │
│ │                                        │ inhibitors of mitochondrial            │        │ │
│ │                                        │ sn-glycerol 3-phosphate                │        │ │
│ │                                        │ dehydrogenase**. *PLoS One* (2014)     │        │ │
│ │                                        │ **9**                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 80. Bertholet A.M.. **The use of the   │        │ │
│ │                                        │ patch-clamp technique to study the     │        │ │
│ │                                        │ thermogenic capacity of                │        │ │
│ │                                        │ mitochondria**. *J. Vis. Exp.* (2021)  │        │ │
│ │                                        │ **2021**. DOI: 10.3791/62618           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 81. Vacanti N.M., Divakaruni A.S.,     │        │ │
│ │                                        │ Green C.R., Parker S.J., Henry R.R.,   │        │ │
│ │                                        │ Ciaraldi T.P.. **Regulation of         │        │ │
│ │                                        │ substrate utilization by the           │        │ │
│ │                                        │ mitochondrial pyruvate carrier**.      │        │ │
│ │                                        │ *Mol. Cell* (2014). DOI:               │        │ │
│ │                                        │ 10.1016/j.molcel.2014.09.024           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 82. Cordes T., Metallo C.M..           │        │ │
│ │                                        │ **Quantifying intermediary metabolism  │        │ │
│ │                                        │ and lipogenesis in cultured mammalian  │        │ │
│ │                                        │ cells using stable isotope tracing and │        │ │
│ │                                        │ mass spectrometry**. *Methods Mol.     │        │ │
│ │                                        │ Biol.* (2019) **1978** 219-241. PMID:  │        │ │
│ │                                        │ 31119666                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 83. Trefely S., Ashwell P., Snyder     │        │ │
│ │                                        │ N.W.. **FluxFix: automatic             │        │ │
│ │                                        │ isotopologue normalization for         │        │ │
│ │                                        │ metabolic tracer analysis**. *BMC      │        │ │
│ │                                        │ Bioinform.* (2016). DOI:               │        │ │
│ │                                        │ 10.1186/s12859-016-1360-7              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 84. Chen M., Gao C., Yu J., Ren S.,    │        │ │
│ │                                        │ Wang M., Wynn R.M.. **Therapeutic      │        │ │
│ │                                        │ effect of targeting branched-chain     │        │ │
│ │                                        │ amino acid catabolic flux in           │        │ │
│ │                                        │ pressure-overload induced heart        │        │ │
│ │                                        │ failure**. *J. Am. Heart Assoc.*       │        │ │
│ │                                        │ (2019) **8**. DOI:                     │        │ │
│ │                                        │ 10.1161/JAHA.118.011625                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │ title: Impaired branched chain amino   │        │ │
│ │                                        │ acid oxidation contributes to cardiac  │        │ │
│ │                                        │ insulin                                │        │ │
│ │                                        │   resistance in heart failure          │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Golam M. Uddin                       │        │ │
│ │                                        │ - Liyan Zhang                          │        │ │
│ │                                        │ - Saumya Shah                          │        │ │
│ │                                        │ - Arata Fukushima                      │        │ │
│ │                                        │ - Cory S. Wagg                         │        │ │
│ │                                        │ - Keshav Gopal                         │        │ │
│ │                                        │ - Rami Al Batran                       │        │ │
│ │                                        │ - Simran Pherwani                      │        │ │
│ │                                        │ - Kim L. Ho                            │        │ │
│ │                                        │ - Jamie Boisvenue                      │        │ │
│ │                                        │ - Qutuba G. Karwi                      │        │ │
│ │                                        │ - Tariq Altamimi                       │        │ │
│ │                                        │ - David S. Wishart                     │        │ │
│ │                                        │ - Jason R. B. Dyck                     │        │ │
│ │                                        │ - John R. Ussher                       │        │ │
│ │                                        │ - Gavin Y. Oudit                       │        │ │
│ │                                        │ - Gary D. Lopaschuk                    │        │ │
│ │                                        │ journal: Cardiovascular Diabetology    │        │ │
│ │                                        │ year: 2019                             │        │ │
│ │                                        │ pmcid: PMC6610921                      │        │ │
│ │                                        │ doi: 10.1186/s12933-019-0892-3         │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # Impaired branched chain amino acid   │        │ │
│ │                                        │ oxidation contributes to cardiac       │        │ │
│ │                                        │ insulin resistance in heart failure    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ### Background                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Branched chain amino acids (BCAA) can  │        │ │
│ │                                        │ impair insulin signaling, and cardiac  │        │ │
│ │                                        │ insulin resistance can occur in the    │        │ │
│ │                                        │ failing heart. We, therefore,          │        │ │
│ │                                        │ determined if cardiac BCAA             │        │ │
│ │                                        │ accumulation occurs in patients with   │        │ │
│ │                                        │ dilated cardiomyopathy (DCM), due to   │        │ │
│ │                                        │ an impaired catabolism of BCAA, and if │        │ │
│ │                                        │ stimulating cardiac BCAA oxidation can │        │ │
│ │                                        │ improve cardiac function in mice with  │        │ │
│ │                                        │ heart failure.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ### Method                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ For human cohorts of DCM and control,  │        │ │
│ │                                        │ both male and female patients of ages  │        │ │
│ │                                        │ between 22 and 66 years were recruited │        │ │
│ │                                        │ with informed consent from University  │        │ │
│ │                                        │ of Alberta hospital. Left ventricular  │        │ │
│ │                                        │ biopsies were obtained at the time of  │        │ │
│ │                                        │ transplantation. Control biopsies were │        │ │
│ │                                        │ obtained from non-transplanted donor   │        │ │
│ │                                        │ hearts without heart disease history.  │        │ │
│ │                                        │ To determine if stimulating BCAA       │        │ │
│ │                                        │ catabolism could lessen the severity   │        │ │
│ │                                        │ of heart failure, C57BL/6J mice        │        │ │
│ │                                        │ subjected to a transverse aortic       │        │ │
│ │                                        │ constriction (TAC) were treated        │        │ │
│ │                                        │ between 1 to 4-week post-surgery with  │        │ │
│ │                                        │ either vehicle or a stimulator of BCAA │        │ │
│ │                                        │ oxidation (BT2, 40 mg/kg/day).         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ### Result                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Echocardiographic data showed a        │        │ │
│ │                                        │ reduction in ejection fraction (54.3 ± │        │ │
│ │                                        │ 2.3 to 22.3 ± $2.2\%$) and an enhanced │        │ │
│ │                                        │ formation of cardiac fibrosis in DCM   │        │ │
│ │                                        │ patients when compared to the control  │        │ │
│ │                                        │ patients. Cardiac BCAA levels were     │        │ │
│ │                                        │ dramatically elevated in left          │        │ │
│ │                                        │ ventricular samples of patients with   │        │ │
│ │                                        │ DCM. Hearts from DCM patients showed a │        │ │
│ │                                        │ blunted insulin signalling pathway, as │        │ │
│ │                                        │ indicated by an increase in            │        │ │
│ │                                        │ P-IRS1ser$\frac{636}{639}$ and its     │        │ │
│ │                                        │ upstream modulator P-p70S6K, but a     │        │ │
│ │                                        │ decrease in its downstream modulators  │        │ │
│ │                                        │ P-AKT ser473 and in P-GSK3β ser9.      │        │ │
│ │                                        │ Cardiac BCAA oxidation in isolated     │        │ │
│ │                                        │ working hearts was significantly       │        │ │
│ │                                        │ enhanced by BT2, compared to vehicle,  │        │ │
│ │                                        │ following either acute or chronic      │        │ │
│ │                                        │ treatment. Treatment of TAC mice with  │        │ │
│ │                                        │ BT2 significantly improved cardiac     │        │ │
│ │                                        │ function in both sham and TAC mice     │        │ │
│ │                                        │ (63.0 ± 1.8 and 56.9 ± $3.8\%$         │        │ │
│ │                                        │ ejection fraction respectively).       │        │ │
│ │                                        │ Furthermore, P-BCKDH and BCKDK         │        │ │
│ │                                        │ expression was significantly decreased │        │ │
│ │                                        │ in the BT2 treated groups.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ### Conclusion                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We conclude that impaired cardiac BCAA │        │ │
│ │                                        │ catabolism and insulin signaling occur │        │ │
│ │                                        │ in human heart failure, while          │        │ │
│ │                                        │ enhancing BCAA oxidation can improve   │        │ │
│ │                                        │ cardiac function in the failing mouse  │        │ │
│ │                                        │ heart.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ### Electronic supplementary material  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The online version of this article     │        │ │
│ │                                        │ (10.1186/s12933-019-0892-3) contains   │        │ │
│ │                                        │ supplementary material, which is       │        │ │
│ │                                        │ available to authorized users.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Background                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A strong positive association between  │        │ │
│ │                                        │ branched chain amino acids (BCAAs:     │        │ │
│ │                                        │ valine, leucine and isoleucine) and    │        │ │
│ │                                        │ whole-body insulin resistance has been │        │ │
│ │                                        │ demonstrated in obesity and diabetes   │        │ │
│ │                                        │ [1–4]. Insulin resistance also occurs  │        │ │
│ │                                        │ in the failing heart and contributes   │        │ │
│ │                                        │ to the severity of cardiac dysfunction │        │ │
│ │                                        │ [5, 6]. However, while BCAAs increase  │        │ │
│ │                                        │ in the failing heart [7, 8], it is not │        │ │
│ │                                        │ clear if this results in the           │        │ │
│ │                                        │ development of cardiac insulin         │        │ │
│ │                                        │ resistance and heart failure.          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mechanism by which BCAAs           │        │ │
│ │                                        │ contribute to whole body insulin       │        │ │
│ │                                        │ resistance has yet to be fully         │        │ │
│ │                                        │ determined. One proposal is that high  │        │ │
│ │                                        │ levels of BCAAs increase muscle BCAA   │        │ │
│ │                                        │ oxidation, which decreases glucose and │        │ │
│ │                                        │ fatty acid oxidation, leading to       │        │ │
│ │                                        │ insulin resistance [1]. However, we    │        │ │
│ │                                        │ have shown in the heart that           │        │ │
│ │                                        │ accumulation of BCAAs occurs in        │        │ │
│ │                                        │ conjunction with a decrease, rather    │        │ │
│ │                                        │ than an increase, in BCAA oxidation in │        │ │
│ │                                        │ obese mice [9]. In addition, the       │        │ │
│ │                                        │ contribution of cardiac BCAA oxidation │        │ │
│ │                                        │ to cardiac energy production is less   │        │ │
│ │                                        │ than $1\%$, suggesting that altered    │        │ │
│ │                                        │ cardiac BCAA oxidation is unlikely to  │        │ │
│ │                                        │ effectively compete with fatty acid    │        │ │
│ │                                        │ and glucose oxidation as a source of   │        │ │
│ │                                        │ acetyl CoA for the TCA cycle [9].      │        │ │
│ │                                        │ However, while altering BCAA oxidation │        │ │
│ │                                        │ is unlikely to directly compete with   │        │ │
│ │                                        │ the use of other cardiac energy        │        │ │
│ │                                        │ substrates, it still has the potential │        │ │
│ │                                        │ to alter cardiac BCAA levels. This is  │        │ │
│ │                                        │ important as the accumulation of BCAAs │        │ │
│ │                                        │ can activate mammalian target of       │        │ │
│ │                                        │ rapamycin (mTOR) [10] and impair       │        │ │
│ │                                        │ insulin signaling, due to its ability  │        │ │
│ │                                        │ to phosphorylate IRS1 via directly     │        │ │
│ │                                        │ activating p70S6K through mTOR [1,     │        │ │
│ │                                        │ 11–13]. Thus, a decrease in cardiac    │        │ │
│ │                                        │ BCAA oxidation has the potential to    │        │ │
│ │                                        │ increase cardiac BCAA levels, which    │        │ │
│ │                                        │ may activate mTOR signaling and reduce │        │ │
│ │                                        │ cardiac insulin sensitivity. However,  │        │ │
│ │                                        │ it remains unclear whether cardiac     │        │ │
│ │                                        │ insulin signaling is impaired along    │        │ │
│ │                                        │ with a decreased BCAA catabolism and   │        │ │
│ │                                        │ activation of mTOR pathway in human    │        │ │
│ │                                        │ failing hearts.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BCAA metabolism starts with            │        │ │
│ │                                        │ transamination by branched chain       │        │ │
│ │                                        │ aminotransferase (BCAT) to produce     │        │ │
│ │                                        │ branched chain keto acids (BCKAs).     │        │ │
│ │                                        │ BCKAs are then catabolized by          │        │ │
│ │                                        │ branched-chain α-keto acid             │        │ │
│ │                                        │ dehydrogenase (BCKDH) to produce       │        │ │
│ │                                        │ substrates for the TCA cycle. BCKDH    │        │ │
│ │                                        │ can be phosphorylated and inactivated  │        │ │
│ │                                        │ by branched-chain α-keto acid          │        │ │
│ │                                        │ dehydrogenase kinase (BCKDK) [14], or  │        │ │
│ │                                        │ dephosphorylated and activated by a    │        │ │
│ │                                        │ mitochondrial localized 2C-type        │        │ │
│ │                                        │ serine-threonine protein phosphatase   │        │ │
│ │                                        │ (PP2Cm) [15]. The first BCAA catabolic │        │ │
│ │                                        │ enzyme, BCATm has been shown to be     │        │ │
│ │                                        │ reduced in human heart failure and TAC │        │ │
│ │                                        │ induced heart failure in mice [16].    │        │ │
│ │                                        │ Inhibition of BCATm should result in   │        │ │
│ │                                        │ an accumulation of BCAAs and a         │        │ │
│ │                                        │ decrease in BCKAs. Therefore,          │        │ │
│ │                                        │ inhibition of BCATm would allow to     │        │ │
│ │                                        │ increase BCAA levels and decrease BCKA │        │ │
│ │                                        │ levels. This may lead to a different   │        │ │
│ │                                        │ scientific question and hypothesis. On │        │ │
│ │                                        │ the other hand, decreased BCKDH        │        │ │
│ │                                        │ activity is the main cause of          │        │ │
│ │                                        │ increased levels of BCAA and BCKA in   │        │ │
│ │                                        │ maple syrup urine disease [17], and    │        │ │
│ │                                        │ plays a role in mediating metabolic    │        │ │
│ │                                        │ reprogramming in the failing hearts    │        │ │
│ │                                        │ [2].                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ One potential approach to increasing   │        │ │
│ │                                        │ BCAA oxidation is to inhibit BCKDK     │        │ │
│ │                                        │ with                                   │        │ │
│ │                                        │ 3,6-dichlorobenzothiophene-2-carboxyl… │        │ │
│ │                                        │ acid (BT2) [2]. BT2 significantly      │        │ │
│ │                                        │ reduces the phosphorylation of the     │        │ │
│ │                                        │ BCKDH subunit E1α in the mouse heart,  │        │ │
│ │                                        │ resulting in an increase in its        │        │ │
│ │                                        │ activity [2]. However, whether BT2     │        │ │
│ │                                        │ actually enhances cardiac BCAA         │        │ │
│ │                                        │ oxidation has not been directly        │        │ │
│ │                                        │ assessed.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The objectives of this study were to   │        │ │
│ │                                        │ determine whether cardiac BCAA         │        │ │
│ │                                        │ catabolism is defective in patients    │        │ │
│ │                                        │ with dilated cardiomyopathy (DCM), and │        │ │
│ │                                        │ whether this occurs in conjunction     │        │ │
│ │                                        │ with an impaired cardiac insulin       │        │ │
│ │                                        │ signaling along with an activation of  │        │ │
│ │                                        │ the mTOR pathway. We also determined   │        │ │
│ │                                        │ whether cardiac BCAA oxidation could   │        │ │
│ │                                        │ be increased by BT2, and whether this  │        │ │
│ │                                        │ improved cardiac function in the       │        │ │
│ │                                        │ failing mouse heart.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Human explanted heart samples       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Both male and female patients of ages  │        │ │
│ │                                        │ between 22 and 66 years were           │        │ │
│ │                                        │ recruited. The LV free wall samples    │        │ │
│ │                                        │ were obtained at the time of           │        │ │
│ │                                        │ transplantation (within 15 min post    │        │ │
│ │                                        │ excision) from the patients with       │        │ │
│ │                                        │ dilated cardiomyopathy (DCM, male $$n  │        │ │
│ │                                        │ = 11$$; female $$n = 3$$; see          │        │ │
│ │                                        │ Additional file 1: Table S1) and the   │        │ │
│ │                                        │ non-failing control (NFC) hearts from  │        │ │
│ │                                        │ non-transplanted donor hearts (NFC,    │        │ │
│ │                                        │ male $$n = 5$$; female $$n = 2$$;      │        │ │
│ │                                        │ median age = 47 year (range 31–56      │        │ │
│ │                                        │ year)) without heart disease, as       │        │ │
│ │                                        │ previously described [18, 19]. Human   │        │ │
│ │                                        │ echocardiographic data were obtained   │        │ │
│ │                                        │ at the clinical pre-operative          │        │ │
│ │                                        │ assessment, as described previously    │        │ │
│ │                                        │ [18]. Patients were evaluated by       │        │ │
│ │                                        │ standard echocardiographic methods to  │        │ │
│ │                                        │ determine % ejection fraction (%EF)    │        │ │
│ │                                        │ [20].                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Measurement of cardiac BCAAs        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Metabolomic analysis of the human      │        │ │
│ │                                        │ heart samples were performed to        │        │ │
│ │                                        │ measure BCAA content, using an NMR     │        │ │
│ │                                        │ spectroscopy. Frozen heart tissue      │        │ │
│ │                                        │ samples (DCM, male $$n = 11$$; female  │        │ │
│ │                                        │ $$n = 3$$) and non-transplanted donor  │        │ │
│ │                                        │ hearts (NFC, male $$n = 5$$; female    │        │ │
│ │                                        │ $$n = 2$$) were thawed on ice. An      │        │ │
│ │                                        │ exact amount (0.5–0.75 g) of samples   │        │ │
│ │                                        │ were transferred to a pre-chilled      │        │ │
│ │                                        │ mortar and finely powdered in liquid   │        │ │
│ │                                        │ nitrogen using pestle. 4 mL of cold    │        │ │
│ │                                        │ methanol and 0.85 mL of cold water     │        │ │
│ │                                        │ were added to homogenize the tissue    │        │ │
│ │                                        │ sample for 3 min with a pestle. The    │        │ │
│ │                                        │ extract was transferred to a 4 dram    │        │ │
│ │                                        │ vial and 2.75 mL cold chloroform was   │        │ │
│ │                                        │ added. The mortar was rinsed with 1.5  │        │ │
│ │                                        │ mL of cold methanol for the complete   │        │ │
│ │                                        │ recovery of the extract. The vial was  │        │ │
│ │                                        │ vortexed for 5 min and then            │        │ │
│ │                                        │ centrifuged for 10 min at 3000 rpm.    │        │ │
│ │                                        │ The supernatant was transferred into a │        │ │
│ │                                        │ new 4 dram glass vial and 2.75 mL cold │        │ │
│ │                                        │ chloroform and 4 mL cold water were    │        │ │
│ │                                        │ added. Again vortexed vials for 3 min  │        │ │
│ │                                        │ at high speed and centrifuged for 10   │        │ │
│ │                                        │ min at 3000 rpm. This gave a biphasic  │        │ │
│ │                                        │ mixture. The upper aqueous layer       │        │ │
│ │                                        │ (water-soluble metabolites) was        │        │ │
│ │                                        │ transferred into a 15 mL falcon tube   │        │ │
│ │                                        │ and 2.5 mL HPLC water was added to the │        │ │
│ │                                        │ water-soluble metabolite extract and   │        │ │
│ │                                        │ flash freeze it in liquid nitrogen.    │        │ │
│ │                                        │ The above falcon tube was lyophilized  │        │ │
│ │                                        │ with frozen water-soluble metabolites  │        │ │
│ │                                        │ for 24 h. 15 mg of the resultant       │        │ │
│ │                                        │ freeze dried powder of water-soluble   │        │ │
│ │                                        │ metabolites was then aliquoted for NMR │        │ │
│ │                                        │ analysis.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15 mg of lyophilized water-soluble     │        │ │
│ │                                        │ extract from heart tissue was taken in │        │ │
│ │                                        │ 1.5 mL eppendorf tube. To this powder  │        │ │
│ │                                        │ in eppendorf tube, 570 µL of water was │        │ │
│ │                                        │ added. The sample was sonicated for 15 │        │ │
│ │                                        │ min in a bath sonicator. 60 µL of      │        │ │
│ │                                        │ reconstitution buffer (585 mM          │        │ │
│ │                                        │ phosphate buffer with 11.67 mM DSS)    │        │ │
│ │                                        │ and 70 µL of D2O were added. The       │        │ │
│ │                                        │ solution was vortexed for 1 min and    │        │ │
│ │                                        │ centrifuged at 10,000 rpm for 15 min   │        │ │
│ │                                        │ at ambient temperature. Clear          │        │ │
│ │                                        │ supernatant was transferred into NMR   │        │ │
│ │                                        │ tube (Shigemi, Inc., Allison Park, PA) │        │ │
│ │                                        │ for NMR analysis.                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All 1H-NMR spectra were collected on a │        │ │
│ │                                        │ Varian 500 MHz Inova spectrometer      │        │ │
│ │                                        │ equipped with a 5 mm HCN Z-gradient    │        │ │
│ │                                        │ pulsed-field gradient (PFG) cyrogenic  │        │ │
│ │                                        │ probe (Varian Inc. Palo Alto, CA).     │        │ │
│ │                                        │ 1H-NMR spectra were acquired at 25 °C  │        │ │
│ │                                        │ using the first transient of the       │        │ │
│ │                                        │ Varian tnnoesy pulse sequence, which   │        │ │
│ │                                        │ was chosen for its high degree of      │        │ │
│ │                                        │ selective water suppression and        │        │ │
│ │                                        │ quantitative accuracy of resonances    │        │ │
│ │                                        │ around the solvent. Water suppression  │        │ │
│ │                                        │ pulses were calibrated to achieve a    │        │ │
│ │                                        │ bandwidth of 80 gausses. Spectra were  │        │ │
│ │                                        │ collected with 128 transient and 8     │        │ │
│ │                                        │ steady-state scans using a 4 s         │        │ │
│ │                                        │ acquisition time (48,000 complex       │        │ │
│ │                                        │ points) and a 1 s recycle delay.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Prior to spectral analysis, all FIDs   │        │ │
│ │                                        │ were zero-filled to 64,000 data points │        │ │
│ │                                        │ and line broadened 0.5 Hz. The methyl  │        │ │
│ │                                        │ singlet produced by a known quantity   │        │ │
│ │                                        │ of DSS was used as an internal         │        │ │
│ │                                        │ standard for chemical shift with       │        │ │
│ │                                        │ reference set to 0 ppm and for         │        │ │
│ │                                        │ quantification. All 1H-NMR spectra     │        │ │
│ │                                        │ were processed and analyzed using the  │        │ │
│ │                                        │ Chenomx NMR Suite Professional         │        │ │
│ │                                        │ software package version 8.1 (Chenomx  │        │ │
│ │                                        │ Inc., Edmonton, AB). The Chenomx NMR   │        │ │
│ │                                        │ Suite software allows for qualitative  │        │ │
│ │                                        │ and quantitative analysis of an NMR    │        │ │
│ │                                        │ spectrum by manually fitting spectral  │        │ │
│ │                                        │ signatures from an internal database   │        │ │
│ │                                        │ to the spectrum. Typically, $90\%$ of  │        │ │
│ │                                        │ visible peaks were assigned to a       │        │ │
│ │                                        │ compound and more than $90\%$ of the   │        │ │
│ │                                        │ spectral area could be routinely fit   │        │ │
│ │                                        │ using the Chenomx spectral analysis    │        │ │
│ │                                        │ software. Most of the visible peaks    │        │ │
│ │                                        │ are annotated with a compound name.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Histology                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Masson’s trichrome staining and        │        │ │
│ │                                        │ picrosirius red staining of            │        │ │
│ │                                        │ paraffin-embedded left ventricular     │        │ │
│ │                                        │ human heart sections taken             │        │ │
│ │                                        │ mid-papillary were visualized using a  │        │ │
│ │                                        │ Leica DMLA microscope (Leica           │        │ │
│ │                                        │ Microsystems, Wetzlar, Germany)        │        │ │
│ │                                        │ equipped with a Retiga 1300i FAST 1394 │        │ │
│ │                                        │ CCD camera (OImaging, Surrey, BC,      │        │ │
│ │                                        │ Canada), as described previously [19]. │        │ │
│ │                                        │ Three representative images were taken │        │ │
│ │                                        │ from each sample and densitometric     │        │ │
│ │                                        │ analysis was performed using the       │        │ │
│ │                                        │ ImageJ software (National Institutes   │        │ │
│ │                                        │ of Health, Bethesda, MD, USA).         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Animals                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mice were housed at the Health         │        │ │
│ │                                        │ Sciences Lab Animal Services Facility  │        │ │
│ │                                        │ at the University of Alberta in a      │        │ │
│ │                                        │ temperature and humidity-controlled    │        │ │
│ │                                        │ room with a 12 h light dark cycle. All │        │ │
│ │                                        │ the animals were euthanized in a       │        │ │
│ │                                        │ non-fasted state at the end of         │        │ │
│ │                                        │ experiments.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Heart failure mouse model           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Male C57BL/6 mice at 10 weeks of age   │        │ │
│ │                                        │ were randomly assigned to either a     │        │ │
│ │                                        │ sham ($$n = 24$$) or transverse aortic │        │ │
│ │                                        │ constriction (TAC, $$n = 26$$)         │        │ │
│ │                                        │ surgical procedure. Mice were          │        │ │
│ │                                        │ anesthetized with $0.75\%$ isoflurane  │        │ │
│ │                                        │ to surgical plane, following which a   │        │ │
│ │                                        │ horizontal skin incision was made at   │        │ │
│ │                                        │ the level of second intercostal space. │        │ │
│ │                                        │ A 6-0 silk suture was passed under the │        │ │
│ │                                        │ aortic arch followed by placing a bent │        │ │
│ │                                        │ 27-gauge needle next to the aortic     │        │ │
│ │                                        │ arch. After constricting the aorta and │        │ │
│ │                                        │ closing the incision, the mice were    │        │ │
│ │                                        │ allowed to recover on a warming pad.   │        │ │
│ │                                        │ The sham animals went through the same │        │ │
│ │                                        │ procedure without constricting the     │        │ │
│ │                                        │ aorta. Echocardiography was used to    │        │ │
│ │                                        │ confirm a similar pressure gradient    │        │ │
│ │                                        │ across the TAC.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Treatment with the BCKDK inhibitor  │        │ │
│ │                                        │ BT2                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Sham ($$n = 12$$) and TAC mice ($$n =  │        │ │
│ │                                        │ 13$$) were randomized into four        │        │ │
│ │                                        │ groups, at 1-week post-surgery, for    │        │ │
│ │                                        │ daily intraperitoneal injection (IP)   │        │ │
│ │                                        │ for 3 weeks with either vehicle ($5\%$ │        │ │
│ │                                        │ DMSO, $10\%$ cremophor EL, and $85\%$  │        │ │
│ │                                        │ 0.1 M sodium bicarbonate, pH 9.0) or 6 │        │ │
│ │                                        │ mg/mL BT2                              │        │ │
│ │                                        │ (3,6-dichloro-1-benzothiophene-2-carb… │        │ │
│ │                                        │ acid, Sigma-Aldrich) (final dose 40    │        │ │
│ │                                        │ mg/kg/day).                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Assessment of BCAA oxidation        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The isolated working heart perfusion   │        │ │
│ │                                        │ principle and experimental procedure   │        │ │
│ │                                        │ were followed as described previously  │        │ │
│ │                                        │ [21]. Isolated working hearts were     │        │ │
│ │                                        │ perfused with Krebs–Henseleit solution │        │ │
│ │                                        │ (118.5 mM NaCl, 25 mM NaHCO3, 1.2 mM   │        │ │
│ │                                        │ MgSO4, 4.7 mM KCl, 1.2 mM KH2PO4, 2.5  │        │ │
│ │                                        │ mM CaCl2) supplemented with 0.8 mM     │        │ │
│ │                                        │ palmitate bound to $3\%$ fatty acid    │        │ │
│ │                                        │ free bovine serum albumin, 5 mM        │        │ │
│ │                                        │ glucose, 0.15 mM leucine, 0.15 mM      │        │ │
│ │                                        │ isoleucine, and 0.2 mM valine. BCAA    │        │ │
│ │                                        │ oxidation was measured by trapping and │        │ │
│ │                                        │ measuring 14CO2 released by the        │        │ │
│ │                                        │ metabolism of [U-14C]                  │        │ │
│ │                                        │ valine/leucine/isoleucine. The 14CO2   │        │ │
│ │                                        │ released during BCAA oxidation         │        │ │
│ │                                        │ (respective keto acid decarboxylation  │        │ │
│ │                                        │ and tricarboxylic acid cycle) was      │        │ │
│ │                                        │ trapped using 1 M hyamine hydroxide.   │        │ │
│ │                                        │ Quantitative collection of 14CO2 was   │        │ │
│ │                                        │ performed by continuously bubbling the │        │ │
│ │                                        │ outflow air from the perfusion         │        │ │
│ │                                        │ apparatus through 15 mL of hyamine     │        │ │
│ │                                        │ hydroxide and then, sampling the       │        │ │
│ │                                        │ hyamine hydroxide (300 µL) every 10    │        │ │
│ │                                        │ min, starting at 0 min. The hyamine    │        │ │
│ │                                        │ hydroxide samples were counted using   │        │ │
│ │                                        │ CytoScint scintillation cocktail.      │        │ │
│ │                                        │ Quantitative 14CO2 production was      │        │ │
│ │                                        │ measured by adding together the values │        │ │
│ │                                        │ for 14CO2 obtained from the outflow    │        │ │
│ │                                        │ air and solution. However, there is a  │        │ │
│ │                                        │ limitation of measuring the BCAA       │        │ │
│ │                                        │ oxidation in this method. BT2 (200 µM) │        │ │
│ │                                        │ was also added to the perfusate when   │        │ │
│ │                                        │ assessing the acute BT2 effects on     │        │ │
│ │                                        │ BCAA oxidation. At the end of the 60   │        │ │
│ │                                        │ min perfusion period, hearts were snap │        │ │
│ │                                        │ frozen in liquid N2 immediately after  │        │ │
│ │                                        │ perfusion and stored at − 80 °C for    │        │ │
│ │                                        │ later biochemical analysis.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Mice echocardiography and tissue    │        │ │
│ │                                        │ doppler imaging                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Echocardiographic analysis on mice was │        │ │
│ │                                        │ performed at 0-week (baseline) and at  │        │ │
│ │                                        │ 4-weeks post-surgery, by using a       │        │ │
│ │                                        │ Visualsonic Vevo 770 high-resolution   │        │ │
│ │                                        │ echocardiography imaging system        │        │ │
│ │                                        │ equipped with a 30-MHz transducer      │        │ │
│ │                                        │ (RMV-707B; VisualSonics, Toronto,      │        │ │
│ │                                        │ Canada). M-mode images were obtained   │        │ │
│ │                                        │ for measurements of ejection fraction  │        │ │
│ │                                        │ (%EF), LVPW;d, LVPWD;s, and LV mass. A │        │ │
│ │                                        │ non-invasive measurement of area under │        │ │
│ │                                        │ the curve (mmHg) in pulse wave         │        │ │
│ │                                        │ Doppler-mode was used to measure the   │        │ │
│ │                                        │ pressure gradient across the           │        │ │
│ │                                        │ transverse aortic constriction site.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Western blot analysis               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Frozen heart tissues were homogenized  │        │ │
│ │                                        │ in a buffer containing 50 mM Tris HCl, │        │ │
│ │                                        │ 1 mM EDTA, $10\%$ glycerol, $0.02\%$   │        │ │
│ │                                        │ Brij-35, 1 mM DTT, protease and        │        │ │
│ │                                        │ phosphatase inhibitors (Sigma). Thirty │        │ │
│ │                                        │ µg of protein from the resulting       │        │ │
│ │                                        │ supernatant were subjected to SDS-PAGE │        │ │
│ │                                        │ followed by western blotting           │        │ │
│ │                                        │ procedures. Primary antibodies include │        │ │
│ │                                        │ BCKDH (Ab138460), BCKDK (Ab128935) and │        │ │
│ │                                        │ mitochondrial protein phosphatase 2C   │        │ │
│ │                                        │ (PP2Cm: Ab135286) from Abcam;          │        │ │
│ │                                        │ p-p70s6kinase Thr389 (9206s),          │        │ │
│ │                                        │ p70S6kinase (9202s), p-mTOR Ser2448    │        │ │
│ │                                        │ (2971s), mTOR (4517s), pAkt Ser473     │        │ │
│ │                                        │ (9271s), AKT (9272s) and pGSK3 α/β     │        │ │
│ │                                        │ Ser$\frac{21}{9}$ (9331s), GSK         │        │ │
│ │                                        │ (9315s), pIRS1 Ser$\frac{636}{639}$    │        │ │
│ │                                        │ (2388s) and IRS1 (2382s) from Cell     │        │ │
│ │                                        │ signaling; α tubulin (Sigma, T6074);   │        │ │
│ │                                        │ pBCKDH Ser293 (Bethyl A303-567A); and  │        │ │
│ │                                        │ mitochondrial BCAT(BCATm, Thermo       │        │ │
│ │                                        │ Scientific, PA5-21549). Enhanced       │        │ │
│ │                                        │ chemiluminescence (Perkin Elmer) was   │        │ │
│ │                                        │ used to visualize protein bands on     │        │ │
│ │                                        │ autoradiography films, and             │        │ │
│ │                                        │ quantification of the protein bands    │        │ │
│ │                                        │ was performed with Image J.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Statistical analysis                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Data are presented as the mean ± SEM.  │        │ │
│ │                                        │ P value of < 0.05 were considered      │        │ │
│ │                                        │ statistically different. Data from the │        │ │
│ │                                        │ human studies were analyzed by an      │        │ │
│ │                                        │ unpaired Student’s t test. In the      │        │ │
│ │                                        │ animal studies with > 2 groups, ANOVA  │        │ │
│ │                                        │ or appropriate nonparametric tests     │        │ │
│ │                                        │ were applied to analyze the            │        │ │
│ │                                        │ difference.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Patients with DCM have a markedly   │        │ │
│ │                                        │ decreased %EF, decreased cardiac       │        │ │
│ │                                        │ SERCA2 expression, increased cardiac   │        │ │
│ │                                        │ α-SKA, and increased cardiac fibrosis  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To characterize the cardiac            │        │ │
│ │                                        │ dysfunction in patients with DCM,      │        │ │
│ │                                        │ echocardiographic analysis at the      │        │ │
│ │                                        │ clinical pre-operative assessment were │        │ │
│ │                                        │ performed. The patients with DCM had   │        │ │
│ │                                        │ significantly reduced %EF, a           │        │ │
│ │                                        │ representative parameter of systolic   │        │ │
│ │                                        │ dysfunction, compared to the           │        │ │
│ │                                        │ non-failing control (NFC) ($p \leq     │        │ │
│ │                                        │ 0.05$, Fig. 1a). At a molecular level, │        │ │
│ │                                        │ a decrease in expression of SERCA2     │        │ │
│ │                                        │ (Fig. 1b, c) was observed in the DCM   │        │ │
│ │                                        │ hearts, while an increase in alpha     │        │ │
│ │                                        │ skeletal muscle actin (α-SKA)          │        │ │
│ │                                        │ expression was seen (Fig. 1b, d). In   │        │ │
│ │                                        │ addition, accumulation of collagen     │        │ │
│ │                                        │ (Fig. 1e), as a pathologic feature of  │        │ │
│ │                                        │ fibrosis, was evident in the DCM       │        │ │
│ │                                        │ hearts relative to the NFC hearts.     │        │ │
│ │                                        │ Fig. 1Decreased %EF, SERCA2 expression │        │ │
│ │                                        │ and increased α-SKA and fibrosis in    │        │ │
│ │                                        │ patients with DCM. Ejection fraction   │        │ │
│ │                                        │ (%) (NFC, $$n = 7$$; DCM, $$n = 14$$)  │        │ │
│ │                                        │ based on echocardiographic analysis at │        │ │
│ │                                        │ the clinical pre-operative assessment  │        │ │
│ │                                        │ (a). Representative blots of SERCA2    │        │ │
│ │                                        │ and α-SkA with Tubulin as the loading  │        │ │
│ │                                        │ control (b). Densitometry analysis of  │        │ │
│ │                                        │ SERCA2 (c) and α-SkA (d), normalized   │        │ │
│ │                                        │ to Tubulin, respectively (NFC, $$n =   │        │ │
│ │                                        │ 6$$; DCM, $$n = 6$$). Collagen         │        │ │
│ │                                        │ visualization and trichrome staining   │        │ │
│ │                                        │ expressed as collagen area (%) (NFC,   │        │ │
│ │                                        │ $$n = 7$$; DCM, $$n = 10$$) (e). Data  │        │ │
│ │                                        │ are presented as mean ± SEM. Data were │        │ │
│ │                                        │ analysed by t-test. * $p \leq 0.05$    │        │ │
│ │                                        │ was considered statistically           │        │ │
│ │                                        │ significant                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Patients with DCM have elevated     │        │ │
│ │                                        │ levels of cardiac BCAA and an impaired │        │ │
│ │                                        │ BCAA catabolic pathway                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To explore the potential association   │        │ │
│ │                                        │ between heart failure and BCAA,        │        │ │
│ │                                        │ cardiac BCAA levels and the key        │        │ │
│ │                                        │ enzymes for BCAA catabolism were       │        │ │
│ │                                        │ assessed in failing human explanted    │        │ │
│ │                                        │ hearts with DCM (Fig. 2a). Elevated    │        │ │
│ │                                        │ cardiac BCAA levels were observed in   │        │ │
│ │                                        │ the DCM hearts (Fig. 2b), in           │        │ │
│ │                                        │ conjunction with a reduced protein     │        │ │
│ │                                        │ expression of mitochondrial BCATm      │        │ │
│ │                                        │ (Fig. 2c, d). In addition, a           │        │ │
│ │                                        │ significant reduction in the total     │        │ │
│ │                                        │ expression of BCKDH (Fig. 2c, f) and   │        │ │
│ │                                        │ phosphorylation of BCKDH was seen in   │        │ │
│ │                                        │ the DCM hearts (Fig. 2c, e). Decreased │        │ │
│ │                                        │ protein expression could be the result │        │ │
│ │                                        │ of reduced phosphorylation of BCKDH in │        │ │
│ │                                        │ DCM patients, which was observed when  │        │ │
│ │                                        │ normalised to the loading control      │        │ │
│ │                                        │ (Fig. 2e). As a result, an increased   │        │ │
│ │                                        │ ratio of P-BCKDH over the total BCKDH  │        │ │
│ │                                        │ was observed in the DCM hearts         │        │ │
│ │                                        │ relative to the NFC hearts (Fig. 2g),  │        │ │
│ │                                        │ implying a decreased BCKDH activity in │        │ │
│ │                                        │ the DCM hearts that is controlled at   │        │ │
│ │                                        │ both translational and                 │        │ │
│ │                                        │ post-translational levels. Of          │        │ │
│ │                                        │ interest, expression of cardiac PP2Cm, │        │ │
│ │                                        │ the phosphatase responsible for        │        │ │
│ │                                        │ dephosphorylating and activating       │        │ │
│ │                                        │ BCKDH, was reduced in the DCM hearts   │        │ │
│ │                                        │ (Fig. 2h) without an alteration in     │        │ │
│ │                                        │ BCKDK expression (Fig. 2i).            │        │ │
│ │                                        │ Furthermore, a reduced protein         │        │ │
│ │                                        │ expression of cardiac KLF15, an        │        │ │
│ │                                        │ upstream modulator of BCAA catabolic   │        │ │
│ │                                        │ enzymes [2, 22, 23], was evident in    │        │ │
│ │                                        │ the DCM hearts (Fig. 2j). This         │        │ │
│ │                                        │ suggests an association between the    │        │ │
│ │                                        │ accumulation of cardiac BCAA and KLF15 │        │ │
│ │                                        │ mediated down-regulation of BCATm and  │        │ │
│ │                                        │ PP2Cm. Fig. 2Elevated BCAAs and        │        │ │
│ │                                        │ impaired BCAA catabolic pathway in the │        │ │
│ │                                        │ hearts of patients with DCM. Schematic │        │ │
│ │                                        │ drawing of BCAA catabolic pathway (a). │        │ │
│ │                                        │ Levels of cardiac BCAAs (NFC, $$n =    │        │ │
│ │                                        │ 7$$; DCM, $$n = 14$$) (b).             │        │ │
│ │                                        │ Representative blots of proteins of    │        │ │
│ │                                        │ the BCAA catabolic pathway (c).        │        │ │
│ │                                        │ Densitometry analysis of BCATm         │        │ │
│ │                                        │ normalized to Tubulin (d).             │        │ │
│ │                                        │ Densitometry analysis of P-BCKDH (e),  │        │ │
│ │                                        │ and BCKDH (f), normalized to Tubulin,  │        │ │
│ │                                        │ respectively. Ratio of P-BCKDH (Ser    │        │ │
│ │                                        │ 293) over the total BCKDH (g).         │        │ │
│ │                                        │ Densitometry analysis of PP2Cm (h),    │        │ │
│ │                                        │ BCKDK (i) and KLF15 (j), normalized to │        │ │
│ │                                        │ Tubulin, respectively. Densitometry    │        │ │
│ │                                        │ analysis of P-p38MAPK (k) and P-TAK1   │        │ │
│ │                                        │ (thr187) (l), normalized to Tubulin,   │        │ │
│ │                                        │ respectively ($$n = 6$$/group). Data   │        │ │
│ │                                        │ are presented as mean ± SEM. Data were │        │ │
│ │                                        │ analysed by t-test. * $p \leq 0.05$    │        │ │
│ │                                        │ was considered statistically           │        │ │
│ │                                        │ significant Transforming growth        │        │ │
│ │                                        │ factor-β mediated activation of        │        │ │
│ │                                        │ p38MAPK is necessary and sufficient to │        │ │
│ │                                        │ inhibit KLF15 expression [24]. Indeed, │        │ │
│ │                                        │ the phosphorylation of p38MAPK (Fig.   │        │ │
│ │                                        │ 2c, k) was increased in the DCM hearts │        │ │
│ │                                        │ as was the phosphorylation of          │        │ │
│ │                                        │ transforming growth factor-β           │        │ │
│ │                                        │ activating kinase 1 (P-TAK1) (Fig. 2c, │        │ │
│ │                                        │ l), suggesting that accumulation of    │        │ │
│ │                                        │ cardiac BCAA in the DCM hearts may be  │        │ │
│ │                                        │ triggered by the activation of TAK1,   │        │ │
│ │                                        │ thereby inhibiting KLF15 to            │        │ │
│ │                                        │ down-regulate BCAA catabolism.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Patients with DCM have impaired     │        │ │
│ │                                        │ cardiac insulin signaling and          │        │ │
│ │                                        │ activation of the mTOR pathway         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To understand if activation of mTOR    │        │ │
│ │                                        │ occurred along with an impaired        │        │ │
│ │                                        │ insulin signaling in the DCM hearts    │        │ │
│ │                                        │ (Fig. 3a), the mTOR and insulin        │        │ │
│ │                                        │ signaling pathway was examined. An     │        │ │
│ │                                        │ increase in the phosphorylation of     │        │ │
│ │                                        │ mTOR1Ser2448 was observed in the DCM   │        │ │
│ │                                        │ hearts (Fig. 3b, c), in conjunction    │        │ │
│ │                                        │ with an elevated phosphorylation of    │        │ │
│ │                                        │ p70S6K (Fig. 3b, d) and                │        │ │
│ │                                        │ P-IRS1ser$\frac{636}{639}$ (Fig. 3b,   │        │ │
│ │                                        │ e), the down-stream targets of mTOR.   │        │ │
│ │                                        │ In addition, P-AKT (Fig. 3b, f), a     │        │ │
│ │                                        │ down-stream target of IRS1, was        │        │ │
│ │                                        │ decreased in the DCM hearts, as was    │        │ │
│ │                                        │ P-GSK3 (Fig. 3b, g), a down-stream     │        │ │
│ │                                        │ target of P-AKT. Thus, impaired        │        │ │
│ │                                        │ insulin signaling co-exists with an    │        │ │
│ │                                        │ activated mTOR pathway in human DCM    │        │ │
│ │                                        │ hearts. Fig. 3Impaired insulin         │        │ │
│ │                                        │ signaling and activation of mTOR       │        │ │
│ │                                        │ pathway in the hearts of patients with │        │ │
│ │                                        │ DCM. Schematic drawing of mTOR         │        │ │
│ │                                        │ activation and insulin signaling under │        │ │
│ │                                        │ normal condition (a) and               │        │ │
│ │                                        │ representative blots for proteins in   │        │ │
│ │                                        │ the signaling pathway (b).             │        │ │
│ │                                        │ Densitometry analysis of mTOR          │        │ │
│ │                                        │ (Ser2448) (c) and P-p70S6K(thr389)     │        │ │
│ │                                        │ (d), P-IRS1(Ser$\frac{636}{639}$) (e), │        │ │
│ │                                        │ P-AKT(Ser473) (f) and P-GSK3ß(Ser9)    │        │ │
│ │                                        │ (g), normalized to its total protein,  │        │ │
│ │                                        │ ($$n = 6$$/group). Data are presented  │        │ │
│ │                                        │ as mean ± SEM. Data were analysed by   │        │ │
│ │                                        │ t-test. * $p \leq 0.05$ was considered │        │ │
│ │                                        │ statistically significant              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Treatment of BT2 increases cardiac  │        │ │
│ │                                        │ BCAA oxidation in mouse hearts         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Similar to the human DCM hearts,       │        │ │
│ │                                        │ accumulation of BCAA was also evident  │        │ │
│ │                                        │ in the mouse failing heart induced by  │        │ │
│ │                                        │ TAC (Fig. 4a). Interestingly, levels   │        │ │
│ │                                        │ of cardiac BCAAs are much higher in    │        │ │
│ │                                        │ mouse compared to human samples, which │        │ │
│ │                                        │ is consistent with the finding         │        │ │
│ │                                        │ previously published by Sun et al. [   │        │ │
│ │                                        │ 16]. Accumulation of BCAAs are         │        │ │
│ │                                        │ concomitant with a reduced protein     │        │ │
│ │                                        │ expression of BCATm (Fig. 4b).         │        │ │
│ │                                        │ Inhibiting BCKDK activity by BT2 (Fig. │        │ │
│ │                                        │ 4c) can effectively activate BCKDH in  │        │ │
│ │                                        │ various tissues [25]. Therefore, we    │        │ │
│ │                                        │ explored whether the effect of BT2     │        │ │
│ │                                        │ could be translated into enhanced BCAA │        │ │
│ │                                        │ oxidation in the mouse heart. The      │        │ │
│ │                                        │ acute effect of BT2 was examined in    │        │ │
│ │                                        │ isolated working mouse hearts. BCAA    │        │ │
│ │                                        │ oxidation was significantly increased  │        │ │
│ │                                        │ in the mouse heart with BT2 relative   │        │ │
│ │                                        │ to vehicle (Fig. 4d). Similarly, a     │        │ │
│ │                                        │ chronic treatment with BT2 via an IP   │        │ │
│ │                                        │ injection for 3 week enhanced cardiac  │        │ │
│ │                                        │ BCAA oxidation in mice (Fig. 4e).      │        │ │
│ │                                        │ Either, acute or chronic treatment of  │        │ │
│ │                                        │ BT2, did not cause any changes in the  │        │ │
│ │                                        │ ex vivo working heart function, as     │        │ │
│ │                                        │ observed in cardiac work (Fig. 4f, g)  │        │ │
│ │                                        │ respectively. Fig. 4Accumulation of    │        │ │
│ │                                        │ cardiac BCAAs in TAC mouse hearts. BT2 │        │ │
│ │                                        │ increases cardiac BCAA oxidation in    │        │ │
│ │                                        │ mouse. Levels of cardiac BCAAs ($$n =  │        │ │
│ │                                        │ 5$$/group) (a). Densitometry analysis  │        │ │
│ │                                        │ of BCATm protein expression normalized │        │ │
│ │                                        │ to Tubulin ($$n = 6$$/group) (b).      │        │ │
│ │                                        │ Schematic drawing of BT2 inhibition on │        │ │
│ │                                        │ BCAA catabolic pathway (c). Rates of   │        │ │
│ │                                        │ BCAA oxidation in normal hearts        │        │ │
│ │                                        │ perfused with BT2 (200 µM) ($$n =      │        │ │
│ │                                        │ 4$$/group) (d). Rates of BCAA          │        │ │
│ │                                        │ oxidation in normal hearts at 3 week   │        │ │
│ │                                        │ post daily BT2 treatment (40           │        │ │
│ │                                        │ mg/kg/day) (Vehicle, $$n = 6$$; BT2    │        │ │
│ │                                        │ Inhibitor, n =) (e). Cardiac work for  │        │ │
│ │                                        │ acute and chronic BT2 treatment was    │        │ │
│ │                                        │ measured as a functional parameter     │        │ │
│ │                                        │ during ex vivo working heart perfusion │        │ │
│ │                                        │ f and g respectively. Data are         │        │ │
│ │                                        │ presented as mean ± SEM. Data were     │        │ │
│ │                                        │ analysed by t-test. * $p \leq 0.05$    │        │ │
│ │                                        │ was considered statistically           │        │ │
│ │                                        │ significant                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Stimulating BCAA oxidation improves │        │ │
│ │                                        │ % ejection fraction (%EF) without      │        │ │
│ │                                        │ altering cardiac hypertrophy           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Since we demonstrated that BT2 could   │        │ │
│ │                                        │ increase cardiac BCAA oxidation (Fig.  │        │ │
│ │                                        │ 4), we explored if chronic treatment   │        │ │
│ │                                        │ of BT2 could improve cardiac function  │        │ │
│ │                                        │ in failing mouse hearts (Fig. 5a).     │        │ │
│ │                                        │ There was no change observed in whole  │        │ │
│ │                                        │ body glucose tolerance test between    │        │ │
│ │                                        │ the groups (data not shown). BT2       │        │ │
│ │                                        │ treatment significantly reduced BCAA   │        │ │
│ │                                        │ accumulation in both sham and TAC      │        │ │
│ │                                        │ hearts (Fig. 5c). As expected, BT2     │        │ │
│ │                                        │ treatment effectively reduced cardiac  │        │ │
│ │                                        │ P-BCKDH (Fig. 5b, d), along with a     │        │ │
│ │                                        │ reduction on cardiac BCKDK expression  │        │ │
│ │                                        │ (Fig. 5b, e) in both sham and TAC      │        │ │
│ │                                        │ mouse hearts. In addition, the TAC     │        │ │
│ │                                        │ mouse hearts showed an impaired %EF    │        │ │
│ │                                        │ when compared to sham mice (Fig. 5f).  │        │ │
│ │                                        │ Treatment of TAC mice with BT2         │        │ │
│ │                                        │ significantly increased %EF in the TAC │        │ │
│ │                                        │ hearts. BT2 also increased in %EF in   │        │ │
│ │                                        │ the sham hearts, but this increase did │        │ │
│ │                                        │ not reach the statistical significance │        │ │
│ │                                        │ ($$p \leq 0.09$$) (Fig. 5e). Despite   │        │ │
│ │                                        │ of an increase in %EF, treatment of    │        │ │
│ │                                        │ BT2 had no effect on altering cardiac  │        │ │
│ │                                        │ hypertrophy in the TAC mice, as        │        │ │
│ │                                        │ reflected by the unaltered LV mass     │        │ │
│ │                                        │ (Fig. 5g), as well as the lack of      │        │ │
│ │                                        │ change in posterior wall thickness in  │        │ │
│ │                                        │ diastole (Fig. 5h) and in systole      │        │ │
│ │                                        │ (Fig. 5i). To rule out the possibility │        │ │
│ │                                        │ that the increase in the %EF could be  │        │ │
│ │                                        │ due to the differences in the severity │        │ │
│ │                                        │ of heart failure among the TAC hearts, │        │ │
│ │                                        │ we also examined the pressure gradient │        │ │
│ │                                        │ across the aortic banding. As          │        │ │
│ │                                        │ expected, the pressure gradients were  │        │ │
│ │                                        │ greater in the TAC mice than in sham   │        │ │
│ │                                        │ mice (Fig. 5j), but were not altered   │        │ │
│ │                                        │ by the treatment of BT2, confirming    │        │ │
│ │                                        │ that the effect of BT2 on increasing   │        │ │
│ │                                        │ cardiac %EF was not due to a           │        │ │
│ │                                        │ difference in the severity of the      │        │ │
│ │                                        │ TAC.Fig. 5Improved %EF and unaltered   │        │ │
│ │                                        │ cardiac hypertrophy in TAC mouse       │        │ │
│ │                                        │ hearts post chronic treatment with     │        │ │
│ │                                        │ BT2. Schematic drawing of the protocol │        │ │
│ │                                        │ for TAC surgery along with BT2         │        │ │
│ │                                        │ treatment (40 mg/kg/day), a GTT was    │        │ │
│ │                                        │ conducted followed by 6 h fasting (2   │        │ │
│ │                                        │ g/kg body weight) (a). Representative  │        │ │
│ │                                        │ blots of P-BCKDH, total BCKDH and      │        │ │
│ │                                        │ BCKDH with VDAC as a loading control   │        │ │
│ │                                        │ (b). Levels of cardiac BCAAs ($$n =    │        │ │
│ │                                        │ 6$$/group) (c). Densitometry analysis  │        │ │
│ │                                        │ of P-BCKDH normalized to total BCKDH   │        │ │
│ │                                        │ (d), and BCKDK normalized to VDAC ($$n │        │ │
│ │                                        │ = 6$$/group) (e). Changes in ejection  │        │ │
│ │                                        │ fraction (%) (f). Changes in left      │        │ │
│ │                                        │ ventricular mass (g), and posterior    │        │ │
│ │                                        │ wall thickness in diastole (h) and     │        │ │
│ │                                        │ systole (i), as well as peak pressure  │        │ │
│ │                                        │ gradient (j) at 4 week post daily BT2  │        │ │
│ │                                        │ treatment ($$n = 9$$–14/group). Data   │        │ │
│ │                                        │ are presented as mean ± SEM. Data were │        │ │
│ │                                        │ analysed by using one-way ANOVA with   │        │ │
│ │                                        │ multiple comparison. * or #, as $p     │        │ │
│ │                                        │ \leq 0.05$ was considered              │        │ │
│ │                                        │ statistically significant              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Discussion                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ There are several novel findings of    │        │ │
│ │                                        │ this study: [1] while a number of      │        │ │
│ │                                        │ human studies have predicted a         │        │ │
│ │                                        │ relationship between circulating BCAAs │        │ │
│ │                                        │ and insulin resistance [1, 3, 4, 26,   │        │ │
│ │                                        │ 27], this is the first study to        │        │ │
│ │                                        │ demonstrate that accumulation of       │        │ │
│ │                                        │ cardiac BCAAs (with a coordinated      │        │ │
│ │                                        │ decrease in BCAA catabolic enzymes) is │        │ │
│ │                                        │ associated with impaired cardiac       │        │ │
│ │                                        │ insulin signaling in the failing human │        │ │
│ │                                        │ heart, [2] impaired insulin signaling  │        │ │
│ │                                        │ is accompanied by activation of the    │        │ │
│ │                                        │ mTOR pathway in the human failing      │        │ │
│ │                                        │ heart, [3] reduction of KLF15          │        │ │
│ │                                        │ expression is associated with the      │        │ │
│ │                                        │ impaired BCAA catabolism in the human  │        │ │
│ │                                        │ failing hearts through a mechanism     │        │ │
│ │                                        │ that may be associated with the        │        │ │
│ │                                        │ activation of TAK1 and p38MAPK, and    │        │ │
│ │                                        │ [4] stimulation of BCAA oxidation in   │        │ │
│ │                                        │ the failing mouse heart improves       │        │ │
│ │                                        │ contractile function. These findings   │        │ │
│ │                                        │ support the concept that increasing    │        │ │
│ │                                        │ cardiac BCAA oxidation may be a        │        │ │
│ │                                        │ potential therapeutic strategy to      │        │ │
│ │                                        │ treat heart failure.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A hypothesized mechanism of insulin    │        │ │
│ │                                        │ resistance has linked increased BCAA   │        │ │
│ │                                        │ or BCKA levels to the activation of    │        │ │
│ │                                        │ mTOR signaling [28–30]. Our previous   │        │ │
│ │                                        │ studies have shown, by directly        │        │ │
│ │                                        │ measuring BCAA oxidation in hearts of  │        │ │
│ │                                        │ mice subjected to a high-fat diet,     │        │ │
│ │                                        │ that rates of BCAA oxidation are       │        │ │
│ │                                        │ decreased, rather than increased, in   │        │ │
│ │                                        │ insulin-resistant hearts [9]. In the   │        │ │
│ │                                        │ current study, decreased cardiac BCAA  │        │ │
│ │                                        │ oxidation, as evidenced by decreased   │        │ │
│ │                                        │ expression of BCAA catabolic enzymes,  │        │ │
│ │                                        │ was also observed in heart failure     │        │ │
│ │                                        │ patients. In line with this, it has    │        │ │
│ │                                        │ been demonstrated that defects in BCAA │        │ │
│ │                                        │ oxidation enzymes in diseases, such as │        │ │
│ │                                        │ methylmalonic acidemia are associated  │        │ │
│ │                                        │ with human cardiomyopathy [29]. These  │        │ │
│ │                                        │ results suggest that a rise in BCAA    │        │ │
│ │                                        │ and/or BCAA metabolites is             │        │ │
│ │                                        │ attributable to a decline in cardiac   │        │ │
│ │                                        │ BCAA oxidation that results in the     │        │ │
│ │                                        │ development of cardiac insulin         │        │ │
│ │                                        │ resistance. Accumulation of BCKA       │        │ │
│ │                                        │ levels with unaltered BCAA levels has  │        │ │
│ │                                        │ been reported in heart failure         │        │ │
│ │                                        │ patients [2]. However, in contrast, we │        │ │
│ │                                        │ observed a marked increase in BCAA     │        │ │
│ │                                        │ levels in our human failing heart      │        │ │
│ │                                        │ samples (Fig. 2). Elevated levels of   │        │ │
│ │                                        │ intracellular BCAA has been observed   │        │ │
│ │                                        │ in cultured cardiomyocytes coinciding  │        │ │
│ │                                        │ with an activation of mTOR [31], which │        │ │
│ │                                        │ is consistent with the observations    │        │ │
│ │                                        │ not only in our patients with DCM      │        │ │
│ │                                        │ hearts, but also in murine failing     │        │ │
│ │                                        │ hearts induced by either pressure      │        │ │
│ │                                        │ overload or myocardial infarction [2,  │        │ │
│ │                                        │ 25, 32, 33]. In our study, we did not  │        │ │
│ │                                        │ assess the levels of cardiac BCKA in   │        │ │
│ │                                        │ the DCM hearts, neither the causal     │        │ │
│ │                                        │ effect of BCAAs or its metabolites on  │        │ │
│ │                                        │ mTOR activation. Thus, the possibility │        │ │
│ │                                        │ that mTOR was activated as a result of │        │ │
│ │                                        │ increased autophagy in the heart       │        │ │
│ │                                        │ failure can’t be rule out [34]. As a   │        │ │
│ │                                        │ result, their potential contribution   │        │ │
│ │                                        │ to the activated mTOR pathway and      │        │ │
│ │                                        │ impaired insulin signaling remains     │        │ │
│ │                                        │ unclear.                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Of interest, an experiment conducted   │        │ │
│ │                                        │ in mice with BCATm knockdown indicated │        │ │
│ │                                        │ that BCKA must be converted back to    │        │ │
│ │                                        │ BCAA for insulin resistance to occur   │        │ │
│ │                                        │ [35]. Thus, the question as to whether │        │ │
│ │                                        │ the accumulation of BCKA rather of     │        │ │
│ │                                        │ BCAA is a critical factor responsible  │        │ │
│ │                                        │ for metabolic consequences needs       │        │ │
│ │                                        │ further clarification. A               │        │ │
│ │                                        │ pharmacological or a transcriptional   │        │ │
│ │                                        │ inhibition of the BCATm should result  │        │ │
│ │                                        │ in accumulation of the BCAAs and       │        │ │
│ │                                        │ reduce its oxidation, also, this       │        │ │
│ │                                        │ should indicate if BCAAs are critical  │        │ │
│ │                                        │ factor responsible for insulin         │        │ │
│ │                                        │ resistance in the heart failure.       │        │ │
│ │                                        │ Furthermore, there is a very little    │        │ │
│ │                                        │ information available about the        │        │ │
│ │                                        │ cytosolic and/or mitochondrial BCAA    │        │ │
│ │                                        │ accumulation, as well as, its          │        │ │
│ │                                        │ catabolic enzymes distribution         │        │ │
│ │                                        │ throughout the cell and tissue. Based  │        │ │
│ │                                        │ on the concept that in the BCAA        │        │ │
│ │                                        │ catabolic pathway, BCAAs are first     │        │ │
│ │                                        │ converted into branched-chain          │        │ │
│ │                                        │ alpha-ketoacids (BCKA) by BCAT in a    │        │ │
│ │                                        │ reversible reaction, it is possible    │        │ │
│ │                                        │ that accumulation of mitochondrial     │        │ │
│ │                                        │ BCAA could export back to cytosol.     │        │ │
│ │                                        │ However, the cytosolic BCAT is not     │        │ │
│ │                                        │ primarily expressed in the heart, but  │        │ │
│ │                                        │ rather in the brain, testes and        │        │ │
│ │                                        │ ovaries. This suggests that the        │        │ │
│ │                                        │ backward reaction from BCKA to BCAA is │        │ │
│ │                                        │ unlikely a major pathway in the heart. │        │ │
│ │                                        │ In addition, they are the most         │        │ │
│ │                                        │ hydrophobic [36], which suggests that  │        │ │
│ │                                        │ they are not freely exported back into │        │ │
│ │                                        │ cytosol.                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Despite evidence for a role for KLF15  │        │ │
│ │                                        │ in regulating cardiac BCAA catabolic   │        │ │
│ │                                        │ gene expression [37–40], the           │        │ │
│ │                                        │ information regarding the regulatory   │        │ │
│ │                                        │ molecules of KLF15 is scarce. It has   │        │ │
│ │                                        │ been reported that stimulation of      │        │ │
│ │                                        │ transforming growth factor beta (TGFβ) │        │ │
│ │                                        │ expression in myocytes can activate    │        │ │
│ │                                        │ p38α kinase (p38MAPK) via              │        │ │
│ │                                        │ TGFβ-activated kinase 1 (TAK1) and     │        │ │
│ │                                        │ cause inhibition of KLF15 expression   │        │ │
│ │                                        │ [22]. Of interest, we found an         │        │ │
│ │                                        │ increased phosphorylation of TAK1 and  │        │ │
│ │                                        │ p38MAPK, along with a decrease in      │        │ │
│ │                                        │ KLF15 expression in the human DCM      │        │ │
│ │                                        │ hearts. These results suggest that     │        │ │
│ │                                        │ TGFβ mediated TAK1/p38MAPK/KLF15       │        │ │
│ │                                        │ signaling may be a mechanism           │        │ │
│ │                                        │ underlying the defect of BCAA          │        │ │
│ │                                        │ catabolism in the human DCM hearts.    │        │ │
│ │                                        │ This notion is further supported by a  │        │ │
│ │                                        │ study showing that increased           │        │ │
│ │                                        │ production of TGFβ can cause           │        │ │
│ │                                        │ cardiomyocyte hypertrophy along with a │        │ │
│ │                                        │ p38MAPK-dependent suppression of KLF15 │        │ │
│ │                                        │ mRNA and protein [41]. In addition, it │        │ │
│ │                                        │ has recently been demonstrated that    │        │ │
│ │                                        │ the cAMP response element binding      │        │ │
│ │                                        │ protein (CREB) contains a binding      │        │ │
│ │                                        │ element on the KLF15 promoter, and     │        │ │
│ │                                        │ overexpression of CREB is sufficient   │        │ │
│ │                                        │ to attenuate high glucose induced      │        │ │
│ │                                        │ downregulation of KLF15 and BCAA       │        │ │
│ │                                        │ catabolic enzymes [31]. As p38MAPK is  │        │ │
│ │                                        │ an upstream modulator of CREB in rat   │        │ │
│ │                                        │ hearts [42], it is reasonable to       │        │ │
│ │                                        │ propose that signaling through the     │        │ │
│ │                                        │ TAK1/p38MAPK/CREB/KLF15 axis may be a  │        │ │
│ │                                        │ mechanism responsible for mediating    │        │ │
│ │                                        │ BCAA catabolism in the heart.          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The beneficial effects of the BT2      │        │ │
│ │                                        │ inhibitor have been demonstrated by    │        │ │
│ │                                        │ others in the failing mouse heart, due │        │ │
│ │                                        │ to inhibition of BCKDK activity and a  │        │ │
│ │                                        │ decreased phosphorylation of BCKDH     │        │ │
│ │                                        │ [2]. In mice hearts, we show that BT2  │        │ │
│ │                                        │ can significantly enhance BCAA         │        │ │
│ │                                        │ oxidation, presumably secondary to     │        │ │
│ │                                        │ activation of BCKDH (Fig. 4). We and   │        │ │
│ │                                        │ others have shown that the             │        │ │
│ │                                        │ contribution of cardiac BCAA oxidation │        │ │
│ │                                        │ to energy production is as low as      │        │ │
│ │                                        │ 1–$3\%$ [9, 43]. Therefore, increasing │        │ │
│ │                                        │ BCAA oxidation cannot effectively      │        │ │
│ │                                        │ compete with fatty acid and glucose    │        │ │
│ │                                        │ oxidation as a source of acetyl CoA    │        │ │
│ │                                        │ for the TCA cycle. Instead, we propose │        │ │
│ │                                        │ that the BT2-mediated rise in cardiac  │        │ │
│ │                                        │ BCAA oxidation in the failing hearts   │        │ │
│ │                                        │ would decrease BCAA levels, and        │        │ │
│ │                                        │ therefore improve cardiac insulin      │        │ │
│ │                                        │ sensitivity. Importantly, we have also │        │ │
│ │                                        │ demonstrated that the pressure         │        │ │
│ │                                        │ gradient across the aortic banding is  │        │ │
│ │                                        │ greater in the TAC hearts relative to  │        │ │
│ │                                        │ sham, while BT2 has no effect on       │        │ │
│ │                                        │ changing it. Thus, the improved %EF in │        │ │
│ │                                        │ the TAC mouse heart is more likely due │        │ │
│ │                                        │ to the effect of BT2 on increasing     │        │ │
│ │                                        │ BCAA oxidation, rather than a surgical │        │ │
│ │                                        │ effect on manipulating the severity of │        │ │
│ │                                        │ heart failure.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Limitations                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ [1] Activation of the signaling        │        │ │
│ │                                        │ through the TAK1/p38MAP/KLF15 axis     │        │ │
│ │                                        │ could be a potential mechanism         │        │ │
│ │                                        │ associated with the impaired BCAA      │        │ │
│ │                                        │ catabolism in human DCM hearts.        │        │ │
│ │                                        │ However, further studies with the cell │        │ │
│ │                                        │ culture system and relative animal     │        │ │
│ │                                        │ models are needed to corroborate this  │        │ │
│ │                                        │ conclusion; [2] The effect of BT2 on   │        │ │
│ │                                        │ altering cardiac BCAA content along    │        │ │
│ │                                        │ with enhancing cardiac BCAA oxidation  │        │ │
│ │                                        │ and ex vivo cardiac work needs to be   │        │ │
│ │                                        │ investigated in mouse TAC hearts,      │        │ │
│ │                                        │ which would further support the        │        │ │
│ │                                        │ improvement of %EF in vivo. Also,      │        │ │
│ │                                        │ level of fibrosis in this animal could │        │ │
│ │                                        │ be one of the explanation of this      │        │ │
│ │                                        │ improvement; [3] *In this* study, some │        │ │
│ │                                        │ variations in the expression of the    │        │ │
│ │                                        │ BCAA catabolic enzymes in the failing  │        │ │
│ │                                        │ heart occurred between mice versus     │        │ │
│ │                                        │ humans. However, there also are        │        │ │
│ │                                        │ similarities. For instance, in this    │        │ │
│ │                                        │ current study, we found a reduction of │        │ │
│ │                                        │ the upstream enzyme BCATm and an       │        │ │
│ │                                        │ accumulation of the cardiac BCAAs due  │        │ │
│ │                                        │ to TAC surgery in mice, a finding also │        │ │
│ │                                        │ seen in the human failing heart        │        │ │
│ │                                        │ samples. Similar to this finding, in a │        │ │
│ │                                        │ previous study we demonstrated that    │        │ │
│ │                                        │ cardiac insulin resistance due to high │        │ │
│ │                                        │ fat diet-induced obesity in mice is    │        │ │
│ │                                        │ associated with a reduced BCAA         │        │ │
│ │                                        │ oxidation, but we did not see any      │        │ │
│ │                                        │ changes in P-BCKDH and BCKDH levels    │        │ │
│ │                                        │ [9]. Unlike what we found in our       │        │ │
│ │                                        │ study, a reduction of BCKDH complexes  │        │ │
│ │                                        │ due to TAC surgery in mice has been    │        │ │
│ │                                        │ reported by Sun et al. [ 16], which    │        │ │
│ │                                        │ parallels what we see in the human     │        │ │
│ │                                        │ heart failure studies. Therefore,      │        │ │
│ │                                        │ while a number of changes in BCAA      │        │ │
│ │                                        │ catabolism were similar between mouse  │        │ │
│ │                                        │ and human failing hearts, other        │        │ │
│ │                                        │ changes were not similar. Some of      │        │ │
│ │                                        │ these differences may be related to    │        │ │
│ │                                        │ the severity of heart failure between  │        │ │
│ │                                        │ the mice and the humans. The severity  │        │ │
│ │                                        │ of the heart failure due to the TAC    │        │ │
│ │                                        │ surgery did not reach to the level as  │        │ │
│ │                                        │ we have anticipated. Although we have  │        │ │
│ │                                        │ seen a significant change in upstream  │        │ │
│ │                                        │ BCAA catabolic enzymes and cardiac     │        │ │
│ │                                        │ BCAAs, however, no significant changes │        │ │
│ │                                        │ in the downstream enzymes or insulin   │        │ │
│ │                                        │ signaling markers may be a result of   │        │ │
│ │                                        │ the less severe TAC surgery.           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Conclusions                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In conclusion, signaling through the   │        │ │
│ │                                        │ TAK1/P38MAPK axis in the human failing │        │ │
│ │                                        │ heart leads to an inhibition of KLF15  │        │ │
│ │                                        │ expression and inhibition of the BCAA  │        │ │
│ │                                        │ catabolic pathway, resulting in        │        │ │
│ │                                        │ elevated cardiac BCAA levels. The      │        │ │
│ │                                        │ result of this is a BCAA mediated      │        │ │
│ │                                        │ activation of the mTOR initiated       │        │ │
│ │                                        │ P-p70S6K/P-IRS1ser636 pathway, which   │        │ │
│ │                                        │ results in blunted insulin signaling.  │        │ │
│ │                                        │ Lowering cardiac BCAA levels (or BCAA  │        │ │
│ │                                        │ metabolites) by enhancing BCAA         │        │ │
│ │                                        │ oxidation, may have therapeutic        │        │ │
│ │                                        │ potential for treating heart failure.  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Additional file                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Additional file 1: Table S1. Clinical  │        │ │
│ │                                        │ profile of patients with dilated       │        │ │
│ │                                        │ cardiomyopathy.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. Newgard CB, An J, Bain JR,          │        │ │
│ │                                        │ Muehlbauer MJ, Stevens RD, Lien LF,    │        │ │
│ │                                        │ Haqq AM, Shah SH, Arlotto M, Slentz    │        │ │
│ │                                        │ CA. **A branched-chain amino           │        │ │
│ │                                        │ acid-related metabolic signature that  │        │ │
│ │                                        │ differentiates obese and lean humans   │        │ │
│ │                                        │ and contributes to insulin             │        │ │
│ │                                        │ resistance**. *Cell Metab* (2009.0)    │        │ │
│ │                                        │ **9** 311-326. PMID: 19356713          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. Sun H, Olson KC, Gao C, Prosdocimo  │        │ │
│ │                                        │ DA, Zhou M, Wang Z, Jeyaraj D, Youn    │        │ │
│ │                                        │ JY, Ren S, Liu Y. **Catabolic defect   │        │ │
│ │                                        │ of branched-chain amino acids promotes │        │ │
│ │                                        │ heart failure**. *Circulation*         │        │ │
│ │                                        │ (2016.0) **133** 2038-2049. PMID:      │        │ │
│ │                                        │ 27059949                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Wang TJ, Larson MG, Vasan RS, Cheng │        │ │
│ │                                        │ S, Rhee EP, McCabe E, Lewis GD, Fox    │        │ │
│ │                                        │ CS, Jacques PF, Fernandez C.           │        │ │
│ │                                        │ **Metabolite profiles and the risk of  │        │ │
│ │                                        │ developing diabetes**. *Nat Med*       │        │ │
│ │                                        │ (2011.0) **17** 448. PMID: 21423183    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Würtz P, Soininen P, Kangas AJ,     │        │ │
│ │                                        │ Rönnemaa T, Lehtimäki T, Kähönen M,    │        │ │
│ │                                        │ Viikari JS, Raitakari OT, Ala-Korpela  │        │ │
│ │                                        │ M. **Branched-chain and aromatic amino │        │ │
│ │                                        │ acids are predictors of insulin        │        │ │
│ │                                        │ resistance in young adults**.          │        │ │
│ │                                        │ *Diabetes Care* (2012.0) **36**        │        │ │
│ │                                        │ 648-655. PMID: 23129134                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Swan JW, Anker SD, Walton C,        │        │ │
│ │                                        │ Godsland IF, Clark AL, Leyva F,        │        │ │
│ │                                        │ Stevenson JC, Coats AJ. **Insulin      │        │ │
│ │                                        │ resistance in chronic heart failure:   │        │ │
│ │                                        │ relation to severity and etiology of   │        │ │
│ │                                        │ heart failure**. *J Am Coll Cardiol*   │        │ │
│ │                                        │ (1997.0) **30** 527-532. PMID: 9247528 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Zhang L, Jaswal JS, Ussher JR,      │        │ │
│ │                                        │ Sankaralingam S, Wagg C, Zaugg M,      │        │ │
│ │                                        │ Lopaschuk GD. **Cardiac insulin        │        │ │
│ │                                        │ resistance and decreased mitochondrial │        │ │
│ │                                        │ energy production precede the          │        │ │
│ │                                        │ development of systolic heart failure  │        │ │
│ │                                        │ following pressure overload            │        │ │
│ │                                        │ hypertrophy**. *Circ Heart Fail*       │        │ │
│ │                                        │ (2013.0) **6** 1039-1048. PMID:        │        │ │
│ │                                        │ 23861485                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. Karwi QG, Zhang L, Wagg CS, Wang W, │        │ │
│ │                                        │ Ghandi M, Thai D, Yan H, Ussher JR,    │        │ │
│ │                                        │ Oudit GY, Lopaschuk GD. **Targeting    │        │ │
│ │                                        │ the glucagon receptor improves cardiac │        │ │
│ │                                        │ function and enhances insulin          │        │ │
│ │                                        │ sensitivity following a myocardial     │        │ │
│ │                                        │ infarction**. *Cardiovasc Diabetol*    │        │ │
│ │                                        │ (2019.0) **18** 1. PMID: 30626440      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Wang W, Zhang F, Xia Y, Zhao S, Yan │        │ │
│ │                                        │ W, Wang H, Lee Y, Li C, Zhang L, Lian  │        │ │
│ │                                        │ K. **Defective branched chain amino    │        │ │
│ │                                        │ acid catabolism contributes to cardiac │        │ │
│ │                                        │ dysfunction and remodeling following   │        │ │
│ │                                        │ myocardial infarction**. *Am J Physiol │        │ │
│ │                                        │ Heart Circ Physiol* (2016.0) **311**   │        │ │
│ │                                        │ H1160-H1169. PMID: 27542406            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Fillmore N, Wagg CS, Zhang L,       │        │ │
│ │                                        │ Fukushima A, Lopaschuk GD. **Cardiac   │        │ │
│ │                                        │ branched-chain amino acid oxidation is │        │ │
│ │                                        │ reduced during insulin resistance in   │        │ │
│ │                                        │ the heart**. *Am J Physiol Endocrinol  │        │ │
│ │                                        │ Metab* (2018.0) **315** E1046-E1052.   │        │ │
│ │                                        │ PMID: 30106622                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Lynch CJ, Adams SH.                │        │ │
│ │                                        │ **Branched-chain amino acids in        │        │ │
│ │                                        │ metabolic signalling and insulin       │        │ │
│ │                                        │ resistance**. *Nat Rev Endocrinol*     │        │ │
│ │                                        │ (2014.0) **10** 723. PMID: 25287287    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Dodd KM, Tee AR. **Leucine and     │        │ │
│ │                                        │ mTORC1: a complex relationship**. *Am  │        │ │
│ │                                        │ J Physiol Endocrinol Metab* (2012.0)   │        │ │
│ │                                        │ **302** E1329-E1342. PMID: 22354780    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Han JM, Jeong SJ, Park MC, Kim G,  │        │ │
│ │                                        │ Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S. │        │ │
│ │                                        │ **Leucyl-tRNA synthetase is an         │        │ │
│ │                                        │ intracellular leucine sensor for the   │        │ │
│ │                                        │ mTORC1-signaling pathway**. *Cell*     │        │ │
│ │                                        │ (2012.0) **149** 410-424. PMID:        │        │ │
│ │                                        │ 22424946                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Wolfson RL, Chantranupong L,       │        │ │
│ │                                        │ Saxton RA, Shen K, Scaria SM, Cantor   │        │ │
│ │                                        │ JR, Sabatini DM. **Sestrin2 is a       │        │ │
│ │                                        │ leucine sensor for the mTORC1          │        │ │
│ │                                        │ pathway**. *Science* (2015.0) **351**  │        │ │
│ │                                        │ 43-48. PMID: 26449471                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Harper A, Miller R, Block K.       │        │ │
│ │                                        │ **Branched-chain amino acid            │        │ │
│ │                                        │ metabolism**. *Annu Rev Nutr* (1984.0) │        │ │
│ │                                        │ **4** 409-454. PMID: 6380539           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Lu G, Sun H, She P, Youn J-Y,      │        │ │
│ │                                        │ Warburton S, Ping P, Vondriska TM, Cai │        │ │
│ │                                        │ H, Lynch CJ, Wang Y. **Protein         │        │ │
│ │                                        │ phosphatase 2Cm is a critical          │        │ │
│ │                                        │ regulator of branched-chain amino acid │        │ │
│ │                                        │ catabolism in mice and cultured        │        │ │
│ │                                        │ cells**. *J Clin Investig* (2009.0)    │        │ │
│ │                                        │ **119** 1678-1687. PMID: 19411760      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Sun H, Olson KC, Gao C, Prosdocimo │        │ │
│ │                                        │ DA, Zhou M, Wang Z, Jeyaraj D, Youn    │        │ │
│ │                                        │ J-Y, Ren S, Liu Y. **Catabolic defect  │        │ │
│ │                                        │ of branched-chain amino acids promotes │        │ │
│ │                                        │ heart failure**. *Circulation*         │        │ │
│ │                                        │ (2016.0) **133** 2038-2049. PMID:      │        │ │
│ │                                        │ 27059949                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. Mitsubuchi H, Nobukuni Y,          │        │ │
│ │                                        │ Hayashida Y, Ohta K, Indo Y, Akaboshi  │        │ │
│ │                                        │ I, Endo F, Matsuda I. **Gene analysis  │        │ │
│ │                                        │ of maple syrup urine disease (MSUD)**. │        │ │
│ │                                        │ *Rinsho Byori* (1993.0) **41**         │        │ │
│ │                                        │ 484-491. PMID: 8350511                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Jana S, Zhang H, Lopaschuk GD,     │        │ │
│ │                                        │ Freed DH, Sergi C, Kantor PF, Oudit    │        │ │
│ │                                        │ GY, Kassiri Z. **Disparate remodeling  │        │ │
│ │                                        │ of the extracellular matrix and        │        │ │
│ │                                        │ proteoglycans in failing pediatric     │        │ │
│ │                                        │ versus adult hearts**. *J Am Heart     │        │ │
│ │                                        │ Assoc* (2018.0) **7** e010427. PMID:   │        │ │
│ │                                        │ 30371322                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Patel VB, Zhabyeyev P, Chen X,     │        │ │
│ │                                        │ Wang F, Paul M, Fan D, McLean BA, Basu │        │ │
│ │                                        │ R, Zhang P, Shah S.                    │        │ │
│ │                                        │ **PI3Kalpha-regulated gelsolin         │        │ │
│ │                                        │ activity is a critical determinant of  │        │ │
│ │                                        │ cardiac cytoskeletal remodeling and    │        │ │
│ │                                        │ heart disease**. *Nat Commun* (2018.0) │        │ │
│ │                                        │ **9** 5390. PMID: 30568254             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. 20.Tajik AJ, Seward J, Hagler D,   │        │ │
│ │                                        │ Mair D, Lie J. Two-dimensional         │        │ │
│ │                                        │ real-time ultrasonic imaging of the    │        │ │
│ │                                        │ heart and great vessels. Technique,    │        │ │
│ │                                        │ image orientation, structure           │        │ │
│ │                                        │ identification, and validation. In:    │        │ │
│ │                                        │ Mayo Clinic Proceedings: 1978; 1978:   │        │ │
│ │                                        │ p. 271–303.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Belke DD, Larsen TS, Lopaschuk GD, │        │ │
│ │                                        │ Severson DL. **Glucose and fatty acid  │        │ │
│ │                                        │ metabolism in the isolated working     │        │ │
│ │                                        │ mouse heart**. *Am J Physiol Regul     │        │ │
│ │                                        │ Integr Comp Physiol* (1999.0) **277**  │        │ │
│ │                                        │ R1210-R1217                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. Hoa N, Ge L, Korach KS, Levin ER.  │        │ │
│ │                                        │ **Estrogen receptor beta maintains     │        │ │
│ │                                        │ expression of KLF15 to prevent cardiac │        │ │
│ │                                        │ myocyte hypertrophy in female          │        │ │
│ │                                        │ rodents**. *Mol Cell Endocrinol*       │        │ │
│ │                                        │ (2018.0) **470** 240-250. PMID:        │        │ │
│ │                                        │ 29127073                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Leenders JJ, Wijnen WJ, Hiller M,  │        │ │
│ │                                        │ van der Made I, Lentink V, van Leeuwen │        │ │
│ │                                        │ RE, Herias V, Pokharel S, Heymans S,   │        │ │
│ │                                        │ de Windt LJ. **Regulation of cardiac   │        │ │
│ │                                        │ gene expression by KLF15, a repressor  │        │ │
│ │                                        │ of myocardin activity**. *J Biol Chem* │        │ │
│ │                                        │ (2010.0) **285** 27449-27456. PMID:    │        │ │
│ │                                        │ 20566642                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Leenders JJ, Wijnen WJ, Hiller M,  │        │ │
│ │                                        │ van der Made I, Lentink V, van Leeuwen │        │ │
│ │                                        │ RE, Herias V, Pokharel S, Heymans S,   │        │ │
│ │                                        │ de Windt LJ. **Regulation of cardiac   │        │ │
│ │                                        │ gene expression by KLF15, a repressor  │        │ │
│ │                                        │ of myocardin activity**. *J Biol Chem* │        │ │
│ │                                        │ (2010.0) **285** 27449-27456. PMID:    │        │ │
│ │                                        │ 20566642                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Tso SC, Gui WJ, Wu CY, Chuang JL,  │        │ │
│ │                                        │ Qi X, Skvora KJ, Dork K, Wallace AL,   │        │ │
│ │                                        │ Morlock LK, Lee BH. **Benzothiophene   │        │ │
│ │                                        │ carboxylate derivatives as novel       │        │ │
│ │                                        │ allosteric inhibitors of               │        │ │
│ │                                        │ branched-chain alpha-ketoacid          │        │ │
│ │                                        │ dehydrogenase kinase**. *J Biol Chem*  │        │ │
│ │                                        │ (2014.0) **289** 20583-20593. PMID:    │        │ │
│ │                                        │ 24895126                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Adibi SA. **Influence of dietary   │        │ │
│ │                                        │ deprivations on plasma concentration   │        │ │
│ │                                        │ of free amino acids of man**. *J Appl  │        │ │
│ │                                        │ Physiol* (1968.0) **25** 52-57. PMID:  │        │ │
│ │                                        │ 5661154                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. Felig P, Marliss E, Cahill GF.     │        │ │
│ │                                        │ **Plasma amino acid levels and insulin │        │ │
│ │                                        │ secretion in obesity**. *N Engl J Med* │        │ │
│ │                                        │ (1969.0) **281** 811-816. PMID:        │        │ │
│ │                                        │ 5809519                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Batch BC, Shah SH, Newgard CB,     │        │ │
│ │                                        │ Turer CB, Haynes C, Bain JR,           │        │ │
│ │                                        │ Muehlbauer M, Patel MJ, Stevens RD,    │        │ │
│ │                                        │ Appel LJ. **Branched chain amino acids │        │ │
│ │                                        │ are novel biomarkers for               │        │ │
│ │                                        │ discrimination of metabolic            │        │ │
│ │                                        │ wellness**. *Metabolism* (2013.0)      │        │ │
│ │                                        │ **62** 961-969. PMID: 23375209         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Huang Y, Zhou M, Sun H, Wang Y.    │        │ │
│ │                                        │ **Branched-chain amino acid metabolism │        │ │
│ │                                        │ in heart disease: an epiphenomenon or  │        │ │
│ │                                        │ a real culprit?**. *Cardiovasc Res*    │        │ │
│ │                                        │ (2011.0) **90** 220-223. PMID:         │        │ │
│ │                                        │ 21502372                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Newgard CB. **Interplay between    │        │ │
│ │                                        │ lipids and branched-chain amino acids  │        │ │
│ │                                        │ in development of insulin              │        │ │
│ │                                        │ resistance**. *Cell Metab* (2012.0)    │        │ │
│ │                                        │ **15** 606-614. PMID: 22560213         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Shao D, Villet O, Zhang Z, Choi    │        │ │
│ │                                        │ SW, Yan J, Ritterhoff J, Gu H,         │        │ │
│ │                                        │ Djukovic D, Christodoulou D, Kolwicz   │        │ │
│ │                                        │ SC. **Glucose promotes cell growth by  │        │ │
│ │                                        │ suppressing branched-chain amino acid  │        │ │
│ │                                        │ degradation**. *Nat Commun* (2018.0)   │        │ │
│ │                                        │ **9** 2935. PMID: 30050148             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Li T, Zhang Z, Kolwicz SC, Abell   │        │ │
│ │                                        │ L, Roe ND, Kim M, Zhou B, Cao Y,       │        │ │
│ │                                        │ Ritterhoff J, Gu H. **Defective        │        │ │
│ │                                        │ branched-chain amino acid catabolism   │        │ │
│ │                                        │ disrupts glucose metabolism and        │        │ │
│ │                                        │ sensitizes the heart to                │        │ │
│ │                                        │ ischemia-reperfusion injury**. *Cell   │        │ │
│ │                                        │ Metab* (2017.0) **25** 374-385. PMID:  │        │ │
│ │                                        │ 28178567                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Sun H, Wang Y. **Branched chain    │        │ │
│ │                                        │ amino acid metabolic reprogramming in  │        │ │
│ │                                        │ heart failure**. *Biochim Biophys      │        │ │
│ │                                        │ Acta* (2016.0) **1862** 2270-2275.     │        │ │
│ │                                        │ PMID: 27639835                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 34. Nemchenko A, Chiong M, Turer A,    │        │ │
│ │                                        │ Lavandero S, Hill JA. **Autophagy as a │        │ │
│ │                                        │ therapeutic target in cardiovascular   │        │ │
│ │                                        │ disease**. *J Mol Cell Cardiol*        │        │ │
│ │                                        │ (2011.0) **51** 584-593. PMID:         │        │ │
│ │                                        │ 21723289                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 35. Zhou Y, Jetton TL, Goshorn S,      │        │ │
│ │                                        │ Lynch CJ, She P. **Transamination is   │        │ │
│ │                                        │ required for {alpha}-ketoisocaproate   │        │ │
│ │                                        │ but not leucine to stimulate insulin   │        │ │
│ │                                        │ secretion**. *J Biol Chem* (2010.0)    │        │ │
│ │                                        │ **285** 33718-33726. PMID: 20736162    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 36. Creighton TE. *Proteins:           │        │ │
│ │                                        │ structures and molecular properties*   │        │ │
│ │                                        │ (1993.0)                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 37. Chaillou T, Lee JD, England JH,    │        │ │
│ │                                        │ Esser KA, McCarthy JJ. **Time course   │        │ │
│ │                                        │ of gene expression during mouse        │        │ │
│ │                                        │ skeletal muscle hypertrophy**. *J Appl │        │ │
│ │                                        │ Physiol* (2013.0) **115** 1065-1074.   │        │ │
│ │                                        │ PMID: 23869057                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 38. Gray S, Wang B, Orihuela Y, Hong   │        │ │
│ │                                        │ E-G, Fisch S, Haldar S, Cline GW, Kim  │        │ │
│ │                                        │ JK, Peroni OD, Kahn BB. **Regulation   │        │ │
│ │                                        │ of gluconeogenesis by Krüppel-like     │        │ │
│ │                                        │ factor 15**. *Cell Metab* (2007.0)     │        │ │
│ │                                        │ **5** 305-312. PMID: 17403374          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 39. Haldar SM, Lu Y, Jeyaraj D,        │        │ │
│ │                                        │ Kawanami D, Cui Y, Eapen SJ, Hao C, Li │        │ │
│ │                                        │ Y, Doughman Y-Q, Watanabe M. **Klf15   │        │ │
│ │                                        │ deficiency is a molecular link between │        │ │
│ │                                        │ heart failure and aortic aneurysm      │        │ │
│ │                                        │ formation**. *Sci Transl Med* (2010.0) │        │ │
│ │                                        │ **2** 26                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 40. Prosdocimo DA, Anand P, Liao X,    │        │ │
│ │                                        │ Zhu H, Shelkay S, Calderon PA, Zhang   │        │ │
│ │                                        │ L, Kirsh J, Rosca MG, Vazquez E.       │        │ │
│ │                                        │ **Kruppel-like factor 15 is a critical │        │ │
│ │                                        │ regulator of cardiac lipid             │        │ │
│ │                                        │ metabolism**. *J Biol Chem* (2014.0)   │        │ │
│ │                                        │ **289** 5914-5924. PMID: 24407292      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 41. Leenders JJ, Wijnen WJ, van der    │        │ │
│ │                                        │ Made I, Hiller M, Swinnen M,           │        │ │
│ │                                        │ Vandendriessche T, Chuah M, Pinto YM,  │        │ │
│ │                                        │ Creemers EE. **Repression of cardiac   │        │ │
│ │                                        │ hypertrophy by KLF15: underlying       │        │ │
│ │                                        │ mechanisms and therapeutic             │        │ │
│ │                                        │ implications**. *PLoS ONE* (2012.0)    │        │ │
│ │                                        │ **7** e36754. PMID: 22586493           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 42. Li L, Fan D, Wang C, Wang JY, Cui  │        │ │
│ │                                        │ XB, Wu D, Zhou Y, Wu LL. **Angiotensin │        │ │
│ │                                        │ II increases periostin expression via  │        │ │
│ │                                        │ Ras/p38 MAPK/CREB and ERK1/2/TGF-beta1 │        │ │
│ │                                        │ pathways in cardiac fibroblasts**.     │        │ │
│ │                                        │ *Cardiovasc Res* (2011.0) **91**       │        │ │
│ │                                        │ 80-89. PMID: 21367774                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 43. Ichihara K, Neely JR, Siehl DL,    │        │ │
│ │                                        │ Morgan HE. **Utilization of leucine by │        │ │
│ │                                        │ working rat heart**. *Am J Physiol*    │        │ │
│ │                                        │ (1980.0) **239** E430-E436. PMID:      │        │ │
│ │                                        │ 6778220                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │ title: Downregulation of               │        │ │
│ │                                        │ extramitochondrial BCKDH and its       │        │ │
│ │                                        │ uncoupling from AMP deaminase          │        │ │
│ │                                        │   in type 2 diabetic OLETF rat hearts  │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Toshifumi Ogawa                      │        │ │
│ │                                        │ - Hidemichi Kouzu                      │        │ │
│ │                                        │ - Arata Osanami                        │        │ │
│ │                                        │ - Yuki Tatekoshi                       │        │ │
│ │                                        │ - Tatsuya Sato                         │        │ │
│ │                                        │ - Atsushi Kuno                         │        │ │
│ │                                        │ - Yugo Fujita                          │        │ │
│ │                                        │ - Shoya Ino                            │        │ │
│ │                                        │ - Masaki Shimizu                       │        │ │
│ │                                        │ - Yuki Toda                            │        │ │
│ │                                        │ - Wataru Ohwada                        │        │ │
│ │                                        │ - Toshiyuki Yano                       │        │ │
│ │                                        │ - Masaya Tanno                         │        │ │
│ │                                        │ - Takayuki Miki                        │        │ │
│ │                                        │ - Tetsuji Miura                        │        │ │
│ │                                        │ journal: Physiological Reports         │        │ │
│ │                                        │ year: 2023                             │        │ │
│ │                                        │ pmcid: PMC9938007                      │        │ │
│ │                                        │ doi: 10.14814/phy2.15608               │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # Downregulation of extramitochondrial │        │ │
│ │                                        │ BCKDH and its uncoupling from AMP      │        │ │
│ │                                        │ deaminase in type 2 diabetic OLETF rat │        │ │
│ │                                        │ hearts                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Systemic branched‐chain amino acid     │        │ │
│ │                                        │ (BCAA) metabolism is dysregulated in   │        │ │
│ │                                        │ cardiometabolic diseases. We           │        │ │
│ │                                        │ previously demonstrated that           │        │ │
│ │                                        │ upregulated AMP deaminase 3 (AMPD3)    │        │ │
│ │                                        │ impairs cardiac energetics in a rat    │        │ │
│ │                                        │ model of obese type 2 diabetes, Otsuka │        │ │
│ │                                        │ Long‐Evans‐Tokushima fatty (OLETF).    │        │ │
│ │                                        │ Here, we hypothesized that the cardiac │        │ │
│ │                                        │ BCAA levels and the activity of        │        │ │
│ │                                        │ branched‐chain α‐keto acid             │        │ │
│ │                                        │ dehydrogenase (BCKDH), a rate‐limiting │        │ │
│ │                                        │ enzyme in BCAA metabolism, are altered │        │ │
│ │                                        │ by type 2 diabetes (T2DM), and that    │        │ │
│ │                                        │ upregulated AMPD3 expression is        │        │ │
│ │                                        │ involved in the alteration. Performing │        │ │
│ │                                        │ proteomic analysis combined with       │        │ │
│ │                                        │ immunoblotting, we discovered that     │        │ │
│ │                                        │ BCKDH localizes not only to            │        │ │
│ │                                        │ mitochondria but also to the           │        │ │
│ │                                        │ endoplasmic reticulum (ER), where it   │        │ │
│ │                                        │ interacts with AMPD3. Knocking down    │        │ │
│ │                                        │ AMPD3 in neonatal rat cardiomyocytes   │        │ │
│ │                                        │ (NRCMs) increased BCKDH activity,      │        │ │
│ │                                        │ suggesting that AMPD3 negatively       │        │ │
│ │                                        │ regulates BCKDH. Compared with control │        │ │
│ │                                        │ rats (Long‐Evans Tokushima Otsuka      │        │ │
│ │                                        │ [LETO] rats), OLETF rats exhibited     │        │ │
│ │                                        │ $49\%$ higher cardiac BCAA levels and  │        │ │
│ │                                        │ $49\%$ lower BCKDH activity. In the    │        │ │
│ │                                        │ cardiac ER of the OLETF rats,          │        │ │
│ │                                        │ BCKDH‐E1α subunit expression was       │        │ │
│ │                                        │ downregulated, while AMPD3 expression  │        │ │
│ │                                        │ was upregulated, resulting in an       │        │ │
│ │                                        │ $80\%$ lower AMPD3‐E1α interaction     │        │ │
│ │                                        │ compared to LETO rats. Knocking down   │        │ │
│ │                                        │ E1α expression in NRCMs upregulated    │        │ │
│ │                                        │ AMPD3 expression and recapitulated the │        │ │
│ │                                        │ imbalanced AMPD3‐BCKDH expressions     │        │ │
│ │                                        │ observed in OLETF rat hearts. E1α      │        │ │
│ │                                        │ knockdown in NRCMs inhibited glucose   │        │ │
│ │                                        │ oxidation in response to insulin,      │        │ │
│ │                                        │ palmitate oxidation, and lipid droplet │        │ │
│ │                                        │ biogenesis under oleate loading.       │        │ │
│ │                                        │ Collectively, these data revealed      │        │ │
│ │                                        │ previously unrecognized                │        │ │
│ │                                        │ extramitochondrial localization of     │        │ │
│ │                                        │ BCKDH in the heart and its reciprocal  │        │ │
│ │                                        │ regulation with AMPD3 and imbalanced   │        │ │
│ │                                        │ AMPD3‐BCKDH interactions in OLETF.     │        │ │
│ │                                        │ Downregulation of BCKDH in             │        │ │
│ │                                        │ cardiomyocytes induced profound        │        │ │
│ │                                        │ metabolic changes that are observed in │        │ │
│ │                                        │ OLETF hearts, providing insight into   │        │ │
│ │                                        │ mechanisms contributing to the         │        │ │
│ │                                        │ development of diabetic                │        │ │
│ │                                        │ cardiomyopathy.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The present study revealed previously  │        │ │
│ │                                        │ unrecognized extramitochondrial        │        │ │
│ │                                        │ localization of branched‐chain α‐keto  │        │ │
│ │                                        │ acid dehydrogenase (BCKDH) and its     │        │ │
│ │                                        │ reciprocal regulation with AMPD3 in    │        │ │
│ │                                        │ cardiomyocytes and imbalanced          │        │ │
│ │                                        │ AMPD3‐BCKDH interactions in a rat      │        │ │
│ │                                        │ model of type 2 diabetes, Otsuka       │        │ │
│ │                                        │ Long‐Evans‐Tokushima fatty (OLETF).    │        │ │
│ │                                        │ Downregulation of BCKDH in             │        │ │
│ │                                        │ cardiomyocytes induced profound        │        │ │
│ │                                        │ metabolic changes that are observed in │        │ │
│ │                                        │ OLETF hearts, providing insight into   │        │ │
│ │                                        │ mechanisms contributing to the         │        │ │
│ │                                        │ development of diabetic                │        │ │
│ │                                        │ cardiomyopathy.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## INTRODUCTION                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Diabetic cardiomyopathy is defined as  │        │ │
│ │                                        │ cardiac dysfunction involving          │        │ │
│ │                                        │ structural, functional, and metabolic  │        │ │
│ │                                        │ changes not associated with coronary   │        │ │
│ │                                        │ artery disease (Miki et al., 2013).    │        │ │
│ │                                        │ Its metabolic hallmark is reduced      │        │ │
│ │                                        │ substrate flexibility, with augmented  │        │ │
│ │                                        │ fatty acid uptake and oxidation and    │        │ │
│ │                                        │ suppressed glucose oxidation (Miki et  │        │ │
│ │                                        │ al., 2013). The augmented influx of    │        │ │
│ │                                        │ fatty acids leads to intracellular     │        │ │
│ │                                        │ accumulation of various lipid species  │        │ │
│ │                                        │ and is believed to cause cardiac       │        │ │
│ │                                        │ lipotoxicity (Lopaschuk et al., 2010;  │        │ │
│ │                                        │ Wende & Abel, 2010). However,          │        │ │
│ │                                        │ increasing evidence suggests that not  │        │ │
│ │                                        │ all the accumulated lipid species are  │        │ │
│ │                                        │ necessarily harmful (Goldberg et al.,  │        │ │
│ │                                        │ 2018). Specifically,                   │        │ │
│ │                                        │ triglyceride‐containing lipid droplet  │        │ │
│ │                                        │ biogenesis in the endoplasmic          │        │ │
│ │                                        │ reticulum (ER) reportedly sequesters   │        │ │
│ │                                        │ potentially toxic fatty acids in       │        │ │
│ │                                        │ excess (Listenberger et al., 2003; Liu │        │ │
│ │                                        │ et al., 2009). Lipid droplets serve    │        │ │
│ │                                        │ not only as efficient reservoirs of    │        │ │
│ │                                        │ fatty acids for mitochondrial          │        │ │
│ │                                        │ oxidation (Banke et al., 2010) but     │        │ │
│ │                                        │ also as essential sources of lipid     │        │ │
│ │                                        │ ligands for peroxisome                 │        │ │
│ │                                        │ proliferator‐activated receptor‐α      │        │ │
│ │                                        │ (PPARα) activation, a critical step in │        │ │
│ │                                        │ fatty acid metabolism (Haemmerle et    │        │ │
│ │                                        │ al., 2011). A more detailed            │        │ │
│ │                                        │ understanding of diabetes‐induced      │        │ │
│ │                                        │ metabolic remodeling may lead to       │        │ │
│ │                                        │ metabolic therapies for diabetic       │        │ │
│ │                                        │ cardiomyopathy.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Myocardial fatty acid metabolism is    │        │ │
│ │                                        │ tightly coupled with amino acid        │        │ │
│ │                                        │ catabolism in normal hearts (Murashige │        │ │
│ │                                        │ et al., 2020). When fatty acids are    │        │ │
│ │                                        │ dominant fuel sources, such as in      │        │ │
│ │                                        │ fasting, the heart takes up            │        │ │
│ │                                        │ branched‐chain amino acids (BCAAs) and │        │ │
│ │                                        │ glutamate. In addition, the heart      │        │ │
│ │                                        │ secretes nitrogen‐rich amino acids,    │        │ │
│ │                                        │ such as glutamine. Although the        │        │ │
│ │                                        │ contribution of BCAA oxidation to      │        │ │
│ │                                        │ mitochondrial ATP production is        │        │ │
│ │                                        │ negligible (Fillmore et al., 2018;     │        │ │
│ │                                        │ Murashige et al., 2020; Neinast, Jang, │        │ │
│ │                                        │ et al., 2019), experimental disruption │        │ │
│ │                                        │ of BCAA catabolism consistently        │        │ │
│ │                                        │ induced maladaptive cardiac remodeling │        │ │
│ │                                        │ (Li et al., 2017; Lu et al., 2007; Sun │        │ │
│ │                                        │ et al., 2016), suggesting that BCAAs   │        │ │
│ │                                        │ play crucial roles in addition to      │        │ │
│ │                                        │ being energy substrates. Given the     │        │ │
│ │                                        │ emerging evidence showing that         │        │ │
│ │                                        │ systemic BCAA metabolism is            │        │ │
│ │                                        │ dysregulated in cardiometabolic        │        │ │
│ │                                        │ disease (Lynch & Adams, 2014; White &  │        │ │
│ │                                        │ Newgard, 2019), it is tempting to      │        │ │
│ │                                        │ speculate that impaired myocardial     │        │ │
│ │                                        │ BCAA metabolism is somehow involved in │        │ │
│ │                                        │ the metabolic remodeling of diabetic   │        │ │
│ │                                        │ cardiomyopathy and maybe a potential   │        │ │
│ │                                        │ therapeutic target.                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We recently reported that upregulated  │        │ │
│ │                                        │ expression of AMP deaminase 3 (AMPD3), │        │ │
│ │                                        │ a rate‐limiting enzyme in the purine   │        │ │
│ │                                        │ nucleotide cycle, is involved in       │        │ │
│ │                                        │ abnormal cardiac energetics in Otsuka  │        │ │
│ │                                        │ Long‐Evans‐Tokushima fatty (OLETF)     │        │ │
│ │                                        │ rats, models of type 2 diabetes (T2DM) │        │ │
│ │                                        │ (Igaki et al., 2021; Kouzu et al.,     │        │ │
│ │                                        │ 2015; Tatekoshi et al., 2018). The     │        │ │
│ │                                        │ elevated AMPD activity was associated  │        │ │
│ │                                        │ with ATP depletion during acute        │        │ │
│ │                                        │ pressure overload due to excessive     │        │ │
│ │                                        │ degradation of adenine nucleotides     │        │ │
│ │                                        │ (Kouzu et al., 2015; Tatekoshi et al., │        │ │
│ │                                        │ 2018), which subsequently facilitated  │        │ │
│ │                                        │ reactive oxygen species production via │        │ │
│ │                                        │ downstream xanthine oxidoreductase and │        │ │
│ │                                        │ led to mitochondrial respiratory       │        │ │
│ │                                        │ failure (Igaki et al., 2021).          │        │ │
│ │                                        │ Meanwhile, AMPD3 was found to play a   │        │ │
│ │                                        │ central role in coupling fatty acid    │        │ │
│ │                                        │ and BCAA metabolism in skeletal muscle │        │ │
│ │                                        │ (Hong et al., 2017). However, the      │        │ │
│ │                                        │ roles of AMPD3 in cardiac BCAA         │        │ │
│ │                                        │ metabolism and their modifications by  │        │ │
│ │                                        │ T2DM have not been examined.           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Considering these findings, we         │        │ │
│ │                                        │ hypothesized that the cardiac BCAA     │        │ │
│ │                                        │ levels and the activity of             │        │ │
│ │                                        │ branched‐chain α‐keto acid             │        │ │
│ │                                        │ dehydrogenase (BCKDH), a rate‐limiting │        │ │
│ │                                        │ enzyme complex in BCAA catabolism that │        │ │
│ │                                        │ is localized in the mitochondrial      │        │ │
│ │                                        │ matrix, are altered by T2DM, and that  │        │ │
│ │                                        │ upregulated AMPD3 expression is        │        │ │
│ │                                        │ involved in the alteration. To test    │        │ │
│ │                                        │ this hypothesis, we used OLETF rats as │        │ │
│ │                                        │ models of T2DM since they are suitable │        │ │
│ │                                        │ for use in elucidating the role of     │        │ │
│ │                                        │ impaired BCAA metabolism in T2DM.      │        │ │
│ │                                        │ OLETF rats have higher circulating     │        │ │
│ │                                        │ BCAAs and lower hepatic BCKDH activity │        │ │
│ │                                        │ (Kuzuya et al., 2008); therefore,      │        │ │
│ │                                        │ these rats recapitulate dysregulation  │        │ │
│ │                                        │ of BCAA metabolism in patients with    │        │ │
│ │                                        │ T2DM (Lynch & Adams, 2014).            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Animal models                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Animal studies were conducted          │        │ │
│ │                                        │ according to the Guide for the Care    │        │ │
│ │                                        │ and Use of Laboratory Animals          │        │ │
│ │                                        │ published by the National Research     │        │ │
│ │                                        │ Council of the National Academies, USA │        │ │
│ │                                        │ [2011] and was approved by the Animal  │        │ │
│ │                                        │ Use Committee of Sapporo Medical       │        │ │
│ │                                        │ University. In this study, we          │        │ │
│ │                                        │ primarily used male OLETF rats and     │        │ │
│ │                                        │ Long‐Evans Tokushima Otsuka (LETO)     │        │ │
│ │                                        │ rats that were 34–40 weeks old. OLETF  │        │ │
│ │                                        │ develops T2DM by hyperphagia. In our   │        │ │
│ │                                        │ previous studies, we repetitively      │        │ │
│ │                                        │ confirmed elevation of body weight,    │        │ │
│ │                                        │ plasma glucose, serum triglycerides,   │        │ │
│ │                                        │ and plasma insulin levels in OLETF at  │        │ │
│ │                                        │ the age of 29–35 weeks compared with   │        │ │
│ │                                        │ those in LETO (Hotta et al., 2010;     │        │ │
│ │                                        │ Kouzu et al., 2015; Miki et al., 2009; │        │ │
│ │                                        │ Tatekoshi et al., 2018), and insulin   │        │ │
│ │                                        │ resistance in OLETF at the same ages   │        │ │
│ │                                        │ was demonstrated by the glucose clamp  │        │ │
│ │                                        │ method (Hotta et al., 2010). We also   │        │ │
│ │                                        │ used 9–10‐week‐old Sprague–Dawley rats │        │ │
│ │                                        │ to examine the intracellular           │        │ │
│ │                                        │ localization of AMPD3 and BCKDH. Rats  │        │ │
│ │                                        │ were purchased from Sankyo Labo        │        │ │
│ │                                        │ Service Corporation. The rats were     │        │ │
│ │                                        │ housed in standard plastic cages with  │        │ │
│ │                                        │ paper chip bedding and maintained in a │        │ │
│ │                                        │ 14 h/10 h light–dark cycle             │        │ │
│ │                                        │ temperature‐controlled room (22 ± 1°C) │        │ │
│ │                                        │ with free access to water and a        │        │ │
│ │                                        │ standard rodent chow (CRF‐1, Charales  │        │ │
│ │                                        │ River Laboratories). Data for          │        │ │
│ │                                        │ myocardial BCAA levels were retrieved  │        │ │
│ │                                        │ from metabolomics database obtained in │        │ │
│ │                                        │ our previous study (Kouzu et al.,      │        │ │
│ │                                        │ 2015).                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Cell culture                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ H9c2 and HEK293 cells (American Type   │        │ │
│ │                                        │ Culture Collection) were cultured in   │        │ │
│ │                                        │ DMEM (Wako 044‐29765) or DMEM/F‐12     │        │ │
│ │                                        │ (Gibco 11320‐033) supplemented with    │        │ │
│ │                                        │ $10\%$ fetal bovine serum (FBS) at     │        │ │
│ │                                        │ 37°C with $5\%$ CO2. The cells were    │        │ │
│ │                                        │ used for experiments when they were    │        │ │
│ │                                        │ $70\%$–$90\%$ confluent. Neonatal rat  │        │ │
│ │                                        │ cardiomyocytes (NRCMs) were isolated   │        │ │
│ │                                        │ as previously described (Tatekoshi et  │        │ │
│ │                                        │ al., 2018). NRCMs were plated on       │        │ │
│ │                                        │ fibronectin‐coated plates in culture   │        │ │
│ │                                        │ medium; 500 mL of Medium 199 (Gibco    │        │ │
│ │                                        │ 11150‐059) was fortified by the        │        │ │
│ │                                        │ addition of 5 mL of MEM (Gibco         │        │ │
│ │                                        │ 11140‐050), 5 mL l‐glutamine (200 mM,  │        │ │
│ │                                        │ Gibco 25030‐081), 1.75 g of glucose, 1 │        │ │
│ │                                        │ mg of vitamin B12, 5 mL of HEPES (1 M, │        │ │
│ │                                        │ Gibco 15630‐080), $10\%$ FBS and 100   │        │ │
│ │                                        │ μM bromodeoxyuridine. The final        │        │ │
│ │                                        │ glucose concentration was 25 mM. The   │        │ │
│ │                                        │ culture medium was replaced with fresh │        │ │
│ │                                        │ medium containing $2\%$ FBS the next   │        │ │
│ │                                        │ day.                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Transfection                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ siRNAs were purchased from Dharmacon.  │        │ │
│ │                                        │ The following siRNAs were used in this │        │ │
│ │                                        │ study: rat AMPD3 (M‐091904‐01), rat    │        │ │
│ │                                        │ BCKDHA (M‐081866‐01), and              │        │ │
│ │                                        │ non‐targeting control (D‐001206‐13,    │        │ │
│ │                                        │ D‐001810‐10). The siRNAs were          │        │ │
│ │                                        │ transfected using Dharmafect 1         │        │ │
│ │                                        │ transfection reagent (Dharmacon        │        │ │
│ │                                        │ T‐2001) or RNAiMAX (Thermo Fisher      │        │ │
│ │                                        │ Scientific 13778). Experiments were    │        │ │
│ │                                        │ performed 24–48 h after transfection.  │        │ │
│ │                                        │ FLAG‐AMPD3 or FLAG‐control vector was  │        │ │
│ │                                        │ transfected into H9c2 cells using      │        │ │
│ │                                        │ FuGENE HD (Promega E2311) as           │        │ │
│ │                                        │ previously described (Tatekoshi et     │        │ │
│ │                                        │ al., 2018).                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BCKDH activity assay                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Tissue BCKDH activity was measured as  │        │ │
│ │                                        │ previously described with slight       │        │ │
│ │                                        │ modification (White et al., 2018).     │        │ │
│ │                                        │ Briefly, 50 μL of tissue homogenate    │        │ │
│ │                                        │ was added to 300 μL of assay buffer    │        │ │
│ │                                        │ (50 mM HEPES, pH 7.5; 30 mM Kpi pH     │        │ │
│ │                                        │ 7.5; 0.4 mM CoA; 3 mM NAD+; $5\%$ FBS; │        │ │
│ │                                        │ 2 mM thiamine pyrophosphate; 2 mM      │        │ │
│ │                                        │ MgCl2; and 86.6 μM α‐keto [1‐14C]      │        │ │
│ │                                        │ isovalerate, 3838 cpm/nmol of specific │        │ │
│ │                                        │ radioactivity) in a 1.7 mL Eppendorf   │        │ │
│ │                                        │ tube, which was immediately connected  │        │ │
│ │                                        │ to another tube containing a raised 1  │        │ │
│ │                                        │ M NaOH CO2 trap. The tubes were sealed │        │ │
│ │                                        │ with parafilm and incubated for 30 min │        │ │
│ │                                        │ at 37°C. The reaction mixture was      │        │ │
│ │                                        │ acidified by the injection of $70\%$   │        │ │
│ │                                        │ perchloric acid and reconnected to the │        │ │
│ │                                        │ CO2 trap tube, where it remained at    │        │ │
│ │                                        │ room temperature for 1 h. The 14CO2    │        │ │
│ │                                        │ contained in the trap was counted in a │        │ │
│ │                                        │ liquid scintillation counter (AccuFLEX │        │ │
│ │                                        │ LSC‐8000). An assay with intact cells  │        │ │
│ │                                        │ was conducted as previously described  │        │ │
│ │                                        │ (Chuang & Chuang, 2000).               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Measurement of cardiac AMP          │        │ │
│ │                                        │ deaminase activity                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ AMP deaminase activity was measured as │        │ │
│ │                                        │ previously described (Igaki et al.,    │        │ │
│ │                                        │ 2021; Kouzu et al., 2015; Tatekoshi et │        │ │
│ │                                        │ al., 2018).                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Tissue and cell fractionation       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Fractionation of tissues was performed │        │ │
│ │                                        │ as previously reported (Ma et al.,     │        │ │
│ │                                        │ 2017; Wieckowski et al., 2009) with    │        │ │
│ │                                        │ slight modification. Briefly, 0.5 g of │        │ │
│ │                                        │ freshly harvested tissue was manually  │        │ │
│ │                                        │ homogenized with a Dounce homogenizer  │        │ │
│ │                                        │ in 4 mL of ice‐cold buffer (225 mM     │        │ │
│ │                                        │ mannitol, 75 mM sucrose, $0.5\%$ BSA,  │        │ │
│ │                                        │ 30 mM Tris–HCl (pH 7.4), and 0.5 mM    │        │ │
│ │                                        │ EGTA). Nuclei and unbroken cells were  │        │ │
│ │                                        │ pelleted by centrifugation. The        │        │ │
│ │                                        │ supernatant was collected and          │        │ │
│ │                                        │ centrifuged to separate crude          │        │ │
│ │                                        │ mitochondria from the cytosol and ER   │        │ │
│ │                                        │ fractions. After two washes, the crude │        │ │
│ │                                        │ mitochondrial fraction was suspended   │        │ │
│ │                                        │ in 0.5 mL of mitochondrial             │        │ │
│ │                                        │ resuspension buffer (MRB, 250 mM       │        │ │
│ │                                        │ mannitol, 5 mM HEPES (pH 7.40), and    │        │ │
│ │                                        │ 0.5 mM EGTA), layered on 4 mL of       │        │ │
│ │                                        │ *Percoll medium* (225 mM mannitol, 25  │        │ │
│ │                                        │ mM HEPES (pH 7.4), 1 mM EGTA, and      │        │ │
│ │                                        │ $30\%$ Percoll (vol/vol)) and less     │        │ │
│ │                                        │ than 0.5 mL of MRB, and then           │        │ │
│ │                                        │ centrifuged at 95,000 g for 30 min.    │        │ │
│ │                                        │ The pure mitochondrial fraction was    │        │ │
│ │                                        │ collected from the Percoll gradient    │        │ │
│ │                                        │ and centrifuged to obtain a pellet.    │        │ │
│ │                                        │ The supernatant containing the cytosol │        │ │
│ │                                        │ and ER fractions was centrifuged at    │        │ │
│ │                                        │ 20,000 g for 60 min, followed by       │        │ │
│ │                                        │ 100,000 g for 60 min, resulting in the │        │ │
│ │                                        │ isolation of ER (pellet) and cytosolic │        │ │
│ │                                        │ (supernatant) fractions. The protocol  │        │ │
│ │                                        │ for cultured cells was identical       │        │ │
│ │                                        │ except that BSA was removed from the   │        │ │
│ │                                        │ homogenization buffer. In our          │        │ │
│ │                                        │ experiments, 10 confluent dishes (Φ 15 │        │ │
│ │                                        │ cm) containing HEK293 cells were       │        │ │
│ │                                        │ sufficient to isolate enough crude     │        │ │
│ │                                        │ mitochondrial fraction.                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Immunoprecipitation of AMPD3        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Precleared tissue or cell lysates (500 │        │ │
│ │                                        │ μg) were incubated with 0.64 μg of     │        │ │
│ │                                        │ anti‐AMPD3 antibody (Proteintech       │        │ │
│ │                                        │ 23997‐1‐AP) or 1 μg of rabbit control  │        │ │
│ │                                        │ IgG (Cell Signaling 2729 S) in IP      │        │ │
│ │                                        │ buffer (150 mM NaCl, 10 mM Tris–HCl    │        │ │
│ │                                        │ (pH 7.4), 1 mM EDTA, 1 mM EGTA (pH     │        │ │
│ │                                        │ 8.0), 0.2 mM sodium orthovanadate, 0.2 │        │ │
│ │                                        │ mM PMSF, $1\%$ Triton X‐100, and       │        │ │
│ │                                        │ $0.5\%$ NP‐40) at 4°C overnight with   │        │ │
│ │                                        │ rotation. The antibody‐AMPD3 complex   │        │ │
│ │                                        │ was collected with magnetic beads (New │        │ │
│ │                                        │ England Biolabs #S1425S) and washed    │        │ │
│ │                                        │ with IP buffer. The immunoprecipitates │        │ │
│ │                                        │ were subjected to mass spectrometry or │        │ │
│ │                                        │ immunoblotting.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Mass spectrometry                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Immunoprecipitates obtained with an    │        │ │
│ │                                        │ anti‐AMPD3 antibody or rabbit control  │        │ │
│ │                                        │ IgG were eluted with glycine buffer    │        │ │
│ │                                        │ (0.1 M glycine and 0.02 M HCl, pH      │        │ │
│ │                                        │ 2.5–3.0) and then neutralized by the   │        │ │
│ │                                        │ addition of Tris–HCl (pH 8.5).         │        │ │
│ │                                        │ Subsequent proteomic analyses were     │        │ │
│ │                                        │ performed at the Proteomics Facility   │        │ │
│ │                                        │ at our institute. Briefly, after       │        │ │
│ │                                        │ reduction and alkylation, in‐solution  │        │ │
│ │                                        │ digestion with trypsin was performed   │        │ │
│ │                                        │ overnight at 37°C. Samples were        │        │ │
│ │                                        │ dissolved in $0.1\%$ formic acid and   │        │ │
│ │                                        │ loaded onto a nanoflow                 │        │ │
│ │                                        │ ultrahigh‐performance liquid           │        │ │
│ │                                        │ chromatograph column (Easy‐nLC 1000    │        │ │
│ │                                        │ system, Thermo Fisher Scientific)      │        │ │
│ │                                        │ coupled online to an Orbitrap mass     │        │ │
│ │                                        │ spectrometer equipped with a nanospray │        │ │
│ │                                        │ ion source (Q‐Exactive Plus, Thermo    │        │ │
│ │                                        │ Fisher Scientific). The samples were   │        │ │
│ │                                        │ separated on a 75 μm × 20 cm capillary │        │ │
│ │                                        │ column with a particle size of 3 μm    │        │ │
│ │                                        │ (NTCC‐360, Nikkyo Technos) by applying │        │ │
│ │                                        │ a linear gradient ranging from $5\%$   │        │ │
│ │                                        │ to $35\%$ buffer B ($100\%$            │        │ │
│ │                                        │ acetonitrile and $0.1\%$ formic acid)  │        │ │
│ │                                        │ at a flow rate of 300 nL/min for 120   │        │ │
│ │                                        │ min. Through mass spectrometry         │        │ │
│ │                                        │ analysis, survey spectra were acquired │        │ │
│ │                                        │ at a resolution of 70,000 at 200 m/z   │        │ │
│ │                                        │ with a target value of 3e6 ions,       │        │ │
│ │                                        │ ranging from 350 to 2000 m/z with      │        │ │
│ │                                        │ charge states between 1+ and 4+. We    │        │ │
│ │                                        │ applied a data‐dependent top‐10        │        │ │
│ │                                        │ method, which generates high‐energy    │        │ │
│ │                                        │ collision dissociation fragments for   │        │ │
│ │                                        │ the 10 most intense precursor ions per │        │ │
│ │                                        │ survey scan. The tandem mass           │        │ │
│ │                                        │ spectrometry resolution was 17,500 at  │        │ │
│ │                                        │ 200 m/z with a target value of 1e5     │        │ │
│ │                                        │ ions. The data were searched against   │        │ │
│ │                                        │ the SWISS‐PROT human proteome database │        │ │
│ │                                        │ using the Sequest HT search engine     │        │ │
│ │                                        │ with Proteome Discoverer 2.2 software  │        │ │
│ │                                        │ (Thermo Fisher Scientific).            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Immunoblotting                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To obtain total lysates, frozen tissue │        │ │
│ │                                        │ samples or fresh cultured cells were   │        │ │
│ │                                        │ homogenized in ice‐cold buffer         │        │ │
│ │                                        │ (CelLytic™ MT Cell Lysis Reagent for   │        │ │
│ │                                        │ tissue samples or CelLytic™ M Cell     │        │ │
│ │                                        │ Lysis Reagent for cultured cells,      │        │ │
│ │                                        │ Sigma Aldrich) with protease inhibitor │        │ │
│ │                                        │ cocktail (NACALAI TESQUE 25955‐11) and │        │ │
│ │                                        │ phosphatase inhibitor cocktail         │        │ │
│ │                                        │ (NACALAI TESQUE 07574‐61). The         │        │ │
│ │                                        │ homogenate was centrifuged at 13,000 g │        │ │
│ │                                        │ for 15 min at 4°C to obtain the        │        │ │
│ │                                        │ supernatant. Fractionation samples     │        │ │
│ │                                        │ were prepared as described above.      │        │ │
│ │                                        │ Protein concentration was determined   │        │ │
│ │                                        │ using a BCA Protein Assay Kit (TaKaRa  │        │ │
│ │                                        │ Bio T9300A). Equal amounts of proteins │        │ │
│ │                                        │ (5–10 μg) were electrophoresed on      │        │ │
│ │                                        │ $7.5\%$ or $10\%$ polyacrylamide gels  │        │ │
│ │                                        │ and then blotted onto PVDF membranes.  │        │ │
│ │                                        │ After blocking with a TBS‐T buffer     │        │ │
│ │                                        │ containing $5\%$ nonfat dry milk or    │        │ │
│ │                                        │ $5\%$ BSA, the blots were incubated    │        │ │
│ │                                        │ with primary antibodies at 4°C         │        │ │
│ │                                        │ overnight. The following primary and   │        │ │
│ │                                        │ secondary antibodies were used in this │        │ │
│ │                                        │ study: anti‐AMPD3 (Proteintech         │        │ │
│ │                                        │ 23997‐1‐AP, 1:1000–1:2000);            │        │ │
│ │                                        │ anti‐BCKDHA (Abcam ab138460,           │        │ │
│ │                                        │ 1:2000–1:4000); anti‐BCKDHA            │        │ │
│ │                                        │ (phospho‐S293) (Abcam ab200577,        │        │ │
│ │                                        │ 1:2000); anti‐DBT (Abcam ab151991,     │        │ │
│ │                                        │ 1:2000); anti‐DLD (Gene Tex GTX101245, │        │ │
│ │                                        │ 1:2000); anti‐KLF15 (Santa Cruz        │        │ │
│ │                                        │ sc271675, 1:500); anti‐BCAT1           │        │ │
│ │                                        │ (Proteintech 13640‐1‐AP, 1:2000);      │        │ │
│ │                                        │ anti‐BCAT2 (Proteintech 16417‐1‐AP,    │        │ │
│ │                                        │ 1:1000); anti‐PP2Cm (Proteintech       │        │ │
│ │                                        │ 14573‐1‐AP, 1:500); anti‐BCKDK (Santa  │        │ │
│ │                                        │ Cruz sc374425, 1:100); anti‐AKT        │        │ │
│ │                                        │ (phospho‐S473) (Cell Signaling 9271 S, │        │ │
│ │                                        │ 1:1000); anti‐AKT (Cell Signaling 9272 │        │ │
│ │                                        │ S, 1:1000); anti‐CPT1B (Proteintech    │        │ │
│ │                                        │ 22170‐1‐AP, 1:2000); anti‐PGK1 (Gene   │        │ │
│ │                                        │ Tex GTX107614, 1:2000); anti‐calnexin  │        │ │
│ │                                        │ (Abcam ab22595, 1:40000); anti‐SERCA2  │        │ │
│ │                                        │ ATPase (Abcam ab2861, 1:2500);         │        │ │
│ │                                        │ anti‐cyclophilin D (Gene Tex           │        │ │
│ │                                        │ GTX117951, 1:1000); anti‐COX4 (Santa   │        │ │
│ │                                        │ Cruz sc517553, 1:400); anti‐cytochrome │        │ │
│ │                                        │ c (Cell Signaling 4272 S, 1:1000);     │        │ │
│ │                                        │ anti‐VDAC1 (Santa Cruz sc390996,       │        │ │
│ │                                        │ 1:2000); anti‐vinculin (Sigma Aldrich  │        │ │
│ │                                        │ V9131, 1:8000); anti‐AMPK              │        │ │
│ │                                        │ (phospho‐T172) (Cell Signaling 2535 S, │        │ │
│ │                                        │ 1:2000); anti‐AMPK (Cell Signaling     │        │ │
│ │                                        │ 2532 S, 1:2000); anti‐ACC              │        │ │
│ │                                        │ (phospho‐S79) (Cell Signaling 3661 S,  │        │ │
│ │                                        │ 1:1000); anti‐ACC (Cell Signaling 3676 │        │ │
│ │                                        │ S, 1:1000); anti‐DGAT1(Abcam ab54037,  │        │ │
│ │                                        │ 1:500); anti‐ATGL (Cell Signaling 2138 │        │ │
│ │                                        │ S, 1:1000); anti‐ATP‐citrate lyase     │        │ │
│ │                                        │ (Cell Signaling 4332 S, 1:2000);       │        │ │
│ │                                        │ anti‐mouse IgG (Cytiva NA931V,         │        │ │
│ │                                        │ 1:5000); anti‐rabbit IgG (Cytiva       │        │ │
│ │                                        │ NA934V, 1:2000); and anti‐rabbit IgG   │        │ │
│ │                                        │ (Light‐Chain Specific) (Cell Signaling │        │ │
│ │                                        │ 45262, 1:2000). Immunoblotted proteins │        │ │
│ │                                        │ were visualized by using an Immobilon  │        │ │
│ │                                        │ Western Detection Kit (Millipore       │        │ │
│ │                                        │ WBKLS0500). Image J software (National │        │ │
│ │                                        │ Institutes of Health) was used for     │        │ │
│ │                                        │ quantifying signals of each blot.      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Quantitative RT–PCR                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mRNA levels of AMPD3, PPARα, and   │        │ │
│ │                                        │ CD36 were measured as previously       │        │ │
│ │                                        │ described (Tatekoshi et al., 2018).    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Measurement of mitochondrial        │        │ │
│ │                                        │ respiration                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mitochondrial oxygen consumption   │        │ │
│ │                                        │ rate (OCR) was measured with a         │        │ │
│ │                                        │ Seahorse XFe96 Analyzer (Agilent       │        │ │
│ │                                        │ Technologies, Santa Clara, CA).        │        │ │
│ │                                        │ Twenty‐four hours after NRCMs were     │        │ │
│ │                                        │ plated at a density of 30,000 cells    │        │ │
│ │                                        │ per well, siRNA transfection was       │        │ │
│ │                                        │ performed and the cells were incubated │        │ │
│ │                                        │ for 24 h. After replacement with fresh │        │ │
│ │                                        │ culture medium containing 0.5 mM       │        │ │
│ │                                        │ L‐carnitine, the cells were incubated  │        │ │
│ │                                        │ for an additional 24 h. One hour       │        │ │
│ │                                        │ before the assay was performed, the    │        │ │
│ │                                        │ culture medium was replaced with an    │        │ │
│ │                                        │ assay medium (Seahorse XF DMEM,        │        │ │
│ │                                        │ Agilent Technologies 103575‐100)       │        │ │
│ │                                        │ supplemented with 2 mM glucose and 0.5 │        │ │
│ │                                        │ mM L‐carnitine, pH 7.4. Before the     │        │ │
│ │                                        │ assay was performed, BSA‐conjugated    │        │ │
│ │                                        │ palmitate (molar ratio 6:1, final      │        │ │
│ │                                        │ concentration 167 μM; the XF           │        │ │
│ │                                        │ palmitate‐BSA FAO substrate, Agilent   │        │ │
│ │                                        │ Technologies 102720‐100) or control    │        │ │
│ │                                        │ BSA was added to each well. To avoid   │        │ │
│ │                                        │ fatty acid‐induced cardiomyocyte       │        │ │
│ │                                        │ apoptosis (Sparagna et al., 2000), we  │        │ │
│ │                                        │ adopted the low palmitate              │        │ │
│ │                                        │ concentration, which has been          │        │ │
│ │                                        │ validated in previous studies          │        │ │
│ │                                        │ (Angelini et al., 2022; Readnower et   │        │ │
│ │                                        │ al., 2012). OCR was measured as        │        │ │
│ │                                        │ previously described (Igaki et al.,    │        │ │
│ │                                        │ 2021). In preliminary experiments      │        │ │
│ │                                        │ using NRCMs, we confirmed that 40 μM   │        │ │
│ │                                        │ etomoxir completely blocked the        │        │ │
│ │                                        │ palmitate‐stimulated increase in OCR.  │        │ │
│ │                                        │ To assess nonfatty acid oxidation, an  │        │ │
│ │                                        │ assay medium supplemented with 5.5 mM  │        │ │
│ │                                        │ glucose, 1 mM pyruvate, and 2 mM       │        │ │
│ │                                        │ glutamine was used instead of the      │        │ │
│ │                                        │ palmitate‐supplemented assay medium.   │        │ │
│ │                                        │ Insulin was added 15 min before assay  │        │ │
│ │                                        │ with a final concentration of 100 nM.  │        │ │
│ │                                        │ OCR was also measured in H9c2 cells 48 │        │ │
│ │                                        │ h after transfection with either       │        │ │
│ │                                        │ FLAG‐AMPD3 or FLAG‐control.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Lipid droplet assay                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A lipid droplet assay was conducted as │        │ │
│ │                                        │ previously reported with slight        │        │ │
│ │                                        │ modification (Nguyen et al., 2017).    │        │ │
│ │                                        │ Briefly, 24 h after transfection,      │        │ │
│ │                                        │ NRCMs were incubated with fresh        │        │ │
│ │                                        │ culture medium containing different    │        │ │
│ │                                        │ concentrations of BSA‐conjugated       │        │ │
│ │                                        │ oleate (molar ratio 2:1, final         │        │ │
│ │                                        │ concentration $\frac{2}{10}$/20 μM;    │        │ │
│ │                                        │ Sigma Aldrich O3008) for 24 h. Before  │        │ │
│ │                                        │ fixation, lipid droplets were stained  │        │ │
│ │                                        │ with BODIPY $\frac{493}{503}$ (Thermo  │        │ │
│ │                                        │ Fisher Scientific D3922) for 15 min    │        │ │
│ │                                        │ according to the manufacturer's        │        │ │
│ │                                        │ instructions. Nuclei were stained with │        │ │
│ │                                        │ Hoechst. Images were obtained by       │        │ │
│ │                                        │ confocal microscopy (ELYRAS.1LSM780,   │        │ │
│ │                                        │ ZEISS) with a 63x oil immersion        │        │ │
│ │                                        │ objective and analyzed using ImageJ    │        │ │
│ │                                        │ software. Images were analyzed on the  │        │ │
│ │                                        │ basis of threshold data, and then, the │        │ │
│ │                                        │ number and area of BODIPY              │        │ │
│ │                                        │ $\frac{493}{503}$‐stained lipid        │        │ │
│ │                                        │ droplets were quantified and           │        │ │
│ │                                        │ normalized on the basis of cell        │        │ │
│ │                                        │ counts. For group comparisons, each    │        │ │
│ │                                        │ experimental group consisted of 6–7    │        │ │
│ │                                        │ samples, and the lipid droplets in     │        │ │
│ │                                        │ 30–40 cells in each sample were        │        │ │
│ │                                        │ quantified.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Statistical analysis                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The data are expressed as the means ±  │        │ │
│ │                                        │ SEM. Differences in metabolite,        │        │ │
│ │                                        │ protein, and mRNA expression and       │        │ │
│ │                                        │ enzyme activity between groups were    │        │ │
│ │                                        │ analysis by Student's 2‐tailed t‐test  │        │ │
│ │                                        │ or one‐way ANOVA. Differences in lipid │        │ │
│ │                                        │ droplet assays were tested by two‐way  │        │ │
│ │                                        │ ANOVA. Mitochondrial respiration       │        │ │
│ │                                        │ assays were tested by two‐way          │        │ │
│ │                                        │ repeated‐measures ANOVA. Tukey–Kramer  │        │ │
│ │                                        │ test was performed for multiple        │        │ │
│ │                                        │ comparisons when ANOVA indicated       │        │ │
│ │                                        │ significant differences. A difference  │        │ │
│ │                                        │ was considered significant when the    │        │ │
│ │                                        │ p‐value was <0.05. The analysis was    │        │ │
│ │                                        │ conducted using GraphPad Prism 9       │        │ │
│ │                                        │ software.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Downregulation of BCAA catabolic    │        │ │
│ │                                        │ pathway is associated with BCAA        │        │ │
│ │                                        │ accumulation in T2DM hearts            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As we previously described (Hotta et   │        │ │
│ │                                        │ al., 2010; Kouzu et al., 2015; Miki et │        │ │
│ │                                        │ al., 2009; Tatekoshi et al., 2018),    │        │ │
│ │                                        │ OLETF rats had significantly higher    │        │ │
│ │                                        │ body weight and casual blood glucose   │        │ │
│ │                                        │ than LETO rats (Figure 1a,b),          │        │ │
│ │                                        │ confirming the OLETF rat as an obese   │        │ │
│ │                                        │ T2DM model. BCAA is converted to       │        │ │
│ │                                        │ branched‐chain keto acid (BCKA)        │        │ │
│ │                                        │ through transamination by              │        │ │
│ │                                        │ branched‐chain amino acid              │        │ │
│ │                                        │ aminotransferase (BCAT) and then       │        │ │
│ │                                        │ oxidized by BCKDH. BCKDH activity is   │        │ │
│ │                                        │ inhibited by phosphorylation of its    │        │ │
│ │                                        │ E1α subunit at the serine 293 residue  │        │ │
│ │                                        │ by branched‐chain keto acid            │        │ │
│ │                                        │ dehydrogenase kinase (BCKDK), and      │        │ │
│ │                                        │ dephosphorylation of E1α is realized   │        │ │
│ │                                        │ by mitochondrial matrix‐targeted       │        │ │
│ │                                        │ protein phosphatase 2C family member   │        │ │
│ │                                        │ (PP2Cm), which activates BCKDH (Figure │        │ │
│ │                                        │ 1c). Myocardial BCAAs were             │        │ │
│ │                                        │ significantly accumulated in OLETF     │        │ │
│ │                                        │ rats compared to LETO rats (Figure     │        │ │
│ │                                        │ 1d), and this accumulation was         │        │ │
│ │                                        │ associated with lower BCKDH activity   │        │ │
│ │                                        │ (Figure 1e), consistent with previous  │        │ │
│ │                                        │ animal models demonstrating impaired   │        │ │
│ │                                        │ cardiac BCAA metabolism and increased  │        │ │
│ │                                        │ tissue concentrations of BCAAs         │        │ │
│ │                                        │ (McGarrah & White, 2022). In addition, │        │ │
│ │                                        │ elevated circulating BCAAs in OLETF    │        │ │
│ │                                        │ (Kuzuya et al., 2008) may have also    │        │ │
│ │                                        │ contributed to the higher cardiac      │        │ │
│ │                                        │ BCAAs, as the plasma level is another  │        │ │
│ │                                        │ determinant of cardiac BCAAs (McGarrah │        │ │
│ │                                        │ & White, 2022).                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 1:** *Downregulation of       │        │ │
│ │                                        │ branched‐chain amino acid (BCAA)       │        │ │
│ │                                        │ catabolic pathway is associated with   │        │ │
│ │                                        │ BCAA accumulation in type 2 diabetes   │        │ │
│ │                                        │ (T2DM) hearts. (a, b) Body weight (a;  │        │ │
│ │                                        │ N = 7 in each group) and casual blood  │        │ │
│ │                                        │ glucose (b; N = 7 in each group) in    │        │ │
│ │                                        │ LETO and OLETF rats. (c) A schematic   │        │ │
│ │                                        │ showing the BCAA degradation pathway.  │        │ │
│ │                                        │ A red circle indicates the amino group │        │ │
│ │                                        │ in BCAA, and a blue circle indicates   │        │ │
│ │                                        │ its carbon backbone. (d, e) Myocardial │        │ │
│ │                                        │ BCAA levels (d; N = 5 in each group)   │        │ │
│ │                                        │ and BCKDH activity (e; N = 12–13 in    │        │ │
│ │                                        │ each group) in LETO and OLETF rats.    │        │ │
│ │                                        │ (f) Representative Western blot        │        │ │
│ │                                        │ showing BCKDH catabolic pathway in the │        │ │
│ │                                        │ total lysate of LETO and OLETF rat     │        │ │
│ │                                        │ hearts and summary of the densitometry │        │ │
│ │                                        │ analysis (N = 4 in each group). BCAAs, │        │ │
│ │                                        │ branched‐chain amino acids; BCAT,      │        │ │
│ │                                        │ branched‐chain amino acid              │        │ │
│ │                                        │ aminotransferase; BCKA, branched‐chain │        │ │
│ │                                        │ keto acid; BCKDH, branched‐chain       │        │ │
│ │                                        │ a‐keto acid dehydrogenase; BCKDK,      │        │ │
│ │                                        │ branched‐chain keto acid dehydrogenase │        │ │
│ │                                        │ kinase; PP2Cm, mitochondrial           │        │ │
│ │                                        │ matrix‐targeted protein phosphatase 2C │        │ │
│ │                                        │ family member; KLF15, Krüppel‐like     │        │ │
│ │                                        │ factors 15. Data were analyzed by      │        │ │
│ │                                        │ unpaired Student's t‐test. *p < 0.05   │        │ │
│ │                                        │ between BCAA levels in LETO and OLETF  │        │ │
│ │                                        │ rats. The p‐values obtained for        │        │ │
│ │                                        │ comparisons of the groups at both ends │        │ │
│ │                                        │ of the line are shown.*                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Krüppel‐like factors 15 (KLF15), a     │        │ │
│ │                                        │ transcriptional factor that regulates  │        │ │
│ │                                        │ the gene expressions of the BCAA       │        │ │
│ │                                        │ catabolic pathway (Sun et al., 2016),  │        │ │
│ │                                        │ was significantly downregulated by     │        │ │
│ │                                        │ $66\%$ in OLETF rats (Figure 1f).      │        │ │
│ │                                        │ Consistent with the KLF15              │        │ │
│ │                                        │ downregulation, the expressions of its │        │ │
│ │                                        │ downstream targets, including the      │        │ │
│ │                                        │ cytosolic form of BCAT1, E1α, and E2   │        │ │
│ │                                        │ subunit of BCKDH, and PP2Cm were       │        │ │
│ │                                        │ significantly decreased. Despite the   │        │ │
│ │                                        │ downregulation of PP2Cm, we did not    │        │ │
│ │                                        │ observe a significant difference in    │        │ │
│ │                                        │ the level of E1α phosphorylation       │        │ │
│ │                                        │ between the LETO and OLETF rats        │        │ │
│ │                                        │ (Figure S1). Thus, the suppressed      │        │ │
│ │                                        │ BCKDH activity in OLETF rats appeared  │        │ │
│ │                                        │ to be attributable to the              │        │ │
│ │                                        │ downregulation of BCKDH components     │        │ │
│ │                                        │ rather than posttranslational          │        │ │
│ │                                        │ modification of E1α.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## AMPD3 expression negatively         │        │ │
│ │                                        │ regulates BCKDH activity, in which     │        │ │
│ │                                        │ direct interaction of AMPD3 and BCKDH  │        │ │
│ │                                        │ might be involved                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Our previous proteomic analysis based  │        │ │
│ │                                        │ on two‐dimensional gel electrophoresis │        │ │
│ │                                        │ indicated that AMPD3 interacts with    │        │ │
│ │                                        │ the E1α subunit of BCKDH in rat        │        │ │
│ │                                        │ cardiac tissues (Tatekoshi et al.,     │        │ │
│ │                                        │ 2018). We verified this finding by     │        │ │
│ │                                        │ performing direct proteomic analyses   │        │ │
│ │                                        │ of AMPD3 immunoprecipitates in the     │        │ │
│ │                                        │ LETO and OLETF rat heart lysates       │        │ │
│ │                                        │ (Table S1). The top candidates for     │        │ │
│ │                                        │ binding were the E3 subunit of BCKDH   │        │ │
│ │                                        │ and BCKDK, which binds to the E2       │        │ │
│ │                                        │ subunit then phosphorylates the E1α    │        │ │
│ │                                        │ subunit (Zhou et al., 2012). These     │        │ │
│ │                                        │ results suggest that AMPD3 interacts   │        │ │
│ │                                        │ with the BCKDH enzyme complex. Next,   │        │ │
│ │                                        │ we validated the interaction by        │        │ │
│ │                                        │ immunoblotting. As we previously       │        │ │
│ │                                        │ reported (Tatekoshi et al., 2018), rat │        │ │
│ │                                        │ AMPD3 is expressed as 2 isoforms:      │        │ │
│ │                                        │ full‐length AMPD3 (90 kDa) and         │        │ │
│ │                                        │ N‐terminus‐truncated AMPD3 (78 kDa).   │        │ │
│ │                                        │ Full‐length AMPD3 interacted with the  │        │ │
│ │                                        │ E1α and E2 subunits but not with the   │        │ │
│ │                                        │ E3 subunit and BCKDK in NRCMs (Figure  │        │ │
│ │                                        │ 2a). We could not determine whether    │        │ │
│ │                                        │ truncated AMPD3 can interact with      │        │ │
│ │                                        │ BCKDH because the antibody we used did │        │ │
│ │                                        │ not immunoprecipitate this isoform.    │        │ │
│ │                                        │ Knocking down AMPD3 in NRCMs           │        │ │
│ │                                        │ significantly increased BCKDH activity │        │ │
│ │                                        │ 2.4‐fold, indicating that AMPD3        │        │ │
│ │                                        │ negatively regulates BCKDH (Figure     │        │ │
│ │                                        │ 2b). Unexpectedly, the enhanced BCKDH  │        │ │
│ │                                        │ activity by AMPD3 knockdown was not    │        │ │
│ │                                        │ associated with a decrease in E1α      │        │ │
│ │                                        │ phosphorylation or increase in protein │        │ │
│ │                                        │ levels of E1α, E2, and E3; the         │        │ │
│ │                                        │ subunits of BCKDH were rather reduced  │        │ │
│ │                                        │ by AMPD3 knockdown (Figure S2).        │        │ │
│ │                                        │ Knockdown of E1α expression by $75\%$  │        │ │
│ │                                        │ reduced BCKDH activity by $80\%$ in    │        │ │
│ │                                        │ H9c2 cells (data not shown),           │        │ │
│ │                                        │ confirming the protein level of BCKDH  │        │ │
│ │                                        │ being a determinant of its activity.   │        │ │
│ │                                        │ These results suggest that there are   │        │ │
│ │                                        │ contribution of a previously           │        │ │
│ │                                        │ unidentified mechanism to the increase │        │ │
│ │                                        │ in BCKDH activity and negative         │        │ │
│ │                                        │ feedback response of BCKDH expression  │        │ │
│ │                                        │ in cells with knockdown of AMPD3       │        │ │
│ │                                        │ expression. However, we cannot exclude │        │ │
│ │                                        │ the possibility that regulatory        │        │ │
│ │                                        │ mechanisms of BCKDH by AMPD3 differ    │        │ │
│ │                                        │ between intracellular compartments.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 2:** *AMP deaminase 3 (AMPD3) │        │ │
│ │                                        │ expression negatively regulates        │        │ │
│ │                                        │ branched‐chain α‐keto acid             │        │ │
│ │                                        │ dehydrogenase (BCKDH) activity, in     │        │ │
│ │                                        │ which direct interaction of AMPD3 and  │        │ │
│ │                                        │ BCKDH might be involved. (a)           │        │ │
│ │                                        │ Representative Western blot showing    │        │ │
│ │                                        │ the AMPD3‐BCKDH interaction in         │        │ │
│ │                                        │ neonatal rat cardiomyocytes (NRCMs)    │        │ │
│ │                                        │ and summary of the densitometry        │        │ │
│ │                                        │ analysis (N = 2). (b) BCKDH activity   │        │ │
│ │                                        │ (N = 17 in each group) in NRCMs with   │        │ │
│ │                                        │ or without AMPD3 knocked down. (c)     │        │ │
│ │                                        │ Western blot showing AMPD3 and BCKDH   │        │ │
│ │                                        │ components in subcellular compartments │        │ │
│ │                                        │ of hearts from LETO rat and summary of │        │ │
│ │                                        │ the densitometry analysis. (d)         │        │ │
│ │                                        │ Representative Western blot showing    │        │ │
│ │                                        │ BCKDH components in subcellular        │        │ │
│ │                                        │ compartments of LETO and OLETF rat     │        │ │
│ │                                        │ hearts and summary of the densitometry │        │ │
│ │                                        │ analysis (N = 4 in each group).        │        │ │
│ │                                        │ Normalization was performed using the  │        │ │
│ │                                        │ corresponding loading control for each │        │ │
│ │                                        │ fraction. (e) Representative Western   │        │ │
│ │                                        │ blot showing the AMPD3‐BCKDH           │        │ │
│ │                                        │ interaction in the ER fraction (N = 4  │        │ │
│ │                                        │ in each group) of LETO and OLETF rat   │        │ │
│ │                                        │ hearts and summary of the densitometry │        │ │
│ │                                        │ analysis. ER, endoplasmic reticulum;   │        │ │
│ │                                        │ C‐Mito, crude mitochondria; P‐Mito,    │        │ │
│ │                                        │ pure mitochondria. Data were analyzed  │        │ │
│ │                                        │ by unpaired Student's t‐test. The      │        │ │
│ │                                        │ p‐values obtained for comparisons of   │        │ │
│ │                                        │ the groups at both ends of the line    │        │ │
│ │                                        │ are shown.*                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The interaction of BCKDH with AMPD3    │        │ │
│ │                                        │ led us to examine the subcellular      │        │ │
│ │                                        │ localization of BCKDH in cardiac       │        │ │
│ │                                        │ tissues because AMPD3 was reported to  │        │ │
│ │                                        │ localize with cytoplasmic membrane     │        │ │
│ │                                        │ (Mahnke‐Zizelman & Sabina, 2002),      │        │ │
│ │                                        │ while BCKDH is a mitochondrial matrix  │        │ │
│ │                                        │ protein complex. As expected,          │        │ │
│ │                                        │ full‐length AMPD3 is predominantly     │        │ │
│ │                                        │ expressed in extramitochondrial        │        │ │
│ │                                        │ compartments obtained from LETO rats   │        │ │
│ │                                        │ (Figure 2c). However, we found that    │        │ │
│ │                                        │ BCKDH components were highly enriched  │        │ │
│ │                                        │ not only in the mitochondrial fraction │        │ │
│ │                                        │ but also in the ER fraction and, to a  │        │ │
│ │                                        │ lesser extent, in the cytosolic        │        │ │
│ │                                        │ fraction. Proteins localized in the    │        │ │
│ │                                        │ outer mitochondrial membrane (VDAC1)   │        │ │
│ │                                        │ and inner mitochondrial membrane space │        │ │
│ │                                        │ (cytochrome C) were detected in the ER │        │ │
│ │                                        │ fraction because the ER and            │        │ │
│ │                                        │ mitochondria structurally interact at  │        │ │
│ │                                        │ the mitochondria‐associated membrane.  │        │ │
│ │                                        │ However, it is unlikely that the ER    │        │ │
│ │                                        │ fraction is heavily contaminated with  │        │ │
│ │                                        │ mitochondrial matrix because there was │        │ │
│ │                                        │ no signal for cyclophilin D,           │        │ │
│ │                                        │ mitochondrial matrix protein, in the   │        │ │
│ │                                        │ ER fraction with comparable signal     │        │ │
│ │                                        │ intensities for BCKDH in the ER and    │        │ │
│ │                                        │ mitochondria fractions (Figure 2c,d).  │        │ │
│ │                                        │ In addition, AMPD3, which is           │        │ │
│ │                                        │ predominantly localized in             │        │ │
│ │                                        │ extramitochondrial compartments, was   │        │ │
│ │                                        │ found to physically interact with      │        │ │
│ │                                        │ BCKDH (Figure 2a, Table S1). Taken     │        │ │
│ │                                        │ together, it would be reasonable to    │        │ │
│ │                                        │ conclude that BCKDH localizes in not   │        │ │
│ │                                        │ only mitochondria but also             │        │ │
│ │                                        │ extramitochondrial compartments.       │        │ │
│ │                                        │ Extramitochondrial BCKDH expression    │        │ │
│ │                                        │ was not limited to this rat strain;    │        │ │
│ │                                        │ notably, along with AMPD3, BCKDH was   │        │ │
│ │                                        │ also highly expressed in the ER        │        │ │
│ │                                        │ fraction obtained from the heart of    │        │ │
│ │                                        │ Sprague–Dawley rats (Figure S3). We    │        │ │
│ │                                        │ also examined whether AMPD3 interacts  │        │ │
│ │                                        │ with BCKDH in HEK293 cells, which are  │        │ │
│ │                                        │ derived from human embryonic kidney    │        │ │
│ │                                        │ cells. Interestingly, although HEK293  │        │ │
│ │                                        │ cells showed different BCKDH and       │        │ │
│ │                                        │ full‐length AMPD3 expression patterns  │        │ │
│ │                                        │ compared to those in the myocardium    │        │ │
│ │                                        │ (i.e., BCKDH is expressed exclusively  │        │ │
│ │                                        │ in mitochondria, while full‐length     │        │ │
│ │                                        │ AMPD3 is ubiquitously expressed,       │        │ │
│ │                                        │ including in mitochondria), the        │        │ │
│ │                                        │ interaction of full‐length AMPD3 with  │        │ │
│ │                                        │ the E1α and E2 subunits was also       │        │ │
│ │                                        │ detected in HEK293 cells (Figure S4).  │        │ │
│ │                                        │ These results indicate that            │        │ │
│ │                                        │ intracellular compartments where       │        │ │
│ │                                        │ AMPD3‐BCKDH interaction occurs are     │        │ │
│ │                                        │ different depending on cell types.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In the OLETF rats, E1α expression was  │        │ │
│ │                                        │ decreased by $43\%$ in the ER fraction │        │ │
│ │                                        │ and $35\%$ in the mitochondrial        │        │ │
│ │                                        │ fraction (Figure 2d). E2 subunit       │        │ │
│ │                                        │ expression also tended to be decreased │        │ │
│ │                                        │ in the ER and mitochondria fractions   │        │ │
│ │                                        │ and was significantly decreased in the │        │ │
│ │                                        │ cytosol fraction, while E3 expression  │        │ │
│ │                                        │ in the ER was increased by $43\%$      │        │ │
│ │                                        │ (Figure 2d, Figure S5a). As expected   │        │ │
│ │                                        │ by their colocalization, AMPD3‐E1α     │        │ │
│ │                                        │ interaction was confirmed in the ER    │        │ │
│ │                                        │ and cytosolic fractions obtained from  │        │ │
│ │                                        │ LETO and OLETF rats (Figure 2e, Figure │        │ │
│ │                                        │ S5b). On the contrary, full‐length     │        │ │
│ │                                        │ AMPD3 in the pure mitochondrial        │        │ │
│ │                                        │ fraction was difficult to obtain by    │        │ │
│ │                                        │ immunoprecipitation, probably due to   │        │ │
│ │                                        │ its low expression in mitochondria. As │        │ │
│ │                                        │ we previously reported (Tatekoshi et   │        │ │
│ │                                        │ al., 2018), full‐length AMPD3          │        │ │
│ │                                        │ expression was upregulated in OLETF    │        │ │
│ │                                        │ rats. The upregulated AMPD3 expression │        │ │
│ │                                        │ and the downregulation of E1α          │        │ │
│ │                                        │ expression resulted in a significantly │        │ │
│ │                                        │ lower E1α‐AMPD3 interaction ratio in   │        │ │
│ │                                        │ OLETF than in LETO rats in the ER and  │        │ │
│ │                                        │ cytosolic fractions (Figure 2e, Figure │        │ │
│ │                                        │ S5b). These results indicate that an   │        │ │
│ │                                        │ imbalanced extramitochondrial          │        │ │
│ │                                        │ AMPD3‐BCKDH interaction may be         │        │ │
│ │                                        │ involved in the suppressed BCKDH       │        │ │
│ │                                        │ activity observed in T2DM hearts.      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Reduced BCKDH‐E1α expression        │        │ │
│ │                                        │ upregulates AMPD3                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We next examined whether the           │        │ │
│ │                                        │ downregulated expression of BCKDH      │        │ │
│ │                                        │ components is causally linked to the   │        │ │
│ │                                        │ upregulated expression of AMPD3        │        │ │
│ │                                        │ observed in OLETF rats. In H9c2        │        │ │
│ │                                        │ cardiomyoblasts, disruption of BCAA    │        │ │
│ │                                        │ metabolism by knocking down E1α        │        │ │
│ │                                        │ subunit expression upregulated         │        │ │
│ │                                        │ full‐length AMPD3 protein expression   │        │ │
│ │                                        │ more than 10‐fold and AMPD3 mRNA       │        │ │
│ │                                        │ expression more than 6‐fold, and AMPD3 │        │ │
│ │                                        │ deamination activity was increased     │        │ │
│ │                                        │ 3.8‐fold (Figure 3a–c). Knocking down  │        │ │
│ │                                        │ E1α expression did not affect E2 and   │        │ │
│ │                                        │ E3 subunit expression levels (Figure   │        │ │
│ │                                        │ 3a). Consistent with the findings with │        │ │
│ │                                        │ NRCMs, the analysis in H9c2 cells      │        │ │
│ │                                        │ revealed that full‐length AMPD3        │        │ │
│ │                                        │ interacted with the E1α and E2         │        │ │
│ │                                        │ subunits but not with the E3 subunit,  │        │ │
│ │                                        │ resulting in a significantly lower     │        │ │
│ │                                        │ AMPD3 interaction with E1α and E2 in   │        │ │
│ │                                        │ cells with E1α knockdown (Figure 3d).  │        │ │
│ │                                        │ Taken together with the changes in     │        │ │
│ │                                        │ BCAA metabolic pathway observed in     │        │ │
│ │                                        │ OLETF hearts (Figure 1f), the results  │        │ │
│ │                                        │ suggest that the downregulation of     │        │ │
│ │                                        │ BCKDH expression is upstream of AMPD3  │        │ │
│ │                                        │ upregulation, which further suppresses │        │ │
│ │                                        │ BCKDH activity in T2DM hearts.         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 3:** *Knockdown of BCKDH‐E1α  │        │ │
│ │                                        │ expression upregulated AMPD3           │        │ │
│ │                                        │ expression. (a–d) Representative       │        │ │
│ │                                        │ Western blot showing AMPD3, BCKDH‐E1α, │        │ │
│ │                                        │ E2 and E3, and summary of the          │        │ │
│ │                                        │ densitometry analysis (a; N = 4 in     │        │ │
│ │                                        │ each group); mRNA levels of AMPD3 (b;  │        │ │
│ │                                        │ N = 6 in each group); AMPD3 activity   │        │ │
│ │                                        │ (c; N = 3 in each group); and a        │        │ │
│ │                                        │ representative Western blot showing    │        │ │
│ │                                        │ the AMPD3‐BCKDH interaction and        │        │ │
│ │                                        │ summary of the densitometry analysis   │        │ │
│ │                                        │ (d; N = 3–4 in each group) in H9c2     │        │ │
│ │                                        │ cardiomyoblasts with or without E1α    │        │ │
│ │                                        │ knocked down. Data were analyzed by    │        │ │
│ │                                        │ unpaired Student's t‐test. The         │        │ │
│ │                                        │ p‐values obtained for comparisons of   │        │ │
│ │                                        │ the groups at both ends of the line    │        │ │
│ │                                        │ are shown.*                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Reduction in BCKDH‐E1α expression   │        │ │
│ │                                        │ level suppresses fatty acid oxidation  │        │ │
│ │                                        │ and insulin‐mediated glucose oxidation │        │ │
│ │                                        │ in cardiomyocytes                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Previous studies showed that the       │        │ │
│ │                                        │ accumulation of BCAA (Li et al., 2017) │        │ │
│ │                                        │ or BCKA (Uddin et al., 2021)           │        │ │
│ │                                        │ suppressed glucose oxidation in the    │        │ │
│ │                                        │ mouse heart. We hypothesized that      │        │ │
│ │                                        │ disruption of the BCAA catabolic       │        │ │
│ │                                        │ pathway also affects cardiomyocyte     │        │ │
│ │                                        │ fatty acid metabolism based on the     │        │ │
│ │                                        │ regulation of BCKDH by AMPD3 (Figure   │        │ │
│ │                                        │ 2, Figure 3) and on the previous study │        │ │
│ │                                        │ demonstrating that AMPD3 mediates the  │        │ │
│ │                                        │ temporal alignment of BCAA and fatty   │        │ │
│ │                                        │ acid metabolism in skeletal muscle     │        │ │
│ │                                        │ (Hong et al., 2017). In NRCMs,         │        │ │
│ │                                        │ knocking down E1α expression           │        │ │
│ │                                        │ upregulated AMPD3 expression more than │        │ │
│ │                                        │ 2‐fold at protein and mRNA levels      │        │ │
│ │                                        │ (Figure 4a,b), consistent with the     │        │ │
│ │                                        │ finding with H9c2 cells. E1α knockdown │        │ │
│ │                                        │ also increased the gene expression of  │        │ │
│ │                                        │ PPARα and membrane fatty acid          │        │ │
│ │                                        │ transporter CD36 (Figure 4c),          │        │ │
│ │                                        │ suggesting that BCAA dysmetabolism     │        │ │
│ │                                        │ promotes substrate preference towards  │        │ │
│ │                                        │ fatty acids. Once fatty acids enter    │        │ │
│ │                                        │ cells, they are incorporated into      │        │ │
│ │                                        │ lipid droplets, which serve as         │        │ │
│ │                                        │ efficient reservoirs for mitochondrial │        │ │
│ │                                        │ oxidation (Banke et al., 2010) and as  │        │ │
│ │                                        │ essential sources of lipid ligands for │        │ │
│ │                                        │ PPARα activation (Haemmerle et al.,    │        │ │
│ │                                        │ 2011). Our previous study revealed     │        │ │
│ │                                        │ that myocardial lipid droplets are     │        │ │
│ │                                        │ significantly increased in OLETF than  │        │ │
│ │                                        │ in LETO (Mizuno et al., 2018). To test │        │ │
│ │                                        │ whether BCAA dysmetabolism is directly │        │ │
│ │                                        │ linked to the altered lipid droplet    │        │ │
│ │                                        │ biogenesis, we next performed an in    │        │ │
│ │                                        │ vitro lipid droplet assay. When NRCMs  │        │ │
│ │                                        │ were incubated with different doses of │        │ │
│ │                                        │ oleate, the control cells exhibited    │        │ │
│ │                                        │ increased lipid droplet formation in a │        │ │
│ │                                        │ dose‐dependent manner. However, the    │        │ │
│ │                                        │ cells in which E1α expression had been │        │ │
│ │                                        │ knocked down exhibited a higher number │        │ │
│ │                                        │ of lipid droplets even before oleate   │        │ │
│ │                                        │ incubation, and oleate‐induced lipid   │        │ │
│ │                                        │ droplet biogenesis was abolished in    │        │ │
│ │                                        │ these cells (Figure 4d), indicating    │        │ │
│ │                                        │ that intact BCAA metabolism is         │        │ │
│ │                                        │ required for physiological lipid       │        │ │
│ │                                        │ storage response in cardiomyocytes.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 4:** *Effects of knockdown of │        │ │
│ │                                        │ BCKDH‐E1α protein expression on fatty  │        │ │
│ │                                        │ acid oxidation and insulin‐mediated    │        │ │
│ │                                        │ glucose oxidation in cardiomyocytes.   │        │ │
│ │                                        │ (a, b) Representative Western blot     │        │ │
│ │                                        │ showing AMPD3 and BCKDH‐E1α and        │        │ │
│ │                                        │ summary of the densitometry results    │        │ │
│ │                                        │ (a; N = 8 in each group) and mRNA      │        │ │
│ │                                        │ levels of AMPD3 (b; N = 7–8 in each    │        │ │
│ │                                        │ group) in NRCMs with or without E1α    │        │ │
│ │                                        │ knocked down. (c) mRNA levels of PPARα │        │ │
│ │                                        │ and CD36 (N = 7–8 in each group) in    │        │ │
│ │                                        │ NRCMs with or without E1α knocked      │        │ │
│ │                                        │ down. (d) Representative image showing │        │ │
│ │                                        │ intracellular lipid droplets and       │        │ │
│ │                                        │ summary of their quantification in     │        │ │
│ │                                        │ NRCMs with or without E1α knocked      │        │ │
│ │                                        │ down. For each dose of oleate, N = 6–7 │        │ │
│ │                                        │ for each group. (e, f) Oxygen          │        │ │
│ │                                        │ consumption rate (OCR) in response to  │        │ │
│ │                                        │ fatty acid (e; N = 19–27 in each       │        │ │
│ │                                        │ group) or nonfatty acid (f; N = 12–21  │        │ │
│ │                                        │ in each group) substrates in NRCMs     │        │ │
│ │                                        │ with or without E1α knocked down, as   │        │ │
│ │                                        │ determined with a Seahorse XFe96       │        │ │
│ │                                        │ analyzer. The concentrations of each   │        │ │
│ │                                        │ reagent were OM, 1.5 μM, FCCP, 1.5 μM, │        │ │
│ │                                        │ Rot, 0.5 μM, AA, 0.5 μM,               │        │ │
│ │                                        │ BSA‐conjugated palmitate (molar ratio  │        │ │
│ │                                        │ 6:1), 167 μM, and INS, 100 nM. Base,   │        │ │
│ │                                        │ baseline; BSA, bovine serum albumin;   │        │ │
│ │                                        │ OM, oligomycin; FCCP,                  │        │ │
│ │                                        │ carbonylcyanide‐4‐trifluoromethoxyphe… │        │ │
│ │                                        │ Rot, rotenone; AA, antimycin; INS,     │        │ │
│ │                                        │ insulin. Data were analyzed by         │        │ │
│ │                                        │ unpaired Student's t‐test (a‐c), 2‐way │        │ │
│ │                                        │ ANOVA (D) or two‐way repeated‐measures │        │ │
│ │                                        │ ANOVA (e, f) with Tukey's test for     │        │ │
│ │                                        │ multiple‐group comparison. *p < 0.05   │        │ │
│ │                                        │ between Cont_palmitate and             │        │ │
│ │                                        │ E1α‐KD_palmitate in (e). *p < 0.05     │        │ │
│ │                                        │ between Cont_INS(+) and E1α‐KD_INS(+), │        │ │
│ │                                        │ †                                      │        │ │
│ │                                        │ p < 0.05 between Cont_INS(−) and       │        │ │
│ │                                        │ Cont_INS(+), #                         │        │ │
│ │                                        │ p < 0.05 between Cont_INS(−) and       │        │ │
│ │                                        │ E1α‐KD_INS(−) in (f). The p‐values     │        │ │
│ │                                        │ obtained for comparisons of the groups │        │ │
│ │                                        │ at both ends of the line or between    │        │ │
│ │                                        │ Cont_palmitate and E1α‐KD_palmitate    │        │ │
│ │                                        │ are shown.*                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Inhibition of BCKDH activity by PP2Cm  │        │ │
│ │                                        │ deletion was shown to inhibit          │        │ │
│ │                                        │ pyruvate‐stimulated complex I          │        │ │
│ │                                        │ respiration but not                    │        │ │
│ │                                        │ palmitoyl‐carnitine‐stimulated complex │        │ │
│ │                                        │ I respiration in isolated cardiac      │        │ │
│ │                                        │ mitochondria (Li et al., 2017),        │        │ │
│ │                                        │ seemingly indicating that the impact   │        │ │
│ │                                        │ of BCAA dysmetabolism on mitochondrial │        │ │
│ │                                        │ respiration is specific to             │        │ │
│ │                                        │ carbohydrate oxidation. However,       │        │ │
│ │                                        │ experiments on isolated mitochondria   │        │ │
│ │                                        │ cannot elucidate the significance of   │        │ │
│ │                                        │ extramitochondrial BCKDH, which        │        │ │
│ │                                        │ interacts with AMPD3. Therefore, we    │        │ │
│ │                                        │ conducted a mitochondrial respiration  │        │ │
│ │                                        │ assay in beating NRCMs. The addition   │        │ │
│ │                                        │ of palmitate to the glucose‐limited    │        │ │
│ │                                        │ assay buffer significantly increased   │        │ │
│ │                                        │ OCR, which was blocked by treatment    │        │ │
│ │                                        │ with etomoxir, a carnitine             │        │ │
│ │                                        │ palmitoyltransferase 1 (CPT I)         │        │ │
│ │                                        │ inhibitor, confirming that NRCMs can   │        │ │
│ │                                        │ utilize palmitates for oxidative       │        │ │
│ │                                        │ phosphorylation (Figure S6). Contrary  │        │ │
│ │                                        │ to the previous finding in isolated    │        │ │
│ │                                        │ mitochondria (Li et al., 2017),        │        │ │
│ │                                        │ palmitate oxidation was significantly  │        │ │
│ │                                        │ decreased by E1α knockdown despite the │        │ │
│ │                                        │ upregulation of PPARα (Figure 4e).     │        │ │
│ │                                        │ When the respiration assay was         │        │ │
│ │                                        │ performed under non‐fatty acid         │        │ │
│ │                                        │ substrate (mainly glucose) incubation, │        │ │
│ │                                        │ E1α knockdown tended to increase OCR   │        │ │
│ │                                        │ (Figure 4f). The addition of insulin   │        │ │
│ │                                        │ to this assay medium significantly     │        │ │
│ │                                        │ enhanced OCR in control cells.         │        │ │
│ │                                        │ However, the effect of insulin on OCR  │        │ │
│ │                                        │ was abolished by E1α knockdown,        │        │ │
│ │                                        │ despite the comparable level of AKT    │        │ │
│ │                                        │ phosphorylation to control cells       │        │ │
│ │                                        │ (Figure S7). Overexpression of AMPD3   │        │ │
│ │                                        │ in H9c2 cells mirrored the effect of   │        │ │
│ │                                        │ E1α knockdown on OCR (Figure S8),      │        │ │
│ │                                        │ suggesting that the upregulation of    │        │ │
│ │                                        │ AMPD3 also contributes to impaired     │        │ │
│ │                                        │ substrate oxidation in cells with BCAA │        │ │
│ │                                        │ dysmetabolism. Taken together, the     │        │ │
│ │                                        │ results indicate that intact BCAA      │        │ │
│ │                                        │ metabolism is required for efficient   │        │ │
│ │                                        │ fatty acid oxidation as well as        │        │ │
│ │                                        │ insulin‐mediated glucose oxidation in  │        │ │
│ │                                        │ cardiomyocytes.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Reduction in BCKDH‐E1α expression   │        │ │
│ │                                        │ level induced discordant upregulation  │        │ │
│ │                                        │ of enzymes regulating fatty acid       │        │ │
│ │                                        │ metabolism                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To deduce the mechanisms by which      │        │ │
│ │                                        │ fatty acid oxidation was suppressed by │        │ │
│ │                                        │ E1α knockdown despite PPARα and CD36   │        │ │
│ │                                        │ upregulation, we additionally examined │        │ │
│ │                                        │ changes in the expression of enzymes   │        │ │
│ │                                        │ regulating fatty acid metabolism       │        │ │
│ │                                        │ (Figure 5a). We focused on those       │        │ │
│ │                                        │ upstream of mitochondrial fatty acid   │        │ │
│ │                                        │ import because BCKDH inhibition        │        │ │
│ │                                        │ reportedly did not affect              │        │ │
│ │                                        │ palmitoyl‐carnitine‐stimulated         │        │ │
│ │                                        │ respiration in isolated cardiac        │        │ │
│ │                                        │ mitochondria (Li et al., 2017). E1α    │        │ │
│ │                                        │ knockdown upregulated ATGL, a lipase   │        │ │
│ │                                        │ that liberates fatty acids from lipid  │        │ │
│ │                                        │ droplets as PPARα ligands (Haemmerle   │        │ │
│ │                                        │ et al., 2011), but not DGAT1,          │        │ │
│ │                                        │ consistent with the substrate          │        │ │
│ │                                        │ preference towards fatty acids as      │        │ │
│ │                                        │ mentioned above. However, E1α          │        │ │
│ │                                        │ knockdown simultaneously upregulated   │        │ │
│ │                                        │ ATP‐citrate lyase (ACL) and acetyl‐CoA │        │ │
│ │                                        │ carboxylase (ACC), likely leading to   │        │ │
│ │                                        │ enhanced production of malonyl‐CoA, a  │        │ │
│ │                                        │ potent endogenous inhibitor of CPT1.   │        │ │
│ │                                        │ Furthermore, the proportion of         │        │ │
│ │                                        │ phosphorylated AMPK, which inhibits    │        │ │
│ │                                        │ ACC activity, was significantly        │        │ │
│ │                                        │ decreased by E1α knockdown.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 5:** *Reduction in BCKDH‐E1α  │        │ │
│ │                                        │ expression level induced discordant    │        │ │
│ │                                        │ upregulation of enzymes regulating     │        │ │
│ │                                        │ fatty acid metabolism. (a)             │        │ │
│ │                                        │ Representative Western blot showing    │        │ │
│ │                                        │ the pathway upstream of mitochondrial  │        │ │
│ │                                        │ fatty acid import and summary of the   │        │ │
│ │                                        │ densitometry analysis in NRCMs with or │        │ │
│ │                                        │ without E1α knocked down (N = 4–9 in   │        │ │
│ │                                        │ each group). (b) A schematic summary   │        │ │
│ │                                        │ showing the changes induced by E1α     │        │ │
│ │                                        │ knockdown in NRCMs. ACL, ATP‐citrate   │        │ │
│ │                                        │ lyase; ACC, acetyl‐CoA carboxylase;    │        │ │
│ │                                        │ CPT1, carnitine palmitoyltransferase   │        │ │
│ │                                        │ 1; DGAT1, diacylglycerol               │        │ │
│ │                                        │ O‐acyltransferase 1; FAS, fatty acid   │        │ │
│ │                                        │ synthase. Data were analyzed by        │        │ │
│ │                                        │ unpaired Student's t‐test. The         │        │ │
│ │                                        │ p‐values obtained for comparisons of   │        │ │
│ │                                        │ the groups at both ends of the line    │        │ │
│ │                                        │ are shown.*                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## DISCUSSION                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In this study, we showed, for the      │        │ │
│ │                                        │ first time, that BCKDH is expressed    │        │ │
│ │                                        │ not only in the mitochondrial matrix   │        │ │
│ │                                        │ but also in extramitochondrial         │        │ │
│ │                                        │ compartments, especially the ER in the │        │ │
│ │                                        │ heart, and that its expression level   │        │ │
│ │                                        │ is downregulated in diabetes. The      │        │ │
│ │                                        │ downregulation of BCKDH in diabetic    │        │ │
│ │                                        │ hearts is likely to be due to the      │        │ │
│ │                                        │ decreased expression of KLF15, a       │        │ │
│ │                                        │ transcriptional factor regulating BCAA │        │ │
│ │                                        │ catabolic pathway (Sun et al., 2016).  │        │ │
│ │                                        │ Our finding of KLF15 downregulation in │        │ │
│ │                                        │ OLETF hearts was consistent with       │        │ │
│ │                                        │ earlier reports for adipose tissue and │        │ │
│ │                                        │ skeletal muscle of insulin‐resistant   │        │ │
│ │                                        │ individuals (Elbein et al., 2011) and  │        │ │
│ │                                        │ rodent diabetic hearts (Tian et al.,   │        │ │
│ │                                        │ 2021). BCAA metabolism has long been   │        │ │
│ │                                        │ considered to occur in the             │        │ │
│ │                                        │ mitochondrial matrix, but several      │        │ │
│ │                                        │ lines of recent evidence support the   │        │ │
│ │                                        │ possibility that it also occurs in     │        │ │
│ │                                        │ extramitochondrial compartments.       │        │ │
│ │                                        │ First, although pharmacological        │        │ │
│ │                                        │ activation of BCKDH by the BCKDK       │        │ │
│ │                                        │ inhibitor BT2 has consistently shown   │        │ │
│ │                                        │ to decrease cardiac BCAA levels and    │        │ │
│ │                                        │ improve cardiac function in several    │        │ │
│ │                                        │ models of heart failure (Chen et al.,  │        │ │
│ │                                        │ 2019; Li et al., 2017; Sun et al.,     │        │ │
│ │                                        │ 2016; Uddin et al., 2019; Wang et al., │        │ │
│ │                                        │ 2016), an in vivo isotopic tracing     │        │ │
│ │                                        │ study in mice after [U‐13C]‐isoleucine │        │ │
│ │                                        │ infusion showed that BT2 treatment led │        │ │
│ │                                        │ to only modest increases in the levels │        │ │
│ │                                        │ of labeled tricarboxylic acid cycle    │        │ │
│ │                                        │ intermediates in the heart (Neinast,   │        │ │
│ │                                        │ Jang, et al., 2019). Second, among the │        │ │
│ │                                        │ major organs that metabolize BCAAs,    │        │ │
│ │                                        │ the expression of SLC25A44, a          │        │ │
│ │                                        │ mitochondrial BCAA transporter, was    │        │ │
│ │                                        │ the lowest in the myocardium (Walejko  │        │ │
│ │                                        │ et al., 2021). To be oxidized by       │        │ │
│ │                                        │ BCKDH, BCAAs first undergo             │        │ │
│ │                                        │ transamination by cytosolic BCAT1 or   │        │ │
│ │                                        │ mitochondrial BCAT2. BCAT2 is the      │        │ │
│ │                                        │ dominant isoform expressed in the      │        │ │
│ │                                        │ myocardium, but BCAT1 is also          │        │ │
│ │                                        │ functional (Walejko et al., 2021). In  │        │ │
│ │                                        │ addition, circulating BCKAs are        │        │ │
│ │                                        │ directly taken up by the heart         │        │ │
│ │                                        │ (Murashige et al., 2020). These        │        │ │
│ │                                        │ findings suggest that                  │        │ │
│ │                                        │ extramitochondrial BCKDH is supplied   │        │ │
│ │                                        │ with its substrates and that the       │        │ │
│ │                                        │ resulting short‐chain acyl‐CoA is      │        │ │
│ │                                        │ consumed for mitochondrial oxidation   │        │ │
│ │                                        │ and also for other metabolic pathways. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Notably, pyruvate dehydrogenase and    │        │ │
│ │                                        │ α‐ketoglutarate dehydrogenase, which   │        │ │
│ │                                        │ share a common E3 subunit with BCKDH,  │        │ │
│ │                                        │ had originally been thought to         │        │ │
│ │                                        │ localize exclusively in mitochondria   │        │ │
│ │                                        │ but were later found to function also  │        │ │
│ │                                        │ in the nucleus (Sutendra et al., 2014; │        │ │
│ │                                        │ Wang et al., 2017), supporting the     │        │ │
│ │                                        │ possibility that BCDKH functions in    │        │ │
│ │                                        │ extramitochondrial compartments,       │        │ │
│ │                                        │ similar to pyruvate dehydrogenase and  │        │ │
│ │                                        │ α‐ketoglutarate dehydrogenase. A       │        │ │
│ │                                        │ recent study showed that               │        │ │
│ │                                        │ short‐branched‐chain acyl‐CoAs, direct │        │ │
│ │                                        │ products of the BCKDH reaction, can    │        │ │
│ │                                        │ escape oxidation and be incorporated   │        │ │
│ │                                        │ into newly synthesized fatty acids in  │        │ │
│ │                                        │ adipocytes (Wallace et al., 2018),     │        │ │
│ │                                        │ suggesting a role for BCAAs as lipid   │        │ │
│ │                                        │ metabolite sources. Further studies    │        │ │
│ │                                        │ are warranted to test whether such a   │        │ │
│ │                                        │ metabolic reaction also occurs in      │        │ │
│ │                                        │ cardiomyocytes or whether BCKDH has    │        │ │
│ │                                        │ noncanonical functions in              │        │ │
│ │                                        │ extramitochondrial compartments.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As another novel finding, this study   │        │ │
│ │                                        │ revealed that AMPD3 directly interacts │        │ │
│ │                                        │ with extramitochondrial BCKDH in the   │        │ │
│ │                                        │ heart. Knocking down AMPD3             │        │ │
│ │                                        │ significantly increased the whole cell │        │ │
│ │                                        │ BCKDH activity in living               │        │ │
│ │                                        │ cardiomyocytes (Figure 2b). It remains │        │ │
│ │                                        │ to be determined whether               │        │ │
│ │                                        │ extramitochondrial BCKDH has           │        │ │
│ │                                        │ physiological activity and is directly │        │ │
│ │                                        │ inhibited by AMPD3 binding or whether  │        │ │
│ │                                        │ AMPD3 indirectly suppresses            │        │ │
│ │                                        │ mitochondrial BCKDH. In addition to    │        │ │
│ │                                        │ inhibitory phosphorylation of E1α,     │        │ │
│ │                                        │ BCKDH activity is likely to be         │        │ │
│ │                                        │ regulated by its protein abundance     │        │ │
│ │                                        │ because cardiac KLF15 expression is    │        │ │
│ │                                        │ upregulated during fasting when BCAAs  │        │ │
│ │                                        │ are actively metabolized (Murashige et │        │ │
│ │                                        │ al., 2020; Prosdocimo et al., 2014).   │        │ │
│ │                                        │ However, despite the enhanced BCKDH    │        │ │
│ │                                        │ activity, knocking down AMPD3 did not  │        │ │
│ │                                        │ change E1α phosphorylation status and  │        │ │
│ │                                        │ instead decreased BCKDH expression     │        │ │
│ │                                        │ (Figure S2), indicating the existence  │        │ │
│ │                                        │ of a mechanism independent of these    │        │ │
│ │                                        │ canonical regulations. Indeed, a       │        │ │
│ │                                        │ previous study demonstrated that in    │        │ │
│ │                                        │ vivo tissue BCAA flux does not         │        │ │
│ │                                        │ necessarily correlate with its BCKDH   │        │ │
│ │                                        │ expression level and E1α               │        │ │
│ │                                        │ phosphorylation (Neinast, Jang, et     │        │ │
│ │                                        │ al., 2019). It is tempting to          │        │ │
│ │                                        │ speculate that extramitochondrial      │        │ │
│ │                                        │ BCKDH has physiological activity with  │        │ │
│ │                                        │ a distinct regulatory mechanism and    │        │ │
│ │                                        │ that its aberrant activation induces   │        │ │
│ │                                        │ compensatory feedback inhibition on    │        │ │
│ │                                        │ the canonical regulation by BCKDH      │        │ │
│ │                                        │ protein abundance.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Physiologically, the involvement of    │        │ │
│ │                                        │ AMPD3 in BCAA metabolism seems         │        │ │
│ │                                        │ plausible, given its potential role in │        │ │
│ │                                        │ intracellular nitrogen homeostasis. In │        │ │
│ │                                        │ the heart, the carbon skeleton of      │        │ │
│ │                                        │ catabolizing amino acids is fed into   │        │ │
│ │                                        │ metabolic pathways, including the      │        │ │
│ │                                        │ tricarboxylic acid cycle, while their  │        │ │
│ │                                        │ nitrogen is transferred to other amino │        │ │
│ │                                        │ acids and excreted (Murashige et al.,  │        │ │
│ │                                        │ 2020). Such amino acid                 │        │ │
│ │                                        │ interconversions could be driven by    │        │ │
│ │                                        │ transamination of BCAA by BCAT and the │        │ │
│ │                                        │ deamination of AMP by AMPD as they     │        │ │
│ │                                        │ predominantly donate nitrogen utilized │        │ │
│ │                                        │ for the process (Arinze, 2005). Thus,  │        │ │
│ │                                        │ BCAA metabolism and AMPD3‐mediated     │        │ │
│ │                                        │ reaction are expected to cooperate     │        │ │
│ │                                        │ when amino acid metabolism is          │        │ │
│ │                                        │ activated. Indeed, overexpression of   │        │ │
│ │                                        │ AMPD3 in C2C12 cells reportedly        │        │ │
│ │                                        │ activated the BCAT forward reaction    │        │ │
│ │                                        │ (Miller et al., 2021). If it is also   │        │ │
│ │                                        │ the case in cardiomyocytes, a question │        │ │
│ │                                        │ is why AMPD3 simultaneously suppresses │        │ │
│ │                                        │ BCKDH activity while it promotes the   │        │ │
│ │                                        │ BCAT forward reaction. Since BCAAs are │        │ │
│ │                                        │ unique amino acids that also function  │        │ │
│ │                                        │ as signaling molecules in various      │        │ │
│ │                                        │ biological processes (Neinast,         │        │ │
│ │                                        │ Murashige, & Arany, 2019), their       │        │ │
│ │                                        │ excess degradation might be prevented  │        │ │
│ │                                        │ by AMPD3.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Aberrant upregulation of AMPD3 and its │        │ │
│ │                                        │ uncoupling with BCKDH appear to be     │        │ │
│ │                                        │ detrimental to energetic metabolism in │        │ │
│ │                                        │ cardiomyocytes. In skeletal muscle,    │        │ │
│ │                                        │ the expression of AMPD3 is increased   │        │ │
│ │                                        │ by the induction of muscle atrophy,    │        │ │
│ │                                        │ such as fasting (Hong et al., 2017;    │        │ │
│ │                                        │ Lecker et al., 2004; Milan et al.,     │        │ │
│ │                                        │ 2015), tumor development (Lecker et    │        │ │
│ │                                        │ al., 2004), renal failure (Lecker et   │        │ │
│ │                                        │ al., 2004), diabetes (Lecker et al.,   │        │ │
│ │                                        │ 2004), denervation (Milan et al.,      │        │ │
│ │                                        │ 2015), aging (Ibebunjo et al., 2013),  │        │ │
│ │                                        │ and muscle unloading (Brocca et al.,   │        │ │
│ │                                        │ 2017). As discussed above, the         │        │ │
│ │                                        │ upregulation of AMDP3 during muscle    │        │ │
│ │                                        │ breakdown seems reasonable, given its  │        │ │
│ │                                        │ role in amino acid catabolism. On the  │        │ │
│ │                                        │ other hand, the uncoupling of BCAA     │        │ │
│ │                                        │ metabolism and AMPD3 activation could  │        │ │
│ │                                        │ hamper cellular energetics. For IMP    │        │ │
│ │                                        │ resulting from AMP deamination to be   │        │ │
│ │                                        │ recycled as adenine nucleotides        │        │ │
│ │                                        │ without degradation, aspartate flux    │        │ │
│ │                                        │ into the purine nucleotide cycle must  │        │ │
│ │                                        │ be maintained (Arinze, 2005). However, │        │ │
│ │                                        │ aspartate synthesis from oxaloacetate  │        │ │
│ │                                        │ in muscle is impaired under BCAA       │        │ │
│ │                                        │ catabolic dysfunction because the      │        │ │
│ │                                        │ reaction indirectly requires BCAA      │        │ │
│ │                                        │ transamination. As a result, adenine   │        │ │
│ │                                        │ nucleotides are more susceptible to    │        │ │
│ │                                        │ degradation (She et al., 2010).        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ How AMPD3 is upregulated by            │        │ │
│ │                                        │ suppression of BCKDH expression has    │        │ │
│ │                                        │ yet to be determined. We previously    │        │ │
│ │                                        │ reported that AMPD3 expression was     │        │ │
│ │                                        │ regulated post‐transcriptionally by    │        │ │
│ │                                        │ miR301b (Tatekoshi et al., 2018).      │        │ │
│ │                                        │ However, E1α expression knockdown did  │        │ │
│ │                                        │ not alter miR301b expression (data not │        │ │
│ │                                        │ shown), suggesting that distinct       │        │ │
│ │                                        │ mechanisms are involved in the altered │        │ │
│ │                                        │ AMPD3 expression. In skeletal muscle,  │        │ │
│ │                                        │ transcriptional factors FoxO           │        │ │
│ │                                        │ $\frac{1}{3}$/4 positively regulated   │        │ │
│ │                                        │ AMPD3 transcription during fasting and │        │ │
│ │                                        │ hindlimb unloading (Brocca et al.,     │        │ │
│ │                                        │ 2017; Milan et al., 2015), while the   │        │ │
│ │                                        │ clock molecule Rev‐erb‐mediated        │        │ │
│ │                                        │ recruitment of histone deacetylase 3   │        │ │
│ │                                        │ to an enhancer region suppressed AMPD3 │        │ │
│ │                                        │ transcription during feeding (Hong et  │        │ │
│ │                                        │ al., 2017). Another recent study also  │        │ │
│ │                                        │ demonstrated that AMPD3 transcription  │        │ │
│ │                                        │ is activated by cyclin‐dependent       │        │ │
│ │                                        │ kinase (CDK) 7‐mediated assembly of    │        │ │
│ │                                        │ super‐enhancer in renal tubular        │        │ │
│ │                                        │ epithelial cells and contributes to    │        │ │
│ │                                        │ the development of autosomal dominant  │        │ │
│ │                                        │ polycystic kidney disease (Mi et al.,  │        │ │
│ │                                        │ 2020). Contributions of the FoxO‐ and  │        │ │
│ │                                        │ CDK‐7‐mediated mechanisms in AMPD3     │        │ │
│ │                                        │ upregulation cardiomyocytes remain to  │        │ │
│ │                                        │ be examined.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We showed that manipulation of BCKDH   │        │ │
│ │                                        │ modulates glucose and fatty acid       │        │ │
│ │                                        │ oxidation, the primary two substrates  │        │ │
│ │                                        │ for cardiomyocytes (Figure 4e,f).      │        │ │
│ │                                        │ Earlier studies have demonstrated the  │        │ │
│ │                                        │ crosstalk between glucose and BCAA     │        │ │
│ │                                        │ metabolism in the heart, in which      │        │ │
│ │                                        │ stimulation of glucose uptake inhibits │        │ │
│ │                                        │ BCAA oxidation and promotes anabolic   │        │ │
│ │                                        │ processes (Shao et al., 2018; Walejko  │        │ │
│ │                                        │ et al., 2021), while BCAA (Li et al.,  │        │ │
│ │                                        │ 2017) or BCKA (Uddin et al., 2021)     │        │ │
│ │                                        │ accumulation brakes glucose            │        │ │
│ │                                        │ metabolism. On the contrary, the       │        │ │
│ │                                        │ myocardium is known to simultaneously  │        │ │
│ │                                        │ utilize fatty acids and BCAAs as fuel  │        │ │
│ │                                        │ during fasting (Murashige et al.,      │        │ │
│ │                                        │ 2020). The metabolism of BCAA and      │        │ │
│ │                                        │ fatty acids seems to be functionally   │        │ │
│ │                                        │ related because previous studies       │        │ │
│ │                                        │ showed that KLF15 regulates not only   │        │ │
│ │                                        │ the BCAA catabolic pathway but also    │        │ │
│ │                                        │ PPARα activity and fatty acid          │        │ │
│ │                                        │ metabolism in cardiomyocytes           │        │ │
│ │                                        │ (Prosdocimo et al., 2014; 2015).       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In the present study, suppression of   │        │ │
│ │                                        │ fatty acid oxidation by knockdown of   │        │ │
│ │                                        │ E1α (Figure 4) was associated with     │        │ │
│ │                                        │ interesting changes in expressions of  │        │ │
│ │                                        │ molecules that regulate fatty acid     │        │ │
│ │                                        │ metabolism (Figure 5). E1α knockdown   │        │ │
│ │                                        │ increased the expressions of PPARα,    │        │ │
│ │                                        │ CD36 (a target of PPARα), and ATGL,    │        │ │
│ │                                        │ indicating increase in substrate       │        │ │
│ │                                        │ preference towards fatty acids (Figure │        │ │
│ │                                        │ 5). The expression of PPARα (Kyriazis  │        │ │
│ │                                        │ et al., 2021) and ATGL (Mori et al.,   │        │ │
│ │                                        │ 2014) in cardiomyocytes is reportedly  │        │ │
│ │                                        │ regulated by FoxO1, a downstream       │        │ │
│ │                                        │ target of AKT. Thus, induction of      │        │ │
│ │                                        │ insulin resistance by impaired BCAA    │        │ │
│ │                                        │ metabolism may partly contribute to    │        │ │
│ │                                        │ aberrant upregulation of PPARα and     │        │ │
│ │                                        │ ATGL in cardiomyocytes. On the         │        │ │
│ │                                        │ contrary, ACL and ACC expressions were │        │ │
│ │                                        │ increased by knockdown of E1α. The     │        │ │
│ │                                        │ upregulation of the two enzymes would  │        │ │
│ │                                        │ inhibit fatty acid oxidation by        │        │ │
│ │                                        │ inhibiting CPT1 through malonyl‐CoA    │        │ │
│ │                                        │ production (Poirier et al., 2002).     │        │ │
│ │                                        │ Thus, E1α knockdown appears to have    │        │ │
│ │                                        │ induced futile fatty acid handling in  │        │ │
│ │                                        │ which fatty acid availability in the   │        │ │
│ │                                        │ cytosol is increased but their import  │        │ │
│ │                                        │ into the mitochondria is inhibited at  │        │ │
│ │                                        │ a level of CPT1.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The upregulation of ACL and ACC may    │        │ │
│ │                                        │ also explain why lipid droplet         │        │ │
│ │                                        │ formation was augmented in NRCMs with  │        │ │
│ │                                        │ E1α knockdown even before oleate       │        │ │
│ │                                        │ incubation, though change in de novo   │        │ │
│ │                                        │ lipogenesis from glucose was not       │        │ │
│ │                                        │ assessed. Interestingly, in the liver, │        │ │
│ │                                        │ the transcription factor ChREBP        │        │ │
│ │                                        │ regulates ACL and ACC gene expression  │        │ │
│ │                                        │ cooperatively as a lipogenic gene      │        │ │
│ │                                        │ cluster, while it simultaneously       │        │ │
│ │                                        │ regulates BCKDH activity by modulating │        │ │
│ │                                        │ gene expression of BCKDK and PP2Cm     │        │ │
│ │                                        │ (White et al., 2018). Whether such a   │        │ │
│ │                                        │ ChREBP‐mediated link between BCKDH and │        │ │
│ │                                        │ the ACL‐ACC pathway is also present in │        │ │
│ │                                        │ cardiomyocytes remains to be examined, │        │ │
│ │                                        │ but it seems an intriguing hypothesis. │        │ │
│ │                                        │ E1α knockdown also reduced the ratio   │        │ │
│ │                                        │ of phospho‐AMPK, a canonical inhibitor │        │ │
│ │                                        │ of ACC, to total AMPK. Taken together, │        │ │
│ │                                        │ findings by BCKDH‐E1α knockdown        │        │ │
│ │                                        │ support the notion that BCKDH plays a  │        │ │
│ │                                        │ significant role in regulation of      │        │ │
│ │                                        │ molecules responsible for transport of │        │ │
│ │                                        │ fatty acids to mitochondria and their  │        │ │
│ │                                        │ oxidation possibly via interaction     │        │ │
│ │                                        │ with AMPD3.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In conclusion, the present study       │        │ │
│ │                                        │ revealed previously unrecognized       │        │ │
│ │                                        │ extramitochondrial localization of     │        │ │
│ │                                        │ BCKDH in the heart and its reciprocal  │        │ │
│ │                                        │ regulation with AMPD3 and found the    │        │ │
│ │                                        │ imbalance in AMPD3‐BCKDH interaction   │        │ │
│ │                                        │ as a feature of diabetic OLETF rat     │        │ │
│ │                                        │ hearts. Downregulation of BCKDH        │        │ │
│ │                                        │ expression in cardiomyocytes induced   │        │ │
│ │                                        │ profound metabolic changes that mimic  │        │ │
│ │                                        │ OLETF rat hearts. Together with a      │        │ │
│ │                                        │ series of our studies on the roles of  │        │ │
│ │                                        │ AMPD3 in dysregulated cardiac          │        │ │
│ │                                        │ energetics and excessive production of │        │ │
│ │                                        │ reactive oxygen species in diabetic    │        │ │
│ │                                        │ hearts (Igaki et al., 2021; Kouzu et   │        │ │
│ │                                        │ al., 2015; Tatekoshi et al., 2018),    │        │ │
│ │                                        │ the present findings provide insights  │        │ │
│ │                                        │ into mechanisms contributing to the    │        │ │
│ │                                        │ development of diabetic cardiomyopathy │        │ │
│ │                                        │ (Figure 6).                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 6:** *Working model for the   │        │ │
│ │                                        │ functions of the AMPD3‐BCKDH           │        │ │
│ │                                        │ interaction in normal and diabetic     │        │ │
│ │                                        │ hearts based on studies using diabetic │        │ │
│ │                                        │ OLETF rats. (a) In normal              │        │ │
│ │                                        │ cardiomyocytes, BCAAs, and fatty acids │        │ │
│ │                                        │ are simultaneously metabolized when    │        │ │
│ │                                        │ glucose availability is limited. In    │        │ │
│ │                                        │ BCAA catabolic pathway,                │        │ │
│ │                                        │ extramitochondrial BCKDH interacts     │        │ │
│ │                                        │ with AMPD3. AMPD3 fine‐tunes BCKDH     │        │ │
│ │                                        │ activity. BCAA catabolism complements  │        │ │
│ │                                        │ efficient fatty acid oxidation. (b)    │        │ │
│ │                                        │ Downregulation of BCKDH expression     │        │ │
│ │                                        │ upregulates AMPD3 expression, which    │        │ │
│ │                                        │ further suppresses BCAA catabolic      │        │ │
│ │                                        │ pathway. The uncoupling of BCAA        │        │ │
│ │                                        │ metabolism and AMPD3 activation causes │        │ │
│ │                                        │ excessive adenine nucleotide           │        │ │
│ │                                        │ degradation (ref. [Kouzu et al., 2015; │        │ │
│ │                                        │ Tatekoshi et al., 2018]) and           │        │ │
│ │                                        │ subsequent reactive oxygen species     │        │ │
│ │                                        │ (ROS) production (ref. [Igaki et al.,  │        │ │
│ │                                        │ 2021]). The disrupted BCAA metabolism  │        │ │
│ │                                        │ compromises physiological lipid        │        │ │
│ │                                        │ droplet biogenesis and fatty acid      │        │ │
│ │                                        │ oxidation. Glucose oxidation is also   │        │ │
│ │                                        │ disturbed by the accumulation of       │        │ │
│ │                                        │ BCAA/BCKA. These metabolic             │        │ │
│ │                                        │ abnormalities mimic the changes seen   │        │ │
│ │                                        │ in diabetic hearts. The figure was     │        │ │
│ │                                        │ created with BioRender.com.*           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## AUTHOR CONTRIBUTIONS                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Toshifumi Ogawa contributed to the     │        │ │
│ │                                        │ methodology, validation, formal        │        │ │
│ │                                        │ analysis, and investigation. Hidemichi │        │ │
│ │                                        │ Kouzu contributed to the               │        │ │
│ │                                        │ conceptualization, methodology, formal │        │ │
│ │                                        │ analysis, investigation,               │        │ │
│ │                                        │ visualization, writing—original draft, │        │ │
│ │                                        │ and funding acquisition. Arata Osanami │        │ │
│ │                                        │ contributed to the methodology, formal │        │ │
│ │                                        │ analysis, and investigation. Tatekoshi │        │ │
│ │                                        │ Yuki and Tatsuya Sato contributed to   │        │ │
│ │                                        │ the formal analysis and investigation. │        │ │
│ │                                        │ Atsushi Kuno contributed to the        │        │ │
│ │                                        │ investigation and supervision. Yugo    │        │ │
│ │                                        │ Fujita, Shoya Ino, Masaki Shimizu,     │        │ │
│ │                                        │ Yuki Toda, and Wataru Ohwada           │        │ │
│ │                                        │ contributed to the investigation.      │        │ │
│ │                                        │ Toshiyuki Yano, Masaya Tanno           │        │ │
│ │                                        │ contributed to the supervision.        │        │ │
│ │                                        │ Takayuki Miki contributed to the data  │        │ │
│ │                                        │ curation and supervision. Tetsuji      │        │ │
│ │                                        │ Miura contributed to the               │        │ │
│ │                                        │ conceptualization, methodology,        │        │ │
│ │                                        │ resources, writing—review and editing, │        │ │
│ │                                        │ supervision, project administration,   │        │ │
│ │                                        │ and funding acquisition.               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## FUNDING INFORMATION                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ This study was supported by Grant 20   │        │ │
│ │                                        │ K08452 (H.K.) from the Japan Society   │        │ │
│ │                                        │ for the Promotion of Science, a grant  │        │ │
│ │                                        │ from MSD Life Science Foundation,      │        │ │
│ │                                        │ Public Interest Incorporated           │        │ │
│ │                                        │ Foundation (H.K.).                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## CONFLICT OF INTEREST STATEMENT      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ None.                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## ETHICS STATEMENT                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Animal studies were conducted          │        │ │
│ │                                        │ according to the Guide for the Care    │        │ │
│ │                                        │ and Use of Laboratory Animals          │        │ │
│ │                                        │ published by the National Research     │        │ │
│ │                                        │ Council of the National Academies, USA │        │ │
│ │                                        │ [2011] and was approved by the Animal  │        │ │
│ │                                        │ Use Committee of Sapporo Medical       │        │ │
│ │                                        │ University.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. Angelini A., Pi X., Xie L..         │        │ │
│ │                                        │ **Evaluation of long‐chain fatty acid  │        │ │
│ │                                        │ respiration in neonatal mouse          │        │ │
│ │                                        │ cardiomyocytes using SeaHorse          │        │ │
│ │                                        │ instrument**. *STAR Protocols* (2022)  │        │ │
│ │                                        │ **3**. PMID: 35600933                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. Arinze I. J.. **Facilitating        │        │ │
│ │                                        │ understanding of the purine nucleotide │        │ │
│ │                                        │ cycle and the one‐carbon pool: Part I: │        │ │
│ │                                        │ The purine nucleotide cycle**.         │        │ │
│ │                                        │ *Biochemistry and Molecular Biology    │        │ │
│ │                                        │ Education* (2005) **33** 165-168.      │        │ │
│ │                                        │ PMID: 21638570                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Banke N. H., Wende A. R., Leone T.  │        │ │
│ │                                        │ C., O'Donnell J. M., Abel E. D., Kelly │        │ │
│ │                                        │ D. P., Lewandowski E. D..              │        │ │
│ │                                        │ **Preferential oxidation of            │        │ │
│ │                                        │ triacylglyceride‐derived fatty acids   │        │ │
│ │                                        │ in heart is augmented by the nuclear   │        │ │
│ │                                        │ receptor PPARalpha**. *Circulation     │        │ │
│ │                                        │ Research* (2010) **107** 233-241.      │        │ │
│ │                                        │ PMID: 20522803                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Brocca L., Toniolo L., Reggiani C., │        │ │
│ │                                        │ Bottinelli R., Sandri M., Pellegrino   │        │ │
│ │                                        │ M. A.. **FoxO‐dependent atrogenes vary │        │ │
│ │                                        │ among catabolic conditions and play a  │        │ │
│ │                                        │ key role in muscle atrophy induced by  │        │ │
│ │                                        │ hindlimb suspension**. *The Journal of │        │ │
│ │                                        │ Physiology* (2017) **595** 1143-1158.  │        │ │
│ │                                        │ PMID: 27767211                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Chen M., Gao C., Yu J., Ren S.,     │        │ │
│ │                                        │ Wang M., Wynn R. M., Chuang D. T.,     │        │ │
│ │                                        │ Wang Y., Sun H.. **Therapeutic effect  │        │ │
│ │                                        │ of targeting branched‐chain amino acid │        │ │
│ │                                        │ catabolic flux in pressure‐overload    │        │ │
│ │                                        │ induced heart failure**. *Journal of   │        │ │
│ │                                        │ the American Heart Association* (2019) │        │ │
│ │                                        │ **8**. PMID: 31433721                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Chuang J. L., Chuang D. T..         │        │ │
│ │                                        │ **Diagnosis and mutational analysis of │        │ │
│ │                                        │ maple syrup urine disease using cell   │        │ │
│ │                                        │ cultures**. *Methods in Enzymology*    │        │ │
│ │                                        │ (2000) **324** 413-423. PMID: 10989449 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. Elbein S. C., Kern P. A., Rasouli   │        │ │
│ │                                        │ N., Yao‐Borengasser A., Sharma N. K.,  │        │ │
│ │                                        │ Das S. K.. **Global gene expression    │        │ │
│ │                                        │ profiles of subcutaneous adipose and   │        │ │
│ │                                        │ muscle from glucose‐tolerant,          │        │ │
│ │                                        │ insulin‐sensitive, and                 │        │ │
│ │                                        │ insulin‐resistant individuals matched  │        │ │
│ │                                        │ for BMI**. *Diabetes* (2011) **60**    │        │ │
│ │                                        │ 1019-1029. PMID: 21266331              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Fillmore N., Wagg C. S., Zhang L.,  │        │ │
│ │                                        │ Fukushima A., Lopaschuk G. D..         │        │ │
│ │                                        │ **Cardiac branched‐chain amino acid    │        │ │
│ │                                        │ oxidation is reduced during insulin    │        │ │
│ │                                        │ resistance in the heart**. *American   │        │ │
│ │                                        │ Journal of Physiology. Endocrinology   │        │ │
│ │                                        │ and Metabolism* (2018) **315**         │        │ │
│ │                                        │ E1046-E1052. PMID: 30106622            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Goldberg I. J., Reue K., Abumrad N. │        │ │
│ │                                        │ A., Bickel P. E., Cohen S., Fisher E.  │        │ │
│ │                                        │ A., Galis Z. S., Granneman J. G.,      │        │ │
│ │                                        │ Lewandowski E. D., Murphy R., Olive    │        │ │
│ │                                        │ M., Schaffer J. E., Schwartz‐Longacre  │        │ │
│ │                                        │ L., Shulman G. I., Walther T. C., Chen │        │ │
│ │                                        │ J.. **Deciphering the role of lipid    │        │ │
│ │                                        │ droplets in cardiovascular disease: A  │        │ │
│ │                                        │ report from the 2017 National Heart,   │        │ │
│ │                                        │ Lung, and Blood Institute workshop**.  │        │ │
│ │                                        │ *Circulation* (2018) **138** 305-315.  │        │ │
│ │                                        │ PMID: 30012703                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Haemmerle G., Moustafa T.,         │        │ │
│ │                                        │ Woelkart G., Büttner S., Schmidt A.,   │        │ │
│ │                                        │ van de Weijer T., Hesselink M., Jaeger │        │ │
│ │                                        │ D., Kienesberger P. C., Zierler K.,    │        │ │
│ │                                        │ Schreiber R., Eichmann T., Kolb D.,    │        │ │
│ │                                        │ Kotzbeck P., Schweiger M., Kumari M.,  │        │ │
│ │                                        │ Eder S., Schoiswohl G., Wongsiriroj    │        │ │
│ │                                        │ N., Zechner R.. **ATGL‐mediated fat    │        │ │
│ │                                        │ catabolism regulates cardiac           │        │ │
│ │                                        │ mitochondrial function via PPAR‐α and  │        │ │
│ │                                        │ PGC‐1**. *Nature Medicine* (2011)      │        │ │
│ │                                        │ **17** 1076-1085                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Hong S., Zhou W., Fang B., Lu W.,  │        │ │
│ │                                        │ Loro E., Damle M., Ding G., Jager J.,  │        │ │
│ │                                        │ Zhang S., Zhang Y., Feng D., Chu Q.,   │        │ │
│ │                                        │ Dill B. D., Molina H., Khurana T. S.,  │        │ │
│ │                                        │ Rabinowitz J. D., Lazar M. A., Sun Z.. │        │ │
│ │                                        │ **Dissociation of muscle insulin       │        │ │
│ │                                        │ sensitivity from exercise endurance in │        │ │
│ │                                        │ mice by HDAC3 depletion**. *Nature     │        │ │
│ │                                        │ Medicine* (2017) **23** 223-234        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Hotta H., Miura T., Miki T.,       │        │ │
│ │                                        │ Togashi N., Maeda T., Kim S. J., Tanno │        │ │
│ │                                        │ M., Yano T., Kuno A., Itoh T., Satoh   │        │ │
│ │                                        │ T., Terashima Y., Ishikawa S.,         │        │ │
│ │                                        │ Shimamoto K.. **Angiotensin II type 1  │        │ │
│ │                                        │ receptor‐mediated upregulation of      │        │ │
│ │                                        │ calcineurin activity underlies         │        │ │
│ │                                        │ impairment of cardioprotective         │        │ │
│ │                                        │ signaling in diabetic hearts**.        │        │ │
│ │                                        │ *Circulation Research* (2010) **106**  │        │ │
│ │                                        │ 129-132. PMID: 19910577                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Ibebunjo C., Chick J. M., Kendall  │        │ │
│ │                                        │ T., Eash J. K., Li C., Zhang Y.,       │        │ │
│ │                                        │ Vickers C., Wu Z., Clarke B. A., Shi   │        │ │
│ │                                        │ J., Cruz J., Fournier B., Brachat S.,  │        │ │
│ │                                        │ Gutzwiller S., Ma Q., Markovits J.,    │        │ │
│ │                                        │ Broome M., Steinkrauss M., Skuba E.,   │        │ │
│ │                                        │ Glass D. J.. **Genomic and proteomic   │        │ │
│ │                                        │ profiling reveals reduced              │        │ │
│ │                                        │ mitochondrial function and disruption  │        │ │
│ │                                        │ of the neuromuscular junction driving  │        │ │
│ │                                        │ rat sarcopenia**. *Molecular and       │        │ │
│ │                                        │ Cellular Biology* (2013) **33**        │        │ │
│ │                                        │ 194-212. PMID: 23109432                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Igaki Y., Tanno M., Sato T., Kouzu │        │ │
│ │                                        │ H., Ogawa T., Osanami A., Yano T.,     │        │ │
│ │                                        │ Kuno A., Miki T., Nakamura T., Miura   │        │ │
│ │                                        │ T.. **Xanthine oxidoreductase‐mediated │        │ │
│ │                                        │ injury is amplified by upregulated AMP │        │ │
│ │                                        │ deaminase in type 2 diabetic rat       │        │ │
│ │                                        │ hearts under the condition of pressure │        │ │
│ │                                        │ overload**. *Journal of Molecular and  │        │ │
│ │                                        │ Cellular Cardiology* (2021) **154**    │        │ │
│ │                                        │ 21-31. PMID: 33548240                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Kouzu H., Miki T., Tanno M., Kuno  │        │ │
│ │                                        │ A., Yano T., Itoh T., Sato T., Sunaga  │        │ │
│ │                                        │ D., Murase H., Tobisawa T., Ogasawara  │        │ │
│ │                                        │ M., Ishikawa S., Miura T.. **Excessive │        │ │
│ │                                        │ degradation of adenine nucleotides by  │        │ │
│ │                                        │ up‐regulated AMP deaminase underlies   │        │ │
│ │                                        │ afterload‐induced diastolic            │        │ │
│ │                                        │ dysfunction in the type 2 diabetic     │        │ │
│ │                                        │ heart**. *Journal of Molecular and     │        │ │
│ │                                        │ Cellular Cardiology* (2015) **80**     │        │ │
│ │                                        │ 136-145. PMID: 25599963                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Kuzuya T., Katano Y., Nakano I.,   │        │ │
│ │                                        │ Hirooka Y., Itoh A., Ishigami M.,      │        │ │
│ │                                        │ Hayashi K., Honda T., Goto H., Fujita  │        │ │
│ │                                        │ Y., Shikano R., Muramatsu Y., Bajotto  │        │ │
│ │                                        │ G., Tamura T., Tamura N., Shimomura    │        │ │
│ │                                        │ Y.. **Regulation of branched‐chain     │        │ │
│ │                                        │ amino acid catabolism in rat models    │        │ │
│ │                                        │ for spontaneous type 2 diabetes        │        │ │
│ │                                        │ mellitus**. *Biochemical and           │        │ │
│ │                                        │ Biophysical Research Communications*   │        │ │
│ │                                        │ (2008) **373** 94-98. PMID: 18541149   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. Kyriazis I. D., Hoffman M.,        │        │ │
│ │                                        │ Gaignebet L., Lucchese A. M.,          │        │ │
│ │                                        │ Markopoulou E., Palioura D., Wang C.,  │        │ │
│ │                                        │ Bannister T. D.,                       │        │ │
│ │                                        │ Christofidou‐Solomidou M., Oka S. I.,  │        │ │
│ │                                        │ Sadoshima J., Koch W. J., Goldberg I.  │        │ │
│ │                                        │ J., Yang V. W., Bialkowska A. B.,      │        │ │
│ │                                        │ Kararigas G., Drosatos K.. **KLF5 is   │        │ │
│ │                                        │ induced by FOXO1 and causes oxidative  │        │ │
│ │                                        │ stress and diabetic cardiomyopathy**.  │        │ │
│ │                                        │ *Circulation Research* (2021) **128**  │        │ │
│ │                                        │ 335-357. PMID: 33539225                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Lecker S. H., Jagoe R. T., Gilbert │        │ │
│ │                                        │ A., Gomes M., Baracos V., Bailey J.,   │        │ │
│ │                                        │ Price S. R., Mitch W. E., Goldberg A.  │        │ │
│ │                                        │ L.. **Multiple types of skeletal       │        │ │
│ │                                        │ muscle atrophy involve a common        │        │ │
│ │                                        │ program of changes in gene             │        │ │
│ │                                        │ expression**. *The FASEB Journal*      │        │ │
│ │                                        │ (2004) **18** 39-51. PMID: 14718385    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Li T., Zhang Z., Kolwicz S. C.,    │        │ │
│ │                                        │ Abell L., Roe N. D., Kim M., Zhou B.,  │        │ │
│ │                                        │ Cao Y., Ritterhoff J., Gu H., Raftery  │        │ │
│ │                                        │ D., Sun H., Tian R.. **Defective       │        │ │
│ │                                        │ branched‐chain amino acid catabolism   │        │ │
│ │                                        │ disrupts glucose metabolism and        │        │ │
│ │                                        │ sensitizes the heart to                │        │ │
│ │                                        │ ischemia‐reperfusion injury**. *Cell   │        │ │
│ │                                        │ Metabolism* (2017) **25** 374-385.     │        │ │
│ │                                        │ PMID: 28178567                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. Listenberger L. L., Han X., Lewis  │        │ │
│ │                                        │ S. E., Cases S., Farese R. V., Ory D.  │        │ │
│ │                                        │ S., Schaffer J. E.. **Triglyceride     │        │ │
│ │                                        │ accumulation protects against fatty    │        │ │
│ │                                        │ acid‐induced lipotoxicity**.           │        │ │
│ │                                        │ *Proceedings of the National Academy   │        │ │
│ │                                        │ of Sciences of the United States of    │        │ │
│ │                                        │ America* (2003) **100** 3077-3082.     │        │ │
│ │                                        │ PMID: 12629214                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Liu L., Shi X., Bharadwaj K. G.,   │        │ │
│ │                                        │ Ikeda S., Yamashita H., Yagyu H.,      │        │ │
│ │                                        │ Schaffer J. E., Yu Y. H., Goldberg I.  │        │ │
│ │                                        │ J.. **DGAT1 expression increases heart │        │ │
│ │                                        │ triglyceride content but ameliorates   │        │ │
│ │                                        │ lipotoxicity**. *The Journal of        │        │ │
│ │                                        │ Biological Chemistry* (2009) **284**   │        │ │
│ │                                        │ 36312-36323. PMID: 19778901            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. Lopaschuk G. D., Ussher J. R.,     │        │ │
│ │                                        │ Folmes C. D., Jaswal J. S., Stanley W. │        │ │
│ │                                        │ C.. **Myocardial fatty acid metabolism │        │ │
│ │                                        │ in health and disease**.               │        │ │
│ │                                        │ *Physiological Reviews* (2010) **90**  │        │ │
│ │                                        │ 207-258. PMID: 20086077                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Lu G., Ren S., Korge P., Choi J.,  │        │ │
│ │                                        │ Dong Y., Weiss J., Koehler C., Chen J. │        │ │
│ │                                        │ N., Wang Y.. **A novel mitochondrial   │        │ │
│ │                                        │ matrix serine/threonine protein        │        │ │
│ │                                        │ phosphatase regulates the mitochondria │        │ │
│ │                                        │ permeability transition pore and is    │        │ │
│ │                                        │ essential for cellular survival and    │        │ │
│ │                                        │ development**. *Genes & Development*   │        │ │
│ │                                        │ (2007) **21** 784-796. PMID: 17374715  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Lynch C. J., Adams S. H..          │        │ │
│ │                                        │ **Branched‐chain amino acids in        │        │ │
│ │                                        │ metabolic signalling and insulin       │        │ │
│ │                                        │ resistance**. *Nature Reviews          │        │ │
│ │                                        │ Endocrinology* (2014) **10** 723-736   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Ma J. H., Shen S., Wang J. J., He  │        │ │
│ │                                        │ Z., Poon A., Li J., Qu J., Zhang S.    │        │ │
│ │                                        │ X.. **Comparative proteomic analysis   │        │ │
│ │                                        │ of the mitochondria‐associated ER      │        │ │
│ │                                        │ membrane (MAM) in a long‐term type 2   │        │ │
│ │                                        │ diabetic rodent model**. *Scientific   │        │ │
│ │                                        │ Reports* (2017) **7** 2062. PMID:      │        │ │
│ │                                        │ 28522876                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Mahnke‐Zizelman D. K., Sabina R.   │        │ │
│ │                                        │ L.. **N‐terminal sequence and distal   │        │ │
│ │                                        │ histidine residues are responsible for │        │ │
│ │                                        │ pH‐regulated cytoplasmic membrane      │        │ │
│ │                                        │ binding of human AMP deaminase isoform │        │ │
│ │                                        │ E**. *The Journal of Biological        │        │ │
│ │                                        │ Chemistry* (2002) **277** 42654-42662. │        │ │
│ │                                        │ PMID: 12213808                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. McGarrah R. W., White P. J..       │        │ │
│ │                                        │ **Branched‐chain amino acids in        │        │ │
│ │                                        │ cardiovascular disease**. *Nature      │        │ │
│ │                                        │ Reviews. Cardiology* (2022) **20**     │        │ │
│ │                                        │ 77-89. DOI: 10.1038/s41569-022-00760-3 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Mi Z., Song Y., Cao X., Lu Y., Liu │        │ │
│ │                                        │ Z., Zhu X., Geng M., Sun Y., Lan B.,   │        │ │
│ │                                        │ He C., Xiong H., Zhang L., Chen Y..    │        │ │
│ │                                        │ **Super‐enhancer‐driven metabolic      │        │ │
│ │                                        │ reprogramming promotes cystogenesis in │        │ │
│ │                                        │ autosomal dominant polycystic kidney   │        │ │
│ │                                        │ disease**. *Nature Metabolism* (2020)  │        │ │
│ │                                        │ **2** 717-731                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Miki T., Miura T., Hotta H., Tanno │        │ │
│ │                                        │ M., Yano T., Sato T., Terashima Y.,    │        │ │
│ │                                        │ Takada A., Ishikawa S., Shimamoto K..  │        │ │
│ │                                        │ **Endoplasmic reticulum stress in      │        │ │
│ │                                        │ diabetic hearts abolishes              │        │ │
│ │                                        │ erythropoietin‐induced myocardial      │        │ │
│ │                                        │ protection by impairment of            │        │ │
│ │                                        │ phospho‐glycogen synthase              │        │ │
│ │                                        │ kinase‐3beta‐mediated suppression of   │        │ │
│ │                                        │ mitochondrial permeability             │        │ │
│ │                                        │ transition**. *Diabetes* (2009) **58** │        │ │
│ │                                        │ 2863-2872. PMID: 19755525              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Miki T., Yuda S., Kouzu H., Miura  │        │ │
│ │                                        │ T.. **Diabetic cardiomyopathy:         │        │ │
│ │                                        │ Pathophysiology and clinical           │        │ │
│ │                                        │ features**. *Heart Failure Reviews*    │        │ │
│ │                                        │ (2013) **18** 149-166. PMID: 22453289  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Milan G., Romanello V., Pescatore  │        │ │
│ │                                        │ F., Armani A., Paik J. H., Frasson L., │        │ │
│ │                                        │ Seydel A., Zhao J., Abraham R.,        │        │ │
│ │                                        │ Goldberg A. L., Blaauw B., DePinho R.  │        │ │
│ │                                        │ A., Sandri M.. **Regulation of         │        │ │
│ │                                        │ autophagy and the ubiquitin‐proteasome │        │ │
│ │                                        │ system by the FoxO transcriptional     │        │ │
│ │                                        │ network during muscle atrophy**.       │        │ │
│ │                                        │ *Nature Communications* (2015) **6**   │        │ │
│ │                                        │ 6670                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Miller S. G., Hafen P. S., Law A.  │        │ │
│ │                                        │ S., Springer C. B., Logsdon D. L.,     │        │ │
│ │                                        │ O'Connell T. M., Witczak C. A., Brault │        │ │
│ │                                        │ J. J.. **AMP deamination is sufficient │        │ │
│ │                                        │ to replicate an atrophy‐like metabolic │        │ │
│ │                                        │ phenotype in skeletal muscle**.        │        │ │
│ │                                        │ *Metabolism* (2021) **123**. PMID:     │        │ │
│ │                                        │ 34400216                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Mizuno M., Kuno A., Yano T., Miki  │        │ │
│ │                                        │ T., Oshima H., Sato T., Nakata K.,     │        │ │
│ │                                        │ Kimura Y., Tanno M., Miura T..         │        │ │
│ │                                        │ **Empagliflozin normalizes the size    │        │ │
│ │                                        │ and number of mitochondria and         │        │ │
│ │                                        │ prevents reduction in mitochondrial    │        │ │
│ │                                        │ size after myocardial infarction in    │        │ │
│ │                                        │ diabetic hearts**. *Physiological      │        │ │
│ │                                        │ Reports* (2018) **6**. PMID: 29932506  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 34. Mori J., Patel V. B., Abo Alrob    │        │ │
│ │                                        │ O., Basu R., Altamimi T., Desaulniers  │        │ │
│ │                                        │ J., Wagg C. S., Kassiri Z., Lopaschuk  │        │ │
│ │                                        │ G. D., Oudit G. Y.. **Angiotensin 1‐7  │        │ │
│ │                                        │ ameliorates diabetic cardiomyopathy    │        │ │
│ │                                        │ and diastolic dysfunction in db/db     │        │ │
│ │                                        │ mice by reducing lipotoxicity and      │        │ │
│ │                                        │ inflammation**. *Circulation. Heart    │        │ │
│ │                                        │ Failure* (2014) **7** 327-339. PMID:   │        │ │
│ │                                        │ 24389129                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 35. Murashige D., Jang C., Neinast M., │        │ │
│ │                                        │ Edwards J. J., Cowan A., Hyman M. C.,  │        │ │
│ │                                        │ Rabinowitz J. D., Frankel D. S., Arany │        │ │
│ │                                        │ Z.. **Comprehensive quantification of  │        │ │
│ │                                        │ fuel use by the failing and nonfailing │        │ │
│ │                                        │ human heart**. *Science* (2020)        │        │ │
│ │                                        │ **370** 364-368. PMID: 33060364        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 36. Neinast M., Murashige D., Arany    │        │ │
│ │                                        │ Z.. **Branched chain amino acids**.    │        │ │
│ │                                        │ *Annual Review of Physiology* (2019)   │        │ │
│ │                                        │ **81** 139-164                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 37. Neinast M. D., Jang C., Hui S.,    │        │ │
│ │                                        │ Murashige D. S., Chu Q., Morscher R.   │        │ │
│ │                                        │ J., Li X., Zhan L., White E., Anthony  │        │ │
│ │                                        │ T. G., Rabinowitz J. D., Arany Z..     │        │ │
│ │                                        │ **Quantitative analysis of the         │        │ │
│ │                                        │ whole‐body metabolic fate of           │        │ │
│ │                                        │ branched‐chain amino acids**. *Cell    │        │ │
│ │                                        │ Metabolism* (2019) **29**              │        │ │
│ │                                        │ 417-429.e414. PMID: 30449684           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 38. Nguyen T. B., Louie S. M., Daniele │        │ │
│ │                                        │ J. R., Tran Q., Dillin A., Zoncu R.,   │        │ │
│ │                                        │ Nomura D. K., Olzmann J. A..           │        │ │
│ │                                        │ **DGAT1‐dependent lipid droplet        │        │ │
│ │                                        │ biogenesis protects mitochondrial      │        │ │
│ │                                        │ function during starvation‐induced     │        │ │
│ │                                        │ autophagy**. *Developmental Cell*      │        │ │
│ │                                        │ (2017) **42** 9-21.e25. PMID: 28697336 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 39. Poirier M., Vincent G., Reszko A.  │        │ │
│ │                                        │ E., Bouchard B., Kelleher J. K.,       │        │ │
│ │                                        │ Brunengraber H., Des R. C.. **Probing  │        │ │
│ │                                        │ the link between citrate and           │        │ │
│ │                                        │ malonyl‐CoA in perfused rat hearts**.  │        │ │
│ │                                        │ *American Journal of Physiology Heart  │        │ │
│ │                                        │ and Circulatory Physiology* (2002)     │        │ │
│ │                                        │ **283** H1379-H1386. PMID: 12234788    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 40. Prosdocimo D. A., Anand P., Liao   │        │ │
│ │                                        │ X., Zhu H., Shelkay S.,                │        │ │
│ │                                        │ Artero‐Calderon P., Zhang L., Kirsh    │        │ │
│ │                                        │ J., Moore D., Rosca M. G., Vazquez E., │        │ │
│ │                                        │ Kerner J., Akat K. M., Williams Z.,    │        │ │
│ │                                        │ Zhao J., Fujioka H., Tuschl T., Bai    │        │ │
│ │                                        │ X., Schulze P. C., Haldar S. M..       │        │ │
│ │                                        │ **Kruppel‐like factor 15 is a critical │        │ │
│ │                                        │ regulator of cardiac lipid             │        │ │
│ │                                        │ metabolism**. *The Journal of          │        │ │
│ │                                        │ Biological Chemistry* (2014) **289**   │        │ │
│ │                                        │ 5914-5924. PMID: 24407292              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 41. Prosdocimo D. A., John J. E.,      │        │ │
│ │                                        │ Zhang L., Efraim E. S., Zhang R., Liao │        │ │
│ │                                        │ X., Jain M. K.. **KLF15 and PPARα      │        │ │
│ │                                        │ cooperate to regulate cardiomyocyte    │        │ │
│ │                                        │ lipid gene expression and oxidation**. │        │ │
│ │                                        │ *PPAR Research* (2015) **2015**. PMID: │        │ │
│ │                                        │ 25815008                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 42. Readnower R. D., Brainard R. E.,   │        │ │
│ │                                        │ Hill B. G., Jones S. P..               │        │ │
│ │                                        │ **Standardized bioenergetic profiling  │        │ │
│ │                                        │ of adult mouse cardiomyocytes**.       │        │ │
│ │                                        │ *Physiological Genomics* (2012) **44** │        │ │
│ │                                        │ 1208-1213. PMID: 23092951              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 43. Shao D., Villet O., Zhang Z., Choi │        │ │
│ │                                        │ S. W., Yan J., Ritterhoff J., Gu H.,   │        │ │
│ │                                        │ Djukovic D., Christodoulou D., Kolwicz │        │ │
│ │                                        │ S. C., Raftery D., Tian R.. **Glucose  │        │ │
│ │                                        │ promotes cell growth by suppressing    │        │ │
│ │                                        │ branched‐chain amino acid              │        │ │
│ │                                        │ degradation**. *Nature Communications* │        │ │
│ │                                        │ (2018) **9** 2935                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 44. She P., Zhou Y., Zhang Z., Griffin │        │ │
│ │                                        │ K., Gowda K., Lynch C. J..             │        │ │
│ │                                        │ **Disruption of BCAA metabolism in     │        │ │
│ │                                        │ mice impairs exercise metabolism and   │        │ │
│ │                                        │ endurance**. *Journal of Applied       │        │ │
│ │                                        │ Physiology (1985)* (2010) **108**      │        │ │
│ │                                        │ 941-949                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 45. Sparagna G. C., Hickson‐Bick D.    │        │ │
│ │                                        │ L., Buja L. M., McMillin J. B.. **A    │        │ │
│ │                                        │ metabolic role for mitochondria in     │        │ │
│ │                                        │ palmitate‐induced cardiac myocyte      │        │ │
│ │                                        │ apoptosis**. *American Journal of      │        │ │
│ │                                        │ Physiology. Heart and Circulatory      │        │ │
│ │                                        │ Physiology* (2000) **279**             │        │ │
│ │                                        │ H2124-H2132. PMID: 11045945            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 46. Sun H., Olson K. C., Gao C.,       │        │ │
│ │                                        │ Prosdocimo D. A., Zhou M., Wang Z.,    │        │ │
│ │                                        │ Jeyaraj D., Youn J. Y., Ren S., Liu    │        │ │
│ │                                        │ Y., Rau C. D., Shah S., Ilkayeva O.,   │        │ │
│ │                                        │ Gui W. J., William N. S., Wynn R. M.,  │        │ │
│ │                                        │ Newgard C. B., Cai H., Xiao X., Wang   │        │ │
│ │                                        │ Y.. **Catabolic defect of              │        │ │
│ │                                        │ branched‐chain amino acids promotes    │        │ │
│ │                                        │ heart failure**. *Circulation* (2016)  │        │ │
│ │                                        │ **133** 2038-2049. PMID: 27059949      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 47. Sutendra G., Kinnaird A.,          │        │ │
│ │                                        │ Dromparis P., Paulin R., Stenson T.    │        │ │
│ │                                        │ H., Haromy A., Hashimoto K., Zhang N., │        │ │
│ │                                        │ Flaim E., Michelakis E. D.. **A        │        │ │
│ │                                        │ nuclear pyruvate dehydrogenase complex │        │ │
│ │                                        │ is important for the generation of     │        │ │
│ │                                        │ acetyl‐CoA and histone acetylation**.  │        │ │
│ │                                        │ *Cell* (2014) **158** 84-97. PMID:     │        │ │
│ │                                        │ 24995980                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 48. Tatekoshi Y., Tanno M., Kouzu H.,  │        │ │
│ │                                        │ Abe K., Miki T., Kuno A., Yano T.,     │        │ │
│ │                                        │ Ishikawa S., Ohwada W., Sato T.,       │        │ │
│ │                                        │ Niinuma T., Suzuki H., Miura T..       │        │ │
│ │                                        │ **Translational regulation by miR‐301b │        │ │
│ │                                        │ upregulates AMP deaminase in diabetic  │        │ │
│ │                                        │ hearts**. *Journal of Molecular and    │        │ │
│ │                                        │ Cellular Cardiology* (2018) **119**    │        │ │
│ │                                        │ 138-146. PMID: 29733818                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 49. Tian Y., Wang Z., Zheng X., Song   │        │ │
│ │                                        │ W., Cai L., Rane M., Zhao Y.. **KLF15  │        │ │
│ │                                        │ negatively regulates cardiac fibrosis  │        │ │
│ │                                        │ by which SDF‐1β attenuates cardiac     │        │ │
│ │                                        │ fibrosis in type 2 diabetic mice**.    │        │ │
│ │                                        │ *Toxicology and Applied Pharmacology*  │        │ │
│ │                                        │ (2021) **427**. PMID: 34310909         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 50. Uddin G. M., Karwi Q. G., Pherwani │        │ │
│ │                                        │ S., Gopal K., Wagg C. S., Biswas D.,   │        │ │
│ │                                        │ Atnasious M., Wu Y., Wu G., Zhang L.,  │        │ │
│ │                                        │ Ho K. L., Pulinilkunnil T., Ussher J.  │        │ │
│ │                                        │ R., Lopaschuk G. D.. **Deletion of     │        │ │
│ │                                        │ BCATm increases insulin‐stimulated     │        │ │
│ │                                        │ glucose oxidation in the heart**.      │        │ │
│ │                                        │ *Metabolism* (2021) **124**. PMID:     │        │ │
│ │                                        │ 34478752                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 51. Uddin G. M., Zhang L., Shah S.,    │        │ │
│ │                                        │ Fukushima A., Wagg C. S., Gopal K., Al │        │ │
│ │                                        │ Batran R., Pherwani S., Ho K. L.,      │        │ │
│ │                                        │ Boisvenue J., Karwi Q. G., Altamimi    │        │ │
│ │                                        │ T., Wishart D. S., Dyck J. R. B.,      │        │ │
│ │                                        │ Ussher J. R., Oudit G. Y., Lopaschuk   │        │ │
│ │                                        │ G. D.. **Impaired branched chain amino │        │ │
│ │                                        │ acid oxidation contributes to cardiac  │        │ │
│ │                                        │ insulin resistance in heart failure**. │        │ │
│ │                                        │ *Cardiovascular Diabetology* (2019)    │        │ │
│ │                                        │ **18** 86. PMID: 31277657              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 52. Walejko J. M., Christopher B. A.,  │        │ │
│ │                                        │ Crown S. B., Zhang G. F.,              │        │ │
│ │                                        │ Pickar‐Oliver A., Yoneshiro T., Foster │        │ │
│ │                                        │ M. W., Page S., van Vliet S., Ilkayeva │        │ │
│ │                                        │ O., Muehlbauer M. J., Carson M. W.,    │        │ │
│ │                                        │ Brozinick J. T., Hammond C. D., Gimeno │        │ │
│ │                                        │ R. E., Moseley M. A., Kajimura S.,     │        │ │
│ │                                        │ Gersbach C. A., Newgard C. B.,         │        │ │
│ │                                        │ McGarrah R. W.. **Branched‐chain       │        │ │
│ │                                        │ α‐ketoacids are preferentially         │        │ │
│ │                                        │ reaminated and activate protein        │        │ │
│ │                                        │ synthesis in the heart**. *Nature      │        │ │
│ │                                        │ Communications* (2021) **12** 1680     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 53. Wallace M., Green C. R., Roberts   │        │ │
│ │                                        │ L. S., Lee Y. M., McCarville J. L.,    │        │ │
│ │                                        │ Sanchez‐Gurmaches J., Meurs N.,        │        │ │
│ │                                        │ Gengatharan J. M., Hover J. D.,        │        │ │
│ │                                        │ Phillips S. A., Ciaraldi T. P.,        │        │ │
│ │                                        │ Guertin D. A., Cabrales P., Ayres J.   │        │ │
│ │                                        │ S., Nomura D. K., Loomba R., Metallo   │        │ │
│ │                                        │ C. M.. **Enzyme promiscuity drives     │        │ │
│ │                                        │ branched‐chain fatty acid synthesis in │        │ │
│ │                                        │ adipose tissues**. *Nature Chemical    │        │ │
│ │                                        │ Biology* (2018) **14** 1021-1031.      │        │ │
│ │                                        │ PMID: 30327559                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 54. Wang W., Zhang F., Xia Y., Zhao    │        │ │
│ │                                        │ S., Yan W., Wang H., Lee Y., Li C.,    │        │ │
│ │                                        │ Zhang L., Lian K., Gao E., Cheng H.,   │        │ │
│ │                                        │ Tao L.. **Defective branched chain     │        │ │
│ │                                        │ amino acid catabolism contributes to   │        │ │
│ │                                        │ cardiac dysfunction and remodeling     │        │ │
│ │                                        │ following myocardial infarction**.     │        │ │
│ │                                        │ *American Journal of Physiology Heart  │        │ │
│ │                                        │ and Circulatory Physiology* (2016)     │        │ │
│ │                                        │ **311** H1160-H1169. PMID: 27542406    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 55. Wang Y., Guo Y. R., Liu K., Yin    │        │ │
│ │                                        │ Z., Liu R., Xia Y., Tan L., Yang P.,   │        │ │
│ │                                        │ Lee J. H., Li X. J., Hawke D., Zheng   │        │ │
│ │                                        │ Y., Qian X., Lyu J., He J., Xing D.,   │        │ │
│ │                                        │ Tao Y. J., Lu Z.. **KAT2A coupled with │        │ │
│ │                                        │ the α‐KGDH complex acts as a histone   │        │ │
│ │                                        │ H3 succinyltransferase**. *Nature*     │        │ │
│ │                                        │ (2017) **552** 273-277. PMID: 29211711 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 56. Wende A. R., Abel E. D..           │        │ │
│ │                                        │ **Lipotoxicity in the heart**.         │        │ │
│ │                                        │ *Biochimica et Biophysica Acta* (2010) │        │ │
│ │                                        │ **1801** 311-319. PMID: 19818871       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 57. White P. J., McGarrah R. W.,       │        │ │
│ │                                        │ Grimsrud P. A., Tso S. C., Yang W. H., │        │ │
│ │                                        │ Haldeman J. M., Grenier‐Larouche T.,   │        │ │
│ │                                        │ An J., Lapworth A. L., Astapova I.,    │        │ │
│ │                                        │ Hannou S. A., George T., Arlotto M.,   │        │ │
│ │                                        │ Olson L. B., Lai M., Zhang G. F.,      │        │ │
│ │                                        │ Ilkayeva O., Herman M. A., Wynn R. M., │        │ │
│ │                                        │ Newgard C. B.. **The BCKDH kinase and  │        │ │
│ │                                        │ phosphatase integrate BCAA and lipid   │        │ │
│ │                                        │ metabolism via regulation of           │        │ │
│ │                                        │ ATP‐citrate Lyase**. *Cell Metabolism* │        │ │
│ │                                        │ (2018) **27** 1281-1293.e1287. PMID:   │        │ │
│ │                                        │ 29779826                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 58. White P. J., Newgard C. B..        │        │ │
│ │                                        │ **Branched‐chain amino acids in        │        │ │
│ │                                        │ disease**. *Science* (2019) **363**    │        │ │
│ │                                        │ 582-583. PMID: 30733403                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 59. Wieckowski M. R., Giorgi C.,       │        │ │
│ │                                        │ Lebiedzinska M., Duszynski J., Pinton  │        │ │
│ │                                        │ P.. **Isolation of                     │        │ │
│ │                                        │ mitochondria‐associated membranes and  │        │ │
│ │                                        │ mitochondria from animal tissues and   │        │ │
│ │                                        │ cells**. *Nature Protocols* (2009)     │        │ │
│ │                                        │ **4** 1582-1590. PMID: 19816421        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 60. Zhou M., Lu G., Gao C., Wang Y.,   │        │ │
│ │                                        │ Sun H.. **Tissue‐specific and nutrient │        │ │
│ │                                        │ regulation of the branched‐chain       │        │ │
│ │                                        │ α‐keto acid dehydrogenase phosphatase, │        │ │
│ │                                        │ protein phosphatase 2Cm (PP2Cm)**.     │        │ │
│ │                                        │ *The Journal of Biological Chemistry*  │        │ │
│ │                                        │ (2012) **287** 23397-23406. PMID:      │        │ │
│ │                                        │ 22589535                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │ title: BCAA catabolism targeted        │        │ │
│ │                                        │ therapy for heart failure with         │        │ │
│ │                                        │ preserved ejection                     │        │ │
│ │                                        │   fraction                             │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Meng Wang                            │        │ │
│ │                                        │ - Zhao Liu                             │        │ │
│ │                                        │ - Shuxun Ren                           │        │ │
│ │                                        │ - Jinyun Zhu                           │        │ │
│ │                                        │ - Norihiko Morisawa                    │        │ │
│ │                                        │ - Geok Lin Chua                        │        │ │
│ │                                        │ - Xuewen Zhang                         │        │ │
│ │                                        │ - Yun Ka Wong                          │        │ │
│ │                                        │ - Liping Su                            │        │ │
│ │                                        │ - Ming Xiang Wong                      │        │ │
│ │                                        │ - Jieping Yang                         │        │ │
│ │                                        │ - Marc Titze Jens                      │        │ │
│ │                                        │ - Zhaoping Li                          │        │ │
│ │                                        │ - Haipeng Sun                          │        │ │
│ │                                        │ - Yibin Wang                           │        │ │
│ │                                        │ - Christoph D. Raul                    │        │ │
│ │                                        │ - Sanjiv J. Shah                       │        │ │
│ │                                        │ - Chen Gao                             │        │ │
│ │                                        │ - Yunxia Liu                           │        │ │
│ │                                        │ journal: Theranostics                  │        │ │
│ │                                        │ year: 2025                             │        │ │
│ │                                        │ pmcid: PMC12159833                     │        │ │
│ │                                        │ doi: 10.7150/thno.105894               │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # BCAA catabolism targeted therapy for │        │ │
│ │                                        │ heart failure with preserved ejection  │        │ │
│ │                                        │ fraction                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Rationale: Heart failure with          │        │ │
│ │                                        │ preserved ejection fraction (HFpEF) is │        │ │
│ │                                        │ a major unmet medical need with        │        │ │
│ │                                        │ limited effective treatments. A        │        │ │
│ │                                        │ significant contributing factor to     │        │ │
│ │                                        │ HFpEF, a multifactorial disease, is    │        │ │
│ │                                        │ underlying metabolic dysfunction.      │        │ │
│ │                                        │ While much of the prior research has   │        │ │
│ │                                        │ been on glucose and fatty acid         │        │ │
│ │                                        │ metabolic defects in the pathogenesis  │        │ │
│ │                                        │ of HFpEF, other metabolic activities   │        │ │
│ │                                        │ remain under investigated.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Methods: System-based metabolomics and │        │ │
│ │                                        │ targeted mass spectrometry were        │        │ │
│ │                                        │ employed to analyze serum and tissue   │        │ │
│ │                                        │ samples from a deep-phenotyped human   │        │ │
│ │                                        │ HFpEF cohort. A preclinical mouse      │        │ │
│ │                                        │ model of HFpEF was developed by        │        │ │
│ │                                        │ combined administration of a high-fat  │        │ │
│ │                                        │ diet (HFD) and the nitric oxide (NO)   │        │ │
│ │                                        │ synthase inhibitor                     │        │ │
│ │                                        │ N[w]-nitro-l-arginine methyl ester     │        │ │
│ │                                        │ (L-NAME). The branched-chain amino     │        │ │
│ │                                        │ acid (BCAA) catabolic activities were  │        │ │
│ │                                        │ enhanced by genetic inactivation of    │        │ │
│ │                                        │ branched-chain ketoacid-dehydrogenase  │        │ │
│ │                                        │ kinase (BCKDK) or treatment with BT2   │        │ │
│ │                                        │ (3,6-dichlorobenzo[b]thiophene-2-carb… │        │ │
│ │                                        │ acid), a highly selective inhibitor of │        │ │
│ │                                        │ BCKDK. Cardiac function, myocardial    │        │ │
│ │                                        │ remodeling and insulin signaling in    │        │ │
│ │                                        │ the left ventricle were assessed       │        │ │
│ │                                        │ across all experimental cohorts.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Results: The systems-based             │        │ │
│ │                                        │ metabolomics analysis of the           │        │ │
│ │                                        │ deep-phenotyped HFpEF and non-HFpEF    │        │ │
│ │                                        │ patients revealed that abnormal        │        │ │
│ │                                        │ circulating BCAA levels were           │        │ │
│ │                                        │ significantly associated with adverse  │        │ │
│ │                                        │ outcomes. In the rodent model of       │        │ │
│ │                                        │ HFpEF, significant impairment of BCAA  │        │ │
│ │                                        │ catabolic activities in the heart and  │        │ │
│ │                                        │ abnormal circulating BCAA levels were  │        │ │
│ │                                        │ also observed. In adult mice,          │        │ │
│ │                                        │ inducible knockout of BCKDK, the       │        │ │
│ │                                        │ rate-limiting negative regulator of    │        │ │
│ │                                        │ BCAA catabolic flux, markedly          │        │ │
│ │                                        │ augmented BCAA catabolic activities.   │        │ │
│ │                                        │ Compared with the controls, BCKDK      │        │ │
│ │                                        │ inactivation blunted diastolic         │        │ │
│ │                                        │ dysfunction, cardiac hypertrophy and   │        │ │
│ │                                        │ myocardial remodeling in response to   │        │ │
│ │                                        │ chronic treatment with HFD/L-NAME.     │        │ │
│ │                                        │ This functional amelioration was       │        │ │
│ │                                        │ associated with improved insulin       │        │ │
│ │                                        │ signaling in the myocardium and        │        │ │
│ │                                        │ reduced S-nitrosylation of cardiac     │        │ │
│ │                                        │ proteins, without any impact on        │        │ │
│ │                                        │ systemic blood pressure. Finally,      │        │ │
│ │                                        │ pharmacological inhibition of BCKDK in │        │ │
│ │                                        │ HFpEF mice significantly reversed the  │        │ │
│ │                                        │ diastolic dysfunction and cardiac      │        │ │
│ │                                        │ hypertrophy associated with HFpEF.     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Conclusions: Our study provides the    │        │ │
│ │                                        │ first proof-of-concept evidence that   │        │ │
│ │                                        │ global catabolic impairment of BCAAs   │        │ │
│ │                                        │ is an important pathogenic contributor │        │ │
│ │                                        │ and metabolic signature of HFpEF and   │        │ │
│ │                                        │ restoring BCAA catabolic flux could be │        │ │
│ │                                        │ an efficacious therapeutic strategy    │        │ │
│ │                                        │ for HFpEF.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Introduction                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Heart failure with preserved ejection  │        │ │
│ │                                        │ fraction (HFpEF) accounts for more     │        │ │
│ │                                        │ than $50\%$ of heart failure cases and │        │ │
│ │                                        │ is arguably the most significant unmet │        │ │
│ │                                        │ medical need amongst cardiovascular    │        │ │
│ │                                        │ diseases because of its poor outcomes  │        │ │
│ │                                        │ and lack of effective therapies 1, 2.  │        │ │
│ │                                        │ HFpEF is a heterogeneous disease often │        │ │
│ │                                        │ associated with multiple comorbidities │        │ │
│ │                                        │ and risk factors, including obesity,   │        │ │
│ │                                        │ diabetes, hypertension and aging.      │        │ │
│ │                                        │ HFpEF pathology is characterized by    │        │ │
│ │                                        │ heart failure symptoms with a normal   │        │ │
│ │                                        │ range of ejection fraction but         │        │ │
│ │                                        │ profound defects in diastolic          │        │ │
│ │                                        │ function, cardiac hypertrophy and      │        │ │
│ │                                        │ fibrotic remodeling. The pathogenesis  │        │ │
│ │                                        │ of HFpEF remains elusive but clearly   │        │ │
│ │                                        │ involves cardiac metabolic remodeling  │        │ │
│ │                                        │ in combination with other mechanical   │        │ │
│ │                                        │ or neural-hormonal stresses 3-5.       │        │ │
│ │                                        │ However, standard treatment strategies │        │ │
│ │                                        │ for heart failure with reduced         │        │ │
│ │                                        │ ejection fraction (HFrEF), such as     │        │ │
│ │                                        │ β-blockers, ACEi and spironolactone,   │        │ │
│ │                                        │ fail to improve the clinical outcome   │        │ │
│ │                                        │ for HFpEF patients 6-9. In contrast,   │        │ │
│ │                                        │ studies on the outcomes of patients    │        │ │
│ │                                        │ with anti-diabetic SGLT-2 inhibitors   │        │ │
│ │                                        │ and anti-obesity GLP-1 receptor        │        │ │
│ │                                        │ agonists have demonstrated exciting    │        │ │
│ │                                        │ and unexpected benefits for HFpEF,     │        │ │
│ │                                        │ highlighting the potential of          │        │ │
│ │                                        │ metabolism-targeted therapy for this   │        │ │
│ │                                        │ disease 10-14. However, despite the    │        │ │
│ │                                        │ overall positive outcomes observed     │        │ │
│ │                                        │ from the entire study population,      │        │ │
│ │                                        │ subgroup analyses within these trials  │        │ │
│ │                                        │ have also revealed reduced benefits    │        │ │
│ │                                        │ for significant portions of patients   │        │ │
│ │                                        │ with HFpEF 10, 15. Therefore, better   │        │ │
│ │                                        │ stratification and new targeted        │        │ │
│ │                                        │ therapies for HFpEF are still urgently │        │ │
│ │                                        │ needed.                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The branched-chain amino acids         │        │ │
│ │                                        │ (BCAAs), including leucine (Leu),      │        │ │
│ │                                        │ isoleucine (Ile) and valine (Val), are │        │ │
│ │                                        │ essential amino acids primarily        │        │ │
│ │                                        │ obtained from protein-containing foods │        │ │
│ │                                        │ 16. Previous research has reported     │        │ │
│ │                                        │ that the BCAA catabolic pathway is     │        │ │
│ │                                        │ highly enriched among the              │        │ │
│ │                                        │ differentially expressed genes         │        │ │
│ │                                        │ detected in both mouse and human       │        │ │
│ │                                        │ failing hearts 17-19. Transcriptomic   │        │ │
│ │                                        │ analysis of a large animal model of    │        │ │
│ │                                        │ HFpEF has also revealed significant    │        │ │
│ │                                        │ changes in the BCAA metabolic pathway  │        │ │
│ │                                        │ 20. More recently, a metabolomic       │        │ │
│ │                                        │ analysis in myocardial tissues from    │        │ │
│ │                                        │ HFpEF patients has further revealed    │        │ │
│ │                                        │ impaired BCAA catabolic activity in    │        │ │
│ │                                        │ the human HFpEF hearts 21.             │        │ │
│ │                                        │ Surprisingly, despite these lines of   │        │ │
│ │                                        │ evidence supporting the notion that    │        │ │
│ │                                        │ impaired BCAA catabolism is a          │        │ │
│ │                                        │ conserved pathological feature         │        │ │
│ │                                        │ associated with HFpEF, whether BCAA    │        │ │
│ │                                        │ catabolism can serve as both a         │        │ │
│ │                                        │ biomarker and a therapeutic target for │        │ │
│ │                                        │ HFpEF has never been directly          │        │ │
│ │                                        │ demonstrated in the current            │        │ │
│ │                                        │ literature.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BCAA homeostasis is tightly regulated  │        │ │
│ │                                        │ by dietary intake, and BCAA catabolism │        │ │
│ │                                        │ primarily occurs in the mitochondria.  │        │ │
│ │                                        │ The BCAA catabolic pathway includes    │        │ │
│ │                                        │ reversible transamination to branched  │        │ │
│ │                                        │ chain α-ketoacids (BCKAs) followed by  │        │ │
│ │                                        │ irreversible BCKA oxidation catalyzed  │        │ │
│ │                                        │ by the rate-limiting enzyme complex of │        │ │
│ │                                        │ BCKA dehydrogenase (BCKDH) 16, 22,     │        │ │
│ │                                        │ BCKAs include keto-isocaproate (KIC),  │        │ │
│ │                                        │ keto-isovalerate (KIV) and             │        │ │
│ │                                        │ keto-methylvalerate (KMV). BCKDH       │        │ │
│ │                                        │ enzymatic activity is tightly          │        │ │
│ │                                        │ regulated by the phosphorylation of    │        │ │
│ │                                        │ its E1α subunit (BCKDHA). BCKD kinase  │        │ │
│ │                                        │ (BCKDK) inhibits BCKDH activity,       │        │ │
│ │                                        │ thereby reducing BCAA catabolic flux,  │        │ │
│ │                                        │ whereas the protein phosphatase PPC2m  │        │ │
│ │                                        │ activates BCKDH, leading to an         │        │ │
│ │                                        │ increase in BCAA catabolism 23, 24. In │        │ │
│ │                                        │ this study, we performed an unbiased   │        │ │
│ │                                        │ systems-based metabolomics analysis in │        │ │
│ │                                        │ a deep-phenotyped human cohort of      │        │ │
│ │                                        │ HFpEF and non-HFpEF patients. The      │        │ │
│ │                                        │ results showed that BCAA and glucose   │        │ │
│ │                                        │ were in the same metabolic module with │        │ │
│ │                                        │ the highest correlation with adverse   │        │ │
│ │                                        │ outcomes in HFpEF patients. We further │        │ │
│ │                                        │ demonstrated that systemic catabolic   │        │ │
│ │                                        │ defects in BCAA correlated with        │        │ │
│ │                                        │ disease progression in a mouse model   │        │ │
│ │                                        │ of HFpEF. Importantly, targeted        │        │ │
│ │                                        │ enhancement of BCAA catabolic flux     │        │ │
│ │                                        │ ameliorated the characteristic         │        │ │
│ │                                        │ pathological features of HFpEF,        │        │ │
│ │                                        │ including diastolic dysfunction,       │        │ │
│ │                                        │ cardiac hypertrophy and remodeling.    │        │ │
│ │                                        │ Mechanistically, we demonstrated that  │        │ │
│ │                                        │ BCAA catabolic activation did not      │        │ │
│ │                                        │ affect systemic blood pressure but     │        │ │
│ │                                        │ markedly improved insulin signaling    │        │ │
│ │                                        │ while reducing myocardial              │        │ │
│ │                                        │ S-nitrosylation levels. These findings │        │ │
│ │                                        │ provide the first proof-of-concept     │        │ │
│ │                                        │ evidence that BCAA catabolic defects   │        │ │
│ │                                        │ are functionally important for         │        │ │
│ │                                        │ metabolic remodeling and restoration   │        │ │
│ │                                        │ of the BCAA catabolic flux is a potent │        │ │
│ │                                        │ therapeutic strategy for treating      │        │ │
│ │                                        │ HFpEF.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Human Metabolites Analysis          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Untargeted metabolomic analysis was    │        │ │
│ │                                        │ performed on serum samples collected   │        │ │
│ │                                        │ from a Northwestern cohort of HFpEF    │        │ │
│ │                                        │ and control subjects, and their clinic │        │ │
│ │                                        │ characteristics were described in      │        │ │
│ │                                        │ Supplemental Table 17 as reported by   │        │ │
│ │                                        │ Culler et al 25. Metabolite            │        │ │
│ │                                        │ Enrichment: Metabolites that were      │        │ │
│ │                                        │ significantly different at an FDR of   │        │ │
│ │                                        │ $5\%$ by a Kruskal-Wallis test between │        │ │
│ │                                        │ control and HFpEF individuals were     │        │ │
│ │                                        │ uploaded to the Overrepresentation     │        │ │
│ │                                        │ tool on the MetaboAnalyst 4.0 server   │        │ │
│ │                                        │ (https://currentprotocols.onlinelibra… │        │ │
│ │                                        │ and compared to KEGG pathways to       │        │ │
│ │                                        │ search for enriched pathways           │        │ │
│ │                                        │ associated with changes between HFpEF  │        │ │
│ │                                        │ and control individuals. A total of    │        │ │
│ │                                        │ 707 metabolites with a coefficient of  │        │ │
│ │                                        │ variation greater than $7.5\%$ were    │        │ │
│ │                                        │ examined using Weighted Gene           │        │ │
│ │                                        │ Co-expression Network Analysis (WGCNA) │        │ │
│ │                                        │ (https://bmcbioinformatics.biomedcent… │        │ │
│ │                                        │ using the standard pipeline as         │        │ │
│ │                                        │ described. Briefly, correlations were  │        │ │
│ │                                        │ calculated between each pair of genes  │        │ │
│ │                                        │ using the biweight midcorrelation.     │        │ │
│ │                                        │ Next, these correlations were          │        │ │
│ │                                        │ soft-thresholded (values raised to a   │        │ │
│ │                                        │ power of 3) to achieve a closer fit to │        │ │
│ │                                        │ a scale-free topology. The modified    │        │ │
│ │                                        │ correlations were then converted to a  │        │ │
│ │                                        │ measure of topological overlap as      │        │ │
│ │                                        │ follows: where w_ij is the topological │        │ │
│ │                                        │ overlap between genes i and j, l_ij is │        │ │
│ │                                        │ the sum across all other genes u of    │        │ │
│ │                                        │ the product of the weighted            │        │ │
│ │                                        │ correlations between genes i and u and │        │ │
│ │                                        │ j and u, a_ij is the weighted          │        │ │
│ │                                        │ correlation between genes i and j, and │        │ │
│ │                                        │ k_i is the total sum of all weighted   │        │ │
│ │                                        │ correlations between gene i and all    │        │ │
│ │                                        │ other genes in the dataset. The        │        │ │
│ │                                        │ resulting topological overlap matrix   │        │ │
│ │                                        │ is then subjected to hierarchical      │        │ │
│ │                                        │ clustering, and modules are determined │        │ │
│ │                                        │ using the dynamic tree cut algorithm.  │        │ │
│ │                                        │ The first principal component of each  │        │ │
│ │                                        │ module (termed the 'eigengene') is     │        │ │
│ │                                        │ determined and correlated with         │        │ │
│ │                                        │ phenotypic traits to identify modules  │        │ │
│ │                                        │ that are strongly associated with      │        │ │
│ │                                        │ specific phenotypes of interest.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Animals and Tamoxifen Treatment     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All mice were raised and kept in the   │        │ │
│ │                                        │ animal facility with a 12-hour         │        │ │
│ │                                        │ light/dark cycle at Duke-NUS Medical   │        │ │
│ │                                        │ School, with an approved protocol of   │        │ │
│ │                                        │ the SingHealth Institutional Animal    │        │ │
│ │                                        │ Care and Use Committee, Singapore. The │        │ │
│ │                                        │ bckdkflox/flox-ubiqutin C Cre-ERT2     │        │ │
│ │                                        │ mice (BCKDK-uKO) were generated by     │        │ │
│ │                                        │ crossing the previously established    │        │ │
│ │                                        │ bckdkflox/flox mice 26 with a          │        │ │
│ │                                        │ transgenic line (B6.                   │        │ │
│ │                                        │ Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/1J,       │        │ │
│ │                                        │ strain number 007001, from             │        │ │
│ │                                        │ Jacksonville, FL, USA), where the      │        │ │
│ │                                        │ human ubiquitin C promoter drives the  │        │ │
│ │                                        │ expression of the tamoxifen-inducible  │        │ │
│ │                                        │ Cre transgene. The genotype results    │        │ │
│ │                                        │ were confirmed by genomic DNA PCR      │        │ │
│ │                                        │ (Table S1). At two months of age, a    │        │ │
│ │                                        │ tamoxifen diet was administered for    │        │ │
│ │                                        │ two weeks, followed by one week of     │        │ │
│ │                                        │ washout. Next, cardiac function was    │        │ │
│ │                                        │ evaluated, and the global inactivation │        │ │
│ │                                        │ of the *Bckdk* gene was confirmed by   │        │ │
│ │                                        │ Real-Time PCR and Western blotting at  │        │ │
│ │                                        │ both mRNA and protein levels. The      │        │ │
│ │                                        │ HFpEF mouse model was induced by       │        │ │
│ │                                        │ administration of a $60\%$ high-fat    │        │ │
│ │                                        │ diet (Research Diets, D12492i) plus    │        │ │
│ │                                        │ Nω-Nitro-L-arginine methyl ester       │        │ │
│ │                                        │ (L-NAME: 0.5 mg/mL, Sigma Aldrich) in  │        │ │
│ │                                        │ the drinking water as described        │        │ │
│ │                                        │ previously 27.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Echocardiogram                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mice were anesthetized and         │        │ │
│ │                                        │ maintained under anesthesia with a     │        │ │
│ │                                        │ mixture of $2\%$ isoflurane. Cardiac   │        │ │
│ │                                        │ function was measured using the        │        │ │
│ │                                        │ high-frequency ultrasound system Vevo  │        │ │
│ │                                        │ F2 (FUJIFILM VisualSonics), which is   │        │ │
│ │                                        │ equipped with a 57-MHz linear          │        │ │
│ │                                        │ transducer (UHF57x) for precise        │        │ │
│ │                                        │ imaging. The left ventricular ejection │        │ │
│ │                                        │ fraction (LVEF) was measured using the │        │ │
│ │                                        │ Teichholz formula, and images were     │        │ │
│ │                                        │ acquired in short-axis view (SAX) in   │        │ │
│ │                                        │ M-mode. The E/A ratio, E/e' ratio and  │        │ │
│ │                                        │ IVRT (isovolumetric relaxation time)   │        │ │
│ │                                        │ were obtained via an apical 4-chamber  │        │ │
│ │                                        │ view with pulse wave Doppler (PWD) and │        │ │
│ │                                        │ tissue Doppler imaging (TDI).          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 Treatment                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The compound BT2 (3,6-dichlorobenzo[b] │        │ │
│ │                                        │ thiophene-2-carboxylic acid) was       │        │ │
│ │                                        │ obtained from the laboratory of Dr.    │        │ │
│ │                                        │ David T. Chuang from UT Southwestern   │        │ │
│ │                                        │ as a kind gift. Upon successful        │        │ │
│ │                                        │ establishment of the HFpEF model based │        │ │
│ │                                        │ on the echocardiography data, BT2 or   │        │ │
│ │                                        │ vehicle was administered at a dose of  │        │ │
│ │                                        │ 40 mg/kg per day for 4 weeks as        │        │ │
│ │                                        │ previously described 28. BT2 was       │        │ │
│ │                                        │ dissolved in a pH 9.0 buffer solution  │        │ │
│ │                                        │ containing $5\%$ dimethyl sulfoxide,   │        │ │
│ │                                        │ $10\%$ Cremophor EL, and $85\%$ 0.1    │        │ │
│ │                                        │ mol/L sodium bicarbonate. The BCKD     │        │ │
│ │                                        │ complex activity in cardiac tissue, as │        │ │
│ │                                        │ well as the BCAA and BCAA downstream   │        │ │
│ │                                        │ metabolite levels in both cardiac      │        │ │
│ │                                        │ tissue and plasma, were measured as    │        │ │
│ │                                        │ previously described 17.               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Radio Telemetry Monitoring of Blood │        │ │
│ │                                        │ Pressure                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Systolic blood pressure (SBP),         │        │ │
│ │                                        │ diastolic blood pressure (DBP), mean   │        │ │
│ │                                        │ arterial pressure (MAP), pulse         │        │ │
│ │                                        │ pressure (PP) and heart rate (HR) were │        │ │
│ │                                        │ measured using a radio telemetry       │        │ │
│ │                                        │ system (Data Sciences International,   │        │ │
│ │                                        │ St. Paul, MN, USA). The mice were      │        │ │
│ │                                        │ anesthetized briefly with 1.5-$2\%$    │        │ │
│ │                                        │ isoflurane. The left common carotid    │        │ │
│ │                                        │ artery was then isolated before the    │        │ │
│ │                                        │ advancement of a catheter tip of a     │        │ │
│ │                                        │ radio telemetry transmitter (PA-C10;   │        │ │
│ │                                        │ Data Sciences International, St. Paul, │        │ │
│ │                                        │ MN, USA) into the thoracic aorta. The  │        │ │
│ │                                        │ transducer was positioned along the    │        │ │
│ │                                        │ left flank. An RPC-1 receiver system   │        │ │
│ │                                        │ (Data Sciences International, St.      │        │ │
│ │                                        │ Paul, MN, USA) was used to measure     │        │ │
│ │                                        │ SBP, DBP, MAP, PP and HR. The data     │        │ │
│ │                                        │ were subsequently collected and        │        │ │
│ │                                        │ analyzed using Dataquest ART version   │        │ │
│ │                                        │ 4.31 (DSI). Blood pressure monitoring  │        │ │
│ │                                        │ was recorded every 5 min for two weeks │        │ │
│ │                                        │ after surgery.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Histology and Masson's Trichrome    │        │ │
│ │                                        │ Staining                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The morphology was detected by         │        │ │
│ │                                        │ hematoxylin and eosin (H&E) staining,  │        │ │
│ │                                        │ and fibrosis was detected by Masson's  │        │ │
│ │                                        │ trichrome staining. All stained        │        │ │
│ │                                        │ samples were imaged with an EVOS M7000 │        │ │
│ │                                        │ Imaging System (Thermo Fisher          │        │ │
│ │                                        │ Scientific, Pittsburgh, PA, USA).      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Glucose Tolerance Test              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mice were fasted for 6 hours and   │        │ │
│ │                                        │ then injected intraperitoneally with   │        │ │
│ │                                        │ D-glucose (Sigma) at a dose of 1.5     │        │ │
│ │                                        │ g/kg body weight. Blood glucose levels │        │ │
│ │                                        │ were detected in the tail vein by a    │        │ │
│ │                                        │ portable glucometer at different       │        │ │
│ │                                        │ timepoints (0, 15, 30, 60, and 120     │        │ │
│ │                                        │ min) after D-glucose injection.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Exercise Exhaustion Test            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ After three days of acclimatization to │        │ │
│ │                                        │ the treadmill (Columbus Instruments),  │        │ │
│ │                                        │ all mice underwent a warm-up period at │        │ │
│ │                                        │ a speed of 5 m/min for 4 min.          │        │ │
│ │                                        │ Following this initial phase, the      │        │ │
│ │                                        │ treadmill speed was incrementally      │        │ │
│ │                                        │ increased every two min by 2 m/s until │        │ │
│ │                                        │ the mice reached exhaustion, defined   │        │ │
│ │                                        │ as the point at which they were in     │        │ │
│ │                                        │ contact with the electric-stimulus     │        │ │
│ │                                        │ grid for 3 s. The running time and     │        │ │
│ │                                        │ distance were recorded for each mouse  │        │ │
│ │                                        │ during the test.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Sample preparation                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The plasma and heart samples were      │        │ │
│ │                                        │ stored at -80 °C until analysis. The   │        │ │
│ │                                        │ plasma samples were thawed on ice,     │        │ │
│ │                                        │ after which 10 µl was transferred to a │        │ │
│ │                                        │ new tube and extracted with 100 µl of  │        │ │
│ │                                        │ acetonitrile: methanol (1:1, v/v)      │        │ │
│ │                                        │ containing 5 µM internal standards.    │        │ │
│ │                                        │ The samples were vortexed and          │        │ │
│ │                                        │ centrifuged at 14,000 rpm for 10 min.  │        │ │
│ │                                        │ The supernatants were then transferred │        │ │
│ │                                        │ to a new tube and dried in a vacuum    │        │ │
│ │                                        │ concentrator at 4 °C. After the        │        │ │
│ │                                        │ extracts were reconstituted with 50 µl │        │ │
│ │                                        │ of $5\%$ acetonitrile in water, the    │        │ │
│ │                                        │ mixture was vortexed for 2 min and     │        │ │
│ │                                        │ centrifuged for 10 min at 14,000 rpm   │        │ │
│ │                                        │ to remove the insoluble debris. The    │        │ │
│ │                                        │ supernatants were transferred to glass │        │ │
│ │                                        │ vials for LC/MS injection. For heart   │        │ │
│ │                                        │ tissue, 40 mg samples were homogenized │        │ │
│ │                                        │ with 400 µl of water at 4 °C. Then,    │        │ │
│ │                                        │ 800 µl of acetonitrile: methanol (1:1, │        │ │
│ │                                        │ v/v) containing internal standards was │        │ │
│ │                                        │ added to 200 µl of tissue homogenate   │        │ │
│ │                                        │ for metabolite extraction. The         │        │ │
│ │                                        │ mixtures were vortexed, sonicated for  │        │ │
│ │                                        │ 10 min at 4 °C in a water bath and     │        │ │
│ │                                        │ incubated for 30 min at -80 °C to      │        │ │
│ │                                        │ facilitate protein precipitation. The  │        │ │
│ │                                        │ samples were centrifuged at 14,000 rpm │        │ │
│ │                                        │ for 10 min, and the supernatants were  │        │ │
│ │                                        │ dried under a vacuum concentrator.     │        │ │
│ │                                        │ Before LC/MS analysis, the dried       │        │ │
│ │                                        │ samples were reconstituted with 100 µl │        │ │
│ │                                        │ of $5\%$ acetonitrile in water,        │        │ │
│ │                                        │ centrifuged for 10 min at 14,000 rpm   │        │ │
│ │                                        │ and transferred to glass vials. The    │        │ │
│ │                                        │ injection volume was set constant at   │        │ │
│ │                                        │ 10 µl.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## LC/MS analysis                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The samples were run with a Waters BEH │        │ │
│ │                                        │ C18 column (150 × 4.6 mm, 2.5 μm,      │        │ │
│ │                                        │ Waters, Milford, MA) on a Thermo UHPLC │        │ │
│ │                                        │ system coupled with a Q Exactive Plus  │        │ │
│ │                                        │ mass spectrometer (QE MS, Thermo       │        │ │
│ │                                        │ Scientific, San Jose, CA). The         │        │ │
│ │                                        │ separation was performed using a       │        │ │
│ │                                        │ gradient of solvent A (5 mM ammonium   │        │ │
│ │                                        │ acetate and $0.1\%$ ammonium hydroxide │        │ │
│ │                                        │ in water) and solvent B (methanol).    │        │ │
│ │                                        │ The LC flow rate was 0.5 ml/min with   │        │ │
│ │                                        │ an initial gradient of $2\%$ B. The    │        │ │
│ │                                        │ gradient program was as follows: 0-1   │        │ │
│ │                                        │ min $2\%$ B, 1-5 min $20\%$ B, 5-6 min │        │ │
│ │                                        │ $50\%$ B, 6-8 min $90\%$ B, and 8-10   │        │ │
│ │                                        │ min $90\%$ B, followed by              │        │ │
│ │                                        │ re-equilibration of the column to the  │        │ │
│ │                                        │ initial run conditions ($2\%$ B) for   │        │ │
│ │                                        │ 4.0 min. All the compounds were        │        │ │
│ │                                        │ ionized in negative mode using         │        │ │
│ │                                        │ electrospray ionization. The MS        │        │ │
│ │                                        │ parameters are as follows: heater      │        │ │
│ │                                        │ temperature, 350 °C; sheath gas, 55;   │        │ │
│ │                                        │ auxiliary gas, 15; and spray voltage,  │        │ │
│ │                                        │ 3.8 kV. The capillary temperature was  │        │ │
│ │                                        │ set to 350 °C, and the S-lens was set  │        │ │
│ │                                        │ to 50. The analysis was performed in   │        │ │
│ │                                        │ parallel reaction monitor (PRM) mode   │        │ │
│ │                                        │ with a resolution of 15,000 (at m/z    │        │ │
│ │                                        │ 200), and the isolation window was set │        │ │
│ │                                        │ at 1.5 m/z. The raw data were          │        │ │
│ │                                        │ collected using Thermo Xcalibur        │        │ │
│ │                                        │ Software 4.1, and the data were        │        │ │
│ │                                        │ processed using TraceFinder 4.1.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Western Blot Analysis               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ After the mice were euthanized, 20 mg  │        │ │
│ │                                        │ of the left ventricle was used for     │        │ │
│ │                                        │ total protein extraction. Protein      │        │ │
│ │                                        │ levels were measured and quantified    │        │ │
│ │                                        │ using a BCA protein assay kit          │        │ │
│ │                                        │ (PierceTM, Thermo Fisher Scientific).  │        │ │
│ │                                        │ The proteins were resolved using       │        │ │
│ │                                        │ sodium dodecyl sulfate-polyacrylamide  │        │ │
│ │                                        │ gel electrophoresis (SDS-PAGE) and     │        │ │
│ │                                        │ then transferred to polyvinylidene     │        │ │
│ │                                        │ difluoride (PVDF) membranes            │        │ │
│ │                                        │ (Millipore). The membranes were        │        │ │
│ │                                        │ blocked with $5\%$ milk and incubated  │        │ │
│ │                                        │ with the following primary antibodies: │        │ │
│ │                                        │ anti-BCKDK, anti-BCKDHA, anti-p-BCKDHA │        │ │
│ │                                        │ (Ser 293), anti-p-AKT (Ser 473),       │        │ │
│ │                                        │ anti-AKT, anti-p-AMPKα, anti-AMPKα,    │        │ │
│ │                                        │ anti-p-P70S6K (Thr 389) and            │        │ │
│ │                                        │ anti-P70S6K (Table S2). After washing, │        │ │
│ │                                        │ the membranes were incubated with an   │        │ │
│ │                                        │ anti-rabbit IgG (H+L) HRP secondary    │        │ │
│ │                                        │ antibody and an anti-mouse IgG (H+L)   │        │ │
│ │                                        │ HRP secondary antibody (Table S2) for  │        │ │
│ │                                        │ 1 h before imaging using Chemi-Doc     │        │ │
│ │                                        │ (BioRad). Immunodetection of           │        │ │
│ │                                        │ housekeeping proteins is routinely     │        │ │
│ │                                        │ performed to detect differences in     │        │ │
│ │                                        │ electrophoresis loading. Quantitative  │        │ │
│ │                                        │ analysis of the images was performed   │        │ │
│ │                                        │ using ImageJ software.                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## RNA Extraction and Real-Time PCR    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ A total of 20 mg of the left ventricle │        │ │
│ │                                        │ was used for total RNA extraction with │        │ │
│ │                                        │ TRIzol Reagent (Thermo Fisher          │        │ │
│ │                                        │ Scientific) following the              │        │ │
│ │                                        │ manufacturer's instructions. One       │        │ │
│ │                                        │ microgram of total RNA was reverse     │        │ │
│ │                                        │ transcribed into cDNA using a reverse  │        │ │
│ │                                        │ transcription kit (Takara              │        │ │
│ │                                        │ Biotechnology, Japan). The expression  │        │ │
│ │                                        │ of target genes was analyzed using     │        │ │
│ │                                        │ CFX96 Touch Real-Time PCR system with  │        │ │
│ │                                        │ SYBR Green (Bio-Rad). The relative     │        │ │
│ │                                        │ expression levels of the target genes  │        │ │
│ │                                        │ were detected according to the primers │        │ │
│ │                                        │ listed in Table S3.                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## S-Nitrosylation Blot                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ S-Nitrosylation blot (Thermo Fisher)   │        │ │
│ │                                        │ was conducted following the            │        │ │
│ │                                        │ manufacturer's instructions. Protein   │        │ │
│ │                                        │ was prepared at a concentration of 1   │        │ │
│ │                                        │ mg/ml in 100 µl of HENS buffer. For    │        │ │
│ │                                        │ each analysis, 100 µg of protein was   │        │ │
│ │                                        │ used to ensure equal amount across     │        │ │
│ │                                        │ samples. Prior to precipitation with   │        │ │
│ │                                        │ acetone, 2 µl of 1 M MMTS was added to │        │ │
│ │                                        │ the protein sample. The protein was    │        │ │
│ │                                        │ then recovered in 100 µl of HENS       │        │ │
│ │                                        │ buffer, labeled with the labeling      │        │ │
│ │                                        │ reagent and sodium ascorbate, and      │        │ │
│ │                                        │ allowed to react for 2 hours at room   │        │ │
│ │                                        │ temperature prior to Western blot      │        │ │
│ │                                        │ analysis.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Pressure-Volume (PV) Loop           │        │ │
│ │                                        │ Measurements                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The PV loop was performed according to │        │ │
│ │                                        │ previously described methods 29. The   │        │ │
│ │                                        │ mice were anesthetized via             │        │ │
│ │                                        │ intraperitoneal injection of a mixture │        │ │
│ │                                        │ of $2\%$ isoflurane and etomidate and  │        │ │
│ │                                        │ then mechanically ventilated with a    │        │ │
│ │                                        │ mixture of $2\%$ isoflurane and $95\%$ │        │ │
│ │                                        │ oxygen. The mice were placed on a      │        │ │
│ │                                        │ heating pad, and the core body         │        │ │
│ │                                        │ temperature was maintained at 37 °C.   │        │ │
│ │                                        │ The left ventricle was exposed, and a  │        │ │
│ │                                        │ specialized catheter with a diameter   │        │ │
│ │                                        │ of 0.42 mm was inserted through the    │        │ │
│ │                                        │ apex of the heart. The hemodynamic     │        │ │
│ │                                        │ parameters were recorded and analyzed  │        │ │
│ │                                        │ using LabChart 8.0 (AD Instruments).   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Statistical Analysis                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The experimental data was analyzed     │        │ │
│ │                                        │ using GraphPad Prism 8.3.0 and is      │        │ │
│ │                                        │ presented as the means ± SEMs. The     │        │ │
│ │                                        │ data distribution normality was        │        │ │
│ │                                        │ determined using Shapiro-Wilk test for │        │ │
│ │                                        │ any sample size n > 6. For normally    │        │ │
│ │                                        │ distributed data, parametric tests     │        │ │
│ │                                        │ were used. Comparisons of two          │        │ │
│ │                                        │ variables were tested using the        │        │ │
│ │                                        │ Student's t-test. Comparisons among    │        │ │
│ │                                        │ multiple variables were determined     │        │ │
│ │                                        │ using one-way ANOVA with Tukey's or    │        │ │
│ │                                        │ Fisher's post hoc test. For the        │        │ │
│ │                                        │ analysis involving two categories of   │        │ │
│ │                                        │ variables (time/treatment groups),     │        │ │
│ │                                        │ two-way ANOVA followed by Tukey's test │        │ │
│ │                                        │ or LSD post hoc test was used as       │        │ │
│ │                                        │ indicated specifically in the figure   │        │ │
│ │                                        │ legend. $p \leq 0.05$ was considered   │        │ │
│ │                                        │ statistically significant. The         │        │ │
│ │                                        │ experimental schematics were designed  │        │ │
│ │                                        │ using BioRender.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abnormal systemic BCAAs in HFpEF    │        │ │
│ │                                        │ patients                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Metabolic disorders are known risk     │        │ │
│ │                                        │ factors for HFpEF 30, 31, however, the │        │ │
│ │                                        │ underlying mechanism for the           │        │ │
│ │                                        │ pathogenic contribution of metabolic   │        │ │
│ │                                        │ impairments remains to be fully        │        │ │
│ │                                        │ established. To identify potential     │        │ │
│ │                                        │ metabolic pathways affected in HFpEF,  │        │ │
│ │                                        │ we conducted comprehensive serum       │        │ │
│ │                                        │ metabolomics profiling on a cohort of  │        │ │
│ │                                        │ 255 deep-phenotyped patients with      │        │ │
│ │                                        │ HFpEF alongside non-HFpEF controls 25. │        │ │
│ │                                        │ The demographic information and        │        │ │
│ │                                        │ clinical characteristics of the study  │        │ │
│ │                                        │ subjects are reported previously in    │        │ │
│ │                                        │ detail 25. The mass spectrometry-based │        │ │
│ │                                        │ metabolomics profile covered nearly    │        │ │
│ │                                        │ 200 primary metabolite species,        │        │ │
│ │                                        │ including all amino acids and          │        │ │
│ │                                        │ carbohydrate derivatives, 375 species  │        │ │
│ │                                        │ of biogenic amines, and approximately  │        │ │
│ │                                        │ 500 lipid species. We performed a      │        │ │
│ │                                        │ systems-based analysis of these        │        │ │
│ │                                        │ metabolites in association with the    │        │ │
│ │                                        │ clinical outcome (Figure 1A). Based on │        │ │
│ │                                        │ co-expression patterns among the       │        │ │
│ │                                        │ cohorts, the metabolites were          │        │ │
│ │                                        │ clustered into different modules using │        │ │
│ │                                        │ unsupervised clustering method (see    │        │ │
│ │                                        │ Methods for details). Further          │        │ │
│ │                                        │ correlation analysis was performed     │        │ │
│ │                                        │ using principal component from each    │        │ │
│ │                                        │ module against key clinical            │        │ │
│ │                                        │ parameters, including metabolic        │        │ │
│ │                                        │ indices (body mass index, fasting      │        │ │
│ │                                        │ glucose level, and history of          │        │ │
│ │                                        │ diabetes), cardiovascular indices      │        │ │
│ │                                        │ (blood pressure, heart rate,           │        │ │
│ │                                        │ hypertension, and pro-BNP level),      │        │ │
│ │                                        │ kidney function indices (BUN, GFR, and │        │ │
│ │                                        │ CKD), and death outcomes (Figure 1B).  │        │ │
│ │                                        │ Among the different metabolite         │        │ │
│ │                                        │ modules, the Module Yellow showed the  │        │ │
│ │                                        │ most significant and highest number of │        │ │
│ │                                        │ correlations with detrimental clinical │        │ │
│ │                                        │ features, including early death,       │        │ │
│ │                                        │ abnormal diastolic blood pressure,     │        │ │
│ │                                        │ diabetes, obesity and kidney diseases  │        │ │
│ │                                        │ (Figure 1C). Further examination of    │        │ │
│ │                                        │ the metabolite components within the   │        │ │
│ │                                        │ Module Yellow revealed glucose- and    │        │ │
│ │                                        │ gluconeogenesis-related metabolites,   │        │ │
│ │                                        │ as well as a number of amino acids,    │        │ │
│ │                                        │ including all members of the           │        │ │
│ │                                        │ branched-chain amino acids (BCAAs):    │        │ │
│ │                                        │ valine, leucine and isoleucine (Figure │        │ │
│ │                                        │ 1D). This observation is in line with  │        │ │
│ │                                        │ findings of an earlier report of       │        │ │
│ │                                        │ metabolomics analysis from an          │        │ │
│ │                                        │ independent cohort of HFpEF patients   │        │ │
│ │                                        │ in which abnormal serum BCAA levels    │        │ │
│ │                                        │ were also detected comparing with      │        │ │
│ │                                        │ those of non-HFpEF patients 30,        │        │ │
│ │                                        │ highlighting that abnormal BCAA level  │        │ │
│ │                                        │ is a metabolic hallmark of HFpEF       │        │ │
│ │                                        │ disease progression in human patients. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BCAA catabolic pathway in HFpEF     │        │ │
│ │                                        │ progression                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To further establish the correlation   │        │ │
│ │                                        │ between BCAA catabolic changes and     │        │ │
│ │                                        │ HFpEF, we investigated the changes in  │        │ │
│ │                                        │ BCAA levels throughout the progression │        │ │
│ │                                        │ of HFpEF using a well-established      │        │ │
│ │                                        │ preclinical mouse model 27. Adult male │        │ │
│ │                                        │ C57BL/6 mice were administered 0.5     │        │ │
│ │                                        │ mg/ml L-NAME in their drinking water   │        │ │
│ │                                        │ and fed a $60\%$ HFD for up to 20      │        │ │
│ │                                        │ weeks. Cardiac function was assessed   │        │ │
│ │                                        │ by echocardiography, and blood samples │        │ │
│ │                                        │ were collected at different time       │        │ │
│ │                                        │ points as indicated (Figure 2A-B). As  │        │ │
│ │                                        │ reported earlier, these mice developed │        │ │
│ │                                        │ cardiac pathologies characteristic of  │        │ │
│ │                                        │ HFpEF over time, including preserved   │        │ │
│ │                                        │ ejection fraction and fraction         │        │ │
│ │                                        │ shortening (Figure 2C and S1A),        │        │ │
│ │                                        │ elevated E/e' ratio (Figure 2D) and    │        │ │
│ │                                        │ prolonged isovolumic relaxation time   │        │ │
│ │                                        │ (IVRT) as early as 8 weeks after       │        │ │
│ │                                        │ L-NAME/HFD treatment (Figure S1B),     │        │ │
│ │                                        │ along with an increasing trend in the  │        │ │
│ │                                        │ E/A ratio (Figure S1C). When assessed  │        │ │
│ │                                        │ at week 20 post induction of HFpEF,    │        │ │
│ │                                        │ these mice also exhibited significant  │        │ │
│ │                                        │ cardiac hypertrophy, pulmonary         │        │ │
│ │                                        │ congestion and exercise intolerance    │        │ │
│ │                                        │ (Figure 2E-G), as well as impaired     │        │ │
│ │                                        │ systemic glucose clearance (Figure     │        │ │
│ │                                        │ 2H). Cardiac remodeling was further    │        │ │
│ │                                        │ demonstrated by extensive cardiac      │        │ │
│ │                                        │ fibrosis based on histology and        │        │ │
│ │                                        │ Masson's trichrome staining (Figure    │        │ │
│ │                                        │ S2). At the molecular level, the HFpEF │        │ │
│ │                                        │ hearts exhibited increased expression  │        │ │
│ │                                        │ of genes related to cardiac            │        │ │
│ │                                        │ hypertrophy, inflammation and          │        │ │
│ │                                        │ fibrosis, including B-type natriuretic │        │ │
│ │                                        │ peptide (BNP), C-reactive protein      │        │ │
│ │                                        │ (CRP) and Collagen type I alpha 1      │        │ │
│ │                                        │ chain (Col1α1) (Figure S3A-C), as well │        │ │
│ │                                        │ as significantly elevated global       │        │ │
│ │                                        │ protein S-nitrosylation (Figure        │        │ │
│ │                                        │ S3D-E). These data indicate that, in   │        │ │
│ │                                        │ agreement with previous publications,  │        │ │
│ │                                        │ early signs of diastolic impairment    │        │ │
│ │                                        │ developed after a minimum of 10 weeks  │        │ │
│ │                                        │ of L-NAME/HFD treatment, which         │        │ │
│ │                                        │ progressed into profound diastolic     │        │ │
│ │                                        │ dysfunction and pathological           │        │ │
│ │                                        │ remodeling in the heart at week 20.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To cover the period of critical        │        │ │
│ │                                        │ transition during the onset and        │        │ │
│ │                                        │ progression of HFpEF, we then measured │        │ │
│ │                                        │ the levels of BCAA and BCKA in plasma  │        │ │
│ │                                        │ from the same experimental cohorts at  │        │ │
│ │                                        │ three time points, including weeks 8,  │        │ │
│ │                                        │ 11 and 13 after HFpEF induction.       │        │ │
│ │                                        │ Notably, fasting BCAA/BCKA levels were │        │ │
│ │                                        │ significantly elevated at week 13 of   │        │ │
│ │                                        │ HFpEF induction but not prior to this  │        │ │
│ │                                        │ time point (Figure S4A-F). When the    │        │ │
│ │                                        │ experiment was terminated at week 20   │        │ │
│ │                                        │ post HFpEF induction, the BCAA         │        │ │
│ │                                        │ catabolic defect was evident, as both  │        │ │
│ │                                        │ serum and intra-tissue BCAA and BCKA   │        │ │
│ │                                        │ levels were significantly elevated in  │        │ │
│ │                                        │ response to BCAA challenge, whereas    │        │ │
│ │                                        │ downstream BCAA metabolites were       │        │ │
│ │                                        │ markedly lower than those in non-HFpEF │        │ │
│ │                                        │ control mice (Figure 2I-M). These data │        │ │
│ │                                        │ suggest that BCAA catabolic defects    │        │ │
│ │                                        │ develop with the onset and progression │        │ │
│ │                                        │ of HFpEF.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To elucidate the mechanism of BCAA     │        │ │
│ │                                        │ metabolic defect in HFpEF, we          │        │ │
│ │                                        │ determined the levels of key           │        │ │
│ │                                        │ proteins/enzymes involved in BCAA      │        │ │
│ │                                        │ catabolism in the heart tissue of      │        │ │
│ │                                        │ HFpEF mice at week 20 post HFpEF       │        │ │
│ │                                        │ induction. Quantitative RT-PCR         │        │ │
│ │                                        │ analysis showed a significant increase │        │ │
│ │                                        │ in the expression of Bckdha and Bckdk  │        │ │
│ │                                        │ mRNA (Figure S4G), whereas Western     │        │ │
│ │                                        │ blot analysis revealed a significant   │        │ │
│ │                                        │ decrease in BCKDHA and PP2Cm protein   │        │ │
│ │                                        │ expression but elevated BCKDHA         │        │ │
│ │                                        │ phosphorylation in the HFpEF hearts    │        │ │
│ │                                        │ compared with that in control hearts   │        │ │
│ │                                        │ (Figure 2N-O and S4H-I). Since BCKDHA  │        │ │
│ │                                        │ phosphorylation represses BCKDH        │        │ │
│ │                                        │ activity, both molecular and metabolic │        │ │
│ │                                        │ analyses indicated a state of impaired │        │ │
│ │                                        │ BCAA catabolic flux in HFpEF hearts at │        │ │
│ │                                        │ the step of rate-limiting BCKDH        │        │ │
│ │                                        │ activity (Figure S4J).                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Global BCAA catabolic activation    │        │ │
│ │                                        │ attenuated cardiac dysfunction and     │        │ │
│ │                                        │ remodeling                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ While BCAA catabolic defect appears to │        │ │
│ │                                        │ be significantly associated with the   │        │ │
│ │                                        │ onset and progression of HFpEF, the    │        │ │
│ │                                        │ functional impact has never been       │        │ │
│ │                                        │ directly demonstrated. *To* generate a │        │ │
│ │                                        │ mouse model with increased global BCAA │        │ │
│ │                                        │ catabolic flux, we crossed             │        │ │
│ │                                        │ bckdkflox/flox mice 26 with a          │        │ │
│ │                                        │ transgenic line expressing tamoxifen   │        │ │
│ │                                        │ inducible Cre (ERT2-Cre) under a human │        │ │
│ │                                        │ ubiquitin C promoter (BCKDK-uKO)       │        │ │
│ │                                        │ (Figure S5A). Compared with            │        │ │
│ │                                        │ tamoxifen-treated control mice         │        │ │
│ │                                        │ carrying only the bckdkflox/flox       │        │ │
│ │                                        │ allele, the resulting BCKDK-uKO mice   │        │ │
│ │                                        │ presented a marked reduction in BCKDK  │        │ │
│ │                                        │ mRNA in metabolic organs after two     │        │ │
│ │                                        │ weeks of a tamoxifen-containing diet   │        │ │
│ │                                        │ (Figure S5B). As expected, the         │        │ │
│ │                                        │ phosphorylation of BCKDHA at Ser 293   │        │ │
│ │                                        │ was dramatically decreased in          │        │ │
│ │                                        │ BCKDK-uKO heart and other metabolic    │        │ │
│ │                                        │ tissues (Figure S5C-E). BCKDK-uKO mice │        │ │
│ │                                        │ exhibited gross morphology and         │        │ │
│ │                                        │ metabolic phenotypes similar to those  │        │ │
│ │                                        │ of the control group, including fat    │        │ │
│ │                                        │ mass, lean mass, body weight and       │        │ │
│ │                                        │ glucose tolerance (Figure S5F-I). We   │        │ │
│ │                                        │ assessed cardiac function using        │        │ │
│ │                                        │ echocardiography at 20-24 weeks of age │        │ │
│ │                                        │ for BCKDK-uKO and control mice, and    │        │ │
│ │                                        │ found that BCKDK-uKO mice exhibited    │        │ │
│ │                                        │ similar cardiac function to control    │        │ │
│ │                                        │ mice, including LVEF, FS, IVRT, E/e'   │        │ │
│ │                                        │ and E/A ratio (Figure S5J-N). The      │        │ │
│ │                                        │ heart failure markers Atrial           │        │ │
│ │                                        │ natriuretic peptide (ANP) and BNP,     │        │ │
│ │                                        │ along with the fibrosis markers Col1a1 │        │ │
│ │                                        │ and Col3a1, showed no significant      │        │ │
│ │                                        │ differences between the two groups     │        │ │
│ │                                        │ (Figure S5O-R). Cardiac fibrosis and   │        │ │
│ │                                        │ structure in BCKDK-uKO mice are        │        │ │
│ │                                        │ similar to those in control mice       │        │ │
│ │                                        │ (Figure S5S-T). The serum BCAA/BCKA    │        │ │
│ │                                        │ ratio was markedly lower than that in  │        │ │
│ │                                        │ control heart tissue (Figure S5U-V).   │        │ │
│ │                                        │ These findings suggest that global     │        │ │
│ │                                        │ *Bckdk* gene inactivation does not     │        │ │
│ │                                        │ alter metabolic phenotypes or cardiac  │        │ │
│ │                                        │ function, yet increases BCAA flux      │        │ │
│ │                                        │ under baseline condition.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Adult male BCKDK-uKO and control mice  │        │ │
│ │                                        │ were subsequently treated with L-NAME  │        │ │
│ │                                        │ (0.5 mg/ml) and a $60\%$ HFD for 14    │        │ │
│ │                                        │ weeks (Figure 3A). Consistent with     │        │ │
│ │                                        │ baseline findings, BCKDK deficiency    │        │ │
│ │                                        │ markedly decreased both BCKDK and      │        │ │
│ │                                        │ phosphorylated BCKDHA protein levels   │        │ │
│ │                                        │ compared to control mice (Figure 3B),  │        │ │
│ │                                        │ and the serum BCAA/BCKA levels were    │        │ │
│ │                                        │ significantly lower than that in       │        │ │
│ │                                        │ control mice (Figure 3C-D). The        │        │ │
│ │                                        │ intracardiac tissue BCAA levels were   │        │ │
│ │                                        │ markedly lower (Figure 3E), whereas    │        │ │
│ │                                        │ the cardiac BCKA levels showed a lower │        │ │
│ │                                        │ trend in the BCKDK-uKO mice than in    │        │ │
│ │                                        │ the control genotype (Figure S6A). We  │        │ │
│ │                                        │ further detected the BCKA derivative   │        │ │
│ │                                        │ metabolites, including                 │        │ │
│ │                                        │ 2-hydroxy-3-methylvaleric acid and     │        │ │
│ │                                        │ 2-hydroxyisocaproate (derived from KMV │        │ │
│ │                                        │ and KIC, respectively) and showed that │        │ │
│ │                                        │ they exhibited the same trend of       │        │ │
│ │                                        │ reduction, providing the indirect      │        │ │
│ │                                        │ support for the reduced BCKA levels in │        │ │
│ │                                        │ the BCKDK-uKO mouse hearts (Figure     │        │ │
│ │                                        │ S6B-C), validated again that global    │        │ │
│ │                                        │ inactivation of the *Bckdk* gene leads │        │ │
│ │                                        │ to increased BCAA flux.                │        │ │
│ │                                        │ Echocardiography demonstrated that the │        │ │
│ │                                        │ BCKDK-uKO mice showed a marked         │        │ │
│ │                                        │ improvement in left ventricular (LV)   │        │ │
│ │                                        │ diastolic function, as evidenced by a  │        │ │
│ │                                        │ significant reduction in the E/e'      │        │ │
│ │                                        │ ratio and IVRT, whereas the LVEF and   │        │ │
│ │                                        │ FS remained unaffected post HFpEF      │        │ │
│ │                                        │ stimulation (Figures 3F-I). In         │        │ │
│ │                                        │ addition, Bckdk inactivation did not   │        │ │
│ │                                        │ affect total body weight but           │        │ │
│ │                                        │ significantly reduced cardiac          │        │ │
│ │                                        │ hypertrophy, as demonstrated by        │        │ │
│ │                                        │ decreased heart weights (Figure 3J-L). │        │ │
│ │                                        │ The BCKDK-uKO mice showed a            │        │ │
│ │                                        │ significant reduction in the           │        │ │
│ │                                        │ expression of the Col1α1 and Col3α1    │        │ │
│ │                                        │ genes, as well as a decrease in        │        │ │
│ │                                        │ cardiac fibrosis, as determined by     │        │ │
│ │                                        │ Masson's trichrome staining (Figure    │        │ │
│ │                                        │ 3M-O). Importantly, the BCKDK-uKO mice │        │ │
│ │                                        │ displayed improved glucose clearance   │        │ │
│ │                                        │ capacity (Figure 3P-Q). These results  │        │ │
│ │                                        │ clearly indicate that enhancing BCAA   │        │ │
│ │                                        │ catabolic flux can significantly       │        │ │
│ │                                        │ ameliorate cardiac diastolic           │        │ │
│ │                                        │ dysfunction, cardiac remodeling and    │        │ │
│ │                                        │ metabolic disorder under HFpEF insult. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Enhancing BCAA catabolic activity   │        │ │
│ │                                        │ attenuates cardiac insulin resistance  │        │ │
│ │                                        │ and nitrosative injury                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BCAA catabolic defect is found to be a │        │ │
│ │                                        │ significant causal factor of insulin   │        │ │
│ │                                        │ resistance associated with obesity     │        │ │
│ │                                        │ 32-34, and diabetes/obesity are also   │        │ │
│ │                                        │ major metabolic risk factors for HFpEF │        │ │
│ │                                        │ 35. To assess the impact of BCAA       │        │ │
│ │                                        │ catabolism on cardiac insulin          │        │ │
│ │                                        │ signaling, we measured key signaling   │        │ │
│ │                                        │ pathways downstream of the insulin     │        │ │
│ │                                        │ receptor. As shown in (Figure 4A-B),   │        │ │
│ │                                        │ BCKDK-uKO hearts presented             │        │ │
│ │                                        │ significantly greater insulin-induced  │        │ │
│ │                                        │ AKT phosphorylation in cardiac tissue  │        │ │
│ │                                        │ after 14 weeks of L-NAME/HFD treatment │        │ │
│ │                                        │ than control hearts. Meanwhile, the    │        │ │
│ │                                        │ BCKDK-uKO mice presented a significant │        │ │
│ │                                        │ reduction in phosphorylated P70S6K and │        │ │
│ │                                        │ an increase in phosphorylated AMPKα in │        │ │
│ │                                        │ the heart (Figure 4C-E), supporting a  │        │ │
│ │                                        │ state of attenuated mTOR activity and  │        │ │
│ │                                        │ restored metabolic signaling.          │        │ │
│ │                                        │ Additionally, we observed a remarkable │        │ │
│ │                                        │ reduction in S-nitrosative stress      │        │ │
│ │                                        │ level in BCKDK-uKO hearts compared     │        │ │
│ │                                        │ with those in control hearts under     │        │ │
│ │                                        │ HFpEF stress (Figure 4F-G). These      │        │ │
│ │                                        │ results support the notion that        │        │ │
│ │                                        │ enhancing BCAA catabolic flux          │        │ │
│ │                                        │ ameliorated the key molecular features │        │ │
│ │                                        │ associated with HFpEF involving        │        │ │
│ │                                        │ insulin signaling and NOS signaling    │        │ │
│ │                                        │ defect, as well as nitrosative stress  │        │ │
│ │                                        │ level.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BCKDK inactivation does not affect  │        │ │
│ │                                        │ blood pressure                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Hypertension and metabolic disorders   │        │ │
│ │                                        │ are two major contributing factors to  │        │ │
│ │                                        │ the pathogenesis of HFpEF, as          │        │ │
│ │                                        │ demonstrated in clinical and           │        │ │
│ │                                        │ preclinical models 36, 37. A previous  │        │ │
│ │                                        │ study reported that systemic BCAA      │        │ │
│ │                                        │ catabolic activity is associated with  │        │ │
│ │                                        │ increased blood pressure 38, raising   │        │ │
│ │                                        │ the question of whether enhancing BCAA │        │ │
│ │                                        │ catabolic activity could provide       │        │ │
│ │                                        │ protective effects against HFpEF by    │        │ │
│ │                                        │ reducing blood pressure. To test this  │        │ │
│ │                                        │ possibility, we continuously measured  │        │ │
│ │                                        │ systemic blood pressure in conscious   │        │ │
│ │                                        │ mice using implanted telemetric probes │        │ │
│ │                                        │ as described in the Methods section    │        │ │
│ │                                        │ (Figure 5A and S7A). A comparison of   │        │ │
│ │                                        │ blood pressure before and after        │        │ │
│ │                                        │ tamoxifen treatment in BCKDK-uKO and   │        │ │
│ │                                        │ BCKDKflox/flox controls revealed no    │        │ │
│ │                                        │ differences in systolic or diastolic   │        │ │
│ │                                        │ blood pressure, mean arterial pressure │        │ │
│ │                                        │ and pulse pressure, or heart rate      │        │ │
│ │                                        │ during each circadian cycle (Figure    │        │ │
│ │                                        │ S7B-C and S7E-F and 5B-C and 5E-F and  │        │ │
│ │                                        │ 5H-I). We further evaluated the effect │        │ │
│ │                                        │ of the BCKDK inhibitor BT2 on blood    │        │ │
│ │                                        │ pressure in both BCKDK-uKO and         │        │ │
│ │                                        │ BCKDKflox/flox control mice, and no    │        │ │
│ │                                        │ changes in MAP, PP, HR, SBP and DBP    │        │ │
│ │                                        │ were observed following 2 weeks of BT2 │        │ │
│ │                                        │ treatment (Figure 5D and 5G and 5J and │        │ │
│ │                                        │ S7D and S7G). These results suggest    │        │ │
│ │                                        │ that the amelioration of HFpEF         │        │ │
│ │                                        │ pathogenesis by targeting BCKDK is     │        │ │
│ │                                        │ likely due to restored BCAA catabolic  │        │ │
│ │                                        │ flux rather than lowered blood         │        │ │
│ │                                        │ pressure.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Pharmacological inhibition of BCKDK │        │ │
│ │                                        │ boosts BCAA catabolism in HFpEF        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ *While* genetic inactivation of BCKDK  │        │ │
│ │                                        │ had a significant beneficial effect on │        │ │
│ │                                        │ the pathogenic progression of HFpEF in │        │ │
│ │                                        │ mice, the therapeutic efficacy of      │        │ │
│ │                                        │ BCKDK inhibition in established HFpEF  │        │ │
│ │                                        │ is unknown. Therefore, we investigated │        │ │
│ │                                        │ whether pharmacological inhibition of  │        │ │
│ │                                        │ BCKDK with a highly specific           │        │ │
│ │                                        │ inhibitor, BT2 39, 40, could rebalance │        │ │
│ │                                        │ BCAA catabolism and improve cardiac    │        │ │
│ │                                        │ function in HFpEF mice. In this study, │        │ │
│ │                                        │ 2-month-old male C57BL/6 mice were fed │        │ │
│ │                                        │ a HFD and L-NAME for 10 weeks and then │        │ │
│ │                                        │ randomized to receive either BT2 (40   │        │ │
│ │                                        │ mg/kg/daily oral gavage) for 4 weeks   │        │ │
│ │                                        │ as the treatment group or vehicle as   │        │ │
│ │                                        │ the placebo group (Figure 6A). Mice    │        │ │
│ │                                        │ treated with BT2 effectively inhibited │        │ │
│ │                                        │ BCKDK activity, as evidenced by        │        │ │
│ │                                        │ decreased level of phosphorylated      │        │ │
│ │                                        │ BCKDHA (Figure 6B-C). Furthermore,     │        │ │
│ │                                        │ mass-spectrum analysis showed a        │        │ │
│ │                                        │ significant decrease in BCKAs and      │        │ │
│ │                                        │ their downstream                       │        │ │
│ │                                        │ metabolites-3-hydroxyisobutyrate       │        │ │
│ │                                        │ (3-HIB) and 3-aminoisobutyric acid-    │        │ │
│ │                                        │ levels in both serum and myocardial    │        │ │
│ │                                        │ tissue in the HFpEF mice after BT2     │        │ │
│ │                                        │ treatment comparing with the vehicle   │        │ │
│ │                                        │ treated controls (Figure 6D-E and      │        │ │
│ │                                        │ S8A-D). Similar to the observation in  │        │ │
│ │                                        │ the BCKDK-uKO mice, BT2 treatment      │        │ │
│ │                                        │ significantly reduced cardiac          │        │ │
│ │                                        │ hypertrophy without affecting body     │        │ │
│ │                                        │ weight under HFpEF insult (Figure      │        │ │
│ │                                        │ 6F-G). Compared with the vehicle       │        │ │
│ │                                        │ control, BT2 treatment also tended to  │        │ │
│ │                                        │ improve glucose clearance (Figure      │        │ │
│ │                                        │ 6H-I). Taken together, these results   │        │ │
│ │                                        │ indicate that BT2 treatment can reset  │        │ │
│ │                                        │ BCAA catabolism and improve metabolic  │        │ │
│ │                                        │ remodeling in HFpEF.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## BT2 therapy reverses cardiac        │        │ │
│ │                                        │ diastolic dysfunction in HFpEF         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Cardiac function was measured prior to │        │ │
│ │                                        │ and after BT2 therapy over time        │        │ │
│ │                                        │ (Figure 7A). Notably, the              │        │ │
│ │                                        │ administration of BT2 reversed the     │        │ │
│ │                                        │ cardiac diastolic dysfunction induced  │        │ │
│ │                                        │ by L-NAME/HFD. This was demonstrated   │        │ │
│ │                                        │ by a reduced E/e' ratio and IVRT 4     │        │ │
│ │                                        │ weeks after BT2 treatment compared     │        │ │
│ │                                        │ with those of the same animal cohort   │        │ │
│ │                                        │ prior to BT2 treatment at week 10 of   │        │ │
│ │                                        │ HFpEF induction or the placebo control │        │ │
│ │                                        │ group at any time point, without       │        │ │
│ │                                        │ affecting the left ventricular         │        │ │
│ │                                        │ ejection fraction and fraction         │        │ │
│ │                                        │ shortening (Figure 7B-E and S9A). To   │        │ │
│ │                                        │ further confirm the protective effect  │        │ │
│ │                                        │ of BT2 on cardiac function, invasive   │        │ │
│ │                                        │ hemodynamic measurements were          │        │ │
│ │                                        │ performed to obtain pressure-volume    │        │ │
│ │                                        │ loop at the end of the treatment       │        │ │
│ │                                        │ protocol. As shown in Figure 7F-G, BT2 │        │ │
│ │                                        │ therapy significantly improved cardiac │        │ │
│ │                                        │ function, as evidenced by the decrease │        │ │
│ │                                        │ in tau in the BT2-treated group        │        │ │
│ │                                        │ compared with that of the              │        │ │
│ │                                        │ vehicle-treated control group. In      │        │ │
│ │                                        │ addition, BT2 treatment significantly  │        │ │
│ │                                        │ increased cardiac output (CO) and      │        │ │
│ │                                        │ improved systolic and diastolic        │        │ │
│ │                                        │ performance, as demonstrated by the    │        │ │
│ │                                        │ higher levels of dp/dtmax and dp/dtmin │        │ │
│ │                                        │ in the treatment group than in the     │        │ │
│ │                                        │ vehicle-treated controls (Figure       │        │ │
│ │                                        │ 7H-J). Additionally, we observed a     │        │ │
│ │                                        │ significant reduction in S-nitrosative │        │ │
│ │                                        │ stress level in the HFpEF hearts       │        │ │
│ │                                        │ treated with BT2 compared to the       │        │ │
│ │                                        │ vehicle-treated group (Figure S9B-C).  │        │ │
│ │                                        │ Overall, these data demonstrated that  │        │ │
│ │                                        │ BT2 therapy significantly reversed     │        │ │
│ │                                        │ cardiac dysfunction in established     │        │ │
│ │                                        │ HFpEF.                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Discussion                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In this study, metabolomics analysis   │        │ │
│ │                                        │ of both a patient cohort and a mouse   │        │ │
│ │                                        │ model of HFpEF revealed that impaired  │        │ │
│ │                                        │ BCAA catabolism is a key pathogenic    │        │ │
│ │                                        │ feature of HFpEF. Based on             │        │ │
│ │                                        │ histological and functional analyses   │        │ │
│ │                                        │ in the HFpEF mouse model, inhibition   │        │ │
│ │                                        │ of BCKDK genetically or                │        │ │
│ │                                        │ pharmacologically demonstrates potent  │        │ │
│ │                                        │ therapeutic efficacy against metabolic │        │ │
│ │                                        │ and fibrotic remodeling, leading to    │        │ │
│ │                                        │ improved diastolic function in HFpEF.  │        │ │
│ │                                        │ Mechanistically, this improvement is   │        │ │
│ │                                        │ linked to enhanced cardiac insulin     │        │ │
│ │                                        │ signaling and reduced NOS injury, with │        │ │
│ │                                        │ no observed effect on blood pressure.  │        │ │
│ │                                        │ These findings support the notion that │        │ │
│ │                                        │ impaired BCAA catabolism is a major    │        │ │
│ │                                        │ pathogenic feature of HFpEF and a      │        │ │
│ │                                        │ promising therapeutic target for this  │        │ │
│ │                                        │ disease.                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ HFpEF represents a significant unmet   │        │ │
│ │                                        │ medical need and is often associated   │        │ │
│ │                                        │ with notable metabolic dysfunctions,   │        │ │
│ │                                        │ such as insulin resistance and         │        │ │
│ │                                        │ lipotoxicity 41. In HFpEF, the heart   │        │ │
│ │                                        │ is characterized by energetic defects  │        │ │
│ │                                        │ with an increased cellular pool of     │        │ │
│ │                                        │ FA-derived acetyl-CoA that promotes    │        │ │
│ │                                        │ protein acetylation, reduces glucose   │        │ │
│ │                                        │ metabolism, and enhances fatty acid    │        │ │
│ │                                        │ oxidation (FAO) 42. Moreover, amino    │        │ │
│ │                                        │ acids, which serve as both important   │        │ │
│ │                                        │ nutrients and potent signaling         │        │ │
│ │                                        │ molecules, can also exert significant  │        │ │
│ │                                        │ effects on glucose and lipid           │        │ │
│ │                                        │ metabolism to maintain cardiac         │        │ │
│ │                                        │ function 43, 44. The BCAAs—isoleucine, │        │ │
│ │                                        │ leucine, and valine—are essential in   │        │ │
│ │                                        │ protein synthesis and play a key role  │        │ │
│ │                                        │ in regulating metabolic health 45-47.  │        │ │
│ │                                        │ A previous study revealed that         │        │ │
│ │                                        │ impaired BCAA catabolism contributes   │        │ │
│ │                                        │ to the progression of HFrEF 17, 21. A  │        │ │
│ │                                        │ clinical study from the PRESERVED-HF   │        │ │
│ │                                        │ trial also confirmed that abnormal     │        │ │
│ │                                        │ serum BCAA levels were associated with │        │ │
│ │                                        │ HFpEF disease severity 48. In this     │        │ │
│ │                                        │ study, we analyzed BCAA levels and     │        │ │
│ │                                        │ related metabolites at different time  │        │ │
│ │                                        │ points during the progression of HFpEF │        │ │
│ │                                        │ in a mouse model. Both the serum and   │        │ │
│ │                                        │ cardiac levels of BCAAs and BCKAs are  │        │ │
│ │                                        │ significantly increased, whereas       │        │ │
│ │                                        │ downstream metabolites are decreased   │        │ │
│ │                                        │ longitudinally in association with the │        │ │
│ │                                        │ progression of HFpEF phenotypes.       │        │ │
│ │                                        │ Consistent with the changes in BCAA    │        │ │
│ │                                        │ metabolism, there was a significant    │        │ │
│ │                                        │ increase in the ratio of p-BCKDHA (Ser │        │ │
│ │                                        │ 293) to BCKDHA, indicating an impaired │        │ │
│ │                                        │ BCAA catabolic pathway. Therefore,     │        │ │
│ │                                        │ both clinical and preclinical studies  │        │ │
│ │                                        │ suggest that BCAA catabolic defects    │        │ │
│ │                                        │ are associated with HFpEF progression  │        │ │
│ │                                        │ and may serve as a target for          │        │ │
│ │                                        │ therapeutic intervention.              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Previous studies have demonstrated     │        │ │
│ │                                        │ that systemic activation of BCAA       │        │ │
│ │                                        │ oxidation with BT2 can improve HFrEF   │        │ │
│ │                                        │ induced by pressure overload or        │        │ │
│ │                                        │ ischemic injury 28, 49. BT2 is         │        │ │
│ │                                        │ recognized as a highly specific BCKDK  │        │ │
│ │                                        │ inhibitor, which underlies its         │        │ │
│ │                                        │ therapeutic effect on insulin          │        │ │
│ │                                        │ resistance and heart failure 50, 51.   │        │ │
│ │                                        │ However, there is evidence suggesting  │        │ │
│ │                                        │ that BT2 may have potential            │        │ │
│ │                                        │ "off-target" effects, such as          │        │ │
│ │                                        │ promoting tryptophan catabolism 39. In │        │ │
│ │                                        │ our current study, we employed global  │        │ │
│ │                                        │ Bckdk knockout mice to clarify whether │        │ │
│ │                                        │ the effect of BT2 on HFpEF             │        │ │
│ │                                        │ pathogenesis is on-target. Indeed, we  │        │ │
│ │                                        │ found that genetic knockout of Bckdk   │        │ │
│ │                                        │ can significantly improve diastolic    │        │ │
│ │                                        │ function, heart weight, and insulin    │        │ │
│ │                                        │ resistance and reduce cardiac          │        │ │
│ │                                        │ fibrosis, which is associated with a   │        │ │
│ │                                        │ significant increase in BCAA           │        │ │
│ │                                        │ oxidation. These findings indicate     │        │ │
│ │                                        │ that the cardioprotective effect of    │        │ │
│ │                                        │ BT2 in HFpEF likely also results from  │        │ │
│ │                                        │ its inhibition of BCKDK activity and   │        │ │
│ │                                        │ subsequent enhancement of BCAA         │        │ │
│ │                                        │ catabolism.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Mechanistically, we found that         │        │ │
│ │                                        │ increasing the oxidation of BCAAs      │        │ │
│ │                                        │ provides cardioprotective benefits     │        │ │
│ │                                        │ against HFpEF associated with improved │        │ │
│ │                                        │ insulin resistance without affecting   │        │ │
│ │                                        │ blood pressure. Clinical studies have  │        │ │
│ │                                        │ shown that diabetes is linked to a     │        │ │
│ │                                        │ worse clinical prognosis and a greater │        │ │
│ │                                        │ risk of adverse cardiovascular events  │        │ │
│ │                                        │ in HFpEF patients 52, 53. Metabolomics │        │ │
│ │                                        │ studies in HFrEF have indicated that   │        │ │
│ │                                        │ higher cardiac levels of BCAAs are     │        │ │
│ │                                        │ associated with increased cardiac      │        │ │
│ │                                        │ insulin resistance and reduced cardiac │        │ │
│ │                                        │ function 54, 55. Our previous study    │        │ │
│ │                                        │ demonstrated that reducing insulin     │        │ │
│ │                                        │ resistance with a glucagon receptor    │        │ │
│ │                                        │ antagonist improves cardiac diastolic  │        │ │
│ │                                        │ function across different HFpEF models │        │ │
│ │                                        │ 56. Our results from the current study │        │ │
│ │                                        │ also indicate that genetic inhibition  │        │ │
│ │                                        │ of Bckdk leads to increased            │        │ │
│ │                                        │ phosphorylation of AKT                 │        │ │
│ │                                        │ serine/threonine kinase 1 in response  │        │ │
│ │                                        │ to insulin stimulation. Moreover, we   │        │ │
│ │                                        │ observed a notable reduction in        │        │ │
│ │                                        │ nitrosative stress levels in global    │        │ │
│ │                                        │ Bckdk knockout mice with HFpEF,        │        │ │
│ │                                        │ indicating the molecular downstream    │        │ │
│ │                                        │ effects of BCAA catabolic activity on  │        │ │
│ │                                        │ insulin signaling and NOS regulation.  │        │ │
│ │                                        │ Hypertension is a notable comorbidity  │        │ │
│ │                                        │ of HFpEF 57. In this setting,          │        │ │
│ │                                        │ dapagliflozin has demonstrated         │        │ │
│ │                                        │ benefits by improving left ventricular │        │ │
│ │                                        │ remodeling and reducing aortic         │        │ │
│ │                                        │ sympathetic tone in a pig model of     │        │ │
│ │                                        │ HFpEF 58. Pharmacological activation   │        │ │
│ │                                        │ of BCAA oxidation has been shown to    │        │ │
│ │                                        │ lower blood pressure in a previous     │        │ │
│ │                                        │ report 38. However, when we used a     │        │ │
│ │                                        │ sensitive implanted telemetry method,  │        │ │
│ │                                        │ we did not observe any notable changes │        │ │
│ │                                        │ in systemic blood pressure caused by   │        │ │
│ │                                        │ either genetic or pharmacological      │        │ │
│ │                                        │ inhibition of BCKDK activity in mice.  │        │ │
│ │                                        │ Therefore, insulin sensitivity and NOS │        │ │
│ │                                        │ signaling are likely crucial           │        │ │
│ │                                        │ downstream mechanisms underlying the   │        │ │
│ │                                        │ pathogenic and cardioprotective        │        │ │
│ │                                        │ effects of BCAA catabolism. As         │        │ │
│ │                                        │ numerous signaling effects of BCAAs,   │        │ │
│ │                                        │ including mTOR and autophagy, have     │        │ │
│ │                                        │ been reported, more studies are needed │        │ │
│ │                                        │ to establish the specific molecular    │        │ │
│ │                                        │ processes linking BCAA catabolism and  │        │ │
│ │                                        │ HFpEF pathologies in the heart.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In this study, both pharmacological    │        │ │
│ │                                        │ and genetic inhibition of BCKDK        │        │ │
│ │                                        │ activity affected global BCAA          │        │ │
│ │                                        │ catabolic activities across different  │        │ │
│ │                                        │ organs. In our previous studies,       │        │ │
│ │                                        │ cardiomyocyte-specific inhibition of   │        │ │
│ │                                        │ bckdk failed to confer                 │        │ │
│ │                                        │ cardio-protection against HFrEF 26,    │        │ │
│ │                                        │ supporting the potential contribution  │        │ │
│ │                                        │ of the systemic effect of BCAA         │        │ │
│ │                                        │ catabolism on HFpEF pathogenesis.      │        │ │
│ │                                        │ While the focus of the current study   │        │ │
│ │                                        │ was systemic modulation of BCAA, the   │        │ │
│ │                                        │ role of BCAA catabolism in             │        │ │
│ │                                        │ cardiomyocytes or other organs, such   │        │ │
│ │                                        │ as the liver, skeletal muscle, and     │        │ │
│ │                                        │ adipose tissue, still requires further │        │ │
│ │                                        │ investigation. Even in the heart, the  │        │ │
│ │                                        │ crucial mechanism underlying the       │        │ │
│ │                                        │ effects of BCAA oxidation in various   │        │ │
│ │                                        │ cell types in addition to myocytes,    │        │ │
│ │                                        │ such as fibroblasts, endothelial       │        │ │
│ │                                        │ cells, and macrophages, still remains  │        │ │
│ │                                        │ to be clarified. Importantly, systemic │        │ │
│ │                                        │ treatment with BCKDK inhibitors is     │        │ │
│ │                                        │ currently undergoing clinical study    │        │ │
│ │                                        │ for HFpEF 59, 60. The present study is │        │ │
│ │                                        │ the first proof-of-concept             │        │ │
│ │                                        │ demonstration of targeted BCAA         │        │ │
│ │                                        │ catabolism therapy and a model system  │        │ │
│ │                                        │ for future studies focusing on the     │        │ │
│ │                                        │ mechanism of action.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Author Contributions                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Y.W, C.G, Y.X-L and M.W designed the   │        │ │
│ │                                        │ study, drafted the manuscript and      │        │ │
│ │                                        │ secured funding. M.W and Y.X-L         │        │ │
│ │                                        │ conducted the experiments and analyzed │        │ │
│ │                                        │ the data. G.L-C drafted the manuscript │        │ │
│ │                                        │ and assisted with study design. Z.L,   │        │ │
│ │                                        │ X.S-R, J.Y-Z, N.M, X.W-Z, Y.K-W,       │        │ │
│ │                                        │ M.T-J, Z.P-L, H.P-S, C.D-R and S.J-S   │        │ │
│ │                                        │ assisted with study design and         │        │ │
│ │                                        │ performed a series of experiments. All │        │ │
│ │                                        │ authors have read and approved the     │        │ │
│ │                                        │ final version of the manuscript.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. Borlaug BA. **The pathophysiology   │        │ │
│ │                                        │ of heart failure with preserved        │        │ │
│ │                                        │ ejection fraction**. *Nat Rev Cardiol* │        │ │
│ │                                        │ (2014.0) **11** 507-15. PMID: 24958077 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. Redfield MM, Borlaug BA. **Heart    │        │ │
│ │                                        │ Failure with Preserved Ejection        │        │ │
│ │                                        │ Fraction: A Review**. *JAMA* (2023.0)  │        │ │
│ │                                        │ **329** 827-838. PMID: 36917048        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Omote K, Verbrugge FH, Borlaug BA.  │        │ │
│ │                                        │ **Heart Failure with Preserved         │        │ │
│ │                                        │ Ejection Fraction: Mechanisms and      │        │ │
│ │                                        │ Treatment Strategies**. *Annu Rev Med* │        │ │
│ │                                        │ (2022.0) **27** 73                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Ketema E, Lopaschuk GD. **The       │        │ │
│ │                                        │ impact of obesity on cardiac energy    │        │ │
│ │                                        │ metabolism and efficiency in heart     │        │ │
│ │                                        │ failure with preserved ejection        │        │ │
│ │                                        │ fraction**. *Can J Cardiol* (2025.0)   │        │ │
│ │                                        │ **30** S0828-282X                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Sun Q, Karwi QG, Wong N, Lopaschuk  │        │ │
│ │                                        │ GD. **Advances in myocardial energy    │        │ │
│ │                                        │ metabolism: metabolic remodelling in   │        │ │
│ │                                        │ heart failure and beyond**.            │        │ │
│ │                                        │ *Cardiovasc Res* (2024.0) **120**      │        │ │
│ │                                        │ 1996-2016. PMID: 39453987              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Arnold SV, Silverman DN, Gosch K,   │        │ │
│ │                                        │ Nassif ME, Infeld M, Litwin S.         │        │ │
│ │                                        │ **Beta-Blocker Use and Heart Failure   │        │ │
│ │                                        │ Outcomes in Mildly Reduced and         │        │ │
│ │                                        │ Preserved Ejection Fraction**. *JACC   │        │ │
│ │                                        │ Heart Fail* (2023.0) **11** 893-900.   │        │ │
│ │                                        │ PMID: 37140513                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. Pitt B, Pfeffer MA, Assmann SF,     │        │ │
│ │                                        │ Boineau R, Anand IS, Claggett B.       │        │ │
│ │                                        │ **Spironolactone for heart failure     │        │ │
│ │                                        │ with preserved ejection fraction**. *N │        │ │
│ │                                        │ Engl J Med* (2014.0) **370**           │        │ │
│ │                                        │ 1383-1392. PMID: 24716680              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Solomon SD, McMurray JJV, Anand IS, │        │ │
│ │                                        │ Ge J, Lam CSP, Maggioni AP.            │        │ │
│ │                                        │ **Angiotensin-Neprilysin Inhibition in │        │ │
│ │                                        │ Heart Failure with Preserved Ejection  │        │ │
│ │                                        │ Fraction**. *N Engl J Med* (2019.0)    │        │ │
│ │                                        │ **381** 1609-1620. PMID: 31475794      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Ledwidge M, Dodd JD, Ryan F,        │        │ │
│ │                                        │ Sweeney C, McDonald K, Fox R. **Effect │        │ │
│ │                                        │ of Sacubitril/ Valsartan vs Valsartan  │        │ │
│ │                                        │ on Left Atrial Volume in Patients with │        │ │
│ │                                        │ Pre-Heart Failure with Preserved       │        │ │
│ │                                        │ Ejection Fraction: The PARABLE         │        │ │
│ │                                        │ Randomized Clinical Trial**. *JAMA     │        │ │
│ │                                        │ Cardiol* (2023.0) **8** 366-375. PMID: │        │ │
│ │                                        │ 36884247                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Anker SD, Butler J, Filippatos G,  │        │ │
│ │                                        │ Ferreira JP, Bocchi E, Böhm M.         │        │ │
│ │                                        │ **Empagliflozin in Heart Failure with  │        │ │
│ │                                        │ a Preserved Ejection Fraction**. *N    │        │ │
│ │                                        │ Engl J Med* (2021.0) **385**           │        │ │
│ │                                        │ 1451-1461. PMID: 34449189              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Butler J, Shah SJ, Petrie MC,      │        │ │
│ │                                        │ Borlaug BA, Abildstrøm SZ, Davies MJ.  │        │ │
│ │                                        │ **Semaglutide versus placebo in people │        │ │
│ │                                        │ with obesity-related heart failure     │        │ │
│ │                                        │ with preserved ejection fraction: a    │        │ │
│ │                                        │ pooled analysis of the STEP-HFpEF and  │        │ │
│ │                                        │ STEP-HFpEF DM randomised trials**.     │        │ │
│ │                                        │ *Lancet* (2024.0) **403** 1635-1648.   │        │ │
│ │                                        │ PMID: 38599221                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Tada A, Burkhoff D, Naser JA,      │        │ │
│ │                                        │ Harada T, Pourmussa B, Reddy YNV.      │        │ │
│ │                                        │ **Dapagliflozin Enhances Arterial and  │        │ │
│ │                                        │ Venous Compliance During Exercise in   │        │ │
│ │                                        │ Heart Failure with Preserved Ejection  │        │ │
│ │                                        │ Fraction: Insights From the CAMEO-DAPA │        │ │
│ │                                        │ Trial**. *Circulation* (2024.0)        │        │ │
│ │                                        │ **150** 997-1009. PMID: 39101201       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Bonfioli GB, Rodella L, Metra M,   │        │ │
│ │                                        │ Vizzardi E. **GLP-1 receptor agonists  │        │ │
│ │                                        │ as promising anti-inflammatory agents  │        │ │
│ │                                        │ in heart failure with preserved        │        │ │
│ │                                        │ ejection fraction**. *Heart Fail Rev*  │        │ │
│ │                                        │ (2025.0) **30** 131-136. PMID:         │        │ │
│ │                                        │ 39425816                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Davies MJ, van der Meer P, Verma   │        │ │
│ │                                        │ S, Patel S, Chinnakondepalli KM,       │        │ │
│ │                                        │ Borlaug BA. **Semaglutide in           │        │ │
│ │                                        │ obesity-related heart failure with     │        │ │
│ │                                        │ preserved ejection fraction and type 2 │        │ │
│ │                                        │ diabetes across baseline HbA(1c)       │        │ │
│ │                                        │ levels (STEP-HFpEF DM): a prespecified │        │ │
│ │                                        │ analysis of heart failure and          │        │ │
│ │                                        │ metabolic outcomes from a randomised,  │        │ │
│ │                                        │ placebo-controlled trial**. *Lancet    │        │ │
│ │                                        │ Diabetes Endocrinol* (2025.0) **20**   │        │ │
│ │                                        │ S2213-8587                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Packer M, Zannad F, Anker SD.      │        │ │
│ │                                        │ **Heart Failure and a Preserved        │        │ │
│ │                                        │ Ejection Fraction: A Side-by-Side      │        │ │
│ │                                        │ Examination of the PARAGON-HF and      │        │ │
│ │                                        │ EMPEROR-Preserved Trials**.            │        │ │
│ │                                        │ *Circulation* (2021.0) **144**         │        │ │
│ │                                        │ 1193-1195. PMID: 34459212              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Neinast M, Murashige D, Arany Z.   │        │ │
│ │                                        │ **Branched Chain Amino Acids**. *Annu  │        │ │
│ │                                        │ Rev Physiol* (2019.0) **81** 139-164.  │        │ │
│ │                                        │ PMID: 30485760                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. Sun H, Olson KC, Gao C, Prosdocimo │        │ │
│ │                                        │ DA, Zhou M, Wang Z. **Catabolic Defect │        │ │
│ │                                        │ of Branched-Chain Amino Acids Promotes │        │ │
│ │                                        │ Heart Failure**. *Circulation*         │        │ │
│ │                                        │ (2016.0) **133** 2038-49. PMID:        │        │ │
│ │                                        │ 27059949                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Wang W, Zhang F, Xia Y, Zhao S,    │        │ │
│ │                                        │ Yan W, Wang H. **Defective branched    │        │ │
│ │                                        │ chain amino acid catabolism            │        │ │
│ │                                        │ contributes to cardiac dysfunction and │        │ │
│ │                                        │ remodeling following myocardial        │        │ │
│ │                                        │ infarction**. *Am J Physiol Heart Circ │        │ │
│ │                                        │ Physiol* (2016.0) **311** H1160-H1169. │        │ │
│ │                                        │ PMID: 27542406                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Li Z, Xia H, Sharp TE 3rd, LaPenna │        │ │
│ │                                        │ KB, Elrod JW, Casin KM.                │        │ │
│ │                                        │ **Mitochondrial HS Regulates BCAA      │        │ │
│ │                                        │ Catabolism in Heart Failure**. *Circ   │        │ │
│ │                                        │ Res* (2022.0) **131** 222-235. PMID:   │        │ │
│ │                                        │ 35701874                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. Gibb AA, Murray EK, Eaton DM,      │        │ │
│ │                                        │ Huynh AT, Tomar D, Garbincius JF.      │        │ │
│ │                                        │ **Molecular Signature of HFpEF:        │        │ │
│ │                                        │ Systems Biology in a Cardiac-Centric   │        │ │
│ │                                        │ Large Animal Model**. *JACC Basic      │        │ │
│ │                                        │ Transl Sci* (2021.0) **6** 650-672.    │        │ │
│ │                                        │ PMID: 34466752                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Hahn VS, Petucci C, Kim MS, Bedi   │        │ │
│ │                                        │ KC Jr, Wang H, Mishra S. **Myocardial  │        │ │
│ │                                        │ Metabolomics of Human Heart Failure    │        │ │
│ │                                        │ with Preserved Ejection Fraction**.    │        │ │
│ │                                        │ *Circulation* (2023.0) **147**         │        │ │
│ │                                        │ 1147-1161. PMID: 36856044              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. Hutson SM, Wallin R, Hall TR.      │        │ │
│ │                                        │ **Identification of mitochondrial      │        │ │
│ │                                        │ branched chain aminotransferase and    │        │ │
│ │                                        │ its isoforms in rat tissues**. *J Biol │        │ │
│ │                                        │ Chem* (1992.0) **267** 15681-6. PMID:  │        │ │
│ │                                        │ 1639805                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Harris RA, Hawes JW, Popov KM,     │        │ │
│ │                                        │ Zhao Y, Shimomura Y, Sato J. **Studies │        │ │
│ │                                        │ on the regulation of the mitochondrial │        │ │
│ │                                        │ alpha-ketoacid dehydrogenase complexes │        │ │
│ │                                        │ and their kinases**. *Adv Enzyme       │        │ │
│ │                                        │ Regul* (1997.0) **37** 271-93. PMID:   │        │ │
│ │                                        │ 9381974                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Joshi M, Jeoung NH, Popov KM,      │        │ │
│ │                                        │ Harris RA. **Identification of a novel │        │ │
│ │                                        │ PP2C-type mitochondrial phosphatase**. │        │ │
│ │                                        │ *Biochem Biophys Res Commun* (2007.0)  │        │ │
│ │                                        │ **356** 38-44. PMID: 17336929          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Culler KL, Sinha A, Filipp M, Giro │        │ │
│ │                                        │ P, Allen NB, Taylor KD. **Metabolomic  │        │ │
│ │                                        │ profiling identifies novel metabolites │        │ │
│ │                                        │ associated with cardiac dysfunction**. │        │ │
│ │                                        │ *Sci Rep* (2024.0) **14** 20694. PMID: │        │ │
│ │                                        │ 39237673                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Yu JY, Cao N, Rau CD, Lee RP, Yang │        │ │
│ │                                        │ J, Flach RJR. **Cell-autonomous effect │        │ │
│ │                                        │ of cardiomyocyte branched-chain amino  │        │ │
│ │                                        │ acid catabolism in heart failure in    │        │ │
│ │                                        │ mice**. *Acta Pharmacol Sin* (2023.0)  │        │ │
│ │                                        │ **44** 1380-1390. PMID: 36991098       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. Schiattarella GG, Altamirano F,    │        │ │
│ │                                        │ Tong D, French KM, Villalobos E, Kim   │        │ │
│ │                                        │ SY. **Nitrosative stress drives heart  │        │ │
│ │                                        │ failure with preserved ejection        │        │ │
│ │                                        │ fraction**. *Nature* (2019.0) **568**  │        │ │
│ │                                        │ 351-356. PMID: 30971818                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Chen M, Gao C, Yu J, Ren S, Wang   │        │ │
│ │                                        │ M, Wynn RM. **Therapeutic Effect of    │        │ │
│ │                                        │ Targeting Branched-Chain Amino Acid    │        │ │
│ │                                        │ Catabolic Flux in Pressure-Overload    │        │ │
│ │                                        │ Induced Heart Failure**. *J Am Heart   │        │ │
│ │                                        │ Assoc* (2019.0) **8** e011625. PMID:   │        │ │
│ │                                        │ 31433721                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Takimoto E, Champion HC, Li M, Ren │        │ │
│ │                                        │ S, Rodriguez ER, Tavazzi B. **Oxidant  │        │ │
│ │                                        │ stress from nitric oxide synthase-3    │        │ │
│ │                                        │ uncoupling stimulates cardiac          │        │ │
│ │                                        │ pathologic remodeling from chronic     │        │ │
│ │                                        │ pressure load**. *J Clin Invest*       │        │ │
│ │                                        │ (2005.0) **115** 1221-31. PMID:        │        │ │
│ │                                        │ 15841206                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Naeem F, Leone TC, Petucci C,      │        │ │
│ │                                        │ Shoffler C. **Targeted Quantitative    │        │ │
│ │                                        │ Plasma Metabolomics Identifies         │        │ │
│ │                                        │ Metabolite Signatures that Distinguish │        │ │
│ │                                        │ Heart Failure with Reduced and         │        │ │
│ │                                        │ Preserved Ejection Fraction**.         │        │ │
│ │                                        │ *medRxiv* (2024.0)                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Ni W, Jiang R, Xu D, Zhu J, Chen   │        │ │
│ │                                        │ J, Lin Y. **Association between        │        │ │
│ │                                        │ insulin resistance indices and         │        │ │
│ │                                        │ outcomes in patients with heart        │        │ │
│ │                                        │ failure with preserved ejection        │        │ │
│ │                                        │ fraction**. *Cardiovasc Diabetol*      │        │ │
│ │                                        │ (2025.0) **24** 32. PMID: 39844150     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Zhou M, Shao J, Wu CY, Shu L, Dong │        │ │
│ │                                        │ W, Liu Y. **Targeting BCAA Catabolism  │        │ │
│ │                                        │ to Treat Obesity-Associated Insulin    │        │ │
│ │                                        │ Resistance**. *Diabetes* (2019.0)      │        │ │
│ │                                        │ **68** 1730-1746. PMID: 31167878       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Shah H, Gannaban RB, Haque ZF,     │        │ │
│ │                                        │ Dehghani F, Kramer A, Bowers F.        │        │ │
│ │                                        │ **BCAAs acutely drive glucose          │        │ │
│ │                                        │ dysregulation and insulin              │        │ │
│ │                                        │ resistance:role of AgRP neurons**.     │        │ │
│ │                                        │ *Nutr Diabetes* (2024.0) **14** 40.    │        │ │
│ │                                        │ PMID: 38844453                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 34. Uddin GM, Zhang L, Shah S,         │        │ │
│ │                                        │ Fukushima A, Wagg CS, Gopal K.         │        │ │
│ │                                        │ **Impaired branched chain amino acid   │        │ │
│ │                                        │ oxidation contributes to cardiac       │        │ │
│ │                                        │ insulin resistance in heart failure**. │        │ │
│ │                                        │ *Cardiovasc Diabetol* (2019.0) **18**  │        │ │
│ │                                        │ 86. PMID: 31277657                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 35. Kaze AD, Bertoni AG, Fox ER, Hall  │        │ │
│ │                                        │ ME, Mentz RJ, Berry JD. **Diabetes,    │        │ │
│ │                                        │ Subclinical Myocardial Injury or       │        │ │
│ │                                        │ Stress and Risk of Heart Failure       │        │ │
│ │                                        │ Subtypes: The Jackson Heart Study**.   │        │ │
│ │                                        │ *Diabetes Care. 2025: dc240654*        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 36. Agrawal V, Kropski JA, Gokey JJ,   │        │ │
│ │                                        │ Kobeck E, Murphy MB, Murray KT.        │        │ │
│ │                                        │ **Myeloid Cell Derived IL1β            │        │ │
│ │                                        │ Contributes to Pulmonary Hypertension  │        │ │
│ │                                        │ in HFpEF**. *Circ Res* (2023.0)        │        │ │
│ │                                        │ **133** 885-898. PMID: 37929582        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 37. Ghio S, Raineri C, Scelsi L,       │        │ │
│ │                                        │ Ašanin M, Polovina M, Seferovic P.     │        │ │
│ │                                        │ **Pulmonary hypertension and right     │        │ │
│ │                                        │ ventricular remodeling in HFpEF and    │        │ │
│ │                                        │ HFrEF**. *Heart Fail Rev* (2020.0)     │        │ │
│ │                                        │ **25** 85-91. PMID: 31197562           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 38. Murashige D, Jung JW, Neinast MD,  │        │ │
│ │                                        │ Levin MG, Chu Q, Lambert JP.           │        │ │
│ │                                        │ **Extra-cardiac BCAA catabolism lowers │        │ │
│ │                                        │ blood pressure and protects from heart │        │ │
│ │                                        │ failure**. *Cell Metab* (2022.0)       │        │ │
│ │                                        │ **34** 1749-1764.e1747. PMID: 36223763 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 39. Roth Flach RJ, Bollinger E, Reyes  │        │ │
│ │                                        │ AR, Laforest B, Kormos BL, Liu S.      │        │ │
│ │                                        │ **Small molecule branched-chain        │        │ │
│ │                                        │ ketoacid dehydrogenase kinase (BDK)    │        │ │
│ │                                        │ inhibitors with opposing effects on    │        │ │
│ │                                        │ BDK protein levels**. *Nat Commun*     │        │ │
│ │                                        │ (2023.0) **14** 4812. PMID: 37558654   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 40. Nishi K, Yoshii A, Abell L, Zhou   │        │ │
│ │                                        │ B, Frausto R, Ritterhoff J.            │        │ │
│ │                                        │ **Branched-chain keto acids inhibit    │        │ │
│ │                                        │ mitochondrial pyruvate carrier and     │        │ │
│ │                                        │ suppress gluconeogenesis in            │        │ │
│ │                                        │ hepatocytes**. *Cell Rep* (2023.0)     │        │ │
│ │                                        │ **42** 112641. PMID: 37310861          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 41. Campbell P, Rutten FH, Lee MM,     │        │ │
│ │                                        │ Hawkins NM, Petrie MC. **Heart failure │        │ │
│ │                                        │ with preserved ejection fraction:      │        │ │
│ │                                        │ everything the clinician needs to      │        │ │
│ │                                        │ know**. *Lancet* (2024.0) **403**      │        │ │
│ │                                        │ 1083-1092. PMID: 38367642              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 42. Capone F, Sotomayor-Flores C, Bode │        │ │
│ │                                        │ D, Wang R, Rodolico D, Strocchi S.     │        │ │
│ │                                        │ **Cardiac metabolism in HFpEF: from    │        │ │
│ │                                        │ fuel to signalling**. *Cardiovasc Res* │        │ │
│ │                                        │ (2023.0) **118** 3556-3575. PMID:      │        │ │
│ │                                        │ 36504368                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 43. Zakaria NF, Hamid M, Khayat ME.    │        │ │
│ │                                        │ **Amino Acid-Induced Impairment of     │        │ │
│ │                                        │ Insulin Signaling and Involvement of   │        │ │
│ │                                        │ G-Protein Coupling Receptor**.         │        │ │
│ │                                        │ *Nutrients* (2021.0) **13** 2229.      │        │ │
│ │                                        │ PMID: 34209599                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 44. Kim SG, Buel GR, Blenis J.         │        │ │
│ │                                        │ **Nutrient regulation of the mTOR      │        │ │
│ │                                        │ complex 1 signaling pathway**. *Mol    │        │ │
│ │                                        │ Cells* (2013.0) **35** 463-73. PMID:   │        │ │
│ │                                        │ 23694989                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 45. Choi BH, Hyun S, Koo SH. **The     │        │ │
│ │                                        │ role of BCAA metabolism in metabolic   │        │ │
│ │                                        │ health and disease**. *Exp Mol Med*    │        │ │
│ │                                        │ (2024.0) **56** 1552-1559. PMID:       │        │ │
│ │                                        │ 38956299                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 46. Mansoori S, Ho MY, Ng KK, Cheng    │        │ │
│ │                                        │ KK. **Branched-chain amino acid        │        │ │
│ │                                        │ metabolism: Pathophysiological         │        │ │
│ │                                        │ mechanism and therapeutic intervention │        │ │
│ │                                        │ in metabolic diseases**. *Obes Rev*    │        │ │
│ │                                        │ (2025.0) **26** e13856. PMID: 39455059 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 47. Neinast MD, Jang C, Hui S,         │        │ │
│ │                                        │ Murashige DS, Chu Q, Morscher RJ.      │        │ │
│ │                                        │ **Quantitative Analysis of the         │        │ │
│ │                                        │ Whole-Body Metabolic Fate of           │        │ │
│ │                                        │ Branched-Chain Amino Acids**. *Cell    │        │ │
│ │                                        │ Metab* (2019.0) **29** 417-429.e4.     │        │ │
│ │                                        │ PMID: 30449684                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 48. Selvaraj S, Patel S, Sauer AJ,     │        │ │
│ │                                        │ McGarrah RW, Jones P, Kwee LC.         │        │ │
│ │                                        │ **Targeted Metabolomic Profiling of    │        │ │
│ │                                        │ Dapagliflozin in Heart Failure with    │        │ │
│ │                                        │ Preserved Ejection Fraction: The       │        │ │
│ │                                        │ PRESERVED-HF Trial**. *JACC Heart      │        │ │
│ │                                        │ Fail* (2024.0) **12** 999-1011. PMID:  │        │ │
│ │                                        │ 38639697                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 49. Lian K, Guo X, Wang Q, Liu Y, Wang │        │ │
│ │                                        │ RT, Gao C. **PP2Cm overexpression      │        │ │
│ │                                        │ alleviates MI/R injury mediated by a   │        │ │
│ │                                        │ BCAA catabolism defect and oxidative   │        │ │
│ │                                        │ stress in diabetic mice**. *Eur J      │        │ │
│ │                                        │ Pharmacol* (2020.0) **866** 172796.    │        │ │
│ │                                        │ PMID: 31738932                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 50. Zhao X, Zhang X, Pei J, Liu Y, Niu │        │ │
│ │                                        │ W, Sun H. **Targeting BCAA metabolism  │        │ │
│ │                                        │ to potentiate metformin's therapeutic  │        │ │
│ │                                        │ efficacy in the treatment of diabetes  │        │ │
│ │                                        │ in mice**. *Diabetologia* (2023.0)     │        │ │
│ │                                        │ **66** 2139-2153. PMID: 37581618       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 51. Bollinger E, Peloquin M, Libera J, │        │ │
│ │                                        │ Albuquerque B, Pashos E, Shipstone A.  │        │ │
│ │                                        │ **BDK inhibition acts as a catabolic   │        │ │
│ │                                        │ switch to mimic fasting and improve    │        │ │
│ │                                        │ metabolism in mice**. *Mol Metab*      │        │ │
│ │                                        │ (2022.0) **66** 101611. PMID: 36220546 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 52. Jackson AM, Rørth R, Liu J,        │        │ │
│ │                                        │ Kristensen SL, Anand IS, Claggett BL.  │        │ │
│ │                                        │ **Diabetes and pre-diabetes in         │        │ │
│ │                                        │ patients with heart failure and        │        │ │
│ │                                        │ preserved ejection fraction**. *Eur J  │        │ │
│ │                                        │ Heart Fail* (2022.0) **24** 497-509.   │        │ │
│ │                                        │ PMID: 34918855                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 53. Gopalasingam N, Berg-Hansen K,     │        │ │
│ │                                        │ Christensen KH, Ladefoged BT, Poulsen  │        │ │
│ │                                        │ SH, Andersen MJ. **Randomized          │        │ │
│ │                                        │ Crossover Trial of 2-Week Ketone Ester │        │ │
│ │                                        │ Treatment in Patients with Type 2      │        │ │
│ │                                        │ Diabetes and Heart Failure with        │        │ │
│ │                                        │ Preserved Ejection Fraction**.         │        │ │
│ │                                        │ *Circulation* (2024.0) **150**         │        │ │
│ │                                        │ 1570-1583. PMID: 39162035              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 54. Sansbury BE, DeMartino AM, Xie Z,  │        │ │
│ │                                        │ Brooks AC, Brainard RE, Watson LJ.     │        │ │
│ │                                        │ **Metabolomic analysis of              │        │ │
│ │                                        │ pressure-overloaded and infarcted      │        │ │
│ │                                        │ mouse hearts**. *Circ Heart Fail*      │        │ │
│ │                                        │ (2014.0) **7** 634-642. PMID: 24762972 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 55. J Lerman JB, Giamberardino SN,     │        │ │
│ │                                        │ Hernandez AF, Felker GM, Shah SH,      │        │ │
│ │                                        │ McGarrah RW. **Plasma metabolites      │        │ │
│ │                                        │ associated with functional and         │        │ │
│ │                                        │ clinical outcomes in heart failure     │        │ │
│ │                                        │ with reduced ejection fraction with    │        │ │
│ │                                        │ and without type 2 diabetes**. *Sci    │        │ │
│ │                                        │ Rep* (2022.0) **12** 9183. PMID:       │        │ │
│ │                                        │ 35654972                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 56. Gao C, Xiong Z, Liu Y, Wang M,     │        │ │
│ │                                        │ Wang M, Liu T. **Glucagon Receptor     │        │ │
│ │                                        │ Antagonist for Heart Failure with      │        │ │
│ │                                        │ Preserved Ejection Fraction**. *Circ   │        │ │
│ │                                        │ Res* (2024.0) **135** 614-628. PMID:   │        │ │
│ │                                        │ 39011638                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 57. Van Essen BJ, Emmens JE, Tromp J,  │        │ │
│ │                                        │ Ouwerkerk W, Smit MD, Geluk CA.        │        │ │
│ │                                        │ **Sex-specific risk factors for        │        │ │
│ │                                        │ new-onset heart failure: the PREVEND   │        │ │
│ │                                        │ study at 25 years**. *Eur Heart J*     │        │ │
│ │                                        │ (2024.0)                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 58. Zhang N, Feng B, Ma X, Sun K, Xu   │        │ │
│ │                                        │ G, Zhou Y. **Dapagliflozin improves    │        │ │
│ │                                        │ left ventricular remodeling and aorta  │        │ │
│ │                                        │ sympathetic tone in a pig model of     │        │ │
│ │                                        │ heart failure with preserved ejection  │        │ │
│ │                                        │ fraction**. *Cardiovasc Diabetol*      │        │ │
│ │                                        │ (2019.0) **18** 107. PMID: 31429767    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 59. 59Pipeline P                       │        │ │
│ │                                        │ https://cdn.pfizer.com/pfizercom/prod… │        │ │
│ │                                        │ *Pipeline P*                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 60. 60NCT05807490. A Study to Learn    │        │ │
│ │                                        │ How Different Amounts of the Study     │        │ │
│ │                                        │ Medicine Called PF-07328948 Are        │        │ │
│ │                                        │ Tolerated and Act in the Body in       │        │ │
│ │                                        │ Healthy Adults                         │        │ │
│ │                                        │ https://clinicaltrials.gov/study/NCT0… │        │ │
│ │                                        │ *NCT05807490. A Study to Learn How     │        │ │
│ │                                        │ Different Amounts of the Study         │        │ │
│ │                                        │ Medicine Called PF-07328948 Are        │        │ │
│ │                                        │ Tolerated and Act in the Body in       │        │ │
│ │                                        │ Healthy Adults*                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │ title: Evaluation of therapeutic       │        │ │
│ │                                        │ strategies targeting BCAA catabolism   │        │ │
│ │                                        │ using a systems                        │        │ │
│ │                                        │   pharmacology model                   │        │ │
│ │                                        │ authors:                               │        │ │
│ │                                        │ - Veronika Voronova                    │        │ │
│ │                                        │ - Victor Sokolov                       │        │ │
│ │                                        │ - Yannick Morias                       │        │ │
│ │                                        │ - Malin Jonsson Boezelman              │        │ │
│ │                                        │ - Maria Wågberg                        │        │ │
│ │                                        │ - Marcus Henricsson                    │        │ │
│ │                                        │ - Karl Hansson                         │        │ │
│ │                                        │ - Alexey Goltsov                       │        │ │
│ │                                        │ - Kirill Peskov                        │        │ │
│ │                                        │ - Monika Sundqvist                     │        │ │
│ │                                        │ journal: Frontiers in Pharmacology     │        │ │
│ │                                        │ year: 2022                             │        │ │
│ │                                        │ pmcid: PMC9744226                      │        │ │
│ │                                        │ doi: 10.3389/fphar.2022.993422         │        │ │
│ │                                        │ license: CC BY 4.0                     │        │ │
│ │                                        │ ---                                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ # Evaluation of therapeutic strategies │        │ │
│ │                                        │ targeting BCAA catabolism using a      │        │ │
│ │                                        │ systems pharmacology model             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Abstract                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Background: Abnormal branched-chained  │        │ │
│ │                                        │ amino acids (BCAA) accumulation in     │        │ │
│ │                                        │ cardiomyocytes is associated with      │        │ │
│ │                                        │ cardiac remodeling in heart failure.   │        │ │
│ │                                        │ Administration of branched-chain       │        │ │
│ │                                        │ α-keto acid dehydrogenase (BCKD)       │        │ │
│ │                                        │ kinase inhibitor BT2 has been shown to │        │ │
│ │                                        │ reduce cardiac BCAA levels and         │        │ │
│ │                                        │ demonstrated positive effects on       │        │ │
│ │                                        │ cardiac function in a preclinical      │        │ │
│ │                                        │ setting. The current study is focused  │        │ │
│ │                                        │ on evaluating the impact of BT2 on the │        │ │
│ │                                        │ systemic and cardiac levels of BCAA    │        │ │
│ │                                        │ and their metabolites as well as       │        │ │
│ │                                        │ activities of BCAA catabolic enzymes   │        │ │
│ │                                        │ using a quantitative systems           │        │ │
│ │                                        │ pharmacology model.                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Methods: The model is composed of an   │        │ │
│ │                                        │ ordinary differential equation system  │        │ │
│ │                                        │ characterizing BCAA consumption with   │        │ │
│ │                                        │ food, disposal in the proteins,        │        │ │
│ │                                        │ reversible branched-chain-amino-acid   │        │ │
│ │                                        │ aminotransferase (BCAT)-mediated       │        │ │
│ │                                        │ transamination to branched-chain       │        │ │
│ │                                        │ keto-acids (BCKA), followed by         │        │ │
│ │                                        │ BCKD-mediated oxidation. Activity of   │        │ │
│ │                                        │ BCKD is regulated by the balance of    │        │ │
│ │                                        │ BCKDK and protein phosphatase 2Cm      │        │ │
│ │                                        │ (PP2Cm) activities, affected by BT2    │        │ │
│ │                                        │ treatment. Cardiac BCAA levels are     │        │ │
│ │                                        │ assumed to directly affect left        │        │ │
│ │                                        │ ventricular ejection fraction (LVEF).  │        │ │
│ │                                        │ Biochemical characteristics of the     │        │ │
│ │                                        │ enzymes are taken from the public      │        │ │
│ │                                        │ domains, while plasma and cardiac BCAA │        │ │
│ │                                        │ and BCKA levels in BT2 treated mice    │        │ │
│ │                                        │ are used to inform the model           │        │ │
│ │                                        │ parameters.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Results: The model provides adequate   │        │ │
│ │                                        │ reproduction of the experimental data  │        │ │
│ │                                        │ and predicts synchronous BCAA          │        │ │
│ │                                        │ responses in the systemic and cardiac  │        │ │
│ │                                        │ space, dictated by rapid BCAA          │        │ │
│ │                                        │ equilibration between the tissues. The │        │ │
│ │                                        │ model-based simulations indicate       │        │ │
│ │                                        │ maximum possible effect of BT2         │        │ │
│ │                                        │ treatment on BCAA reduction to be      │        │ │
│ │                                        │ $40\%$ corresponding to $12\%$         │        │ │
│ │                                        │ increase in LVEF. Model sensitivity    │        │ │
│ │                                        │ analysis demonstrates strong impact of │        │ │
│ │                                        │ BCKDK and PP2Cm activities as well as  │        │ │
│ │                                        │ total BCKD and co-substrate levels     │        │ │
│ │                                        │ (glutamate, ketoglutarate and ATP) on  │        │ │
│ │                                        │ BCAA and BCKA levels.                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Conclusion: Model based simulations    │        │ │
│ │                                        │ confirms using of plasma measurements  │        │ │
│ │                                        │ as a marker of cardiac BCAA changes    │        │ │
│ │                                        │ under BCKDK inhibition. The proposed   │        │ │
│ │                                        │ model can be used for optimization of  │        │ │
│ │                                        │ preclinical study design for novel     │        │ │
│ │                                        │ compounds targeting BCAA catabolism.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Introduction                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Branched-chained amino acids           │        │ │
│ │                                        │ (BCAA)—leucine (Leu), isoleucine (Ile) │        │ │
│ │                                        │ and valine (Val) are essential amino   │        │ │
│ │                                        │ acids obtained by food intake (Harper  │        │ │
│ │                                        │ et al., 1984). BCAA are used as        │        │ │
│ │                                        │ precursors for de novo protein         │        │ │
│ │                                        │ synthesis or for energy supply         │        │ │
│ │                                        │ (Neinast et al., 2019). In addition,   │        │ │
│ │                                        │ BCAA have various biological effects   │        │ │
│ │                                        │ including anabolic activity,           │        │ │
│ │                                        │ suppressive effect on the insulin      │        │ │
│ │                                        │ signaling and activation of the        │        │ │
│ │                                        │ insulin and glucagon production        │        │ │
│ │                                        │ (Hutson et al., 2005; Holeček, 2018;   │        │ │
│ │                                        │ Wada et al., 2021). BCAA also plays a  │        │ │
│ │                                        │ role in the neural system by donating  │        │ │
│ │                                        │ nitrogen for the synthesis of          │        │ │
│ │                                        │ neurotransmitters glutamate and        │        │ │
│ │                                        │ γ-amino butyric acid (Hutson et al.,   │        │ │
│ │                                        │ 2005).                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BCAA oxidation is a multistep process  │        │ │
│ │                                        │ that starts with reversible BCAA       │        │ │
│ │                                        │ deamination by                         │        │ │
│ │                                        │ branched-chain-amino-acid              │        │ │
│ │                                        │ aminotransferase (BCAT) enzyme and     │        │ │
│ │                                        │ formation of branched-chain keto acids │        │ │
│ │                                        │ (BCKA)–alpha-ketoisocaproic (KIC),     │        │ │
│ │                                        │ alpha-ketoisovaleric (KIV), and        │        │ │
│ │                                        │ alpha-keto-beta-methylvaleric (KMV)    │        │ │
│ │                                        │ acid. This step requires               │        │ │
│ │                                        │ α-ketoglutarate and glutamate as       │        │ │
│ │                                        │ co-substrates for the forward and      │        │ │
│ │                                        │ reverse reaction, respectively. The    │        │ │
│ │                                        │ BCKA undergo further irreversible      │        │ │
│ │                                        │ oxidative decarboxylation catalyzed by │        │ │
│ │                                        │ the branched-chain α-keto acid         │        │ │
│ │                                        │ dehydrogenase (BCKD) complex localized │        │ │
│ │                                        │ on the inner surface of mitochondrial  │        │ │
│ │                                        │ membrane (Suryawan et al., 1998;       │        │ │
│ │                                        │ Shimomura et al., 2001; Shimomura et   │        │ │
│ │                                        │ al., 2004). Activity of BCKD enzyme is │        │ │
│ │                                        │ tightly regulated by a                 │        │ │
│ │                                        │ phosphorylation-dephosphorylation      │        │ │
│ │                                        │ mechanism, affected by the delicate    │        │ │
│ │                                        │ balance between the BCKD kinase        │        │ │
│ │                                        │ (BCKDK) and protein phosphatase 2Cm    │        │ │
│ │                                        │ (PP2Cm) activities (Shimomura et al.,  │        │ │
│ │                                        │ 2001) (Figure 1).                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 1:** *Model schematics.*      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Distribution of BCAT and BCKD enzymes  │        │ │
│ │                                        │ is shown to significantly vary between │        │ │
│ │                                        │ the tissues with the highest           │        │ │
│ │                                        │ transamination and oxidation           │        │ │
│ │                                        │ capacities, calculated for muscle and  │        │ │
│ │                                        │ liver tissues, respectively (Suryawan  │        │ │
│ │                                        │ et al., 1998; Hutson et al., 2005).    │        │ │
│ │                                        │ This spatial distribution of the       │        │ │
│ │                                        │ enzymes results in interorgan exchange │        │ │
│ │                                        │ of BCAA and BCKA and enables nitrogen  │        │ │
│ │                                        │ cycling within the body (Suryawan et   │        │ │
│ │                                        │ al., 1998; Holeček, 2018; Walejko et   │        │ │
│ │                                        │ al., 2021). Efficacy of intracellular  │        │ │
│ │                                        │ BCAA transport to the mitochondrial    │        │ │
│ │                                        │ space is suggested to be another       │        │ │
│ │                                        │ limiting factor for BCAA oxidation     │        │ │
│ │                                        │ rate. The recent study by Walejko et   │        │ │
│ │                                        │ al. [ 2021] indicates that BCKA        │        │ │
│ │                                        │ undergo reamination rather than        │        │ │
│ │                                        │ oxidation process in rat cardiac       │        │ │
│ │                                        │ tissue, which is hypothesized to be    │        │ │
│ │                                        │ related to low expression of the       │        │ │
│ │                                        │ mitochondrial BCAA transporter         │        │ │
│ │                                        │ SLC25A44. In contrast to this data,    │        │ │
│ │                                        │ Neinast et al. [ 2019] demonstrates    │        │ │
│ │                                        │ significant BCAA oxidation and limited │        │ │
│ │                                        │ BCAA disposal into proteins in mouse   │        │ │
│ │                                        │ heart. These discrepancies can be      │        │ │
│ │                                        │ attributed to the between-species      │        │ │
│ │                                        │ differences in the enzyme expression   │        │ │
│ │                                        │ levels, reported previously (Suryawan  │        │ │
│ │                                        │ et al., 1998).                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Whereas BCAA are being extensively     │        │ │
│ │                                        │ used as food supplements and have been │        │ │
│ │                                        │ tested as a potential treatment option │        │ │
│ │                                        │ for cachexia and liver diseases        │        │ │
│ │                                        │ (Holeček, 2018), abnormalities in BCAA │        │ │
│ │                                        │ catabolism are associated with         │        │ │
│ │                                        │ metabolic disorders (Jørgenrud et al., │        │ │
│ │                                        │ 2015; Arany and Neinast, 2018; Biswas  │        │ │
│ │                                        │ et al., 2020). In diabetic mouse       │        │ │
│ │                                        │ models, plasma BCAA levels are         │        │ │
│ │                                        │ increased whereas expression of BCAA   │        │ │
│ │                                        │ catabolizing enzymes in the liver and  │        │ │
│ │                                        │ the pancreatic islets are              │        │ │
│ │                                        │ downregulated (Arany and Neinast,      │        │ │
│ │                                        │ 2018; Wada et al., 2021). Intravenous  │        │ │
│ │                                        │ BCAA infusions are shown to decrease   │        │ │
│ │                                        │ insulin sensitivity and increase       │        │ │
│ │                                        │ endogenous glucose production in       │        │ │
│ │                                        │ humans which can be related to their   │        │ │
│ │                                        │ effect on the insulin signaling and    │        │ │
│ │                                        │ glucagon production (Krebs et al.,     │        │ │
│ │                                        │ 2002; Krebs et al., 2003; Uddin et     │        │ │
│ │                                        │ al., 2019).                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Pre-clinical animal models and         │        │ │
│ │                                        │ clinical data indicate BCAA            │        │ │
│ │                                        │ involvement in the cardiac remodeling  │        │ │
│ │                                        │ process. Accumulation of BCAA and      │        │ │
│ │                                        │ decrease in expression of BCAA         │        │ │
│ │                                        │ catabolic enzymes in the cardiac       │        │ │
│ │                                        │ tissue are observed in preclinical     │        │ │
│ │                                        │ models of myocardial infarction        │        │ │
│ │                                        │ [coronary artery ligation (CAL)] and   │        │ │
│ │                                        │ heart failure [transverse aortic       │        │ │
│ │                                        │ constriction (TAC)] (Wang et al.,      │        │ │
│ │                                        │ 2016; Uddin et al., 2019; Li et al.,   │        │ │
│ │                                        │ 2020) as well as in patients with      │        │ │
│ │                                        │ dilated cardiomyopathy (Uddin et al.,  │        │ │
│ │                                        │ 2019). Cardiac BCAA accumulation is    │        │ │
│ │                                        │ hypothesized to contribute to          │        │ │
│ │                                        │ myocardial hypertrophy via             │        │ │
│ │                                        │ mTOR-dependent activation of the       │        │ │
│ │                                        │ protein synthesis and is shown to      │        │ │
│ │                                        │ downregulate cardiac fatty acids and   │        │ │
│ │                                        │ glucose oxidation (Huang et al., 2011; │        │ │
│ │                                        │ Li et al., 2017; Li et al., 2020).     │        │ │
│ │                                        │ Given existing experimental evidence   │        │ │
│ │                                        │ indicating BCAA accumulation in the    │        │ │
│ │                                        │ cardiac, pancreatic, and hepatic       │        │ │
│ │                                        │ tissue, and the association of BCAA    │        │ │
│ │                                        │ levels with obesity and metabolic      │        │ │
│ │                                        │ traits, targeting BCAA catabolism      │        │ │
│ │                                        │ represents a conceivable strategy for  │        │ │
│ │                                        │ the treatment of metabolic and cardiac │        │ │
│ │                                        │ diseases.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Among possible therapeutic options     │        │ │
│ │                                        │ targeting the BCAA catabolic pathway,  │        │ │
│ │                                        │ BCKDK inhibitors are being actively    │        │ │
│ │                                        │ investigated. Endogenous BCKDK         │        │ │
│ │                                        │ inhibition by BCKA was discovered by   │        │ │
│ │                                        │ Paxton and Harris and represents       │        │ │
│ │                                        │ regulatory feedback activating BCKA    │        │ │
│ │                                        │ catabolism in case of their            │        │ │
│ │                                        │ accumulation (Paxton and Harris,       │        │ │
│ │                                        │ 1984). Allosteric BCKDK inhibitor BT2, │        │ │
│ │                                        │ identified in 2014 using               │        │ │
│ │                                        │ high-throughput screening by Tso et    │        │ │
│ │                                        │ al. [ 2013]; Tso et al. [ 2014], has   │        │ │
│ │                                        │ been shown to reduce BCAA levels in    │        │ │
│ │                                        │ the systemic circulation and cardiac   │        │ │
│ │                                        │ tissue and demonstrated efficacy in    │        │ │
│ │                                        │ the myocardial infraction and diabetes │        │ │
│ │                                        │ models in preclinical settings (Chen   │        │ │
│ │                                        │ et al., 2019; Uddin et al., 2019; Zhou │        │ │
│ │                                        │ et al., 2019; Lian et al., 2020).      │        │ │
│ │                                        │ However, the complex network of        │        │ │
│ │                                        │ feedbacks underlying the regulations   │        │ │
│ │                                        │ of BCAA catabolism as well as the      │        │ │
│ │                                        │ aspects of drug and target             │        │ │
│ │                                        │ distribution substantiate the need for │        │ │
│ │                                        │ further quantitative research of       │        │ │
│ │                                        │ potential factors influencing the      │        │ │
│ │                                        │ efficacy of BCKDK inhibitors.          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Quantitative systems pharmacology      │        │ │
│ │                                        │ (QSP) is a relatively new modeling     │        │ │
│ │                                        │ discipline, stemming from the roots of │        │ │
│ │                                        │ systems biology and used to get a      │        │ │
│ │                                        │ mechanistic understanding of the       │        │ │
│ │                                        │ systems dynamics and the effects of    │        │ │
│ │                                        │ pharmacological interventions (NIH     │        │ │
│ │                                        │ Workgroup, 2011). In contrast to the   │        │ │
│ │                                        │ empirical                              │        │ │
│ │                                        │ pharmacokinetic/pharmacodynamic        │        │ │
│ │                                        │ (PK/PD) models, QSP model is based on  │        │ │
│ │                                        │ the principles of chemical and         │        │ │
│ │                                        │ enzymological kinetics, homeostatic    │        │ │
│ │                                        │ processes, and multicompartmental      │        │ │
│ │                                        │ structure mimicking physiological      │        │ │
│ │                                        │ distribution of the biological         │        │ │
│ │                                        │ entities (Bradshaw et al., 2019). In   │        │ │
│ │                                        │ this work, a first-in-class QSP model  │        │ │
│ │                                        │ of BCAA catabolism was developed to    │        │ │
│ │                                        │ characterize the dynamic interplay     │        │ │
│ │                                        │ between multiple biological factors    │        │ │
│ │                                        │ (e.g., enzyme activities,              │        │ │
│ │                                        │ concentrations of the co-substrates)   │        │ │
│ │                                        │ and the effect of BT2 inhibition on    │        │ │
│ │                                        │ BCAA concentrations in different       │        │ │
│ │                                        │ compartments. The model serves as a    │        │ │
│ │                                        │ guide for the future preclinical       │        │ │
│ │                                        │ studies and as a basis for the         │        │ │
│ │                                        │ succeeding iterations of the           │        │ │
│ │                                        │ mathematical modeling of the system    │        │ │
│ │                                        │ under investigation.                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Experimental data                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Data from six experiments on healthy   │        │ │
│ │                                        │ female C57Bl6 mice 8–10 weeks old      │        │ │
│ │                                        │ (C57BL/6NCrl Charles River, Germany)   │        │ │
│ │                                        │ were available. Male mice were         │        │ │
│ │                                        │ excluded for practical and ethical     │        │ │
│ │                                        │ reasons: female mice can be housed in  │        │ │
│ │                                        │ group while male mice need to be       │        │ │
│ │                                        │ housed individually to avoid fighting. │        │ │
│ │                                        │ All animal studies were performed      │        │ │
│ │                                        │ according to AstraZeneca Institutional │        │ │
│ │                                        │ Animal Care and Use Committee          │        │ │
│ │                                        │ guidelines. BT2 was formulated in      │        │ │
│ │                                        │ $0.5\%$ HPMC $0.1\%$ Tween. Animals    │        │ │
│ │                                        │ were treated with vehicle only, or a   │        │ │
│ │                                        │ single oral dose of 15, 40 or 120      │        │ │
│ │                                        │ mg/kg or two oral 40 mg/kg doses of    │        │ │
│ │                                        │ BT2 given once daily. Plasma levels of │        │ │
│ │                                        │ BCAA, BCKA and BT2 were measured using │        │ │
│ │                                        │ mass spectrometry at baseline and 20   │        │ │
│ │                                        │ min or 1, 4, 7, 24, 48 h after dosing  │        │ │
│ │                                        │ (Supplementary Table S1). Cardiac BCAA │        │ │
│ │                                        │ and BCKA measurements were available   │        │ │
│ │                                        │ for the vehicle group, measured 48 h   │        │ │
│ │                                        │ post dose. Detailed description of the │        │ │
│ │                                        │ experimental assay procedures is       │        │ │
│ │                                        │ available in the Supplementary         │        │ │
│ │                                        │ Material.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Model structure                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The model is represented by a system   │        │ │
│ │                                        │ of ordinary differential equations     │        │ │
│ │                                        │ reflecting the turnover of individual  │        │ │
│ │                                        │ BCAA (Leu, Ile, Val) through the       │        │ │
│ │                                        │ description of BCAA consumption with   │        │ │
│ │                                        │ food, BCAA and BCKA exchange between   │        │ │
│ │                                        │ systemic circulation and heart tissue, │        │ │
│ │                                        │ systemic and cardiac catabolism as     │        │ │
│ │                                        │ well as BCAA usage for the protein     │        │ │
│ │                                        │ synthesis.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Contribution of each organ to the      │        │ │
│ │                                        │ systemic BCAA catabolism is not        │        │ │
│ │                                        │ considered in the model and the        │        │ │
│ │                                        │ respective systemic reaction rates     │        │ │
│ │                                        │ therefore represent cumulative         │        │ │
│ │                                        │ catabolic tissue capacities. The       │        │ │
│ │                                        │ processes of BCAA catabolism in the    │        │ │
│ │                                        │ heart are mirrored in the systemic     │        │ │
│ │                                        │ circulation and are represented by     │        │ │
│ │                                        │ BCAT-mediated reversible BCAA          │        │ │
│ │                                        │ transamination followed by             │        │ │
│ │                                        │ BCKD-mediated oxidative                │        │ │
│ │                                        │ decarboxylation of BCKA. Activity of   │        │ │
│ │                                        │ BCKD is regulated by BCKDK-mediated    │        │ │
│ │                                        │ phosphorylation and PP2Cm-dependent    │        │ │
│ │                                        │ dephosphorylation. In turn, activity   │        │ │
│ │                                        │ of BCKDK is negatively affected by     │        │ │
│ │                                        │ allosteric inhibitors KIC and BT2.     │        │ │
│ │                                        │ Plasma BT2 dynamics is characterized   │        │ │
│ │                                        │ using a standard 1-compartment         │        │ │
│ │                                        │ pharmacokinetic (PK) model with        │        │ │
│ │                                        │ first-order linear absorption and      │        │ │
│ │                                        │ elimination and dose-dependent         │        │ │
│ │                                        │ bioavailability, with rapid            │        │ │
│ │                                        │ equilibration between systemic         │        │ │
│ │                                        │ circulation and cardiac tissue.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The model structure is reported in     │        │ │
│ │                                        │ Figure 1. List of the model equations  │        │ │
│ │                                        │ as well as derivation of reaction      │        │ │
│ │                                        │ rates is available in the              │        │ │
│ │                                        │ Supplementary Material.                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Model calibration                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The model includes 65 parameters taken │        │ │
│ │                                        │ from the publicly available sources or │        │ │
│ │                                        │ verified based on the experimental     │        │ │
│ │                                        │ data. Kinetic parameters               │        │ │
│ │                                        │ characterizing BCAT, BCKD, BCKDK, and  │        │ │
│ │                                        │ PP2Cm activities and substrate         │        │ │
│ │                                        │ specificities were taken from the      │        │ │
│ │                                        │ respective studies (Pettit et al.,     │        │ │
│ │                                        │ 1978; Paxton and Harris, 1984;         │        │ │
│ │                                        │ Yennawar et al., 2006; Wynn et al.,    │        │ │
│ │                                        │ 2012). Levels of ketoglutarate and ATP │        │ │
│ │                                        │ were assumed to be constant over time  │        │ │
│ │                                        │ and fixed based on the experimental    │        │ │
│ │                                        │ data (Ogawa et al., 2014). Daily BCAA  │        │ │
│ │                                        │ intake was calculated based on the     │        │ │
│ │                                        │ daily food composition and food        │        │ │
│ │                                        │ content information. Rate constants,   │        │ │
│ │                                        │ characterizing BCAA and BCKA exchange  │        │ │
│ │                                        │ between plasma and cardiac tissue,     │        │ │
│ │                                        │ were set to values enabling rapid      │        │ │
│ │                                        │ tissue equilibration of the            │        │ │
│ │                                        │ metabolites in line with observations  │        │ │
│ │                                        │ (Neinast et al., 2019). Parameters     │        │ │
│ │                                        │ quantifying BCAA conversion to         │        │ │
│ │                                        │ proteins, BCKDK to PP2Cm ratio and     │        │ │
│ │                                        │ glutamate concentration were expressed │        │ │
│ │                                        │ using values of other parameters and   │        │ │
│ │                                        │ experimental data (equations are       │        │ │
│ │                                        │ available in Supplementary Material).  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The remaining model parameters were    │        │ │
│ │                                        │ calibrated against the available       │        │ │
│ │                                        │ experimental data using a sequential   │        │ │
│ │                                        │ modeling approach. First, PK           │        │ │
│ │                                        │ parameters characterizing plasma BT2   │        │ │
│ │                                        │ dynamics were estimated using plasma   │        │ │
│ │                                        │ BT2 measurements. Second,              │        │ │
│ │                                        │ placebo-adjusted plasma BCAA and BCKA  │        │ │
│ │                                        │ levels were used to quantify systemic  │        │ │
│ │                                        │ parameters of BCAA catabolism as well  │        │ │
│ │                                        │ as pharmacodynamic parameters,         │        │ │
│ │                                        │ responsible for the inhibitory effect  │        │ │
│ │                                        │ of BT2 on BCKDK. Third, parameters of  │        │ │
│ │                                        │ cardiac BCAA catabolism as well as     │        │ │
│ │                                        │ BCKA efflux from cardiac tissue to     │        │ │
│ │                                        │ plasma were estimated using cardiac    │        │ │
│ │                                        │ BCAA and BCKA measurements in healthy  │        │ │
│ │                                        │ animals. Parameters characterizing     │        │ │
│ │                                        │ total BCKD and BCKDK to PP2Cm ratio in │        │ │
│ │                                        │ the systemic circulation were found to │        │ │
│ │                                        │ be interdependent, thus, total BCKD    │        │ │
│ │                                        │ level was fixed.                       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To reproduce BCAA catabolism in heart  │        │ │
│ │                                        │ failure conditions, model parameters   │        │ │
│ │                                        │ characterizing protein synthesis as    │        │ │
│ │                                        │ well as PP2Cm and BCAT activities in   │        │ │
│ │                                        │ cardiac tissue were modified in line   │        │ │
│ │                                        │ with experimental evidence generated   │        │ │
│ │                                        │ in TAC mice (Sun et al., 2016).        │        │ │
│ │                                        │ Finally, the link between cardiac BCAA │        │ │
│ │                                        │ changes and cardiac status was         │        │ │
│ │                                        │ quantified using LVEF dynamics         │        │ │
│ │                                        │ following TAC surgery and BT2 or       │        │ │
│ │                                        │ vehicle treatment.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The summary of the model parameters    │        │ │
│ │                                        │ can be found in the Supplementary      │        │ │
│ │                                        │ Table S2.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Model based simulations             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To perform sensitivity analysis values │        │ │
│ │                                        │ of the selected model parameters were  │        │ │
│ │                                        │ derived using Latin Hypercube Sampling │        │ │
│ │                                        │ (LHS): parameter values were randomly  │        │ │
│ │                                        │ generated in 0.1–10-fold range from    │        │ │
│ │                                        │ their estimates and used to predict    │        │ │
│ │                                        │ effect of 40 mg/kg daily BT2 dosing on │        │ │
│ │                                        │ various model variables. Pairwise      │        │ │
│ │                                        │ partial correlations between parameter │        │ │
│ │                                        │ values and biomarkers were estimated   │        │ │
│ │                                        │ using Spearman method (Iman et al.,    │        │ │
│ │                                        │ 1981).                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Software                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The model development and parameter    │        │ │
│ │                                        │ estimation were performed in Monolix®  │        │ │
│ │                                        │ 2019R1 software (Lixoft, Antony,       │        │ │
│ │                                        │ France). Exploratory analysis and      │        │ │
│ │                                        │ visualization of the data and the      │        │ │
│ │                                        │ model simulations were performed in R  │        │ │
│ │                                        │ computing environment (R version       │        │ │
│ │                                        │ 3.5.1) using tidyverse (version 1.3.1) │        │ │
│ │                                        │ and RsSimulx (version 1.0.1) packages. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## The model captures the experimental │        │ │
│ │                                        │ data                                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The developed QSP model of BCAA        │        │ │
│ │                                        │ catabolism adequately reproduced the   │        │ │
│ │                                        │ experimental data generated in healthy │        │ │
│ │                                        │ and TAC mice (Figure 2, Supplementary  │        │ │
│ │                                        │ Figure S3). Baseline BCAA              │        │ │
│ │                                        │ concentrations were approximately      │        │ │
│ │                                        │ 5-fold and 500-fold higher compared to │        │ │
│ │                                        │ the BCKA in the systemic circulation   │        │ │
│ │                                        │ and cardiac tissue, respectively       │        │ │
│ │                                        │ (Figure 2A). Larger difference between │        │ │
│ │                                        │ BCKA and BCAA concentrations in the    │        │ │
│ │                                        │ heart relative to the systemic         │        │ │
│ │                                        │ exposure is associated with the higher │        │ │
│ │                                        │ activity of BCKD in the former, as     │        │ │
│ │                                        │ shown in the parameter estimates       │        │ │
│ │                                        │ (Supplementary Table S2). The          │        │ │
│ │                                        │ model-based simulations indicate a     │        │ │
│ │                                        │ decrease in active BCKD due to the     │        │ │
│ │                                        │ change in BCKDK to PP2Cm ratio and     │        │ │
│ │                                        │ showed more pronounced increase in     │        │ │
│ │                                        │ BCKA vs. BCAA levels in the heart in a │        │ │
│ │                                        │ TAC state (Supplementary Figure S4).   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 2:** *Experimental data       │        │ │
│ │                                        │ reproduction by the model: (A)         │        │ │
│ │                                        │ Steady-state BCAA and BCKA levels; (B) │        │ │
│ │                                        │ Change over time in plasma BCAA and    │        │ │
│ │                                        │ BCKA levels under different BT2 doses  │        │ │
│ │                                        │ and regimens (SD—single dose, QD—once  │        │ │
│ │                                        │ daily); (C) LVEF change in mouse after │        │ │
│ │                                        │ TAC surgery, treated with vehicle or   │        │ │
│ │                                        │ BT2. Circles, squares and error        │        │ │
│ │                                        │ bars—observed mean values and standard │        │ │
│ │                                        │ errors, lines—model predictions;       │        │ │
│ │                                        │ dots—individual measurements in        │        │ │
│ │                                        │ plasma, bars—model predictions.*       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The model captures dose-dependent      │        │ │
│ │                                        │ reduction in the systemic BCAA and     │        │ │
│ │                                        │ BCKA levels under BT2 treatment, with  │        │ │
│ │                                        │ observed maximum inhibitory effect of  │        │ │
│ │                                        │ −$25\%$ for Leu, Ile, Val, and of      │        │ │
│ │                                        │ −$25\%$ for KIC, KMV, KIV,             │        │ │
│ │                                        │ respectively (Figure 2B).              │        │ │
│ │                                        │ Treatment-mediated changes in BCAA     │        │ │
│ │                                        │ catabolism were associated with an     │        │ │
│ │                                        │ approximately $20\%$ increase in LVEF  │        │ │
│ │                                        │ compared to the placebo in mice        │        │ │
│ │                                        │ subjected to TAC surgery, in both the  │        │ │
│ │                                        │ model and the observed data, reaching  │        │ │
│ │                                        │ maximum benefit after 2 weeks of       │        │ │
│ │                                        │ treatment (Figure 2C) (Tso et al.,     │        │ │
│ │                                        │ 2013).                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Dose-dependent BT2 effect on        │        │ │
│ │                                        │ metabolites and enzyme activities      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mechanistic model was used to      │        │ │
│ │                                        │ quantify baseline states and           │        │ │
│ │                                        │ dose-response relationships between    │        │ │
│ │                                        │ BT2 and the variety of cardiac and     │        │ │
│ │                                        │ BCAA-related markers in the heart, as  │        │ │
│ │                                        │ well as in systemic circulation.       │        │ │
│ │                                        │ According to the model structure and   │        │ │
│ │                                        │ underlying physiology, BCKD activity,  │        │ │
│ │                                        │ mediated by BCKDK and PP2Cm, is        │        │ │
│ │                                        │ negatively affected by BT2 and BCKA    │        │ │
│ │                                        │ (Figure 3). At baseline, approximately │        │ │
│ │                                        │ $50\%$ of the systemic BCKDK is        │        │ │
│ │                                        │ inhibited by KIC, whereas the          │        │ │
│ │                                        │ contribution of KIC to BCKDK           │        │ │
│ │                                        │ inhibition in cardiac tissue is minor; │        │ │
│ │                                        │ the latter fact is explained by the    │        │ │
│ │                                        │ lower KIC levels in the cardiac vs.    │        │ │
│ │                                        │ the systemic compartment. The BT2      │        │ │
│ │                                        │ treatment decreases KIC concentration, │        │ │
│ │                                        │ thereby indirectly stimulating BCKDK   │        │ │
│ │                                        │ activity. However, this effect is      │        │ │
│ │                                        │ completely overshadowed by the BT2     │        │ │
│ │                                        │ inhibition of BCKDK itself, in a       │        │ │
│ │                                        │ dose-dependent manner.                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 3:** *Model-predicted         │        │ │
│ │                                        │ dose-dependent BT2 effect on various   │        │ │
│ │                                        │ markers of BCAA catabolism in the      │        │ │
│ │                                        │ systemic circulation and the cardiac   │        │ │
│ │                                        │ tissue.*                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Model-based simulations demonstrate    │        │ │
│ │                                        │ matching BCAA reduction relative to    │        │ │
│ │                                        │ the dose between plasma and cardiac    │        │ │
│ │                                        │ tissue, with approximately $40\%$      │        │ │
│ │                                        │ maximum treatment effect and was       │        │ │
│ │                                        │ similar between healthy and TAC        │        │ │
│ │                                        │ animals (Figure 3, Supplementary       │        │ │
│ │                                        │ Figure S4). The associated maximum     │        │ │
│ │                                        │ benefit in LVEF was estimated to be    │        │ │
│ │                                        │ $12\%$. Predicted maximum inhibition   │        │ │
│ │                                        │ of cardiac BCKA levels was less        │        │ │
│ │                                        │ pronounced than that of plasma BCKA,   │        │ │
│ │                                        │ with $80\%$ and $100\%$ reduction,     │        │ │
│ │                                        │ respectively.                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Homeostasis and perturbations of    │        │ │
│ │                                        │ the system                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To gain better understanding of        │        │ │
│ │                                        │ systemic and cardiac BCAA catabolism   │        │ │
│ │                                        │ we performed quantitative analysis of  │        │ │
│ │                                        │ the BCAA and BCKA transamination,      │        │ │
│ │                                        │ oxidation, and transport rates,        │        │ │
│ │                                        │ affecting BCAA and BCKA levels in      │        │ │
│ │                                        │ plasma and cardiac tissue, with and    │        │ │
│ │                                        │ without interventions (Figure 4).      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 4:** *Analysis of the impact  │        │ │
│ │                                        │ of BT2, BCAA or BCKA intake on the     │        │ │
│ │                                        │ homeostatic system. (A) Pre-treatment  │        │ │
│ │                                        │ reaction rates; (B) The effect of      │        │ │
│ │                                        │ interventions on the reaction rates;   │        │ │
│ │                                        │ (C) Changes in metabolite levels under │        │ │
│ │                                        │ the treatment. Simulation design       │        │ │
│ │                                        │ implied single administration of 40    │        │ │
│ │                                        │ mg/kg BT2, 100 umol Leu, or 100 umol   │        │ │
│ │                                        │ KIV; maximal impact of the treatment   │        │ │
│ │                                        │ on biomarkers is shown.*               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The homeostatic nature of the system   │        │ │
│ │                                        │ is ensured at the pre-treatment        │        │ │
│ │                                        │ condition by the complex equilibrium   │        │ │
│ │                                        │ of multiple rates: daily BCAA intake   │        │ │
│ │                                        │ is equal to the sum of BCAA conversion │        │ │
│ │                                        │ to proteins and BCAA transamination    │        │ │
│ │                                        │ rates, with the latter being equal to  │        │ │
│ │                                        │ BCKA oxidation rate. Cardiac BCAA      │        │ │
│ │                                        │ transamination is compensated by the   │        │ │
│ │                                        │ BCAA uptake from the systemic plasma   │        │ │
│ │                                        │ to the heart, while cardiac BCKA       │        │ │
│ │                                        │ oxidation is balanced out by BCAA      │        │ │
│ │                                        │ transamination and BCKA uptake (Figure │        │ │
│ │                                        │ 4A). Given the reversibility of the    │        │ │
│ │                                        │ transamination reaction, de novo BCAA  │        │ │
│ │                                        │ synthesis from BCKA in cardiac tissue  │        │ │
│ │                                        │ is possible but is not predicted by    │        │ │
│ │                                        │ the model at baseline condition.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ BT2 treatment activates the oxidation  │        │ │
│ │                                        │ of BCKA, shifting the equilibrium      │        │ │
│ │                                        │ towards the BCAA transamination into   │        │ │
│ │                                        │ BCKA, leading to the reduction in      │        │ │
│ │                                        │ systemic BCAA and a decrease in the    │        │ │
│ │                                        │ protein synthesis. Resulting drop in   │        │ │
│ │                                        │ the cardiac uptake of both BCAA and    │        │ │
│ │                                        │ BCKA is reflected in the decrease of   │        │ │
│ │                                        │ cardiac transamination and oxidation   │        │ │
│ │                                        │ rates (Figure 4B). Conversely,         │        │ │
│ │                                        │ additional daily intake of BCAA and    │        │ │
│ │                                        │ BCKA results in an increase in cardiac │        │ │
│ │                                        │ concentrations of the respective       │        │ │
│ │                                        │ entities and the compensatory changes  │        │ │
│ │                                        │ in transamination rates (Figures       │        │ │
│ │                                        │ 4B,C).                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Systems analysis of the BCAA        │        │ │
│ │                                        │ catabolism and cardiac function        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The mechanistic origin of the model    │        │ │
│ │                                        │ allows to explore the contribution of  │        │ │
│ │                                        │ various factors within the network of  │        │ │
│ │                                        │ BCAA catabolism (e.g., co-substrate    │        │ │
│ │                                        │ and enzyme concentrations) on both     │        │ │
│ │                                        │ baseline state and the magnitude of    │        │ │
│ │                                        │ BT2 effect, through the process of     │        │ │
│ │                                        │ sensitivity analysis (Figure 5). The   │        │ │
│ │                                        │ model equations did not include        │        │ │
│ │                                        │ cardiac BCAA and BCKA effect on the    │        │ │
│ │                                        │ systemic BCAA and BCKA levels and      │        │ │
│ │                                        │ therefore variation of the parameters  │        │ │
│ │                                        │ characterizing cardiac BCAA catabolism │        │ │
│ │                                        │ did not cause changes in the plasma    │        │ │
│ │                                        │ biomarkers.                            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ **FIGURE 5:** *Global sensitivity      │        │ │
│ │                                        │ analysis using partial rank            │        │ │
│ │                                        │ correlation coefficient (PRCC).        │        │ │
│ │                                        │ Heatmap reflects the degree of         │        │ │
│ │                                        │ association between parameters and     │        │ │
│ │                                        │ biomarkers either at baseline          │        │ │
│ │                                        │ (pre-treatment) or at treatment        │        │ │
│ │                                        │ steady-state (change) after daily BT2  │        │ │
│ │                                        │ administration. Red and blue color     │        │ │
│ │                                        │ denotes positive and negative          │        │ │
│ │                                        │ association, respectively;             │        │ │
│ │                                        │ KG—ketoglutarate, GLU—glutamate.*      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Concentrations of ketoglutarate (KG),  │        │ │
│ │                                        │ glutamate (GLU) and ATP co-substrates, │        │ │
│ │                                        │ BCAT and BCKD enzymes as well as       │        │ │
│ │                                        │ BCKDK/PP2Cm ratio were varied within   │        │ │
│ │                                        │ the pre-defined range while the        │        │ │
│ │                                        │ changes in BCAA, BCKA and BCKD levels  │        │ │
│ │                                        │ (pre-treatment and after BCKDK         │        │ │
│ │                                        │ inhibition) were evaluated.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All co-substrates were found to have a │        │ │
│ │                                        │ significant effect on the levels of    │        │ │
│ │                                        │ amino acids, among them KG and GLU     │        │ │
│ │                                        │ having most prominent effect. As KG is │        │ │
│ │                                        │ positively linked with BCAA            │        │ │
│ │                                        │ deamination rate, high KG              │        │ │
│ │                                        │ concentrations result in a decrease in │        │ │
│ │                                        │ baseline BCAA levels, accumulation of  │        │ │
│ │                                        │ BCKA, and activation of BCKD.          │        │ │
│ │                                        │ Inversely, GLU is negatively           │        │ │
│ │                                        │ associated with the reaction and has   │        │ │
│ │                                        │ the opposite effect on BCAA and BCKA   │        │ │
│ │                                        │ levels. ATP activates BCKD             │        │ │
│ │                                        │ phosphorylation leading to the minor   │        │ │
│ │                                        │ increase in BCKA and BCAA levels       │        │ │
│ │                                        │ through the reduction of BCKA          │        │ │
│ │                                        │ oxidation rate.                        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ As such, in contrast to KG, high ATP   │        │ │
│ │                                        │ or GLU interfere with the BCKDK        │        │ │
│ │                                        │ inhibition and decrease overall net    │        │ │
│ │                                        │ benefit of the BT2 treatment.          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The effects of BCAT, total BCKD as     │        │ │
│ │                                        │ well as BCKDK/PP2Cm ratio variations   │        │ │
│ │                                        │ on BT2 efficacy were different.        │        │ │
│ │                                        │ Changes in BCAT activity did not alter │        │ │
│ │                                        │ baseline BCAA and BCKA levels, as the  │        │ │
│ │                                        │ transamination rate keeps the model in │        │ │
│ │                                        │ the state of equilibrium (Holeček,     │        │ │
│ │                                        │ 2018). However, the increased BCAT     │        │ │
│ │                                        │ activity combined with BT2 treatment   │        │ │
│ │                                        │ boosts the forward transamination      │        │ │
│ │                                        │ rate, resulting in an increased        │        │ │
│ │                                        │ treatment benefit in BCAA. An increase │        │ │
│ │                                        │ in the total BCKD pool negatively      │        │ │
│ │                                        │ affects the steady-state BCAA and BCKA │        │ │
│ │                                        │ concentrations, limiting the efficacy  │        │ │
│ │                                        │ of BT2. Similarly, the BCKDK/PP2Cm     │        │ │
│ │                                        │ ratio strongly affected the BCKD       │        │ │
│ │                                        │ activity, resulting in the             │        │ │
│ │                                        │ accumulation of BCAA and BCKA and      │        │ │
│ │                                        │ decrease in the BT2 treatment effects. │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Discussion                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In our current research, we report the │        │ │
│ │                                        │ development and application of the     │        │ │
│ │                                        │ mechanistic mathematical model of BCAA │        │ │
│ │                                        │ catabolism used to reconstruct and     │        │ │
│ │                                        │ investigate the dose-response          │        │ │
│ │                                        │ relationship of BT2 (a BCKDK           │        │ │
│ │                                        │ inhibitor) efficacy in mice. The       │        │ │
│ │                                        │ proposed multiscale model is the first │        │ │
│ │                                        │ of its kind and integrates 1) the      │        │ │
│ │                                        │ information on BCAT, BCKD, BCKDK and   │        │ │
│ │                                        │ PP2Cm enzymes (e.g. substrate          │        │ │
│ │                                        │ specificities, catalytic constants),   │        │ │
│ │                                        │ which was extracted from the earlier   │        │ │
│ │                                        │ studies (Pettit et al., 1978; Paxton   │        │ │
│ │                                        │ and Harris, 1984; Yennawar et al.,     │        │ │
│ │                                        │ 2006; Wynn et al., 2012), 2)           │        │ │
│ │                                        │ measurements of BCAA and BCKA fluxes   │        │ │
│ │                                        │ in the body reported by Neinast et al. │        │ │
│ │                                        │ [ 2019] and 3) de novo generated BT2   │        │ │
│ │                                        │ pharmacokinetic and pharmacodynamic    │        │ │
│ │                                        │ data.                                  │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ First step in model development was to │        │ │
│ │                                        │ characterize systemic BCAA catabolism. │        │ │
│ │                                        │ It is known that BCAA-related          │        │ │
│ │                                        │ catabolic processes are spatially      │        │ │
│ │                                        │ separated and take place in different  │        │ │
│ │                                        │ organs, with the skeletal muscle and   │        │ │
│ │                                        │ the liver being the key sites of BCAA  │        │ │
│ │                                        │ transamination and BCKA oxidation,     │        │ │
│ │                                        │ respectively (Holeček, 2018). However, │        │ │
│ │                                        │ the amount of the quantitative         │        │ │
│ │                                        │ information on the BCAA, BCKA and      │        │ │
│ │                                        │ co-substrates levels in different      │        │ │
│ │                                        │ organs and the rates of interorgan     │        │ │
│ │                                        │ exchange is limited. As such, in the   │        │ │
│ │                                        │ proposed model systemic BCAA           │        │ │
│ │                                        │ catabolism is not compartmentalized to │        │ │
│ │                                        │ avoid numerous assumptions that can    │        │ │
│ │                                        │ substantially impair predictive power  │        │ │
│ │                                        │ of the model.                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ While BT2 effect on plasma BCAA level  │        │ │
│ │                                        │ has been evaluated previously (Chen et │        │ │
│ │                                        │ al., 2019; Lian et al., 2020; Walejko  │        │ │
│ │                                        │ et al., 2021), only 20, 40 and 50      │        │ │
│ │                                        │ mg/kg doses have been tested in these  │        │ │
│ │                                        │ experiments. Model-based analysis of   │        │ │
│ │                                        │ the newly generated and historical     │        │ │
│ │                                        │ data reveals maximal treatment benefit │        │ │
│ │                                        │ of BT2 to be achieved with the oral    │        │ │
│ │                                        │ dose of 120 mg/kg, which can serve as  │        │ │
│ │                                        │ a point of reference for the future    │        │ │
│ │                                        │ tests in preclinical models of heart   │        │ │
│ │                                        │ failure. According to our results,     │        │ │
│ │                                        │ oral BT2 dose of 15 mg/kg does not     │        │ │
│ │                                        │ lead to a significant BCAA and BCKA    │        │ │
│ │                                        │ response in plasma, whereas            │        │ │
│ │                                        │ intraperitoneal (i.p.) once-daily      │        │ │
│ │                                        │ injections of 20 mg/kg BT2 led to      │        │ │
│ │                                        │ significant reduction in cardiac BCAA  │        │ │
│ │                                        │ levels, as reported in the literature  │        │ │
│ │                                        │ (Wang et al., 2016; Lian et al.,       │        │ │
│ │                                        │ 2020), which can be explained by       │        │ │
│ │                                        │ possible differences in BT2            │        │ │
│ │                                        │ pharmacokinetics following oral and    │        │ │
│ │                                        │ intraperitoneal drug administration.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Calibration of the cardiac BCAA        │        │ │
│ │                                        │ catabolism was complicated by the      │        │ │
│ │                                        │ contradictory experimental data        │        │ │
│ │                                        │ available for the model development    │        │ │
│ │                                        │ but was necessary to evaluate BT2      │        │ │
│ │                                        │ effect on cardiac functional readouts  │        │ │
│ │                                        │ such as LVEF. Significant differences  │        │ │
│ │                                        │ in baseline cardiac BCAA and BCKA      │        │ │
│ │                                        │ levels between published experiments   │        │ │
│ │                                        │ were identified (Sun et al., 2016;     │        │ │
│ │                                        │ Chen et al., 2019; Uddin et al., 2019) │        │ │
│ │                                        │ with the highest biomarker values      │        │ │
│ │                                        │ observed Chen et al. [ 2019]. These    │        │ │
│ │                                        │ measurements were 10-fold higher       │        │ │
│ │                                        │ compared to the data generated by our  │        │ │
│ │                                        │ team and findings by Sun et al. [      │        │ │
│ │                                        │ 2016]. We hypothesized this            │        │ │
│ │                                        │ discrepancy to be a consequence of     │        │ │
│ │                                        │ possible differences in the mouse diet │        │ │
│ │                                        │ as well as extraction and measuring    │        │ │
│ │                                        │ methodologies. Our data indicate       │        │ │
│ │                                        │ slightly lower BCAA levels and         │        │ │
│ │                                        │ approximately 100-fold lower BCKA      │        │ │
│ │                                        │ levels in cardiac tissue vs. plasma.   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ To characterize enzyme activities in   │        │ │
│ │                                        │ the cardiac tissue we used not only    │        │ │
│ │                                        │ cardiac BCAA and BCKA measurements but │        │ │
│ │                                        │ also included information about        │        │ │
│ │                                        │ reaction rates. Data from (Neinast et  │        │ │
│ │                                        │ al., 2019) highlights rapid            │        │ │
│ │                                        │ equilibration between plasma and organ │        │ │
│ │                                        │ BCAA and BCKA levels in the            │        │ │
│ │                                        │ experiments with BCAA and BCKA         │        │ │
│ │                                        │ infusion, respectively, which was      │        │ │
│ │                                        │ reflected in the model parameters.     │        │ │
│ │                                        │ Calculations performed by Neinast et   │        │ │
│ │                                        │ al. [ 2019] indicated $4\%$ of total   │        │ │
│ │                                        │ BCAA oxidation takes place in the      │        │ │
│ │                                        │ heart. Given relatively small heart    │        │ │
│ │                                        │ volume, calculated cardiac oxidation   │        │ │
│ │                                        │ rate per heart volume unit is very     │        │ │
│ │                                        │ fast, which can explain low BCKA       │        │ │
│ │                                        │ levels in cardiac tissue. In contrast, │        │ │
│ │                                        │ recent data from (Walejko et al.,      │        │ │
│ │                                        │ 2021), generated in the perfused rat   │        │ │
│ │                                        │ hearts point towards BCKA reamination  │        │ │
│ │                                        │ rather than oxidation being a          │        │ │
│ │                                        │ predominant process. Information from  │        │ │
│ │                                        │ both studies could not be reproduced   │        │ │
│ │                                        │ by the model simultaneously,           │        │ │
│ │                                        │ therefore, we focused on the study     │        │ │
│ │                                        │ (Neinast et al., 2019), given the      │        │ │
│ │                                        │ similarities in the experimental       │        │ │
│ │                                        │ design.                                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Discrepancies in BT2 impact on cardiac │        │ │
│ │                                        │ BCAA and BCKA were also observed       │        │ │
│ │                                        │ between the previously reported        │        │ │
│ │                                        │ studies. For example, 20 mg/kg once    │        │ │
│ │                                        │ daily intraperitoneal BT2 dosing was   │        │ │
│ │                                        │ shown to reduce cardiac BCAA by $50\%$ │        │ │
│ │                                        │ in the experiment (Wang et al., 2016)  │        │ │
│ │                                        │ whereas other experiment demonstrated  │        │ │
│ │                                        │ 40 mg/kg BT2 treatment resulting only  │        │ │
│ │                                        │ in $30\%$ decrease in BCAA (Uddin et   │        │ │
│ │                                        │ al., 2019). Given poor BT2 solubility  │        │ │
│ │                                        │ we hypothesize these differences to be │        │ │
│ │                                        │ related to the variations in drug      │        │ │
│ │                                        │ bioavailability across the             │        │ │
│ │                                        │ experiments, however, the BT2          │        │ │
│ │                                        │ pharmacokinetic measurements were not  │        │ │
│ │                                        │ reported to confirm or decline this    │        │ │
│ │                                        │ hypothesis. Nonetheless, all           │        │ │
│ │                                        │ identified publications confirmed      │        │ │
│ │                                        │ significant BCAA and BCKA reduction    │        │ │
│ │                                        │ under BT2 treatment (by approximately  │        │ │
│ │                                        │ $27\%$–$45\%$ and $13\%$–$50\%$,       │        │ │
│ │                                        │ respectively) (Wang et al., 2016; Chen │        │ │
│ │                                        │ et al., 2019; Uddin et al., 2019; Lian │        │ │
│ │                                        │ et al., 2020). Model-based simulations │        │ │
│ │                                        │ indicated $35\%$ and $80\%$ decrease   │        │ │
│ │                                        │ in cardiac BCAA and BCKA levels under  │        │ │
│ │                                        │ 40 mg/kg oral BT2 treatment, BCAA      │        │ │
│ │                                        │ response between plasma and heart      │        │ │
│ │                                        │ being very similar, therefore          │        │ │
│ │                                        │ substantiating plasma BCAA             │        │ │
│ │                                        │ measurements as sufficient for         │        │ │
│ │                                        │ evaluation of the BT2 treatment        │        │ │
│ │                                        │ activity.                              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Interestingly, the model analysis      │        │ │
│ │                                        │ revealed a strong connection between   │        │ │
│ │                                        │ systemic BCAA and BCKA and the cardiac │        │ │
│ │                                        │ amino- and ketoacids response to       │        │ │
│ │                                        │ different interventions, i.e., the BT2 │        │ │
│ │                                        │ effect on cardiac BCAA and BCKA levels │        │ │
│ │                                        │ is dependent on the systemic BCAA and  │        │ │
│ │                                        │ BCKA reduction rather than on local    │        │ │
│ │                                        │ inhibitory effect on cardiac BCKDK,    │        │ │
│ │                                        │ which is in line with the hypothesis   │        │ │
│ │                                        │ proposed by Walejko et al. [ 2021].    │        │ │
│ │                                        │ Neinast and others did not observe and │        │ │
│ │                                        │ increase in cardiac BCKA oxidation     │        │ │
│ │                                        │ under BT2 despite pronounced           │        │ │
│ │                                        │ activation of cardiac BCKD, whereas    │        │ │
│ │                                        │ our predictions indicate small         │        │ │
│ │                                        │ reductions in cardiac BCKA oxidation   │        │ │
│ │                                        │ following BT2-mediated reduction of    │        │ │
│ │                                        │ cardiac BCAA and BCKA uptake.          │        │ │
│ │                                        │ Model-based simulations without the    │        │ │
│ │                                        │ systemic BT2 effect (Supplementary     │        │ │
│ │                                        │ Figure S4) indicated no significant    │        │ │
│ │                                        │ changes in cardiac BCKA oxidation      │        │ │
│ │                                        │ despite the notable increase in BCKD   │        │ │
│ │                                        │ activity, which can be attributed      │        │ │
│ │                                        │ towards the low cardiac BCKA level     │        │ │
│ │                                        │ limiting oxidation process.            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Following these findings, systemic     │        │ │
│ │                                        │ administration of BCAA or BCKA (e.g.   │        │ │
│ │                                        │ with food supplements) affect not only │        │ │
│ │                                        │ systemic but also cardiac BCAA         │        │ │
│ │                                        │ catabolism. No information about       │        │ │
│ │                                        │ negative effects of BCAA intake on     │        │ │
│ │                                        │ cardiac functioning was found in the   │        │ │
│ │                                        │ literature. However, observations from │        │ │
│ │                                        │ patients with defected BCAA            │        │ │
│ │                                        │ catabolism, where systemic and cardiac │        │ │
│ │                                        │ BCAA and BCKA accumulation negatively  │        │ │
│ │                                        │ impacted the cardiac function (Huang   │        │ │
│ │                                        │ et al., 2011), support the claim that  │        │ │
│ │                                        │ supraphysiological BCAA intake might   │        │ │
│ │                                        │ have a detrimental effect on heart     │        │ │
│ │                                        │ failure in patients with the defective │        │ │
│ │                                        │ BCAA catabolism, but not in healthy    │        │ │
│ │                                        │ individuals.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Although the model is built on rodent  │        │ │
│ │                                        │ data, it could potentially be used to  │        │ │
│ │                                        │ inform human dose prediction for       │        │ │
│ │                                        │ possible drug candidates. While        │        │ │
│ │                                        │ keeping similar model structure,       │        │ │
│ │                                        │ parameters related to the kinetics of  │        │ │
│ │                                        │ a drug, expression of the enzyme       │        │ │
│ │                                        │ levels as well as BCAA intake would    │        │ │
│ │                                        │ potentially have to be scaled in a     │        │ │
│ │                                        │ suitable manner (Suryawan et al.,      │        │ │
│ │                                        │ 1998). Effect size on functional       │        │ │
│ │                                        │ parameters (i.e. LVEF) would be        │        │ │
│ │                                        │ complicated to scale as very little    │        │ │
│ │                                        │ human data are available on the        │        │ │
│ │                                        │ relationship but could possibly be     │        │ │
│ │                                        │ calibrated in early clinical studies   │        │ │
│ │                                        │ to allow model informed design in      │        │ │
│ │                                        │ later studies.                         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Conclusion                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ We developed a first-in-class          │        │ │
│ │                                        │ multi-scale systems pharmacology model │        │ │
│ │                                        │ of BCAA catabolism that integrates the │        │ │
│ │                                        │ existing knowledge on the enzyme       │        │ │
│ │                                        │ kinetics with the pool of              │        │ │
│ │                                        │ heterogeneous preclinical data to not  │        │ │
│ │                                        │ only quantitatively characterize the   │        │ │
│ │                                        │ changes in BCAA and BCKA levels in     │        │ │
│ │                                        │ response to the BCKDK inhibition       │        │ │
│ │                                        │ across physiological compartments, but │        │ │
│ │                                        │ also to gain better understanding of   │        │ │
│ │                                        │ the underlying homeostatic system and  │        │ │
│ │                                        │ mechanisms of drug action as well as   │        │ │
│ │                                        │ to interpret observed data in mice.    │        │ │
│ │                                        │ The model supports the hypothesis of   │        │ │
│ │                                        │ systemic BCAA measurements being       │        │ │
│ │                                        │ representative of the cardiac levels   │        │ │
│ │                                        │ of the amino acids, deconvolutes the   │        │ │
│ │                                        │ intricate interplay between the        │        │ │
│ │                                        │ markers of BCAA catabolism to          │        │ │
│ │                                        │ reconstruct dose-response of the BT2   │        │ │
│ │                                        │ inhibitor and quantifies the impact of │        │ │
│ │                                        │ the confounding factors (e.g.,         │        │ │
│ │                                        │ co-substrate concentrations) on the    │        │ │
│ │                                        │ relationship via a sensitivity         │        │ │
│ │                                        │ analysis. The proposed model can serve │        │ │
│ │                                        │ as a useful tool for evaluation of in  │        │ │
│ │                                        │ vivo activity of novel BCKDK           │        │ │
│ │                                        │ inhibitors and other compounds         │        │ │
│ │                                        │ affecting BCAA catabolism as well as   │        │ │
│ │                                        │ optimization of preclinical study      │        │ │
│ │                                        │ design, informing sampling, and dosing │        │ │
│ │                                        │ schedules. The model can also be used  │        │ │
│ │                                        │ for mechanistic hypothesis generation  │        │ │
│ │                                        │ to suggest further experiments for     │        │ │
│ │                                        │ elucidation of the system.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Data availability statement         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The data that support the findings of  │        │ │
│ │                                        │ this study are available from the      │        │ │
│ │                                        │ corresponding author upon reasonable   │        │ │
│ │                                        │ request.                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Ethics statement                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The animal study was reviewed and      │        │ │
│ │                                        │ approved by the AstraZeneca            │        │ │
│ │                                        │ Institutional Animal Care and Use      │        │ │
│ │                                        │ Committee.                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Author contributions                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Conceptualization: YM, MB, MW, MH, KH, │        │ │
│ │                                        │ and MS. Methodology: VV, VS, MS, and   │        │ │
│ │                                        │ KP. Formal analysis: VV, MS, and VS.   │        │ │
│ │                                        │ Investigation: MS, VV, and VS.         │        │ │
│ │                                        │ Writing–original draft: VV, VS, and    │        │ │
│ │                                        │ MS. Writing–review and editing: YM,    │        │ │
│ │                                        │ MB, MH, KH, and MS. Visualization: VV. │        │ │
│ │                                        │ Supervision: KP and MS. All authors    │        │ │
│ │                                        │ contributed to the article and         │        │ │
│ │                                        │ approved the submitted version.        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Funding                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ This study received funding from       │        │ │
│ │                                        │ AstraZeneca Pharmaceuticals. The       │        │ │
│ │                                        │ funder bodies were not involved in the │        │ │
│ │                                        │ study design, collection, analysis,    │        │ │
│ │                                        │ interpretation of data, the writing of │        │ │
│ │                                        │ this article or the decision to submit │        │ │
│ │                                        │ it for publication.                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Conflict of interest                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ YM, MB, MW, MH, KH, and MS are         │        │ │
│ │                                        │ employees of AstraZeneca; VV, VS AG,   │        │ │
│ │                                        │ and KP are employed by M&S Decisions   │        │ │
│ │                                        │ LLC and received research funding from │        │ │
│ │                                        │ AstraZeneca.                           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Publisher’s note                    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ All claims expressed in this article   │        │ │
│ │                                        │ are solely those of the authors and do │        │ │
│ │                                        │ not necessarily represent those of     │        │ │
│ │                                        │ their affiliated organizations, or     │        │ │
│ │                                        │ those of the publisher, the editors    │        │ │
│ │                                        │ and the reviewers. Any product that    │        │ │
│ │                                        │ may be evaluated in this article, or   │        │ │
│ │                                        │ claim that may be made by its          │        │ │
│ │                                        │ manufacturer, is not guaranteed or     │        │ │
│ │                                        │ endorsed by the publisher.             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## Supplementary material              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ The Supplementary Material for this    │        │ │
│ │                                        │ article can be found online at:        │        │ │
│ │                                        │ https://www.frontiersin.org/articles/… │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ ## References                          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 1. Arany Z., Neinast M.. **Branched    │        │ │
│ │                                        │ chain amino acids in metabolic         │        │ │
│ │                                        │ disease**. *Curr. Diab. Rep.* (2018)   │        │ │
│ │                                        │ **18** 76. DOI:                        │        │ │
│ │                                        │ 10.1007/s11892-018-1048-7              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 2. Biswas D., Tozer K., Dao K. T.,     │        │ │
│ │                                        │ Perez L. J., Mercer A., Brown A..      │        │ │
│ │                                        │ **Adverse outcomes in obese cardiac    │        │ │
│ │                                        │ surgery patients correlates with       │        │ │
│ │                                        │ altered branched-chain amino acid      │        │ │
│ │                                        │ catabolism in adipose tissue and       │        │ │
│ │                                        │ heart**. *Front. Endocrinol.* (2020)   │        │ │
│ │                                        │ **11** 534. DOI:                       │        │ │
│ │                                        │ 10.3389/fendo.2020.00534               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 3. Bradshaw E. L., Spilker M. E., Zang │        │ │
│ │                                        │ R., Bansal L., He H., Jones R. D. O..  │        │ │
│ │                                        │ **Applications of quantitative systems │        │ │
│ │                                        │ pharmacology in model-informed drug    │        │ │
│ │                                        │ discovery: Perspective on impact and   │        │ │
│ │                                        │ opportunities**. *CPT. Pharmacometrics │        │ │
│ │                                        │ Syst. Pharmacol.* (2019) **8**         │        │ │
│ │                                        │ 777-791. DOI: 10.1002/psp4.12463       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 4. Chen M., Gao C., Yu J., Ren S.,     │        │ │
│ │                                        │ Wang M., Wynn R. M.. **Therapeutic     │        │ │
│ │                                        │ effect of targeting branched‐chain     │        │ │
│ │                                        │ amino acid catabolic flux in           │        │ │
│ │                                        │ pressure-overload induced heart        │        │ │
│ │                                        │ failure**. *J. Am. Heart Assoc.*       │        │ │
│ │                                        │ (2019) **8** e011625. DOI:             │        │ │
│ │                                        │ 10.1161/JAHA.118.011625                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 5. Harper A. E., Miller R. H., Block   │        │ │
│ │                                        │ K. P.. **Branched-chain amino acid     │        │ │
│ │                                        │ metabolism**. *Annu. Rev. Nutr.*       │        │ │
│ │                                        │ (1984) **4** 409-454. DOI:             │        │ │
│ │                                        │ 10.1146/annurev.nu.04.070184.002205    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 6. Holeček M.. **Branched-chain amino  │        │ │
│ │                                        │ acids in health and disease:           │        │ │
│ │                                        │ Metabolism, alterations in blood       │        │ │
│ │                                        │ plasma, and as supplements**. *Nutr.   │        │ │
│ │                                        │ Metab.* (2018) **15** 33. DOI:         │        │ │
│ │                                        │ 10.1186/s12986-018-0271-1              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 7. Huang Y., Zhou M., Sun H., Wang Y.. │        │ │
│ │                                        │ **Branched-chain amino acid metabolism │        │ │
│ │                                        │ in heart disease: An epiphenomenon or  │        │ │
│ │                                        │ a real culprit?**. *Cardiovasc. Res.*  │        │ │
│ │                                        │ (2011) **90** 220-223. DOI:            │        │ │
│ │                                        │ 10.1093/cvr/cvr070                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 8. Hutson S. M., Sweatt A. J., Lanoue  │        │ │
│ │                                        │ K. F.. **Branched-chain [corrected]    │        │ │
│ │                                        │ amino acid metabolism: Implications    │        │ │
│ │                                        │ for establishing safe intakes**. *J.   │        │ │
│ │                                        │ Nutr.* (2005) **135** 1557S-64S. DOI:  │        │ │
│ │                                        │ 10.1093/jn/135.6.1557S                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 9. Iman R. L., Helton J. C., Campbell  │        │ │
│ │                                        │ J. E.. **An approach to sensitivity    │        │ │
│ │                                        │ analysis of computer models: Part      │        │ │
│ │                                        │ I—introduction, input variable         │        │ │
│ │                                        │ selection and preliminary variable     │        │ │
│ │                                        │ assessment**. *J. Qual. Technol.*      │        │ │
│ │                                        │ (1981) **13** 174-183. DOI:            │        │ │
│ │                                        │ 10.1080/00224065.1981.11978748         │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 10. Jørgenrud B., Jalanko M., Heliö    │        │ │
│ │                                        │ T., Jääskeläinen P., Laine M., Hilvo   │        │ │
│ │                                        │ M.. **The metabolome in Finnish        │        │ │
│ │                                        │ carriers of the MYBPC3-q1061x mutation │        │ │
│ │                                        │ for hypertrophic cardiomyopathy**.     │        │ │
│ │                                        │ *PLOS ONE* (2015) **10** e0134184.     │        │ │
│ │                                        │ DOI: 10.1371/journal.pone.0134184      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 11. Krebs M., Brehm A., Krssak M.,     │        │ │
│ │                                        │ Anderwald C., Bernroider E., Nowotny   │        │ │
│ │                                        │ P.. **Direct and indirect effects of   │        │ │
│ │                                        │ amino acids on hepatic glucose         │        │ │
│ │                                        │ metabolism in humans**. *Diabetologia* │        │ │
│ │                                        │ (2003) **46** 917-925. DOI:            │        │ │
│ │                                        │ 10.1007/s00125-003-1129-1              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 12. Krebs M., Krssak M., Bernroider    │        │ │
│ │                                        │ E., Anderwald C., Brehm A., Meyerspeer │        │ │
│ │                                        │ M.. **Mechanism of amino acid-induced  │        │ │
│ │                                        │ skeletal muscle insulin resistance in  │        │ │
│ │                                        │ humans**. *Diabetes* (2002) **51**     │        │ │
│ │                                        │ 599-605. DOI:                          │        │ │
│ │                                        │ 10.2337/diabetes.51.3.599              │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 13. Li T., Zhang Z., Kolwicz S. C.,    │        │ │
│ │                                        │ Abell L., Roe N. D., Kim M..           │        │ │
│ │                                        │ **Defective branched-chain amino acid  │        │ │
│ │                                        │ catabolism disrupts glucose metabolism │        │ │
│ │                                        │ and sensitizes the heart to            │        │ │
│ │                                        │ ischemia-reperfusion injury**. *Cell   │        │ │
│ │                                        │ Metab.* (2017) **25** 374-385. DOI:    │        │ │
│ │                                        │ 10.1016/j.cmet.2016.11.005             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 14. Li Y., Xiong Z., Yan W., Gao E.,   │        │ │
│ │                                        │ Cheng H., Wu G.. **Branched chain      │        │ │
│ │                                        │ amino acids exacerbate myocardial      │        │ │
│ │                                        │ ischemia/reperfusion vulnerability via │        │ │
│ │                                        │ enhancing GCN2/ATF6/PPAR-α             │        │ │
│ │                                        │ pathway-dependent fatty acid           │        │ │
│ │                                        │ oxidation**. *Theranostics* (2020)     │        │ │
│ │                                        │ **10** 5623-5640. DOI:                 │        │ │
│ │                                        │ 10.7150/thno.44836                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 15. Lian K., Guo X., Wang Q., Liu Y.,  │        │ │
│ │                                        │ Wang R. T., Gao C.. **PP2Cm            │        │ │
│ │                                        │ overexpression alleviates MI/R injury  │        │ │
│ │                                        │ mediated by a BCAA catabolism defect   │        │ │
│ │                                        │ and oxidative stress in diabetic       │        │ │
│ │                                        │ mice**. *Eur. J. Pharmacol.* (2020)    │        │ │
│ │                                        │ **866** 866172796. DOI:                │        │ │
│ │                                        │ 10.1016/j.ejphar.2019.172796           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 16. Neinast M. D., Jang C., Hui S.,    │        │ │
│ │                                        │ Murashige D. S., Chu Q., Morscher R.   │        │ │
│ │                                        │ J.. **Quantitative analysis of the     │        │ │
│ │                                        │ whole-body metabolic fate of           │        │ │
│ │                                        │ branched-chain amino acids**. *Cell    │        │ │
│ │                                        │ Metab.* (2019) **29** 417-429. DOI:    │        │ │
│ │                                        │ 10.1016/j.cmet.2018.10.013             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 17. NIH Workgroup (2011). Quantitative │        │ │
│ │                                        │ and systems pharmacology in the        │        │ │
│ │                                        │ post-genomic era: New approaches to    │        │ │
│ │                                        │ discovering drugs and understanding    │        │ │
│ │                                        │ therapeutic mechanisms. Bethesda..     │        │ │
│ │                                        │ *Quantitative and systems pharmacology │        │ │
│ │                                        │ in the post-genomic era: New           │        │ │
│ │                                        │ approaches to discovering drugs and    │        │ │
│ │                                        │ understanding therapeutic mechanisms*  │        │ │
│ │                                        │ (2011)                                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 18. Ogawa T., Washio J., Takahashi T., │        │ │
│ │                                        │ Echigo S., Takahashi N.. **Glucose and │        │ │
│ │                                        │ glutamine metabolism in oral squamous  │        │ │
│ │                                        │ cell carcinoma: Insight from a         │        │ │
│ │                                        │ quantitative metabolomic approach**.   │        │ │
│ │                                        │ *Oral Surg. Oral Med. Oral Pathol.     │        │ │
│ │                                        │ Oral Radiol.* (2014) **118** 218-225.  │        │ │
│ │                                        │ DOI: 10.1016/j.oooo.2014.04.003        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 19. Paxton R., Harris R. A..           │        │ │
│ │                                        │ **Regulation of branched-chain         │        │ │
│ │                                        │ alpha-ketoacid dehydrogenase kinase**. │        │ │
│ │                                        │ *Arch. Biochem. Biophys.* (1984)       │        │ │
│ │                                        │ **231** 48-57. DOI:                    │        │ │
│ │                                        │ 10.1016/0003-9861(84)90361-8           │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 20. Pettit F. H., Yeaman S. J., Reed   │        │ │
│ │                                        │ L. J.. **Purification and              │        │ │
│ │                                        │ characterization of branched chain     │        │ │
│ │                                        │ alpha-keto acid dehydrogenase complex  │        │ │
│ │                                        │ of bovine kidney**. *Proc. Natl. Acad. │        │ │
│ │                                        │ Sci. U. S. A.* (1978) **75**           │        │ │
│ │                                        │ 4881-4885. DOI:                        │        │ │
│ │                                        │ 10.1073/pnas.75.10.4881                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 21. Shimomura Y., Murakami T.,         │        │ │
│ │                                        │ Nagasaki M., Honda T., Goto H., Kotake │        │ │
│ │                                        │ K.. **Regulation of branched-chain     │        │ │
│ │                                        │ amino acid metabolism and              │        │ │
│ │                                        │ pharmacological effects of             │        │ │
│ │                                        │ branched-chain amino acids**.          │        │ │
│ │                                        │ *Hepatol. Res.* (2004) **30** 3-8.     │        │ │
│ │                                        │ DOI: 10.1016/j.hepres.2004.09.001      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 22. Shimomura Y., Obayashi M.,         │        │ │
│ │                                        │ Murakami T., Harris R. A..             │        │ │
│ │                                        │ **Regulation of branched-chain amino   │        │ │
│ │                                        │ acid catabolism: Nutritional and       │        │ │
│ │                                        │ hormonal regulation of activity and    │        │ │
│ │                                        │ expression of the branched-chain       │        │ │
│ │                                        │ α-keto acid dehydrogenase kinase**.    │        │ │
│ │                                        │ *Curr. Opin. Clin. Nutr. Metab. Care*  │        │ │
│ │                                        │ (2001) **4** 419-423. DOI:             │        │ │
│ │                                        │ 10.1097/00075197-200109000-00013       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 23. Sun H., Olson K. C., Gao C.,       │        │ │
│ │                                        │ Prosdocimo D. A., Zhou M., Wang Z..    │        │ │
│ │                                        │ **Catabolic defect of branched-chain   │        │ │
│ │                                        │ amino acids promotes heart failure**.  │        │ │
│ │                                        │ *Circulation* (2016) **133**           │        │ │
│ │                                        │ 2038-2049. DOI:                        │        │ │
│ │                                        │ 10.1161/CIRCULATIONAHA.115.020226      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 24. Suryawan A., Hawes J. W., Harris   │        │ │
│ │                                        │ R. A., Shimomura Y., Jenkins A. E.,    │        │ │
│ │                                        │ Hutson S. M.. **A molecular model of   │        │ │
│ │                                        │ human branched-chain amino acid        │        │ │
│ │                                        │ metabolism**. *Am. J. Clin. Nutr.*     │        │ │
│ │                                        │ (1998) **68** 72-81. DOI:              │        │ │
│ │                                        │ 10.1093/ajcn/68.1.72                   │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 25. Tso S. C., Gui W. J., Wu C. Y.,    │        │ │
│ │                                        │ Chuang J. L., Qi X., Skvora K. J..     │        │ │
│ │                                        │ **Benzothiophene carboxylate           │        │ │
│ │                                        │ derivatives as novel allosteric        │        │ │
│ │                                        │ inhibitors of branched-chain           │        │ │
│ │                                        │ α-ketoacid dehydrogenase kinase**. *J. │        │ │
│ │                                        │ Biol. Chem.* (2014) **289**            │        │ │
│ │                                        │ 20583-20593. DOI:                      │        │ │
│ │                                        │ 10.1074/jbc.M114.569251                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 26. Tso S. C., Qi X., Gui W. J.,       │        │ │
│ │                                        │ Chuang J. L., Morlock L. K., Wallace   │        │ │
│ │                                        │ A. L.. **Structure-based design and    │        │ │
│ │                                        │ mechanisms of allosteric inhibitors    │        │ │
│ │                                        │ for mitochondrial branched-chain       │        │ │
│ │                                        │ α-ketoacid dehydrogenase kinase**.     │        │ │
│ │                                        │ *Proc. Natl. Acad. Sci. U. S. A.*      │        │ │
│ │                                        │ (2013) **110** 9728-9733. DOI:         │        │ │
│ │                                        │ 10.1073/pnas.1303220110                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 27. Uddin G. M., Zhang L., Shah S.,    │        │ │
│ │                                        │ Fukushima A., Wagg C. S., Gopal K..    │        │ │
│ │                                        │ **Impaired branched chain amino acid   │        │ │
│ │                                        │ oxidation contributes to cardiac       │        │ │
│ │                                        │ insulin resistance in heart failure**. │        │ │
│ │                                        │ *Cardiovasc. Diabetol.* (2019) **18**  │        │ │
│ │                                        │ 86. DOI: 10.1186/s12933-019-0892-3     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 28. Wada E., Kobayashi M., Kohno D.,   │        │ │
│ │                                        │ Kikuchi O., Suga T., Matsui S..        │        │ │
│ │                                        │ **Disordered branched chain amino acid │        │ │
│ │                                        │ catabolism in pancreatic islets is     │        │ │
│ │                                        │ associated with postprandial           │        │ │
│ │                                        │ hypersecretion of glucagon in diabetic │        │ │
│ │                                        │ mice**. *J. Nutr. Biochem.* (2021)     │        │ │
│ │                                        │ **97** 108811. DOI:                    │        │ │
│ │                                        │ 10.1016/j.jnutbio.2021.108811          │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 29. Walejko J. M., Christopher B. A.,  │        │ │
│ │                                        │ Crown S. B., Zhang G. F.,              │        │ │
│ │                                        │ Pickar-Oliver A., Yoneshiro T..        │        │ │
│ │                                        │ **Branched-chain α-ketoacids are       │        │ │
│ │                                        │ preferentially reaminated and activate │        │ │
│ │                                        │ protein synthesis in the heart**.      │        │ │
│ │                                        │ *Nat. Commun.* (2021) **12** 1680.     │        │ │
│ │                                        │ DOI: 10.1038/s41467-021-21962-2        │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 30. Wang W., Zhang F., Xia Y., Zhao    │        │ │
│ │                                        │ S., Yan W., Wang H.. **Defective       │        │ │
│ │                                        │ branched chain amino acid catabolism   │        │ │
│ │                                        │ contributes to cardiac dysfunction and │        │ │
│ │                                        │ remodeling following myocardial        │        │ │
│ │                                        │ infarction**. *Am. J. Physiol. Heart   │        │ │
│ │                                        │ Circ. Physiol.* (2016) **311**         │        │ │
│ │                                        │ H1160-H1169. DOI:                      │        │ │
│ │                                        │ 10.1152/ajpheart.00114.2016            │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 31. Wynn R. M., Li J., Brautigam C.    │        │ │
│ │                                        │ A., Chuang J. L., Chuang D. T..        │        │ │
│ │                                        │ **Structural and biochemical           │        │ │
│ │                                        │ characterization of human              │        │ │
│ │                                        │ mitochondrial branched-chain           │        │ │
│ │                                        │ α-ketoacid dehydrogenase               │        │ │
│ │                                        │ phosphatase**. *J. Biol. Chem.* (2012) │        │ │
│ │                                        │ **287** 9178-9192. DOI:                │        │ │
│ │                                        │ 10.1074/jbc.M111.314963                │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 32. Yennawar N. H., Islam M. M.,       │        │ │
│ │                                        │ Conway M., Wallin R., Hutson S. M..    │        │ │
│ │                                        │ **Human mitochondrial branched chain   │        │ │
│ │                                        │ aminotransferase isozyme: Structural   │        │ │
│ │                                        │ role of the CXXC center in             │        │ │
│ │                                        │ catalysis**. *J. Biol. Chem.* (2006)   │        │ │
│ │                                        │ **281** 39660-39671. DOI:              │        │ │
│ │                                        │ 10.1074/jbc.M607552200                 │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ 33. Zhou M., Shao J., Wu C. Y., Shu    │        │ │
│ │                                        │ L., Dong W., Liu Y.. **Targeting BCAA  │        │ │
│ │                                        │ catabolism to treat obesity-associated │        │ │
│ │                                        │ insulin resistance**. *Diabetes*       │        │ │
│ │                                        │ (2019) **68** 1730-1746. DOI:          │        │ │
│ │                                        │ 10.2337/db18-0927                      │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ assistant: Short answer: BT2’s         │        │ │
│ │                                        │ cardioprotective effects in heart      │        │ │
│ │                                        │ failure models are best explained by   │        │ │
│ │                                        │ BT2 acting as a mitochondrial          │        │ │
│ │                                        │ uncoupler in addition to, and          │        │ │
│ │                                        │ sometimes independently from, its      │        │ │
│ │                                        │ inhibition of BCKDK. Tissue-specific   │        │ │
│ │                                        │ Bckdk ablation misses this uncoupling  │        │ │
│ │                                        │ and the broader systemic/b^CAA flux    │        │ │
│ │                                        │ effects, so it does not reproduce      │        │ │
│ │                                        │ BT2’s benefits. The two actions        │        │ │
│ │                                        │ together (mitochondrial uncoupling and │        │ │
│ │                                        │ altered BCAA flux) reconcile the       │        │ │
│ │                                        │ paradox.                               │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ Key points                             │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ - BT2 has dual actions                 │        │ │
│ │                                        │   - BCKDK inhibition: relieves         │        │ │
│ │                                        │ phosphorylation of BCKDH, enhances     │        │ │
│ │                                        │ BCAA/BCKA flux through the canonical   │        │ │
│ │                                        │ BCAA pathway, lowers cardiac BCAA/BCKA │        │ │
│ │                                        │ in many models, and can improve        │        │ │
│ │                                        │ insulin signaling and cardiac function │        │ │
│ │                                        │ when BCAA flux is limiting.            │        │ │
│ │                                        │   - Mitochondrial uncoupling: BT2 acts │        │ │
│ │                                        │ as a chemical uncoupler, increasing    │        │ │
│ │                                        │ proton leak, lowering membrane         │        │ │
│ │                                        │ potential, and reducing mitochondrial  │        │ │
│ │                                        │ ROS (H2O2 efflux) in heart             │        │ │
│ │                                        │ mitochondria. This uncoupling occurs   │        │ │
│ │                                        │ acutely, in both rodent and human      │        │ │
│ │                                        │ cardiomyocytes, and is mechanistically │        │ │
│ │                                        │ separable from BCKDK inhibition.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ - Why tissue BCKDK ablation alone      │        │ │
│ │                                        │ doesn’t mimic BT2                      │        │ │
│ │                                        │   - Cardiac BCAA oxidation contributes │        │ │
│ │                                        │ only a small fraction to energy        │        │ │
│ │                                        │ production in the heart; lowering      │        │ │
│ │                                        │ cardiac BCAA levels by Bckdk ablation  │        │ │
│ │                                        │ in a single tissue does not produce    │        │ │
│ │                                        │ the same systemic metabolic remodeling │        │ │
│ │                                        │ or ROS-suppressing environment as BT2. │        │ │
│ │                                        │   - Ablation in specific tissues       │        │ │
│ │                                        │ (heart, skeletal muscle, liver) fails  │        │ │
│ │                                        │ to reproduce the systemic BCAA/BCKA    │        │ │
│ │                                        │ redistribution and the PK-driven       │        │ │
│ │                                        │ tissue distribution of BT2, which      │        │ │
│ │                                        │ affects multiple organs (liver,        │        │ │
│ │                                        │ adipose, etc.) and their cross-talk    │        │ │
│ │                                        │ with the heart.                        │        │ │
│ │                                        │   - BT2’s cardioprotection in failure  │        │ │
│ │                                        │ models (e.g., TAC, I/R) correlates     │        │ │
│ │                                        │ with reduced mitochondrial ROS and     │        │ │
│ │                                        │ improved energetic/redox balance,      │        │ │
│ │                                        │ effects not achieved by                │        │ │
│ │                                        │ tissue-restricted BCKDK loss alone.    │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ - How uncoupling and BCAA flux         │        │ │
│ │                                        │ interact in the heart                  │        │ │
│ │                                        │   - Uncoupling lowers proton motive    │        │ │
│ │                                        │ force, which reduces mitochondrial ROS │        │ │
│ │                                        │ generation and can stabilize calcium   │        │ │
│ │                                        │ handling, directly protecting          │        │ │
│ │                                        │ myocardium from oxidative stress and   │        │ │
│ │                                        │ ischemic injury.                       │        │ │
│ │                                        │   - Lowered BCAA/BCKA levels           │        │ │
│ │                                        │ (systemically and in the heart) can    │        │ │
│ │                                        │ relieve mTOR-related insulin           │        │ │
│ │                                        │ resistance and improve substrate       │        │ │
│ │                                        │ flexibility, but the heart’s own BCAA  │        │ │
│ │                                        │ oxidation is not a dominant energy     │        │ │
│ │                                        │ source; the systemic BCAA changes plus │        │ │
│ │                                        │ uncoupling together give the strongest │        │ │
│ │                                        │ cardioprotective signal.               │        │ │
│ │                                        │   - A recent mechanistic view shows    │        │ │
│ │                                        │ extramitochondrial BCKDH (e.g.,        │        │ │
│ │                                        │ ER-associated pools) and AMPD3         │        │ │
│ │                                        │ interactions can modulate BCAA flux    │        │ │
│ │                                        │ and intracellular energetics; BT2’s    │        │ │
│ │                                        │ uncoupling can override or bypass such │        │ │
│ │                                        │ compartmental nuances, whereas         │        │ │
│ │                                        │ tissue-specific BCKDK knockouts miss   │        │ │
│ │                                        │ these cross-compartment effects.       │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ - Implications for interpreting BT2’s  │        │ │
│ │                                        │ benefits                               │        │ │
│ │                                        │   - In heart failure, BT2’s protective │        │ │
│ │                                        │ effects are plausibly driven largely   │        │ │
│ │                                        │ by mitochondrial uncoupling (ROS       │        │ │
│ │                                        │ reduction and improved redox state)    │        │ │
│ │                                        │ with a contributory role from altered  │        │ │
│ │                                        │ BCAA flux.                             │        │ │
│ │                                        │   - Tissue-specific BCKDK ablation     │        │ │
│ │                                        │ captures only local changes in BCAA    │        │ │
│ │                                        │ metabolism and misses the systemic     │        │ │
│ │                                        │ distribution, PK/PD, and               │        │ │
│ │                                        │ uncoupling-mediated redox/energetic    │        │ │
│ │                                        │ benefits that BT2 provides.            │        │ │
│ │                                        │   - Systems pharmacology and turnover  │        │ │
│ │                                        │ data support that both systemic BCAA   │        │ │
│ │                                        │ catabolism and mitochondrial           │        │ │
│ │                                        │ uncoupling contribute to BT2’s overall │        │ │
│ │                                        │ effect; when uncoupling is removed (as │        │ │
│ │                                        │ in certain tissue-restricted           │        │ │
│ │                                        │ knockouts), the cardioprotective       │        │ │
│ │                                        │ signal diminishes.                     │        │ │
│ │                                        │                                        │        │ │
│ │                                        │ In short, BT2’s systemic               │        │ │
│ │                                        │ cardioprotection in heart failure      │        │ │
│ │                                        │ models is best explained by it         │        │ │
│ │                                        │ functioning as a mild mitochondrial    │        │ │
│ │                                        │ uncoupler with concurrent, but not     │        │ │
│ │                                        │ solely determinative, effects on BCAA  │        │ │
│ │                                        │ flux. The failure of tissue-specific   │        │ │
│ │                                        │ BCKDK ablation to replicate BT2’s      │        │ │
│ │                                        │ benefits highlights that uncoupling    │        │ │
│ │                                        │ (and systemic metabolic remodeling) is │        │ │
│ │                                        │ essential to BT2’s cardioprotective    │        │ │
│ │                                        │ action.                                │        │ │
│ └────────────────────────────────────────┴────────────────────────────────────────┴────────┘ │
╰──────────────────────────────────────────────────────────────────────────────────────────────╯
--- All ---
Rewards:
reward: avg - 0.060, std - 0.014
r1: [0.051, 0.059, 0.084, 0.064, 0.042]
total_tool_calls: avg - 2.000, std - 0.000
r1: [2.0, 2.0, 2.0, 2.0, 2.0]
search_calls: avg - 1.000, std - 0.000
r1: [1.0, 1.0, 1.0, 1.0, 1.0]
read_calls: avg - 1.000, std - 0.000
r1: [1.0, 1.0, 1.0, 1.0, 1.0]
_f1_reward: avg - 0.060, std - 0.014
r1: [0.051, 0.059, 0.084, 0.064, 0.042]
